Gene References

A B C D E F G H I K L M N O P R S T U V W X Z

CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1)

Aboutabl ME, Zordoky BN, Hammock BD, El-Kadi AO. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J Cardiovasc Pharmacol 2011; 57:273-81.

Ahmad I, Shukla S, Kumar A et al. Maneb and paraquat-induced modulation of toxicant responsive genes in the rat liver: comparison with polymorphonuclear leukocytes. Chem Biol Interact 2010; 188:566-79.

Akgül S, Derman O, Alikaşifoğlu M, Aktaş D. CYP1A1 polymorphism in adolescents with polycystic ovary syndrome. Int J Gynaecol Obstet 2011; 112:8-10.

Alberts R, Lu L, Williams RW, Schughart K. Genome-wide analysis of the mouse lung transcriptome reveals novel molecular gene interaction networks and cell-specific expression signatures. Respir Res 2011; 12:61.

Albrecht EA, Dhanasekaran SM, Tomlins S. Immediate early inflammatory gene responses of human umbilical vein endothelial cells to hemorrhagic venom. Inflamm Res 2011; 60:213-7.

Alvarez-Gonzalez I, Mojica R, Madrigal-Bujaidar E, Camacho-Carranza R, Escobar-García D, Espinosa-Aguirre JJ. The antigenotoxic effects of grapefruit juice on the damage induced by benzo(a)pyrene and evaluation of its interaction with hepatic and intestinal Cytochrome P450 (Cyp) 1a1. Food Chem Toxicol 2011; 49:807-11.

Alves Dos Santos R, Teixeira AC, Mayorano MB, Carrara HH, Moreira de Andrade J, Takahashi CS. Variability in estrogen-metabolizing genes and their association with genomic instability in untreated breast cancer patients and healthy women. J Biomed Biotechnol 2011. doi:10. 1155/2011/571784.

An J, Yin L, Shang Y et al. The combined effects of BDE47 and BaP on oxidatively generated DNA damage in L02 cells and the possible molecular mechanism. Mutat Res 2011; 721:192-8.

Andersson H, Garscha U, Brittebo E. Effects of PCB126 and 17β-oestradiol on endothelium-derived vasoactive factors in human endothelial cells. Toxicology 2011; 285:46-56.

Androutsopoulos VP, Papakyriakou A, Vourloumis D, Spandidos DA. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg Med Chem 2011; 19:2842-9.

Aung HH, Lame MW, Gohil K et al. Comparative gene responses to collected ambient particles in vitro: endothelial responses. Physiol Genomics 2011; 43:917-29.

Azarpira N, Ashraf MJ, Khademi B, Darai M, Hakimzadeh A, Abedi E. Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma. Mol Biol Rep 2011; 38:5443-8.

Badal S, Williams SA, Huang G et al. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri. Fitoterapia 2011; 82:230-6.

Bansal SS, Vadhanam MV, Gupta RC. Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm Res 2011; 28:1121-30.

Berg V, Lyche JL, Karlsson C et al. Accumulation and effects of natural mixtures of persistent organic pollutants (POP) in Zebrafish after two generations of exposure. J Toxicol Environ Health A 2011; 74:407-23.

Bothe H, Gassmann K, Götz C, Fritsche E, Abel J, Haarmann-Stemmann T. Epigallocatechin-3-gallate does not affect the activity of enzymes involved in metabolic activation and cellular excretion of benzo[a]pyrene in human colon carcinoma cells. Toxicol Lett 2011; 203:258-64.

Boutros PC, Yao CQ, Watson JD et al. Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol Appl Pharmacol 2011; 251:119-29.

Braeuning A, Köhle C, Buchmann A, Schwarz M. Coordinate regulation of cytochrome P450 1A1 expression in mouse liver by the aryl hydrocarbon receptor and the {beta}-catenin pathway. Toxicol Sci 2011; 122:16-25.

Bravo CF, Curtis LR, Myers MS et al. Biomarker responses and disease susceptibility in juvenile rainbow trout Oncorhynchus mykiss fed a high molecular weight PAH mixture. Environ Toxicol Chem 2011; 30:704-14.

Bui P, Imaizumi S, Beedanagari SR, Reddy ST, Hankinson O. Human CYP2S1 metabolizes cyclooxygenase- and lipoxygenase-derived eicosanoids. Drug Metab Dispos 2011; 39:180-90.

Cabaret O, Puel O, Botterel F et al. Metabolic detoxication pathways for sterigmatocystin in primary tracheal epithelial cells. Chem Res Toxicol 2010; 23:1673-81.

Cao J, Patisaul HB, Petersen SL. Aryl hydrocarbon receptor activation in lactotropes and gonadotropes interferes with estradiol-dependent and -independent preprolactin, glycoprotein alpha and luteinizing hormone beta gene expression. Mol Cell Endocrinol 2011; 333:151-9.

Chatterjee S, Dhar S, Sengupta B et al. Polymorphisms of CYP1A1, GSTM1 and GSTT1 loci as the genetic predispositions of oral cancers and other oral pathologies: tobacco and alcohol as risk modifiers. Indian J Clin Biochem 2010; 25:260-72.

Chatuphonprasert W, Kondo S, Jarukamjorn K, Kawasaki Y, Sakuma T, Nemoto N. Potent modification of inducible CYP1A1 expression by flavonoids. Biol Pharm Bull 2010; 33:1698-703.

Chen XW, Serag ES, Sneed KB, Zhou SF. Herbal bioactivation, molecular targets and the toxicity relevance. Chem Biol Interact 2011; 192:161-76.

Chen Z, Li Z, Niu X et al. The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis 2011; 26:437-46.

Cheung C, Loy S, Li GX, Liu AB, Yang CS. Rapid induction of colon carcinogenesis in CYP1A-humanized mice by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate. Carcinogenesis 2011; 32:233-9.

Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol 2010; 172:1000-14.

Corchero J, Pimprale S, Kimura S, Gonzalez FJ. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 2001; 11:1-6.

Cornelis MC, Monda KL, Yu K et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 2011. doi:10. 1371/journal. pgen. 1002033.

Couillard CM, Légaré B, Bernier A, Dionne Z. Embryonic exposure to environmentally relevant concentrations of PCB126 affect prey capture ability of Fundulus heteroclitus larvae. Mar Environ Res 2011; 71:257-65.

Crooke PS, Justenhoven C, Brauch H; GENICA Consortium. Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction. Cancer Epidemiol Biomarkers Prev 2011; 20:1502-15.

Cury NM, Russo A, Galbiatti AL et al. Polymorphisms of the CYP1A1 and CYP2E1 genes in head and neck squamous cell carcinoma risk. Mol Biol Rep 2011. doi:10. 1007/s11033-011-0831-1.

Dadkhah A, Allameh A, Khalafi H, Ashrafihelan J. Inhibitory effects of dietary caraway essential oils on 1,2-dimethylhydrazine-induced colon carcinogenesis is mediated by liver xenobiotic metabolizing enzymes. Nutr Cancer 2011; 63:46-54.

Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer Among Lebanese. Genet Test Mol Biomarkers 2011; 15:423-9.

Diaz GJ, Murcia HW, Cepeda SM. Bioactivation of aflatoxin B1 by turkey liver microsomes: responsible cytochrome P450 enzymes. Br Poult Sci 2010; 51:828-37.

Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008; 42:1822-31.

Dragin N, Shi Z, Madan R et al. Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse. Mol Pharmacol 2008; 73:1844-56.

Dunn BK, Greene MH, Kelley JM et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int J Mol Epidemiol Genet 2010; 1:332-49.

Ebina M, Shibazaki M, Kudo K, Kasai S, Kikuchi H. Correlation of dysfunction of nonmuscle myosin IIA with increased induction of Cyp1a1 in Hepa-1 cells. Biochim Biophys Acta 2011; 1809:176-83.

Ehnert S, Seeliger C, Vester H et al. Autologous serum improves yield and metabolic capacity of monocyte-derived hepatocyte-like cells: possible implication for cell transplantation. Cell Transplant 2011. doi:10. 3727/096368910X550224.

Einem Lindeman T, Poirier MC, Divi RL. The resveratrol analogue, 2,3’,4,5’-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene. Mutagenesis 2011; 26:629-35.

El-Sayed WM. Effect of pregnane X receptor (PXR) prototype agonists on chemoprotective and drug metabolizing enzymes in mice. Eur J Pharmacol 2011; 660:291-7.

Erratico CA, Moffatt SC, Bandiera SM. Comparative oxidative metabolism of BDE-47 and BDE-99 by rat hepatic microsomes. Toxicol Sci 2011; 123:37-47.

Fernández-Cruz ML, Valdehita A, Alonso M, Mann E, Herradón B, Navas JM. Biological and chemical studies on aryl hydrocarbon receptor induction by the p53 inhibitor pifithrin-α and its condensation product pifithrin-β. Life Sci 2011; 88:774-83.

Firdous AP, Sindhu ER, Ramnath V, Kuttan R. Anti-mutagenic and anti-carcinogenic potential of the carotenoid meso-zeaxanthin. Asian Pac J Cancer Prev 2010; 11:1795-800.

Fujimura H, Murakami N, Miwa S, Aruga C, Toriumi W. The suitability of rat hepatoma cell line H4IIE for evaluating the potentials of compounds to induce CYP3A23 expression. Exp Toxicol Pathol 2010. doi:10. 1016/j. etp. 2010. 11. 010.

Furumatsu K, Nishiumi S, Kawano Y et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci 2011; 56:2532-44.

García-Suástegui WA, Huerta-Chagoya A, Carrasco-Colín KL et al. Seasonal variations in the levels of PAH-DNA adducts in young adults living in Mexico City. Mutagenesis 2011; 26:385-91.

Genualdo V, Spalenza V, Perucatti A et al. Fluorescence in situ hybridization mapping of six loci containing genes involved in the dioxin metabolism of domestic bovids. J Appl Genet 2011; 52:229-32.

Ghosal A, Lu X, Penner N et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos 2011; 39:30-8.

Giera S, Bansal R, Ortiz-Toro TM, Taub DG, Zoeller RT. Individual polychlorinated biphenyl (PCB) congenersp produce tissue- and gene-specific effects on thyroid hormone signaling during development. Endocrinology 2011; 152:2909-19.

Gilot D, Le Meur N, Giudicelli F et al. RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity. PLoS One 2011. doi:10. 1371/journal. pone. 0018261.

Godard-Codding CA, Clark R, Fossi MC et al. Pacific Ocean-wide profile of CYP1A1 expression, stable carbon and nitrogen isotope ratios, and organic contaminant burden in sperm whale skin biopsies. Environ Health Perspect 2011; 119:337-43.

Goode EL, White KL, Vierkant RA et al. Xenobiotic-metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog 2011; 50:397-402.

Gregoraszczuk E, Ptak A. Involvement of caspase-9 but not caspase-8 in the anti-apoptotic effects of estradiol and 4-OH-Estradiol in MCF-7 human breast cancer cells. Endocr Regul 2011; 45:3-8.

Grover S, Talwar P, Gourie-Devi M et al. Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy. Pharmacogenomics 2010; 11:1525-34.

Gualtieri M, Ovrevik J, Mollerup S et al. Airborne urban particles (Milan winter-PM2. 5) cause mitotic arrest and cell death: Effects on DNA, mitochondria, AhR binding and spindle organization. Mutat Res 2011; 713:18-31.

Haldén AN, Arnoldsson K, Haglund P et al. Retention and maternal transfer of brominated dioxins in zebrafish (Danio rerio) and effects on reproduction, aryl hydrocarbon receptor-regulated genes, and ethoxyresorufin-O-deethylase (EROD) activity. Aquat Toxicol 2011; 102:150-61.

Haluzova I, Modra H, Blahova J, Marsalek P, Siroka Z, Groch L, Svobodova Z. Effects of subchronic exposure to Spartakus (prochloraz) on common carp Cyprinus carpio. Neuro Endocrinol Lett 2010; 31 Suppl 2:105-13.

Hamouchene H, Arlt VM, Giddings I, Phillips DH. Influence of cell cycle on responses of MCF-7 cells to benzo[a]pyrene. BMC Genomics 2011; 12:333.

Han EH, Hwang YP, Kim HG et al. CCAAT/enhancer-binding protein β activation by capsaicin contributes to the regulation of CYP1A1 expression, mediated by the aryl hydrocarbon receptor. Br J Pharmacol 2011. doi:10. 1111/j. 1476-5381. 2011. 01232. x.

Hao B, Chen ZW, Zhou XJ et al. Identification of phase-I metabolites and chronic toxicity study of the Kv1. 3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica 2011; 41:198-211.

Hao M, Ba Q, Yin J, Li J, Zhao Y, Wang H. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. Drug Metab Pharmacokinet 2011; 26:201-5.

Henkens T, Snykers S, Vinken M et al. Preservation of hepatocellular functionality in cultures of primary rat hepatocytes upon exposure to 4-Me2N-BAVAH, a hydroxamate-based HDAC-inhibitor. Toxicol In Vitro 2011; 25:100-9.

Ho SH, Singh M, Holloway AC, Crankshaw DJ. The effects of commercial preparations of herbal supplements commonly used by women on the biotransformation of fluorogenic substrates by human cytochromes P450. Phytother Res 2011. doi:10. 1002/ptr. 3371.

Honetschlägerová Z, Sporková A, Kopkan L et al. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens 2011; 29:1590-601.

Hong H, Su H, Ma L et al. In vitro characterization of the metabolic pathways and P450 inhibition and induction potential of BMS-690514, an ErbB/VEGFR inhibitor. Drug Metab Dispos 2011; 39:1658-67.

Horn J, Milewska M, Arnold SM, Leggas M. Metabolic pathways of the camptothecin analog AR-67. Drug Metab Dispos 2011; 39:683-92.

Houlle S, Charbonnier F, Houivet E et al. Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet 2011; 19:887-92.

Howard CG, Mullins JJ, Mitchell KD. Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin II-dependent malignant hypertension. Am J Med Sci 2011; 341:383-7.

Jaiswal AK, Gonzalez FJ, Nebert DW. Human P(1)-450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Res 1985; 13:4503-20.

Jaiswal AK, Nebert DW. Two RFLPs associated with the human P(1)450 gene linked to the MPI locus on chromosome 15 (HGM8 D15S8). Nucleic Acids Res 1986; 14:4376.

Jiang W, Couroucli XI, Wang L, Barrios R, Moorthy B. Augmented oxygen-mediated transcriptional activation of cytochrome P450 (CYP)1A expression and increased susceptibilities to hyperoxic lung injury in transgenic mice carrying the human CYP1A1 or mouse 1A2 promoter in vivo. Biochem Biophys Res Commun 2011; 407:79-85.

Jiang Z, Dalton TP, Jin L et al. Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus. Hum Mutat 2005; 25:196-206.

Jin JQ, Hu YY, Niu YM et al. CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk: a meta-analysis. World J Gastroenterol 2011; 17:260-6.

Jin M, Arya P, Patel K et al. Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. Alcohol Clin Exp Res 2011; 35:132-9.

Jones SN, Jones PG, Ibarguen H, Caskey CT, Craigen WJ. Induction of the Cyp1a-1 dioxin-responsive enhancer in transgenic mice. Nucleic Acids Res 1991; 19:6547-51.

Kalmes M, Hennen J, Clemens J, Blömeke B. Impact of aryl hydrocarbon receptor (AhR) knockdown on cell cycle progression in human HaCaT keratinocytes. Biol Chem 2011; 392:643-51.

Kang HJ, Hong YB, Kim HJ et al. Detoxification: a novel function of BRCA1 in tumor suppression? Toxicol Sci 2011; 122:26-37.

Kashyap MP, Singh AK, Kumar V et al. Monocrotophos induced apoptosis in PC12 cells: role of xenobiotic metabolizing cytochrome P450s. PLoS One 2011. doi:10. 1371/journal. pone. 0017757.

Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56:72-6.

Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131-3.

Kawajiri K, Watanabe J, Gotoh O, Tagashira Y, Sogawa K, Fujii-Kuriyama Y. Structure and drug inducibility of the human cytochrome P-450c gene. Eur J Biochem 1986; 159:219-25.

Kido T, Sakakibara H, Ohura T et al. Evaluation of chlorinated benz[a]anthracene on hepatic toxicity in rats and mutagenic activity in Salmonella typhimurium. Environ Toxicol 2011. doi:10. 1002/tox. 20693.

Kim EY, Suda T, Tanabe S, Batoev VB, Petrov EA, Iwata H. Evaluation of relative potencies for in vitro transactivation of the Baikal Seal aryl hydrocarbon receptor by dioxin-like compounds. Environ Sci Technol 2011; 45:1652-8.

Kim MJ, Marchand P, Henegar C et al. Fate and complex pathogenic effects of dioxins and polychlorinated biphenyls in obese subjects before and after drastic weight loss. Environ Health Perspect 2011; 119:377-83.

Kim TH, Lee SH, Lee SM. Role of Kupffer cells in pathogenesis of sepsis-induced drug metabolizing dysfunction. FEBS J 2011; 278:2307-17.

Kimura T, Okumura F, Onodera A, Nakanishi T, Itoh N, Isobe M. Chromium (VI) inhibits mouse metallothionein-I gene transcription by modifying the transcription potential of the co-activator p300. J Toxicol Sci 2011; 36:173-80.

Koga N, Ohta C, Kato Y et al. In vitro metabolism of nobiletin, a polymethoxy-flavonoid, by human liver microsomes and cytochrome P450. Xenobiotica 2011; 41:927-33.

Kondo S, Chatuphonprasert W, Jaruchotikamol A, Sakuma T, Nemoto N. Cellular glutathione content modulates the effect of andrographolide on β-naphthoflavone-induced CYP1A1 mRNA expression in mouse hepatocytes. Toxicology 2011; 280:18-23.

Kotrbová V, Mrázová B, Moserová M et al. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. Biochem Pharmacol 2011; 82:669-80.

Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982; 42:5030-7.

Kruber P, Trump S, Behrens J, Lehmann I. T-2 toxin is a cytochrome P450 1A1 inducer and leads to MAPK/p38- but not aryl hydrocarbon receptor-dependent interleukin-8 secretion in the human intestinal epithelial cell line Caco-2. Toxicology 2011; 284:34-41.

Kung MH, Yukata K, O’Keefe RJ, Zuscik MJ. Aryl hydrocarbon receptor-mediated impairment of chondrogenesis and fracture healing by cigarette smoke and benzo(a)pyrene. J Cell Physiol 2011. doi:10. 1002/jcp. 22819.

Lal K, Mani U, Pandey R et al. Multiple approaches to evaluate the toxicity of the biomass fuel cow dung (kanda) smoke. Ecotoxicol Environ Saf 2011; 74:2126-32.

Lee IW, Kuo PH, Su MT, Kuan LC, Hsu CC, Kuo PL. Quantitative trait analysis suggests polymorphisms of estrogen-related genes regulate human sperm concentrations and motility. Hum Reprod 2011; 26:1585-96.

Lee J, Kim HJ, Moon JA et al. Transgenic overexpression of p23 induces spontaneous hydronephrosis in mice. Int J Exp Pathol 2011; 92:251-9.

Levová K, Moserová M, Kotrbová V et al. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci 2011; 121:43-56.

Li ZH, Zlabek V, Velisek J et al. Acute toxicity of carbamazepine to juvenile rainbow trout (Oncorhynchus mykiss): effects on antioxidant responses, hematological parameters and hepatic EROD. Ecotoxicol Environ Saf 2011; 74:319-27.

Liu C, Shi Y, Li H, Wang Y, Yang K. p,p’-DDE disturbs the homeostasis of thyroid hormones via thyroid hormone receptors, transthyretin, and hepatic enzymes. Horm Metab Res 2011; 43:391-6.

Lu YF, Wu Q, Liang SX, Miao JW, Shi JS, Liu J. Evaluation of hepatotoxicity potential of cinnabar-containing An-Gong-Niu-Huang Wan, a patent traditional Chinese medicine. Regul Toxicol Pharmacol 2011; 60:206-11.

Marinković N, Pašalić D, Ferenčak G, Gršković B, Stavljenić Rukavina A. Dioxins and human toxicity. Arh Hig Rada Toksikol 2010; 61:445-53.

Masood N, Kayani MA, Malik FA, Mahjabeen I, Baig RM, Faryal R. Genetic variation in carcinogen metabolizing genes associated with oral cancer in Pakistani population. Asian Pac J Cancer Prev 2011; 12:491-5.

Masood N, Malik FA, Kayani MA. Expression of xenobiotic metabolizing genes in head and neck cancer tissues. Asian Pac J Cancer Prev 2011; 12:377-82.

Matuskova Z, Tunkova A, Anzenbacherova E et al. Effects of probiotic Escherichia coli Nissle 1917 on expression of cytochromes P450 along the gastrointestinal tract of male rats. Neuro Endocrinol Lett 2010; 31 Suppl 2:46-50.

McNulty J, Thorat A, Vurgun N et al. Human cytochrome P450 liability studies of trans-dihydronarciclasine: a readily available, potent, and selective cancer cell growth inhibitor. J Nat Prod 2011; 74:106-8.

Melchini A, Catania S, Stancanelli R, Tommasini S, Costa C. Interaction of a functionalized complex of the flavonoid hesperetin with the AhR pathway and CYP1A1 expression: involvement in its protective effects against benzo[a]pyrene-induced oxidative stress in human skin. Cell Biol Toxicol 2011; 27:371-9.

Michaud V, Frappier M, Dumas MC, Turgeon J. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One 2010. doi:10. 1371/journal. pone. 0015666.

Mizerovská J, Dračínská H, Frei E, Schmeiser HH, Arlt VM, Stiborová M. Induction of biotransformation enzymes by the carcinogenic air-pollutant 3-nitrobenzanthrone in liver, kidney and lung, after intra-tracheal instillation in rats. Mutat Res 2011; 720:34-41.

Mortensen AS, Letcher RJ, Cangialosi MV, Chu S, Arukwe A. Tissue bioaccumulation patterns, xenobiotic biotransformation and steroid hormone levels in Atlantic salmon (Salmo salar) fed a diet containing perfluoroactane sulfonic or perfluorooctane carboxylic acids. Chemosphere 2011; 83:1035-44.

Murray IA, Flaveny CA, Chiaro CR et al. Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3’,4’-dimethoxy-α-naphthoflavone. Mol Pharmacol 2011; 79:508-19.

National Toxicology Program. Toxicology and carcinogenesis studies of 2,3’,4,4’,5-pentachlorobiphenyl (PCB 118) (CAS No. 31508-00-6) in female harlan Sprague-Dawley rats (Gavage studies). Natl Toxicol Program Tech Rep Ser 2010:1-174.

Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem 1987; 56:945-93.

Neri T, Merico V, Fiordaliso F et al. The differentiation of cardiomyocytes from mouse embryonic stem cells is altered by dioxin. Toxicol Lett 2011; 202:226-36.

Nie Q, Yang XN, An SJ et al. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Eur J Cancer 2011; 47:1962-70.

Nimz M, Spitschak M, Fürbass R, Vanselow J. The pre-ovulatory luteinizing hormone surge is followed by down-regulation of CYP19A1, HSD3B1, and CYP17A1 and chromatin condensation of the corresponding promoters in bovine follicles. Mol Reprod Dev 2010; 77:1040-8.

N’jai AU, Larsen MC, Bushkofsky JR, Czuprynski CJ, Jefcoate CR. Acute disruption of bone marrow hematopoiesis by benzo(a)pyrene is selectively reversed by aryl hydrocarbon receptor-mediated processes. Mol Pharmacol 2011; 79:724-34.

Nonaka T, Takakuwa K, Tanaka K. Analysis of the polymorphisms of genes coding biotransformation enzymes in recurrent miscarriage in the Japanese population. J Obstet Gynaecol Res 2011; 37:1352-8.

Nosheen M, Ishrat M, Malik FA, Baig RM, Kayani MA. Association of GSTM1 and GSTT1 gene deletions with risk of head and neck cancer in Pakistan: a case control study. Asian Pac J Cancer Prev 2010; 11:881-5.

Ocraft KP, Muskett JM, Brown S. Localization of the human arylhydrocarbon hydroxylase gene to the 2q31-2pter region of chromosome 2. Ann Hum Genet 1985; 49:237-9.

Ohno M, Darwish WS, Ikenaka Y, Miki W, Ishizuka M. Astaxanthin can alter CYP1A-dependent activities via two different mechanisms: induction of protein expression and inhibition of NADPH P450 reductase dependent electron transfer. Food Chem Toxicol 2011; 49:1285-91.

O’Shaughnessy PJ, Monteiro A, Bhattacharya S, Fowler PA. Maternal smoking and fetal sex significantly affect metabolic enzyme expression in the human fetal liver. J Clin Endocrinol Metab 2011; 96:2851-60.

Ovesen JL, Schnekenburger M, Puga A. Aryl hydrocarbon receptor ligands of widely different toxic equivalency factors induce similar histone marks in target gene chromatin. Toxicol Sci 2011; 121:123-31.

Ovsepian VA, Vinogradova EIu, Sherstneva ES. Cytochrome P4501A1, glutathione S-transferase M1 and T1 gene polymorphisms in chronic myeloid leukemia. Genetika 2010; 46:1360-2.

Ozeki J, Uno S, Ogura M et al. Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated mice. Toxicology 2011; 280:10-7.

Oztürk T, Kahraman OT, Toptas B et al. The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population. In Vivo 2011; 25:663-8.

Paolini M, Cantelli-Forti G, Perocco P, Pedulli GF, Abdel-Rahman SZ, Legator MS. Co-carcinogenic effect of beta-carotene. Nature 1999; 398:760-1.

Perepechaeva M, Kolosova N, Grishanova A. Molecular mechanisms of cold-induced CYP1A activation in rat liver microsomes. J Physiol Biochem 2011. doi:10. 1007/s13105-011-0095-1.

Perera FP. Environment and cancer: who are susceptible? Science 1997; 278:1068-73.

Petersen DD, McKinney CE, Ikeya K. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 1991; 48:720-5.

Procházková J, Kozubík A, Machala M, Vondráček J. Differential effects of indirubin and 2,3,7,8-tetrachlorodibenzo-p-dioxin on the aryl hydrocarbon receptor (AhR) signalling in liver progenitor cells. Toxicology 2011; 279:146-54.

Prud’homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010. doi:10. 1371/journal. pone. 0013831.

Punvittayagul C, Wongpoomchai R, Taya S, Pompimon W. Effect of pinocembrin isolated from Boesenbergia pandurata on xenobiotic-metabolizing enzymes in rat liver. Drug Metab Lett 2011; 5:1-5.

Putra AC, Tanimoto K, Arifin M, Antariksa B, Hiyama K. Genetic variations in detoxification enzymes and HIF-1α in Japanese patients with COPD. Clin Respir J 2011. doi:10. 1111/j. 1752-699X. 2011. 00255. x.

Qiao H, Tong Y, Han H et al. A novel therapeutic regimen for hepatic fibrosis using the combination of mesenchymal stem cells and baicalin. Pharmazie 2011; 66:37-43.

Qu W, Cheng L, Dill AL et al. Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1. Chem Biol Interact 2011; 193:88-96.

Ribonnet L, Callebaut A, Nobels I et al. Modulation of CYP1A1 activity by a Ginkgo biloba extract in the human intestinal Caco-2 cells. Toxicol Lett 2011; 202:193-202.

Rihs HP, Spickenheuer A, Heinze E et al. Modulation of urinary polycyclic aromatic hydrocarbon metabolites by enzyme polymorphisms in workers of the German Human Bitumen Study. Arch Toxicol 2011; 85 Suppl 1:73-9.

Robbins MG, Andersen G, Somoza V, Eshelman BD, Barnes DM, Hanlon PR. Heat treatment of Brussels sprouts retains their ability to induce detoxification enzyme expression in vitro and in vivo. J Food Sci 2011; 76:454-61.

Rodrigues IS, Kuasne H, Losi-Guembarovski R et al. Evaluation of the influence of polymorphic variants CYP1A1*2B, CYP1B1*2, CYP3A4*1B, GSTM1*0, and GSTT1*0 in prostate cancer. Urol Oncol 2010. doi:10. 1016/j. urolonc. 2010. 01. 009.

Rögelsperger O, Wlcek K, Ekmekcioglu C et al. Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. J Recept Signal Transduct Res 2011; 31:180-7.

Roos R, Andersson PL, Halldin K et al. Hepatic effects of a highly purified 2,2’,3,4,4’,5,5’-heptachlorbiphenyl (PCB 180) in male and female rats. Toxicology 2011; 284:42-53.

Rudolph A, Sainz J, Hein R et al. Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. Endocr Relat Cancer 2011; 18:371-84.

Sacks PG, Zhao ZL, Kosinska W, Fleisher KE, Gordon T, Guttenplan JB. Concentration dependent effects of tobacco particulates from different types of cigarettes on expression of drug metabolizing proteins, and benzo(a)pyrene metabolism in primary normal human oral epithelial cells. Food Chem Toxicol 2011; 49:2348-55.

Sainz J, Rudolph A, Hein R et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 2011; 18:265-76.

Samuelsson K, Bergström MA, Jonsson CA, Westman G, Karlberg AT. Diphenylthiourea, a common rubber chemical, is bioactivated to potent skin sensitizers. Chem Res Toxicol 2011; 24:35-44.

Santovito A, Burgarello C, Cervella P, Delpero M. Polymorphisms of cytochrome P450 1A1, glutathione s-transferases M1 and T1 genes in Ouangolodougou (Northern Ivory Coast). Genet Mol Biol 2010; 33:434-7.

Scott JA, Incardona JP, Pelkki K, Shepardson S, Hodson PV. AhR2-mediated, CYP1A-independent cardiovascular toxicity in zebrafish (Danio rerio) embryos exposed to retene. Aquat Toxicol 2011; 101:165-74.

Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF. Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis. Int J Gynecol Cancer 2011; 21:323-31.

Sharma R, Ahuja M, Panda NK, Khullar M. Interactions among genetic variants in tobacco metabolizing genes and smoking are associated with head and neck cancer susceptibility in North Indians. DNA Cell Biol 2011; 30:611-6.

Shatalova EG, Klein-Szanto AJ, Devarajan K, Cukierman E, Clapper ML. Estrogen and cytochrome P450 1B1 contribute to both early- and late-stage head and neck carcinogenesis. Cancer Prev Res 2011; 4:107-15.

Shibahara N, Masunaga Y, Iwano S, Yamazaki H, Kiyotani K, Kamataki T. Human cytochrome P450 1A1 is a novel target gene of liver X receptor α. Drug Metab Pharmacokinet 2011. doi:10. 2133/dmpk. DMPK-11-RG-030.

Shimamoto K, Dewa Y, Ishii Y et al. Indole-3-carbinol enhances oxidative stress responses resulting in the induction of preneoplastic liver cell lesions in partially hepatectomized rats initiated with diethylnitrosamine. Toxicology 2011; 283:109-17.

Shimamoto K, Dewa Y, Kemmochi S et al. Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats. Arch Toxicol 2011; 85:1159-66.

Sommer A, Blanton SH, Weymouth K et al. Smoking, the xenobiotic pathway, and clubfoot. Birth Defects Res A Clin Mol Teratol 2011; 91:20-8.

Sreelekha TT, Rajesh M, Anil Kumar V, Madhavan J, Balaram P. CYP1A1m2 polymorphisms regulate estrogen and interleukin-6 in lung cancer. Mol Med Report 2010; 3:971-6.

Srivastava K, Srivastava A, Sharma KL, Mittal B. Candidate gene studies in gallbladder cancer: A systematic review and meta-analysis. Mutat Res 2011; 728:67-79.

Stejskalova L, Pavek P. The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr Pharm Biotechnol 2011; 12:715-30.

Stejskalova L, Vecerova L, Peréz LM et al. Aryl hydrocarbon receptor (AHR) and aryl hydrocarbon nuclear translocator (ARNT) expression in human and rat placentas and transcription activity in human trophoblast cultures. Toxicol Sci 2011; 123:26-36.

Straser A, Filipič M, Zegura B. Genotoxic effects of the cyanobacterial hepatotoxin cylindrospermopsin in the HepG2 cell line. Arch Toxicol 2011. doi:10. 1007/s00204-011-0716-z.

Sulem P, Gudbjartsson DF, Geller F et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet 2011; 20:2071-7.

Suneetha KJ, Nancy KN, Rajalekshmy KR, Rama R, Sagar TG, Rajkumar T. Role of glutathione-s-transferase and CYP1A1*2A polymorphisms in the therapy outcome of south Indian acute lymphoblastic leukemia patients. Indian J Med Paediatr Oncol 2011; 32:25-29.

Swinney RM, Beuten J, Collier A 3rd et al. Polymorphisms in CYP1A1 and ethnic-specific susceptibility to acute lymphoblastic leukemia in children. Cancer Epidemiol Biomarkers Prev 2011; 20:1537-42.

Szele E, Gombos K, Kovács A, Ember I. Effects of purified glycerol from biodiesel on Cyp1a1 and Cyp2e1 expressions in CBA/CA mice. In Vivo 2011; 25:237-40.

Takamura T, Harama D, Fukumoto S et al. Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis. Immunol Cell Biol 2011; 89:817-22.

Tatematsu K, Koide A, Hirose M, Nishikawa A, Mori Y. Effect of cigarette smoke on mutagenic activation of environmental carcinogens by cytochrome P450 2A8 and inactivation by glucuronidation in hamster liver. Mutagenesis 2011; 26:323-30.

Topic Popovic N, Howell T, Babish JG, Bowser PR. Cross-sectional study of hepatic CYP1A and CYP3A enzymes in hybrid striped bass, channel catfish and Nile tilapia following oxytetracycline treatment. Res Vet Sci 2011. doi:10. 1016/j. rvsc. 2011. 03. 003.

Totlandsdal AI, Cassee FR, Schwarze P, Refsnes M, Låg M. Diesel exhaust particles induce CYP1A1 and pro-inflammatory responses via differential pathways in human bronchial epithelial cells. Part Fibre Toxicol 2010; 7:41.

Trilecová L, Krcková S, Marvanová S et al. Toxic effects of methylated benzo[a]pyrenes in rat liver stem-like cells. Chem Res Toxicol 2011; 24:866-876.

Tröbs L, Henkelmann B, Lenoir D, Reischl A, Schramm KW. Degradative fate of 3-chlorocarbazole and 3,6-dichlorocarbazole in soil. Environ Sci Pollut Res Int 2011; 18:547-55.

Trusov NV, Guseva GV, Aksenov IV, Avren’eva LI, Kravchenko LV, Tutelyan VA. Effects of combined treatment with resveratrol and indole-3-carbinol. Bull Exp Biol Med 2010; 149:213-8.

Tsatsakis AM, Androutsopoulos VP, Zafiropoulos A et al. Associations of xenobiotic-metabolizing enzyme genotypes PON1Q192R, PON1L55M and CYP1A1*2A MspI with pathological symptoms of a rural population in south Greece. Xenobiotica 2011; 41:914-25.

Tsuji G, Takahara M, Uchi H et al. An environmental contaminant, benzo(a)pyrene, induces oxidative stress-mediated interleukin-8 production in human keratinocytes via the aryl hydrocarbon receptor signaling pathway. J Dermatol Sci 2011; 62:42-9.

Tuerxun M, Hamulati W, Bai L, Peng XM, Dolikun M. Study of cytochrome P450 1A1 gene 3’-UTR 6235T-C polymorphism and susceptibility to breast cancer with Uighur medicine. Zhonghua Yi Xue Za Zhi 2011; 91:86-91.

Ukpebor J, Llabjani V, Martin FL, Halsall CJ. Sublethal genotoxicity and cell alterations by organophosphorus pesticides in MCF-7 cells: implications for environmentally relevant concentrations. Environ Toxicol Chem 2011; 30:632-9.

Um JY, Jang CH, Kim SJ et al. Steroid combination therapy and detoxification enzyme gene polymorphisms in sudden sensorineural hearing loss patients. Otol Neurotol 2011; 32:872-6.

Uno S, Endo K, Ishida Y et al. CYP1A1 and CYP1A2 expression: comparing ‘humanized’ mouse lines and wild-type mice; comparing human and mouse hepatoma-derived cell lines. Toxicol Appl Pharmacol 2009; 237:119-26.

Uno Y, Uehara S, Murayama N, Yamazaki H. CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey. Biochem Pharmacol 2011; 81:442-50.

Uppstad H, Osnes GH, Cole KJ, Phillips DH, Haugen A, Mollerup S. Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. Lung Cancer 2011; 71:264-70.

Vanalstine MA, Hough LB. Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome p450s. Drug Metab Dispos 2011; 39:1221-6.

Villard PH, Barlesi F, Armand M et al. CYP1A1 induction in the colon by serum: involvement of the PPARα pathway and evidence for a new specific human PPREα site. PLoS One 2011. doi:10. 1371/journal. pone. 0014629.

Volkova M, Palmeri M, Russell KS, Russell RR. Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart. Cardiovasc Res 2011; 90:305-14.

Vrba J, Vrublova E, Modriansky M, Ulrichova J. Protopine and allocryptopine increase mRNA levels of cytochromes P450 1A in human hepatocytes and HepG2 cells independently of AhR. Toxicol Lett 2011; 203:135-41.

Wang H, Yamamoto JF, Caberto C et al. Genetic variation in the bioactivation pathway for polycyclic hydrocarbons and heterocyclic amines in relation to risk of colorectal neoplasia. Carcinogenesis 2011; 32:203-9.

Wang Q, Li H, Tao P et al. Soy isoflavones, CYP1A1, CYP1B1, and COMT polymorphisms, and breast cancer: a case-control study in Southwestern China. DNA Cell Biol DNA Cell Biol 2011; 30:585-95.

Wang X, Hawkins BT, Miller DS. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 2011; 25:644-52.

Wang X, Zuckerman B, Pearson C. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA 2002; 287:195-202.

Wang Y, Lu C, Sheng Z et al. Enhanced hepatotoxicity induced by repeated exposure to polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-dioxin in combination in male rats. J Environ Sci 2011; 23:119-24.

Wei M, Wanibuchi H, Nakae D et al. Low-dose carcinogenicity of 2-amino-3-methylimidazo[4,5-f ]quinoline in rats: Evidence for the existence of no-effect levels and a mechanism involving p21(Cip / WAF1). Cancer Sci 2011; 102:88-94.

Wickliffe JK, Abdel-Rahman SZ, Lee C et al. CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med 2011; 17:241-7.

Williams-Brown MY, Salih SM, Xu X et al. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol 2011; 126:78-86.

Xiao W, Zhang J, Liang J, Zhu H, Zhou Z, Wu Q. Adverse effects of neonatal exposure to 3,3’,4,4’,5,5’-hexachlorobiphenyl on hormone levels and testicular function in male Sprague-Dawley rats. Environ Toxicol 2011. doi:10. 1002/tox. 20677.

Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996; 5:687-92.

Yadav C, Bajpai M, Kumar V, Ahmed RS, Gupta P, Banerjee BD. Polymorphism in CYP1A1, GSTM 1, GSTT1 genes and organochlorine pesticides in the etiology of hypospadias. Hum Exp Toxicol 2011; 30:1464-74.

Yamazaki K, Suzuki M, Itoh T et al. Structural basis of species differences between human and experimental animal CYP1A1s in metabolism of 3,3’,4,4’,5-pentachlorobiphenyl. J Biochem 2011; 149:487-94.

Yang X, Pfeiffer RM, Goldstein AM. Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the naevoid basal cell carcinoma syndrome. J Med Genet 2006; 43:16.

Yao HT, Lin JH, Chiang MT, Chiang W, Luo MN, Lii CK. Suppressive effect of the ethanolic extract of adlay bran on cytochrome P-450 enzymes in rat liver and lungs. J Agric Food Chem 2011; 59:4306-14.

Yu H, Tu Y, Zhang C et al. Evodiamine as a novel antagonist of aryl hydrocarbon receptor. Biochem Biophys Res Commun 2010; 402:94-8.

Yun JH, Lee SB, Lee HJ et al. Bi-functional induction of the quinone reductase and cytochrome P450 1A1 by youngiasides via Nrf2-ARE and AhR-XRE pathways. Biol Pharm Bull 2010; 33:1650-7.

Zamaratskaia G, Zlabek V. Para-nitrophenol hydroxylation by fish liver microsomes: kinetics and effect of selective cytochrome P450 inhibitors. Fish Physiol Biochem 2011. doi:10. 1007/s10695-011-9494-z.

Zhang R, Sun J, Ma L et al. Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicol Appl Pharmacol 2011; 252:18-27.

Zheng Y, Wang JJ, Sun L, Li HL. Association between CYP1A1 polymorphism and colorectal cancer risk: a meta-analysis. Mol Biol Rep 2011. doi:10. 1007/s11033-011-1126-2.

Zhou J, Wang Y, Chen Z, Gao Y. Modulation of activities and mRNA expression of cytochrome P450 isoenzymes in rat liver by Sophora flaveacens and coadministration with Veratrum nigrum. Zhongguo Zhong Yao Za Zhi 2010; 35:1845-9.

Zhu XX, Hu CP, Gu QH. CYP1A1 polymorphisms, lack of glutathione S-transferase M1 (GSTM1), cooking oil fumes and lung cancer risk in non-smoking women. Zhonghua Jie He He Hu Xi Za Zhi 2010; 33:817-22.

CYP1A2 (cytochrome P450, family 1, subfamily A, polypeptide 2)

Abdull Razis AF, Bagatta M, de Nicola GR, Iori R, Ioannides C. Intact glucosinolates modulate hepatic cytochrome P450 and phase II conjugation activities and may contribute directly to the chemopreventive activity of cruciferous vegetables. Toxicology 2010; 277:74-85.

Abdull Razis AF, Iori R, Ioannides C. The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Int J Cancer 2011; 128:2775-82.

Achour B, Barber J, Rostami-Hodjegan A. Cytochrome P450 Pig Liver Pie: Determination of individual cytochrome P450 isoenzyme contents in microsomes from two pig livers using LC MS. Drug Metab Dispos 2011; 39:2130-4.

Aldrich MC, Selvin S, Hansen HM et al. CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res 2009; 69:2340-8.

Ancrenaz V, Daali Y, Fontana P et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010; 11:667-77.

Antolino-Lobo I, Meulenbelt J, Nijmeijer SM, Scherpenisse P, van den Berg M, van Duursen MB. Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metab Dispos 2010; 38:1105-12.

Apte U, Singh S, Zeng G et al. Beta-catenin activation promotes liver regeneration after acetaminophen-induced injury. Am J Pathol 2009; 175:1056-65.

Arnaud MJ. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol 2011:33-91.

Avti PK, Vaiphei K, Pathak CM, Khanduja KL. Involvement of various molecular events in cellular injury induced by smokeless tobacco. Chem Res Toxicol 2010; 23:1163-74.

Ayed-Boussema I, Pascussi JM, Maurel P, Bacha H, Hassen W. Zearalenone activates pregnane X receptor, constitutive androstane receptor and aryl hydrocarbon receptor and corresponding phase I target genes mRNA in primary cultures of human hepatocytes. Environ Toxicol Pharmacol 2011; 31:79-87.

Ayed-Boussema I, Pascussi JM, Zaied C, Maurel P, Bacha H, Hassen W. Ochratoxin A induces CYP3A4, 2B6, 3A5, 2C9, 1A1, and CYP1A2 gene expression in primary cultured human hepatocytes: a possible activation of nuclear receptors. Drug Chem Toxicol 2011. doi:10. 3109/01480545. 2011. 589438.

Babbar S, Chanda S, Bley K. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 2010; 40:807-16.

Bachleda P, Vrzal R, Pivnicka J, Cvek B, Dvorak Z. Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes. Toxicol Lett 2009; 191:74-8.

Badal S, Williams SA, Huang G et al. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri. Fitoterapia 2011; 82:230-6.

Barker ML, Hathaway LB, Arch DD et al. Hyper- and hypo-induction of cytochrome P450 activities with Aroclor 1254 and 3-methylcholanthrene in Cyp1a2(-/-) mice. Chem Biol Interact 2009; 182:220-6.

Bass SE, Sienkiewicz P, Macdonald CJ et al. Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res 2009; 15:1964-72.

B’chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci 2009; 84:779-84.

Becker C, Bray-French K, Drewe J. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol 2010; 6:1437-44.

Beedanagari SR, Bebenek I, Bui P, Hankinson O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci 2009; 110:61-7.

Bellocq D, Molina J, Rathahao-Paris E, Taché S, Pierre F, Paris A. Metabolic bioactivation of oestradiol-17beta (E2beta) in mouse colon epithelial cells bearing ApcMin mutation. Steroids 2010; 75:665-75.

Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol 2009; 65:959-62.

Bohanec Grabar P, Grabnar I, Rozman B et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009; 37:2061-8.

Böhmer G, Gleiter CH, Hünnemeyer A, Lahu G, Bethke TD. Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. Int J Clin Pharmacol Ther 2011; 49:451-60.

Böhmer GM, Gleiter CH, Mörike K, Nassr N, Walz A, Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol 2011; 51:594-602.

Boutros PC, Yao CQ, Watson JD et al. Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol Appl Pharmacol 2011; 251:119-29.

Braam W, van Geijlswijk I, Keijzer H, Smits MG, Didden R, Curfs LM. Loss of response to melatonin treatment is associated with slow melatonin metabolism. J Intellect Disabil Res 2010; 54:547-55.

Breuer MA, Schmidt B, Schuphan I. Utility of Nicotiana tabacum cell suspension cultures expressing human CYP1A1, CYP1A2 and CYP3A4 to study the oxidative metabolism of the herbicide 14C-fluometuron. Drug Metab Lett 2009; 3:18-27.

Brignac-Huber L, Reed JR, Backes WL. Organization of NADPH-cytochrome P450 reductase and CYP1A2 in the endoplasmic reticulum-microdomain localization affects monooxygenase function. Mol Pharmacol 2011; 79:549-57.

Brouwers EE, Söhne M, Kuipers S et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 2009; 29:59-63.

Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics 2010; 20:647-64.

Budinsky RA, LeCluyse EL, Ferguson SS, Rowlands JC, Simon T. Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran. Toxicol Sci 2010; 118:224-35.

Bui PH, Hsu EL, Hankinson O. Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene-7,8-dihydrodiol. Mol Pharmacol 2009; 76:1044-52.

Buters JTM, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics 1996; 6:291-6.

Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450(PA) (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Nat Acad Sci USA 1989; 86:7696-700.

Cabaret O, Puel O, Botterel F et al. Metabolic detoxication pathways for sterigmatocystin in primary tracheal epithelial cells. Chem Res Toxicol 2010; 23:1673-81.

Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci 2011; 65:3-19.

Campo G, Miccoli M, Tebaldi M et al. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 2011; 22:399-407.

Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23:523-41.

Carvalho RS, Friedrich K, de-Oliveira AC, Suarez-Kurtz G, Paumgartten FJ. Malaria downmodulates mRNA expression and catalytic activities of CYP1A2, 2E1 and 3A11 in mouse liver. Eur J Pharmacol 2009; 616:265-9.

Cash HL, Tao L, Yuan JM et al. LINE-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese. Int J Cancer 2011. doi:10. 1002/ijc. 26098.

Chang SY, Chen C, Yang Z, Rodrigues AD. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos 2009; 37:1667-75.

Chang TK, Chen J, Yang G, Yeung EY. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. J Pineal Res 2010; 48:55-64.

Chen C, Han YH, Yang Z, Rodrigues AD. Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes. Xenobiotica 2011; 41:476-85.

Chen X, Sun CK, Han GZ et al. Protective effect of tea polyphenols against paracetamol-induced hepatotoxicity in mice is significantly correlated with cytochrome P450 suppression. World J Gastroenterol 2009; 15:1829-35.

Chen Y, Kang Z, Yan J et al. Liu wei di huang wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man. J Ethnopharmacol 2010; 132:213-8.

Chen Y, Liu WH, Chen BL et al. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann Pharmacother 2010; 44:1038-45.

Chen Y, Tu JH, He YJ et al. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers. Xenobiotica 2009; 39:508-13.

Chen Y, Xiao CQ, He YJ et al. Genistein alters caffeine exposure in healthy female volunteers. Eur J Clin Pharmacol 2011; 67:347-53.

Chen Y, Xiao P, Ou-Yang DS et al. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin Exp Pharmacol Physiol 2009; 36:828-33.

Chetty M, d’Esposito F, Zhang WV et al. In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation. Br J Clin Pharmacol 2009; 68:574-9.

Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008; 327:288-99.

Chien CF, Wu YT, Lee WC, Lin LC, Tsai TH. Herb-drug interaction of Andrographis paniculata extract and andrographolide on the pharmacokinetics of theophylline in rats. Chem Biol Interact 2010; 184:458-65.

Chiney MS, Schwarzenberg SJ, Johnson LA. Altered xanthine oxidase and N-acetyltransferase activity in obese children. Br J Clin Pharmacol 2011; 72:109-15.

Choi H, Shin DW, Kim W, Doh SJ, Lee SH, Noh M. Asian dust storm particles induce a broad toxicological transcriptional program in human epidermal keratinocytes. Toxicol Lett 2011; 200:92-9.

Choi SY, Fischer L, Yang K, Chung H, Jeong H. Isoform-specific regulation of cytochrome P450 expression and activity by estradiol in female rats. Biochem Pharmacol 2011; 81:777-82.

Choi YH, Lee YS, Lee MG, Kim TK, Lee BY. Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541. J Pharm Pharm Sci 2010; 13:93-106.

Chow HH, Garland LL, Hsu CH et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 2010; 3:1168-75.

Chu CC, Pan KL, Yao HT, Hsu JT. Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism. Biotechnol Bioeng 2011; 108:2932-40.

Chun YJ, Oh YK, Kim BJ et al. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Toxicol Lett 2009; 189:84-9.

Chung HJ, Kang HE, Yang KH, Kim SY, Lee MG. Ipriflavone pharmacokinetics in mutant Nagase analbuminemic rats. Biopharm Drug Dispos 2009; 30:294-304.

Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol 2010; 172:1000-14.

Cornelis MC, Bae SC, Kim I, El-Sohemy A. CYP1A2 genotype and rheumatoid arthritis in Koreans. Rheumatol Int 2010; 30:1349-54.

Couroucli XI, Liang YH, Jiang W et al. Prenatal administration of the cytochrome P4501A inducer, Β-naphthoflavone (BNF), attenuates hyperoxic lung injury in newborn mice: Implications for bronchopulmonary dysplasia (BPD) in premature infants. Toxicol Appl Pharmacol 2011; 256:83-94.

Curran CP, Nebert DW, Genter MB et al. In utero and lactational exposure to PCBs in mice: adult offspring show altered learning and memory depending on Cyp1a2 and Ahr genotypes. Environ Health Perspect 2011; 119:1286-93.

Darwish WS, Ikenaka Y, Eldaly EA et al. Cytochrome P450 1A-dependent activities in deer, cattle and horses. J Vet Med Sci 2010; 72:561-6.

Darwish WS, Kawai Y, Ikenaka Y, Yamamoto H, Muroya T, Ishizuka M. Identification and phylogenetic analysis of novel cytochrome P450 1A genes from ungulate species. J Vet Med Sci 2010; 72:1237-41.

Derks M, Fowler S, Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009; 25:891-902.

Deroussent A, Ré M, Hoellinger H, Cresteil T. Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2010; 52:391-7.

Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. Brit J Clin Pharm 1983; 16:157-66.

Diaz GJ, Murcia HW, Cepeda SM. Bioactivation of aflatoxin B1 by turkey liver microsomes: responsible cytochrome P450 enzymes. Br Poult Sci 2010; 51:828-37.

Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 2011; 39:1415-22.

Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90:117-25.

Doki K, Homma M, Kuga K, Aonuma K, Kohda Y. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 2009; 68:89-96.

Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008; 42:1822-31.

Dong PP, Fang ZZ, Zhang YY et al. Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin 2011; 32:399-407.

Dorn C, Bataille F, Gaebele E, Heilmann J, Hellerbrand C. Xanthohumol feeding does not impair organ function and homoeostasis in mice. Food Chem Toxicol 2010; 48:1890-7.

Dumond JB, Vourvahis M, Rezk NL et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87:735-42.

Dumont J, Jossé R, Lambert C et al. Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines. Toxicol Appl Pharmacol 2010; 249:91-100.

Eisele S, Garbe E, Zeitz M, Schneider T, Somasundaram R. Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature. Int J Clin Pharmacol Ther 2009; 47:165-8.

El Gendy MA, El-Kadi AO. Peganum harmala L. differentially modulates cytochrome P450 gene expression in human hepatoma HepG2 cells. Drug Metab Lett 2009; 3:212-6.

Elsherbiny ME, El-Kadi AO, Brocks DR. The effect of beta-naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. Toxicol Lett 2010; 195:147-54.

Eruvaram NR, Das M. Phenotype of hepatic xenobiotic metabolizing enzymes and CYP450 isoforms of sanguinarine treated rats: effect of P450 inducers on its toxicity. Toxicol Mech Methods 2009; 19:510-7.

Faeste CK, Ivanova L, Uhlig S. In vitro metabolism of the mycotoxin enniatin B in different species and CYP P450 reaction phenotyping. Drug Metab Dispos 2011; 39:1768-76.

Fasullo M, Chen Y, Bortcosh W, Sun M, Egner PA. Aflatoxin B(1)-associated DNA adducts stall S phase and stimulate Rad51 foci in Saccharomyces cerevisiae. J Nucleic Acids 2010. doi:10. 4061/2010/456487.

Feidt DM, Klein K, Nüssler A, Zanger UM. RNA-interference approach to study functions of NADPH: cytochrome P450 oxidoreductase in human hepatocytes. Chem Biodivers 2009; 6:2084-91.

Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC, Foresta C. Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr Relat Cancer 2010; 17:17-25.

Filppula AM, Laitila J, Neuvonen PJ, Backman JT. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos 2011; 39:904-11.

Firdous AP, Sindhu ER, Ramnath V, Kuttan R. Anti-mutagenic and anti-carcinogenic potential of the carotenoid meso-zeaxanthin. Asian Pac J Cancer Prev 2010; 11:1795-800.

Fisher CD, Lickteig AJ, Augustine LM et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009; 37:2087-94.

Flint MS, Hood BL, Sun M, Stewart NA, Jones-Laughner J, Conrads TP. Proteomic analysis of the murine liver in response to a combined exposure to psychological stress and 7,12-dimethylbenz(a)anthracene. J Proteome Res 2010; 9:509-20.

Fonsart J, Menet MC, Debray M et al. Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA). Toxicol Appl Pharmacol 2009; 241:339-47.

Fraga AG, da Silva LL, Fraga CA, Barreiro EJ. CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. Eur J Med Chem 2011; 46:349-55.

Frederick KS, Maurer TS, Kalgutkar AS et al. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human. Xenobiotica 2009; 39:766-81.

Frémin C, Ezan F, Guegan JP et al. The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses. J Cell Physiol 2011. doi:10. 1002/jcp. 22742.

Gallemann D, Wimmer E, Höfer CC et al. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos 2010; 38:905-16.

Gan J, Liu-Kreyche P, Humphreys WG. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1672-2.

Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol 2009; 241:14-22.

Gasnier C, Benachour N, Clair E et al. Dig1 protects against cell death provoked by glyphosate-based herbicides in human liver cell lines. J Occup Med Toxicol 2010; 5:29.

Gasnier C, Laurant C, Decroix-Laporte C et al. Defined plant extracts can protect human cells against combined xenobiotic effects. J Occup Med Toxicol 2011; 6:3.

Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010; 11:431-5.

Genualdo V, Spalenza V, Perucatti A et al. Fluorescence in situ hybridization mapping of six loci containing genes involved in the dioxin metabolism of domestic bovids. J Appl Genet 2011; 52:229-32.

Getachew Y, James L, Lee WM, Thiele DL, Miller BC. Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. Biochem Pharmacol 2010; 79:1363-71.

Ghosal A, Gupta S, Ramanathan R et al. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett 2009; 3:162-70.

Ghose R, Omoluabi O, Gandhi A et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 2011; 89:57-64.

Ghotbi R, Gomez A, Milani L et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 2009; 9:208-17.

Girolami F, Spalenza V, Carletti M et al. Gene expression and inducibility of the aryl hydrocarbon receptor-dependent pathway in cultured bovine blood lymphocytes. Toxicol Lett 2011; 206:204-9.

Goh BC, Reddy NJ, Dandamudi UB et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 2010; 88:652-9.

Gomez CF, Constantine L, Moen M, Vaz A, Wang W, Huggett DB. Ibuprofen metabolism in the liver and gill of rainbow trout, Oncorhynchus mykiss. Bull Environ Contam Toxicol 2011; 86:247-51.

Gotardo MA, Hyssa JT, Carvalho RS et al. Modulation of expression and activity of cytochrome P450s and alteration of praziquantel kinetics during murine schistosomiasis. Mem Inst Oswaldo Cruz 2011; 106:212-9.

Gross-Steinmeyer K, Stapleton PL, Tracy JH et al. Modulation of aflatoxin B1-mediated genotoxicity in primary cultures of human hepatocytes by diindolylmethane, curcumin, and xanthohumols. Toxicol Sci 2009; 112:303-10.

Gross-Steinmeyer K, Stapleton PL, Tracy JH, Bammler TK, Strom SC, Eaton DL. Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression. Toxicol Sci 2010; 116:422-32.

Gu D, McNaughton L, Lemaster D et al. A comprehensive approach to the profiling of the cooked meat carcinogens 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, and their metabolites in human urine. Chem Res Toxicol 2010; 23:788-801.

Guengerich FP, Distlerath LM, Reilly PEB et al. Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. Xenobiotica 1986; 16:367-78.

Gunes A, Ozbey G, Vural EH et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009; 10:769-78.

Guo H, Zou X, Xu H, Liu K. Effects of salvianolic A on rat liver microsomal cytochrome P450 system. Zhongguo Zhong Yao Za Zhi 2010; 35:348-51.

Guo Y, Li F, Ma XC, Cheng XG, Zhou HH, Klaassen CD. CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica 2011; 41:996-1005.

Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol 2011; 67:591-9.

Hakk H, Diliberto JJ, Birnbaum LS. The effect of dose on 2,3,7,8-TCDD tissue distribution, metabolism and elimination in CYP1A2 (-/-) knockout and C57BL/6N parental strains of mice. Toxicol Appl Pharmacol 2009; 241:119-26.

Hakooz NM. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab 2009; 10:329-38.

Hallström H, Melhus H, Glynn A, Lind L, Syvänen AC, Michaëlsson K. Coffee consumption and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study. Nutr Metab 2010; 7:12.

Han YL, Yu HL, Li D et al. In vitro inhibition of Huanglian [Rhizoma coptidis (L. )] and its six active alkaloids on six cytochrome P450 isoforms in human liver microsomes. Phytother Res 2011; 25:1660-5.

Hanlon N, Konsue N, Coldham N, Sauer MJ, Ioannides C. Exposure to isothiocyanates suppresses urinary mutagenicity in rats treated with heterocyclic amine IQ: lack of association with CYP1 activity. Nutr Cancer 2011; 63:300-5.

Haslemo T, Refsum H, Molden E. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol 2011; 71:611-5.

Hawas UW, Gamal-Eldeen AM, El-Toumy SA, Meyer JJ, Hussein AA. Inhibition of the initiation stage of carcinogenesis by Salvia disermas constituents. Z Naturforsch C 2009; 64:831-9.

He L, He F, Bi H et al. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations. Bioorg Med Chem Lett 2010; 20:6008-12.

He X, Luo X, Liu Z, Hu G, Cheng Z. Identification of the human liver cytochrome P450 isoenzymes responsible for the 5-methylhydroxylation of the novel anti-fibrotic drug AKF-PD. Xenobiotica 2011; 41:844-50.

Herraiz T, Guillén H, Arán VJ. Oxidative metabolism of the bioactive and naturally occurring beta-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes. Chem Res Toxicol 2008; 21:2172-80.

Hevir N, Sinkovec J, Rižner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol 2011; 331:158-67.

Hildebrand A, Pfeiffer E, Metzler M. Aromatic hydroxylation and catechol formation: a novel metabolic pathway of the growth promotor zeranol. Toxicol Lett 2010; 192:379-86.

Hirakawa S, Imaeda D, Nakayama K et al. Integrative assessment of potential effects of dioxins and related compounds in wild Baikal seals (Pusa sibirica): Application of microarray and biochemical analyses. Aquat Toxicol 2011; 105:89-99.

Hong H, Su H, Ma L et al. In vitro characterization of the metabolic pathways and P450 inhibition and induction potential of BMS-690514, an ErbB/VEGFR inhibitor. Drug Metab Dispos 2011; 39:1658-67.

Horn J, Milewska M, Arnold SM, Leggas M. Metabolic pathways of the camptothecin analog AR-67. Drug Metab Dispos 2011; 39:683-92.

Hosaka T, Sekimoto M, Nemoto K, Degawa M. Augmentation of 3-methylcholanthrene-induced bioactivation in the human hepatoma cell line HepG2 by the calcium channel blocker nicardipine. Cancer Sci 2010; 101:652-7.

Hrubá E, Trilecová L, Marvanová S et al. Genotoxic polycyclic aromatic hydrocarbons fail to induce the p53-dependent DNA damage response, apoptosis or cell-cycle arrest in human prostate carcinoma LNCaP cells. Toxicol Lett 2010; 197:227-35.

Hu L, Xu W, Zhang X et al. In-vitro and in-vivo evaluations of cytochrome P450 1A2 interactions with nuciferine. J Pharm Pharmacol 2010; 62:658-62.

Hu Y, Yang S, Shilliday FB et al. Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes. Drug Metab Dispos 2010; 38:1522-31.

Huang Q, Szklarz GD. Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2. Drug Metab Dispos 2010; 38:1039-45.

Hughes AN, O’Brien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27:1220-6.

Iba MM, Shin M, Caccavale RJ. Cytochromes P4501 (CYP1): catalytic activities and inducibility by diesel exhaust particle extract and benzo[a]pyrene in intact human lung ex vivo. Toxicology 2010; 273:35-44.

Ibrahim ZS, Ishizuka M, Soliman M et al. Protection by Nigella sativa against carbon tetrachloride-induced downregulation of hepatic cytochrome P450 isozymes in rats. Jpn J Vet Res 2008; 56:119-28.

Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Molec Endocr 1989; 3:1399-408.

Imaizumi T, Higaki Y, Hara M et al. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis 2009; 30:1729-34.

Ishida K, Taguchi M, Akao T, Hashimoto Y. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells. Biol Pharm Bull 2009; 32:513-6.

Iwasaki K, Uno Y. Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica 2009; 39:578-81.

Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69:1777-98.

Jackson JP, Kabirov KK, Kapetanovic IM, Lyubimov A. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes. Chem Biol Interact 2009; 179:263-72.

Jaikang C, Chaiyasut C, Narongchai P, Niwatananun K, Narongchai S, Kusirisin W. Inhibitory effects of caffeic acid ester analogues on free radicals and human liver microsome CYP1A2 activities. Med Chem 2011; 7:99-105.

Jain RB, Wang RY. Association of caffeine consumption and smoking status with the serum concentrations of polychlorinated biphenyls, dioxins, and furans in the general U. S. population: NHANES 2003-2004. J Toxicol Environ Health A 2011; 74:1225-39.

Jaiswal AK, Nebert DW, McBride OW, Gonzalez FJ. Human P(3)450: cDNA and complete protein sequence, repetitive Alu sequences in the 3-prime nontranslated region, and localization of gene to chromosome 15. J Exp Path 1987; 3:1-17.

James MO, Sacco JC, Faux LR. Effects of food natural products on the biotransformation of PCBs. Environ Toxicol Pharmacol 2008; 25:211-7.

Jenkins J, Williams D, Deng Y, Collins DA, Kitchen VS. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 2010; 66:67-76.

Ji HY, Kim SY, Kim DK, Jeong JH, Lee HS. Effects of eupatilin and jaceosidin on cytochrome p450 enzyme activities in human liver microsomes. Molecules 2010; 15:6466-75.

Jiang K, Li K, Qin F, Lu X, Li F. Assessment of a novel β2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities. Toxicol In Vitro 2011; 25:1033-8.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011; 89:165-70.

Jiang W, Wang L, Kondraganti SR et al. Disruption of the gene for CYP1A2, which is expressed primarily in liver, leads to differential regulation of hepatic and pulmonary mouse CYP1A1 expression and augmented human CYP1A1 transcriptional activation in response to 3-methylcholanthrene in vivo. J Pharmacol Exp Ther 2010; 335:369-79.

Jiang W, Wang L, Zhang W, Coffee R, Fazili IS, Moorthy B. Persistent induction of cytochrome P450 (CYP)1A enzymes by 3-methylcholanthrene in vivo in mice is mediated by sustained transcriptional activation of the corresponding promoters. Biochem Biophys Res Commun 2009; 390:1419-24.

Jones AE, Brown KC, Werner RE et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 2010; 66:475-85.

Jorge-Nebert LF, Jiang Z, Chakraborty R et al. Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat 2010; 31:27-40.

Jornil J, Jensen KG, Larsen F, Linnet K. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos 2010; 38:376-85.

Kaddar N, Vigneault P, Pilote S, Patoine D, Simard C, Drolet B. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther 2011. doi:10. 1177/1074248410395020.

Kakan X, Chen P, Zhang J. Clock gene mPer2 functions in diurnal variation of acetaminophen induced hepatotoxicity in mice. Exp Toxicol Pathol 2011; 63:581-5.

Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011; 39:98-105.

Kasai N, Ikushiro S, Hirosue S et al. Enzymatic properties of cytochrome P450 catalyzing 3’-hydroxylation of naringenin from the white-rot fungus Phanerochaete chrysosporium. Biochem Biophys Res Commun 2009; 387:103-8.

Kaushal N, Robson MJ, Vinnakota H et al. Synthesis and pharmacological evaluation of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J 2011; 13:336-46.

Kazui M, Nishiya Y, Ishizuka T et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38:92-9.

Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 2011; 36:1-16.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011; 41:851-62.

Kitamura R, Matsuoka K, Nagayama S, Otagiri M. Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68. Drug Metab Pharmacokinet 2008; 23:421-7.

Kjærstad MB, Nielsen F, Nøhr-Jensen L, Zwisler S, Brøsen K, Andersen HR. Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. Eur J Clin Pharmacol 2010; 66:1189-97.

Klemm M, Eidens M, Lorenz M et al. Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders? Clin Lab 2010; 56:473-80.

Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2011; 50:281-94.

Kobayashi M, Otani T, Iwasaki M et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of colorectal cancer: a hospital-based case-control study in Japan. Scand J Gastroenterol 2009; 44:952-9.

Kobayashi M, Otani T, Iwasaki M et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan. Gastric Cancer 2009; 12:198-205.

Kobayashi T, Homma M, Momo K, Kobayashi D, Kohda Y. A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition. Biomed Chromatogr 2011; 25:435-8.

Koga N, Ohta C, Kato Y et al. In vitro metabolism of nobiletin, a polymethoxy-flavonoid, by human liver microsomes and cytochrome P450. Xenobiotica 2011; 41:927-33.

Koh KH, Xie H, Yu AM, Jeong H. Altered cytochrome P450 expression in mice during pregnancy. Drug Metab Dispos 2011; 39:165-9.

Konsue N, Ioannides C. Modulation of carcinogen-metabolising cytochromes P450 in human liver by the chemopreventive phytochemical phenethyl isothiocyanate, a constituent of cruciferous vegetables. Toxicology 2010; 268:184-90.

Kot M, Daniel WA. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacol Rep 2009; 61:1216-20.

Kotsovolou O, Ingelman-Sundberg M, Lang MA et al. Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1075-84.

Koutros S, Berndt SI, Sinha R et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res 2009; 69:1877-84.

Kravchenko LV, Trusov NV, Aksenov IV et al. Effects of green tea extract and its components on antioxidant status and activities of xenobiotic metabolizing enzymes of rats. Vopr Pitan 2011; 80:9-15.

Kumar V, Schuck EL, Pelletier RD et al. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1687-8.

Kuribayashi S, Goto K, Naito S, Kamataki T, Yamazaki H. Human cytochrome P450 1A2 involvement in the formation of reactive metabolites from a species-specific hepatotoxic pyrazolopyrimidine derivative, 5-n-butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine. Chem Res Toxicol 2009; 22:323-31.

Lahousse SA, Hoenerhoff M, Collins J et al. Gene expression and mutation assessment provide clues of genetic and epigenetic mechanisms in liver tumors of oxazepam-exposed mice. Vet Pathol 2011; 48:875-84.

Lahu G, Nassr N, Herzog R et al. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol 2011; 51:586-93.

Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010; 10:20-9.

Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 2009; 39:11-21.

Lakshmi VM, Hsu FF, Zenser TV. Identification of new 2-amino-3-methylimidazo[4,5-f]quinoline urinary metabolites from beta-naphthoflavone-treated mice. Drug Metab Dispos 2009; 37:1690-7.

Lane S, Al-Zubiedi S, Hatch E et al. The population pharmacokinetics of R and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2011. doi:10. 1111/j. 1365-2125. 2011. 04051. x.

Lee DY, Jung YS, Kim YC, Kim SY, Lee MG. Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding. Biopharm Drug Dispos 2009; 30:107-16.

Lee E, Kim TH, Choi JS et al. Evaluation of liver and thyroid toxicity in Sprague-Dawley rats after exposure to polybrominated diphenyl ether BDE-209. J Toxicol Sci 2010; 35:535-45.

Lee HW, Kim DW, Phapale PB et al. In vitro inhibitory effects of Wen-pi-tang-Hab-Wu-ling-san on human cytochrome P450 isoforms. J Clin Pharm Ther 2011; 36:496-503.

Lee YS, Choi YH, Kim TK, Ryu KH, Lee BY, Lee MG. Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats. Xenobiotica 2010; 40:129-37.

Lewis BC, Mackenzie PI, Miners JO. Application of homolgy modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine. Mol Pharmacol 2011; 80:879-88.

Li E, Hu JP, Wang BL, Li Y. Effect of buagafuran on liver microsomal cytochrome P450 in rats. J Asian Nat Prod Res 2010; 12:371-81.

Li JK, He F, Bi HC et al. Inhibition of human cytochrome P-450 CYP1A2 by flavonoids: a quantitative structure-activity relationship study. Yao Xue Xue Bao 2008; 43:1198-204.

Li T, Li N, Guo Q et al. Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Eur J Drug Metab Pharmacokinet 2011. doi:10. 1007/s13318-011-0050-0.

Li X, Delzer J, Voorman R, de Morais SM, Lao Y. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos 2011; 39:1161-9.

Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010; 38:1238-45.

Li Y, Ren G, Wang YX et al. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J Transl Med 2011; 9:62.

Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. Xenobiotica 2010; 40:721-9.

Li YH, Zhang YQ, Li L, Wang Q, Wang NS. Effect of Danggui and Honghua on cytochrome P450 1A2, 2C11, 2E1 and 3A1 mRNA expression in liver of rats. Am J Chin Med 2008; 36:1071-81.

Lim JS, Singh O, Ramasamy RD et al. Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet 2010; 25:616-23.

Lin KM, Tsou HH, Tsai IJ et al. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics 2010; 11:1535-43.

Lind AB, Reis M, Bengtsson F et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 2009; 48:63-70.

Ling S, Jamali F. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin Pharmacol Toxicol 2009; 105:24-9.

Liu C, Shi Y, Li H, Wang Y, Yang K. p,p’-DDE disturbs the homeostasis of thyroid hormones via thyroid hormone receptors, transthyretin, and hepatic enzymes. Horm Metab Res 2011; 43:391-6.

Liu D, Gao Y, Wang H et al. Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential. Drug Metab Dispos 2010; 38:2259-65.

Liu HX, Hu Y, Liu Y, He YQ, Li W, Yang L. CYP1A2 is the major isoform responsible for paeonol O-demethylation in human liver microsomes. Xenobiotica 2009; 39:672-9.

Lucas D, Goulitquer S, Marienhagen J et al. Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450. J Lipid Res 2010; 51:1125-33.

Lucas S, Heim R, Ries C, Schewe KE, Birk B, Hartmann RW. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. J Med Chem 2008; 51:8077-87.

Lucas S, Negri M, Heim R, Zimmer C, Hartmann RW. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives. J Med Chem 2011; 54:2307-19.

Luo JP, Vashishtha SC, Hawes EM, McKay G, Midha KK, Fang J. In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos 2011; 32:398-407.

MacDonald CJ, Cheng RY, Roberts DD, Wink DA, Yeh GC. Modulation of carcinogen metabolism by nitric oxide-aspirin 2 is associated with suppression of DNA damage and DNA adduct formation. J Biol Chem 2009; 284:22099-107.

Maciolek CM, Ma B, Menzel K et al. Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2011; 39:763-70.

MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 2010; 119:463-74.

Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BS, Kranendonk M. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab Dispos 2010; 38:332-40.

Marumoto S, Oda Y, Miyazawa M. Antigenotoxic activity of naturally occurring furanocoumarins. Environ Mol Mutagen 2011; 52:646-57.

Masek V, Anzenbacherova E, Etrych T, Strohalm J, Ulbrich K, Anzenbacher P. Interaction of HPMA copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450. Comparison with free doxorubicin. Drug Metab Dispos 2011; 39:1704-10.

Masek V, Anzenbacherová E, Machová M, Brabec V, Anzenbacher P. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs 2009; 20:305-11.

Matal J, Matuskova Z, Tunkova A, Anzenbacherova E, Anzenbacher P. Porcine CYP2A19, CYP2E1 and CYP1A2 forms are responsible for skatole biotransformation in the reconstituted system. Neuro Endocrinol Lett 2009; 30 Suppl 1:36-40.

Matsuda Y, Takeuchi H, Yokohira M et al. Enhancing effects of a high fat diet on 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline-induced lung tumorigenesis in female A/J mice. Mol Med Report 2009; 2:701-6.

Matsumoto K, Nemoto E, Hasegawa T, Akimoto M, Sugibayashi K. In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-Methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 2011; 34:734-9.

Matsuoka-Kawano K, Yoshinari K, Nagayama S, Yamazoe Y. TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes. Chem Biol Interact 2010; 185:33-41.

Matuskova Z, Tunkova A, Anzenbacherova E, Zidek Z, Tlaskalova-Hogenova H, Anzenbacher P. Influence of probiotics on rat liver biotransformation enzymes. Neuro Endocrinol Lett 2009; 30 Suppl 1:41-5.

Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119:2553-60.

Metry KJ, Neale JR, Doll MA et al. Effect of rapid human N-acetyltransferase 2 haplotype on DNA damage and mutagenesis induced by 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) and 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline (MeIQx). Mutat Res 2010; 684:66-73.

Meyer MR, Peters FT, Maurer HH. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochem Pharmacol 2009; 77:1725-34.

Miller GP, Jones DR, Sullivan SZ et al. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol 2009; 22:1239-45.

Miller WL, Agrawal V, Sandee D et al. Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 2011; 336:174-9.

Mills BM, Zaya MJ, Walters RR et al. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs. Drug Metab Dispos 2010; 38:396-404.

Miyajima A, Furihata T, Chiba K. Functional analysis of GC Box and its CpG methylation in the regulation of CYP1A2 gene expression. Drug Metab Pharmacokinet 2009; 24:269-76.

Modarai M, Suter A, Kortenkamp A, Heinrich M. The interaction potential of herbal medicinal products: a luminescence-based screening platform assessing effects on cytochrome P450 and its use with devil’s claw (Harpagophyti radix) preparations. J Pharm Pharmacol 2011; 63:429-38.

Momo K, Homma M, Osaka Y, Inomata S, Tanaka M, Kohda Y. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2010; 50:331-7.

Mrozikiewicz PM, Bogacz A, Karasiewicz M et al. The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine 2010; 17:830-3.

Mullen Grey AK, Riddick DS. The aryl hydrocarbon receptor pathway and the response to 3-methylcholanthrene are altered in the liver of adrenalectomized rats. Drug Metab Dispos 2011; 39:83-91.

Murphy M, Antia U, Chang HY et al. Party pills and drug-drug interactions. N Z Med J 2009; 122:3564.

Muschler E, Lal J, Jetter A et al. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol 2009; 105:374-9.

Myers MJ, Farrell DE, Howard KD, Kawalek JC. Effects of intravenous administration of lipopolysaccharide on cytochrome P450 isoforms and hepatic drug metabolizing enzymes in swine. Am J Vet Res 2010; 71:342-8.

Nannelli A, Rossignolo F, Tolando R, Rossato P, Longo V, Gervasi PG. Effect of beta-naphthoflavone on AhR-regulated genes (CYP1A1, 1A2, 1B1, 2S1, Nrf2, and GST) and antioxidant enzymes in various brain regions of pig. Toxicology 2009; 265:69-79.

Nassar AE, King I, Paris BL et al. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes. Drug Metab Dispos 2009; 37:1922-30.

Nassr N, Huennemeyer A, Herzog R et al. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 2009; 68:580-7.

National Toxicology Program. Toxicology and carcinogenesis studies of 2,3’,4,4’,5-pentachlorobiphenyl (PCB 118) (CAS No. 31508-00-6) in female harlan Sprague-Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser 2010:1-174.

Newton-Cheh C, Johnson T, Gateva V et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41:666-76.

Niestroy J, Barbara A, Herbst K, Rode S, van Liempt M, Roos PH. Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol In Vitro 2011; 25:671-83.

Nirogi R, Kandikere V, Bhyrapuneni G, Ponnamaneni RK, Palacharla RC, Manoharan AK. Effect of dimethyl sulfoxide on in vitro cytochrome P450 1A2 mediated phenacetin-o-deethylation in human liver microsomes. Drug Metab Dispos 2011; 39:2162-4.

Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab Pharmacokinet 2011; 26:300-6.

Noh K, Seo YM, Lee SK et al. Effects of rutaecarpine on the metabolism and urinary excretion of caffeine in rats. Arch Pharm Res 2011; 34:119-25.

Nukaya M, Lin BC, Glover E, Moran SM, Kennedy GD, Bradfield CA. The aryl hydrocarbon receptor-interacting protein (AIP) is required for dioxin-induced hepatotoxicity but not for the induction of the Cyp1a1 and Cyp1a2 genes. J Biol Chem 2010; 285:35599-605.

Nukaya M, Moran S, Bradfield CA. The role of the dioxin-responsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biology. Proc Natl Acad Sci USA 2009; 106:4923-8.

Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 2010; 38:1381-91.

O’Donnell EF, Saili KS, Koch DC et al. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One 2010. doi:10. 1371/journal. pone. 0013128

Oganesian A, Shilling AD, Young-Sciame R et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull 2009; 42:47-63.

Okamura T, Ishii Y, Suzuki Y et al. Enhancing effects of carbon tetrachloride on in vivo mutagenicity in the liver of mice fed 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). J Toxicol Sci 2010; 35:709-20.

Oliver P, Lubomirov R, Carcas A. Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clin Chem Lab Med 2010; 48:635-9.

Olivieri EH, da Silva SD, Mendonça FF et al. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients. Oral Oncol 2009; 45:73-9.

Ooi JP, Kuroyanagi M, Sulaiman SF, Muhammad TS, Tan ML. Andrographolide and 14-deoxy-11, 12-didehydroandrographolide inhibit cytochrome P450s in HepG2 hepatoma cells. Life Sci 2011; 88:447-54.

Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today 2009; 45:599-608.

Ozeki J, Uno S, Ogura M et al. Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated mice. Toxicology 2011; 280:10-7.

Palatini P, Ceolotto G, Ragazzo F et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 2009; 27:1594-601.

Pan X, Wang P, Hu N et al. A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans. Drug Metab Pharmacokinet 2011; 26:387-98.

Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 2009; 37:2045-54.

Park KW, Park JJ, Jeon KH et al. Enhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011; 31:665-71.

Paulose T, Hernández-Ochoa I, Basavarajappa MS, Peretz J, Flaws JA. Increased sensitivity of estrogen receptor alpha overexpressing antral follicles to methoxychlor and its metabolites. Toxicol Sci 2011; 120:447-59.

Perepechaeva M, Kolosova N, Grishanova A. Molecular mechanisms of cold-induced CYP1A activation in rat liver microsomes. J Physiol Biochem 2011. doi:10. 1007/s13105-011-0095-1.

Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol 2011; 63:1161-8.

Persiani S, Canciani L, Larger P et al. In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate. Drug Metabol Drug Interact 2009; 24:195-209.

Peterson S, Schwarz Y, Li SS et al. CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidemiol Biomarkers Prev 2009; 18:3118-25.

Pham MH, Rhinn H, Auzeil N et al. Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice. Drug Metab Lett 2011; 5:73-84.

Pithavala YK, Tong W, Mount J et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 2010. doi:10. 1007/s10637-010-9511-6.

Platt KL, Edenharder R, Aderhold S, Muckel E, Glatt H. Fruits and vegetables protect against the genotoxicity of heterocyclic aromatic amines activated by human xenobiotic-metabolizing enzymes expressed in immortal mammalian cells. Mutat Res 2010; 703:90-8.

Polasek TM, Lin FP, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 2011; 71:727-36.

Popat RA, van Den Eeden SK, Tanner CM et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol 2011; 18:756-65.

Potega A, Dabrowska E, Niemira M et al. The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome p450s. Drug Metab Dispos 2011; 39:1423-32.

Pruitt R, Sasi N, Freeman ML, Sekhar KR. Radiosensitization of cancer cells by hydroxychalcones. Bioorg Med Chem Lett 2010; 20:5997-6000

Qian M, Shi LF, Hu JH. Enzyme kinetics of ligustilide metabolism in rat liver microsomes. Yao Xue Xue Bao 2009; 44:395-400.

Qiu LX, Yao L, Mao C et al. Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects. Breast Cancer Res Treat 2010; 122:521-5.

Rasmussen BB, Brix TH, Kyvik KO, Brosen K. The interindividual differences in the 3-demthylation (sic) of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12:473-8.

Rasmussen M, Zamaratskaia G, Ekstrand B. Gender-related differences in cytochrome P450 in porcine liver – implication for activity, expression and inhibition by testicular steroids. Reprod Domest Anim 2011; 46:616-23.

Rasmussen MK, Zamaratskaia G, Ekstrand B. In vivo effect of dried chicory root (Cichorium intybus L. ) on xenobiotica metabolising cytochrome P450 enzymes in porcine liver. Toxicol Lett 2011; 200:88-91.

Rebbeck TR, Su HI, Sammel MD et al. Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause 2010; 17:1026-34.

Reed JR, Cawley GF, Backes WL. Inhibition of cytochrome P450 1A2-mediated metabolism and production of reactive oxygen species by heme oxygenase-1 in rat liver microsomes. Drug Metab Lett 2011; 5:6-16.

Reinicke KE, Kuffel MJ, Goetz MP, Ames MM. Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemother Pharmacol 2010; 66:575-83.

Rhodes SP, Otten JN, Hingorani GP, Hartley DP, Franklin RB. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2. J Pharmacol Toxicol Methods 2011; 63:223-6.

Robbins MG, Hauder J, Somoza V, Eshelman BD, Barnes DM, Hanlon PR. Induction of detoxification enzymes by feeding unblanched Brussels sprouts containing active myrosinase to mice for 2 wk. J Food Sci 2010; 75:190-9.

Rögelsperger O, Wlcek K, Ekmekcioglu C et al. Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. J Recept Signal Transduct Res 2011; 31:180-7.

Roos R, Andersson PL, Halldin K et al. Hepatic effects of a highly purified 2,2’,3,4,4’,5,5’-heptachlorbiphenyl (PCB 180) in male and female rats. Toxicology 2011; 284:42-53.

Rosenquist TA, Einolf HJ, Dickman KG, Wang L, Smith A, Grollman AP. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Dispos 2010; 38:761-8.

Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C-to-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Brit J Clin Pharm 1999; 47:445-9.

Sainz J, Rudolph A, Hein R et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 2011; 18:265-76.

Saito J, Fukushima H, Nagase H. Inhibitory effect of magnolol on Trp-P-2-induced DNA damage in various organs in mice. Phytother Res 2009; 23:901-5.

Salminen KA, Meyer A, Jerabkova L et al. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phytomedicine 2011; 18:533-8.

Sanada N, Gotoh Y, Shimazawa R, Klinge CM, Kizu R. Repression of activated aryl hydrocarbon receptor-induced transcriptional activation by 5alpha-dihydrotestosterone in human prostate cancer LNCaP and human breast cancer T47D cells. J Pharmacol Sci 2009; 109:380-7.

Sangrajrang S, Sato Y, Sakamoto H et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 2009; 125:837-43.

Sani G, Kotzalidis GD, Simonetti A et al. Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype. J Clin Psychopharmacol 2010; 30:737-9.

Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs 2009; 18:1533-40.

Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 2011; 50:371-403.

Schmidt RJ, Romitti PA, Burns TL et al. Caffeine, selected metabolic gene variants, and risk for neural tube defects. Birth Defects Res A Clin Mol Teratol 2010; 88:560-9.

Schober W, Pusch G, Oeder S, Reindl H, Behrendt H, Buters JT. Metabolic activation of phenanthrene by human and mouse cytochromes P450 and pharmacokinetics in CYP1A2 knockout mice. Chem Biol Interact 2010; 183:57-66.

Schroeder JC, Dinatale BC, Murray IA et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010; 49:393-400.

Senggunprai L, Kukongviriyapan U, Jetsrisuparb A, Kukongviriyapan V. Drug metabolizing enzyme CYP1A2 status in pediatric patients with hemoglobin E-beta thalassemia. J Med Assoc Thai 2009; 92:1675-80.

Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Brit J Clin Pharm 1988; 26:363-72.

Shahzadi A, Javed I, Aslam B et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci 2011; 24:63-8.

Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int 2011; 207:183-7.

Shi Z, Chen Y, Dong H, Amos-Kroohs RM, Nebert DW. Generation of a ‘humanized’ hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahrd mouse line harboring the poor-affinity aryl hydrocarbon receptor. Biochem Biophys Res Commun 2008; 376:775-80.

Shimada H, Eto M, Ohtaguro M et al. Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol 2010; 24:230-4.

Shimada N, Iwasaki M, Kasuga Y et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet 2009; 54:209-15.

Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharm Exp Ther 1994; 270:414-23.

Shimazu S, Inui H, Ohkawa H. Phytomonitoring and phytoremediation of agrochemicals and related compounds based on recombinant cytochrome P450s and aryl hydrocarbon receptors (AhRs) J Agric Food Chem 2011; 59:2870-5.

Shiran MR, Lennard MS, Iqbal MZ et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2009; 67:29-37.

Shivanna B, Jiang W, Wang L, Couroucli X, Moorthy B. Omeprazole attenuates hyperoxic lung injury in mice via aryl hydrocarbon receptor activation, and is associated with increased expression of cytochrome P4501A enzymes. J Pharmacol Exp Ther 2011; 339:106-14.

Sibbald M, Yan AT, Huang W et al. Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. Am Heart J 2010; 160:855-61.

Siller M, Anzenbacher P, Anzenbacherova E, Dolezal K, Popa I, Strnad M. Interactions of olomoucine II with human liver microsomal cytochromes P450. Drug Metab Dispos 2009; 37:1198-202.

Simon T, Bhatt DL, Bergougnan L et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 2011; 90:287-95.

Singh S, Singh K, Gupta SP et al. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res 2009; 1283:115-26.

Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP. Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers 2011; 15:343-9.

Skogh E, Sjödin I, Josefsson M, Dahl ML. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31:4-9.

Skupinska K, Misiewicz-Krzeminska I, Stypulkowski R, Lubelska K, Kasprzycka-Guttman T. Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[a]pyrene. J Biochem Mol Toxicol 2009; 23:18-28.

Small DS, Farid NA, Payne CD et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010; 49:777-98.

Sommer A, Blanton SH, Weymouth K et al. Smoking, the xenobiotic pathway, and clubfoot. Birth Defects Res A Clin Mol Teratol 2011; 91:20-8.

Sonesson A, Buur Rasmussen B. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450. Basic Clin Pharmacol Toxicol 2011; 109:195-202.

Song WY, Ji HY, Baek NI, Jeong TS, Lee HS. In vitro metabolism of jaceosidin and characterization of cytochrome P450 and UDP-glucuronosyltransferase enzymes in human liver microsomes. Arch Pharm Res 2010; 33:1985-96.

Stewart NA, Buch SC, Conrads TP, Branch RA. A UPLC-MS/MS assay of the “Pittsburgh cocktail”: six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution. Analyst 2011; 136:605-12.

Stiborova M, Frei E, Arlt VM, Schmeiser HH. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153:5-11.

Storvik M, Huuskonen P, Kyllönen T et al. Aflatoxin B1-a potential endocrine disruptor-up-regulates CYP19A1 in JEG-3 cells. Toxicol Lett 2011; 202:161-7.

Sugahara H, Maebara C, Ohtani H et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol 2009; 65:699-704.

Sulem P, Gudbjartsson DF, Geller F et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet 2011; 20:2071-7.

Sun DX, Lu JC, Fang ZZ et al. Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside. Phytother Res 2010; 24:1670-5.

Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S. Association of CYP1A1*2 polymorphisms with breast cancer risk: a case control study. Indian J Med Sci 2009; 63:13-20.

Suzuki Y, Sugai T, Fukui N et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 2011; 25:908-14.

Taesotikul T, Dumrongsakulchai W, Wattanachai N et al. Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab Pharmacokinet 2011; 26:154-61.

Takemura H, Itoh T, Yamamoto K, Sakakibara H, Shimoi K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem 2010; 18:6310-5.

Tang J, Zhou X, Ji H, Zhu D, Wu L. Effects of Ephedra water decoction and cough tablets containing Ephedra and Liquorice on CYP1A2 and the pharmacokinetics of Theophylline in rats. Phytother Res 2011. doi:10. 1002/ptr. 3565.

Tang L, Ye L, Lv C, Zheng Z, Gong Y, Liu Z. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Toxicol Lett 2011; 202:47-54.

Tao L, Xiang YB, Chan KK et al. Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study. Int J Cancer 2011. doi:10. 1002/ijc. 26121.

Tao L, Xiang YB, Wang R et al. Environmental tobacco smoke in relation to bladder cancer risk-the Shanghai bladder cancer study [corrected]. Cancer Epidemiol Biomarkers Prev 2010; 19:3087-95.

Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM. In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metab Dispos 2009; 37:1286-94.

Tran QT, Xu L, Phan V et al. Chemical genomics of cancer chemopreventive dithiolethiones. Carcinogenesis 2009; 30:480-6.

Trusov NV, Guseva GV, Aksenov IV, Avren’eva LI, Kravchenko LV, Tutelyan VA. Effects of combined treatment with resveratrol and indole-3-carbinol. Bull Exp Biol Med 2010; 149:213-8.

Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, Zanger UM. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 2009; 37:1017-24.

Ueda N, Yoshimura R, Umene-Nakano W et al. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychiatry 2009; 10:832-5.

Ueng YF, Tsai CC, Lo WS, Yun CH. Induction of hepatic cytochrome P450s by the herbal medicine Sophora flavescens extract in rats: impact on the elimination of theophylline. Drug Metab Pharmacokinet 2010; 25:560-7.

Ueno K. Gender differences in pharmacokinetics of anesthetics. Masui 2009; 58:51-8.

Umehara KI, Susaki Y, van Teylingen RH et al. Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism. Eur J Drug Metab Pharmacokinet 2008; 33:211-23.

Uno Y, Uehara S, Murayama N, Yamazaki H. CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey. Biochem Pharmacol 2011; 81:442-50.

Uslu A, Ogus C, Ozdemir T, Bilgen T, Tosun O, Keser I. The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. BMB Rep 2010; 43:530-4.

Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig 2009; 29:35-50.

Valcke M, Krishnan K. An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants. Toxicology 2011; 286:36-47.

Veinlichova A, Jancova P, Siller M et al. Effect of acetylcholinesterase oxime-type reactivators K-48 and HI-6 on human liver microsomal cytochromes P450 in vitro. Chem Biol Interact 2009; 180:449-53.

Vibhuti A, Arif E, Mishra A et al. CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD. Clin Chim Acta 2010; 411:474-80.

Vrzal R, Kubesova K, Pavek P, Dvorak Z. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines. Toxicol Lett 2010; 193:183-8.

Wahawisan J, Kolluru S, Nguyen T, Molina C, Speake J. Methadone toxicity due to smoking cessation-A case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. Ann Pharmacother 2011; 45:34.

Walker AA, Dickmann L, Isoherranen N. Pregnancy decreases rat CYP1A2 activity and expression. Drug Metab Dispos 2011; 39:4-7.

Wang AX, Hu Y, Liu HX et al. C5-hydroxylation of liquiritigenin is catalyzed selectively by CYP1A2. Xenobiotica 2011; 41:349-57.

Wang B, Zhou SF. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem 2009; 16:4066-218.

Wang J, Joshi AD, Corral R et al. Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk. Int J Cancer 2011. doi:10. 1002/ijc. 26199.

Wang L, Zhang D, Raghavan N et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38:448-58.

Wang X, Cheung CM, Lee WY, Or PM, Yeung JH. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine 2010; 17:868-75.

Wang X, Lee WY, Or PM, Yeung JH. Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. Phytomedicine 2009; 16:712-25.

Wang X, Yeung JH. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. J Pharm Pharmacol 2010; 62:1077-83.

Wang XR, Qu ZQ, Li XD et al. Activity of sulfotransferase 1A1 is dramatically upregulated in patients with hepatocellular carcinoma secondary to chronic hepatitis B virus infection. Cancer Sci 2010; 101:412-5.

Washio I, Maeda M, Sugiura C et al. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 2011; 39:1-3.

Wen B, Zhou M. Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. Chem Biol Interact 2009; 181:220-6.

Weng X, Li Y, Yang Q et al. Effects of Wuji pill compound with different compatibility on cytochrome P450 CYP3A1/3A2 in rat liver microsomes in vitro. Zhongguo Zhong Yao Za Zhi 2010; 35:1164-9.

Wickliffe JK, Abdel-Rahman SZ, Lee C et al. CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med 2011; 17:241-7.

Winitthana T, Niwattisaiwong N, Patarapanich C, Tantisira MH, Lawanprasert S. In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450. Toxicol In Vitro 2011; 25:890-6.

Wójcikowski J, Boksa J, Daniel WA. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver-A comparison with other phenothiazines. Biochem Pharmacol 2010; 80:1252-9.

Wójcikowski J, Daniel WA. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism-an in vitro study. Pharmacol Rep 2009; 61:851-8.

Woo SW, Kang TS, Park HJ, Lee JE, Roh J. Comparison of linkage disequilibrium patterns and haplotype structure of eight single nucleotide polymorphisms across the CYP1A2 gene between the Korean, and other populations registered in the International HapMap database. J Clin Pharm Ther 2009; 34:429-36.

Xia CH, Sun JG, Wang GJ et al. Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. Planta Med 2010; 76:245-50.

Xiao Y, Xue X, Wu YF et al. beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism. Acta Pharmacol Sin 2009; 30:1559-65.

Xing PP, Wu WH, Du P, Han FM, Chen Y. Effects of brucine combined with glycyrrhetinic acid or liquiritin on rat hepatic cytochrome P450 activities in vivo. Yao Xue Xue Bao 2011; 46:573-80.

Xiong WJ, Jin H, Li SJ, Jin JC, Ji BN, Yu C. Evaluating human liver reserve function by measuring serum concentrations of phenacetin and its metabolites. J Dig Dis 2010; 11:358-63.

Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010; 79:1691-8.

Yamazaki H, Kuribayashi S, Inoue T et al. Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 2010; 23:152-8.

Yanagiba Y, Ito Y, Kamijima M, Gonzalez FJ, Nakajima T. Octachlorostyrene induces cytochrome P450, UDP-glucuronosyltransferase, and sulfotransferase via the aryl hydrocarbon receptor and constitutive androstane receptor. Toxicol Sci 2009; 111:19-26.

Yang J, He MM, Niu W et al. Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. Br J Clin Pharmacol 2011. doi:10. 1111/j. 1365-2125. 2011. 04076. x.

Yang X, Liao M, Yang Z, Guo J, Gao Q. Effect of Panax notoginseng on genes expression of CYP and GST in liver tissues of rats. Zhongguo Zhong Yao Za Zhi 2009; 34:2390-3.

Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T. Metabolism of sesamin by cytochrome P450 in human liver microsomes. Drug Metab Dispos 2010; 38:2117-23.

Ye L, Tang L, Gong Y et al. Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine. Xenobiotica 2011; 41:46-58.

Ye L, Wang T, Yang C et al. Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species. Toxicol Lett 2011; 204:81-91.

Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Polymorphisms of cytochrome P450 1A2 and N-acetyltransferase genes, meat consumption, and risk of colorectal cancer. Dis Colon Rectum 2009; 52:104-11.

Yi S, Cho JY, Lim KS et al. Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers. Basic Clin Pharmacol Toxicol 2009; 105:249-56.

Yu J, Brown DG, Burdette D. In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism. Drug Metab Dispos 2010; 38:1767-78.

Yu RZ, Geary RS, Flaim JD et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2’-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009; 48:39-50.

Zeng T, Zhang CL, Song FY, Han XY, Xie KQ. The modulatory effects of garlic oil on hepatic cytochrome P450s in mice. Hum Exp Toxicol 2009; 28:777-83.

Zhang C, Wong S, Delarosa EM et al. Inhibitory properties of trapping agents: glutathione, potassium cyanide, and methoxylamine, against major human cytochrome p450 isoforms. Drug Metab Lett 2009; 3:125-9.

Zhang JG, Ho T, Callendrello AL, Crespi CL, Stresser DM. A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin. Drug Metab Lett 2010; 4:185-94.

Zhang R, Sun J, Ma L et al. Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicol Appl Pharmacol 2011; 252:18-27.

Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 2002; 30:314-8.

Zhao M, Li LP, Shen J, Jiang HD. Inhibitory and inductive effects of (-)- and (+)-tetrahydropalmatine on CYP450 in mice. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011; 40:33-9.

Zhao Y, Hellum BH, Liang A, Nilsen OG. The in vitro inhibition of human Cyp1A2, Cyp2D6 and Cyp3A4 by tetrahydropalmatine, neferine and berberine. Phytother Res 2011. doi:10. 1002/ptr. 3554.

Zheng J, Chen B, Jiang B et al. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res 2010; 33:243-6.

Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 2011; 39:703-10.

Zhou D, Linnenbach AJ, Liu R et al. Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells. Drug Metab Dispos 2010; 38:1015-8.

Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010; 42:268-354.

Zhu Q, Liao J, Xie L, Wang GJ, Liu XD. Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 2009; 39:293-301.

Zhu R, Hu L, Li H, Su J, Cao Z, Zhang W. Novel natural inhibitors of CYP1A2 identified by in silico and in vitro screening. Int J Mol Sci 2011; 12:3250-62.

Zhuang XM, Wen YY, Li H et al. Metabolism of 3-cyanomethyl-4-methyl-DCK, a new anti-HIV candidate, in human intestinal microsomes. Yao Xue Xue Bao 2010; 45:1116-22.

Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010; 125:446-63.

CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1)

Abdull Razis AF, Bagatta M, de Nicola GR, Iori R, Ioannides C. Up-regulation of cytochrome P450 and phase II enzyme systems in rat precision-cut rat lung slices by the intact glucosinolates, glucoraphanin and glucoerucin. Lung Cancer 2011; 71:298-305.

Ada AO, C Kunak S, Hancer F et al. CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. Neoplasma 2010; 57:512-21.

Aiyer HS, Gupta RC. Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis by modulating enzymes of estrogen metabolism. Cancer Prev Res 2010; 3:727-37.

Andersson H, Garscha U, Brittebo E. Effects of PCB126 and 17β-oestradiol on endothelium-derived vasoactive factors in human endothelial cells. Toxicology 2011; 285:46-56.

Androutsopoulos VP, Papakyriakou A, Vourloumis D, Spandidos DA. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg Med Chem 2011; 19:2842-9.

Ashton KA, Proietto A, Otton G et al. Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol 2010; 34:328-37.

Azmanov DN, Dimitrova S, Florez L et al. LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population. Eur J Hum Genet 2011; 19:326-33.

Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998; 58:5038-41.

Basavarajappa MS, Craig ZR, Hernández-Ochoa I, Paulose T, Leslie TC, Flaws JA. Methoxychlor reduces estradiol levels by altering steroidogenesis and metabolism in mouse antral follicles in vitro. Toxicol Appl Pharmacol 2011; 253:161-9.

Beedanagari SR, Taylor RT, Bui P, Wang F, Nickerson DW, Hankinson O. Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes. Mol Pharmacol 2010; 78:608-16.

Beedanagari SR, Taylor RT, Hankinson O. Differential regulation of the dioxin-induced Cyp1a1 and Cyp1b1 genes in mouse hepatoma and fibroblast cell lines. Toxicol Lett 2010; 194:26-33.

Bhattacharjee A, Banerjee D, Mookherjee S et al. Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. Mol Vis 2008; 14:841-50.

Bruchova H, Vasikova A, Merkerova M et al. Effect of maternal tobacco smoke exposure on the placental transcriptome. Placenta 2010; 31:186-91.

Burdon KP, Hewitt AW, Mackey DA, Mitchell P, Craig JE. Tag SNPs detect association of the CYP1B1 gene with primary open angle glaucoma. Mol Vis 2010; 16:2286-93.

Celius T, Matthews J. Functional analysis of six human aryl hydrocarbon receptor variants in human breast cancer and mouse hepatoma cell lines. Toxicology 2010; 277:59-65.

Cerne JZ, Novakovic S, Frkovic-Grazio S, Pohar-Perme M, Stegel V, Gersak K. Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer. Oncol Rep 2011; 26:479-85.

Chakrabarti S, Ghanekar Y, Kaur K et al. A polymorphism in the CYP1B1 promoter is functionally associated with primary congenital glaucoma. Hum Mol Genet 2010; 19:4083-90.

Chavarria-Soley G, Sticht H, Aklillu E et al. Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. Hum Mutat 2008; 29:1147-53.

Chen B, Qiu LX, Li Y et al. The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer 2010; 70:247-52.

Chen J, Cai SP, Yu W et al. Sequence analysis of MYOC and CYP1B1 in a Chinese pedigree of primary open-angle glaucoma. Mol Vis 2011; 17:1431-5.

Chen X, Chen Y, Wang L et al. Confirmation and further mapping of the GLC3C locus in primary congenital glaucoma. Front Biosci 2011; 17:2052-9.

Chen Y, Huang C, Zhou T, Zhang S, Chen G. Biochanin A induction of sulfotransferases in rats. J Biochem Mol Toxicol 2010; 24:102-14.

Cheng CH, Leung AY, Chen CF. The effects of two different Ganoderma species (Lingzhi) on gene expression in human monocytic THP-1 cells. Nutr Cancer 2010; 62:648-58.

Chi AC, Appleton K, Henriod JB et al. Differential induction of CYP1A1 and CYP1B1 by benzo[a]pyrene in oral squamous cell carcinoma cell lines and by tobacco smoking in oral mucosa. Oral Oncol 2009; 45:980-5.

Choudhary D, Jansson I, Schenkman JB. CYP1B1, a developmental gene with a potential role in glaucoma therapy. Xenobiotica 2009; 39:606-15.

Chun YJ, Oh YK, Kim BJ et al. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Toxicol Lett 2009; 189:84-9.

Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002; 30:869-74.

de Palma G, Dick FD, Calzetti S et al. A case-control study of Parkinson’s disease and tobacco use: gene-tobacco interactions. Mov Disord 2010; 25:912-9.

Deb S, Bandiera SM. Regulation of cytochrome P450 1B1 expression by luteinizing hormone in mouse MA-10 and rat R2C Leydig cells: role of protein kinase A. Biol Reprod 2011; 85:89-96.

Declèves X, Jacob A, Yousif S, Shawahna R, Potin S, Scherrmann JM. Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr Drug Metab 2011; 12:732-41.

Devlin AH, McIlroy M, McKeen HD et al. Cytochrome P450 1B1 expression in rat esophageal tumorigenesis promoted by gastric and duodenal reflux. Mol Carcinog 2009; 48:110-7.

Devlin AH, Thompson P, Robson T, McKeown SR. Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation. Mol Carcinog 2010; 49:190-9.

Dumas I, Diorio C. Polymorphisms in genes involved in the estrogen pathway and mammographic density. BMC Cancer 2010; 10:636.

Eder C, Frankenberger M, Stanzel F et al. Ultrafine carbon particles down-regulate CYP1B1 expression in human monocytes. Part Fibre Toxicol 2009; 6:27.

El-Gayar S, Ganesh A, Chavarria-Soley G et al. Molecular analysis of CYP1B1 in Omani patients with primary congenital glaucoma: a pilot study. Mol Vis 2009; 15:1325-31.

El-Shennawy GA, Elbialy AA, Isamil AE, El Behery MM. Is genetic polymorphism of ER-α, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma? Arch Gynecol Obstet 2011; 283:1313-8.

Fontana L, Delort L, Joumard L et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res 2009; 29:1631-5.

Frampton GA, Lazcano EA, Li H, Mohamad A, DeMorrow S. Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest 2010; 90:1325-38.

Fuse N, Miyazawa A, Takahashi K, Noro M, Nakazawa T, Nishida K. Mutation spectrum of the CYP1B1 gene for congenital glaucoma in the Japanese population. Jpn J Ophthalmol 2010; 54:1-6.

Gasperino J. Gender is a risk factor for lung cancer. Med Hypotheses 2011; 76:328-31.

Gaudet MM, Chanock S, Lissowska J et al. Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women. Pharmacogenet Genomics 2006; 16:547-53.

Giuffre’ I. Molecular analysis of Italian patients with congenital glaucoma. Ophthalmic Genet 2011. doi:10. 3109/13816810. 2011. 596891.

Gold LS, de Roos AJ, Brown EE et al. Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol 2009; 33:276-80.

Gregoraszczuk E, Ptak A. Involvement of caspase-9 but not caspase-8 in the anti-apoptotic effects of estradiol and 4-OH-Estradiol in MCF-7 human breast cancer cells. Endocr Regul 2011; 45:3-8.

Han EH, Kim HG, Hwang YP, Song GY, Jeong HG. Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERalpha pathway in human breast cancer cells. Toxicol Sci 2010; 114:204-16.

Harth V, Schafer M, Abel J et al. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 2008; 71:887-97.

Helmig S, Seelinger JU, Döhrel J, Schneider J. RNA expressions of AHR, ARNT and CYP1B1 are influenced by AHR Arg554Lys polymorphism. Mol Genet Metab 2011; 104:180-4.

Helmig S, Seelinger JU, Philipp-Gehlhaar M, Döhrel J, Schneider J. Cyp1B1 mRNA expression in correlation to cotinine levels with respect to the Cyp1B1 L432V gene polymorphism. Eur J Epidemiol 2010; 25:867-73.

Hilal L, Boutayeb S, Serrou A et al. Screening of CYP1B1 and MYOC in Moroccan families with primary congenital glaucoma: three novel mutations in CYP1B1. Mol Vis 2010; 16:1215-26.

Hiraki M, Kitajima Y, Koga Y et al. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Ann Surg Oncol 2011; 18:3013-9.

Hlavata I, Vrana D, Smerhovsky Z et al. Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep 2010; 24:1347-53.

Hsu CM, Hsu YA, Tsai Y et al. Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells. Biochem Biophys Res Commun 2010; 392:473-8.

Hu W, Yang H, Sun J et al. Polymorphisms in CYP1B1 modify the risk of idiopathic male infertility with abnormal semen quality. Clin Chim Acta 2011; 412:1778-82.

Huang RS, Duan S, Kistner EO et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 2008; 68:3161-8.

Itoh T, Takemura H, Shimoi K, Yamamoto K. A 3D model of CYP1B1 explains the dominant 4-hydroxylation of estradiol. J Chem Inf Model 2010; 50:1173-8.

Jang HH, Kim DH, Ahn T, Yun CH. Functional and conformational modulation of human cytochrome P450 1B1 by anionic phospholipids. Arch Biochem Biophys 2010; 493:143-50.

Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolism. Pharmacogenetics 2001; 11:793-801.

Jennings BL, Sahan-Firat S, Estes AM et al. Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension 2010; 56:667-74.

Jiao H, Liu C, Guo W, Peng L, Chen Y, Martin FL. Association of CYP1B1 polymorphisms with breast cancer: A case-control Study in the Han population in Ningxia Hui autonomous region, P. R. China. Biomark Insights 2010; 5:21-7.

Kang HJ, Hong YB, Kim HJ et al. Detoxification: A novel function of BRCA1 in tumor suppression? Toxicol Sci 2011; 122:26-37.

Kasimsetty SG, Bialonska D, Reddy MK, Thornton C, Willett KL, Ferreira D. Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. J Agric Food Chem 2009; 57:10636-44.

Kaur K, Mandal AK, Chakrabarti S. Primary congenital glaucoma and the involvement of CYP1B1. Middle East Afr J Ophthalmol 2011; 18:7-16.

Kaur-Knudsen D, Nordestgaard BG, Tybjaerg-Hansen A, Bojesen SE. CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50,000 individuals. Pharmacogenet Genomics 2009; 19:685-94.

Kelberman D, Islam L, Jacques TS et al. CYP1B1-related anterior segment developmental anomalies novel mutations for infantile glaucoma and Von Hippel’s ulcer revisited. Ophthalmology 2011; 118:1865-73.

Khan AO. Genetics of primary glaucoma. Curr Opin Ophthalmol 2011; 22:347-55.

Khan AO, Al-Abdi L, Mohamed JY, Aldahmesh MA, Alkuraya FS. Familial juvenile glaucoma with underlying homozygous p. G61E CYP1B1 mutations. J AAPOS 2011; 15:198-9.

Khan AO, Aldahmesh MA, Alkuraya FS. Genetic and genomic analysis of classic aniridia in Saudi Arabia. Mol Vis 2011; 17:708-14.

Koga N, Ohta C, Kato Y et al. In vitro metabolism of nobiletin, a polymethoxy-flavonoid, by human liver microsomes and cytochrome P450. Xenobiotica 2011; 41:927-33.

Kolokythas A, Schwartz JL, Pytynia KB et al. Analysis of RNA from brush cytology detects changes in B2M, CYP1B1 and KRT17 levels with OSCC in tobacco users. Oral Oncol 2011; 47:532-6.

Korytina GF, Akhmadishina LZ, Viktorova TV. The CYP1B1 and CYP2F1 genes polymorphisms frequency in three ethnic groups of Bashkortostan and chronic obstructive pulmonary disease patients. Mol Biol 2010; 44:33-41.

Kumar V, Singh S, Ahmed RS, Banerjee BD, Ahmed T, Pasha ST. Frequency of common CYP1B1 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol 2009; 28:392-6.

Laroche-Clary A, Le Morvan V, Yamori T, Robert J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. Mol Cancer Ther 2010; 9:3315-21.

Libby RT, Smith RS, Savinova OV et al. Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science 2003; 299:1578-81.

López-Garrido MP, Blanco-Marchite C, Sánchez-Sánchez F et al. Functional analysis of CYP1B1 mutations and association of heterozygous hypomorphic alleles with primary open-angle glaucoma. Clin Genet 2010; 77:70-8.

Loyd JE. Pulmonary arterial hypertension: insights from genetic studies. Proc Am Thorac Soc 2011; 8:154-7.

Macpherson L, Matthews J. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells. Cancer Lett 2010; 299:119-29.

Marsh S, Somlo G, Li X et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007; 7:362-5.

Martinkova E, Dontenwill M, Frei E, Stiborova M. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett 2009; 30 Suppl 1:60-6.

Messina A, Siniscalco A, Puccinelli E, Gervasi PG, Longo V. Cloning and tissues expression of the pig CYP1B1 and CYP2J34. Res Vet Sci 2011. doi:10. 1016/j. rvsc. 2011. 04. 012.

Motushchuk AE, Komarova TIu, Grudinina NA et al. Genetic variants of CYP1B1 and WDR36 in the patients with primary congenital glaucoma and primary open angle glaucoma from Saint-Petersburg. Genetika 2009; 45:1659-67.

Murray GI, Patimalla S, Stewart KN, Miller ID, Heys SD. Profiling the expression of cytochrome P450 in breast cancer. Histopathology 2010; 57:202-11.

Ozbek YK, Oztürk T, Tüzüner BM et al. Combined effect of CYP1B1 codon 432 polymorphism and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer in the Turkish population. Anticancer Res 2010; 30:2885-9.

Pastina I, Giovannetti E, Chioni A et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 2010; 10:511.

Polonikov AV, Ivanov VP, Solodilova MA. Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene-gene and gene-environment interactions for disease susceptibility. J Hum Genet 2009; 54:440-9.

Powis M, Celius T, Matthews J. Differential ligand-dependent activation and a role for Y322 in aryl hydrocarbon receptor-mediated regulation of gene expression. Biochem Biophys Res Commun 2011; 410:859-65.

Rajaraman G, Yang G, Chen J, Chang TK. Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can J Physiol Pharmacol 2009; 87:674-83.

Rizzo R, Spaggiari F, Indelli M et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010; 124:593-8.

Sahan-Firat S, Jennings BL, Yaghini FA et al. 2,3’,4,5’-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Heart Circ Physiol 2010; 299:1891-901.

Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ et al. GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer. Urol Oncol 2011. doi:10. 1016/j. urolonc. 2010. 10. 001.

Schab M, Janiszewska H, Jarzemski P et al. Frequency of CYP1B1 homozygous genotype 355T/T in prostate cancer families from Poland. Eur J Cancer Prev 2010; 19:31-4.

Schneider J, Bernges U. CYP1A1 and CYP1B1 polymorphisms as modifying factors in patients with pneumoconiosis and occupationally related tumours: A pilot study. Mol Med Report 2009; 2:1023-8.

Schults MA, Timmermans L, Godschalk RW et al. Diminished carcinogen detoxification is a novel mechanism for hypoxia-inducible factor 1-mediated genetic instability. J Biol Chem 2010; 285:14558-64.

Shawahna R, Uchida Y, Declèves X et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011; 8:1332-41.

Shimada T, Tanaka K, Takenaka S et al. Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. Chem Res Toxicol 2009; 22:1325-33.

Singh PB, Ragavan N, Ashton KM et al. Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. Asian J Androl 2010; 12:203-14.

Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006; 4:135-50.

Sliwinski T, Sitarek P, Stetkiewicz T, Sobczuk A, Blasiak J. Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. J Obstet Gynaecol Res 2010; 36:311-7.

Song X, Siriwardhana N, Rathore K, Lin D, Wang HC. Grape seed proanthocyanidin suppression of breast cell carcinogenesis induced by chronic exposure to combined 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Mol Carcinog 2010; 49:450-63.

Soucek P, Susova S, Mohelnikova-Duchonova B et al. Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. Neoplasma 2010; 57:415-21.

Takemura H, Itoh T, Yamamoto K, Sakakibara H, Shimoi K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem 2010; 18:6310-5.

Takemura H, Uchiyama H, Ohura T et al. A methoxyflavonoid, chrysoeriol, selectively inhibits the formation of a carcinogenic estrogen metabolite in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2010; 118:70-6.

Tamm ER. Development of the iridocorneal angle and congenital glaucoma. Ophthalmologe 2011; 108:610-7.

Tang Y, Scheef EA, Gurel Z, Sorenson CM, Jefcoate CR, Sheibani N. CYP1B1 and endothelial nitric oxide synthase combine to sustain proangiogenic functions of endothelial cells under hyperoxic stress. Am J Physiol Cell Physiol 2010; 298:665-78.

Tang YM, Green BL, Chen GF et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10:761-6.

Tanwar M, Dada T, Dada R. Axenfeld-Rieger syndrome associated with congenital glaucoma and cytochrome P4501B1 gene mutations. Case Report Med 2010. doi:10. 1155/2010/212656.

Tanwar M, Dada T, Sihota R, Dada R. Identification of four novel cytochrome P4501B1 mutations (p. I94X, p. H279D, p. Q340H, and p. K433K) in primary congenital glaucoma patients. Mol Vis 2009; 15:2926-37.

Tanwar M, Kumar M, Dada T, Sihota R, Dada R. MYOC and FOXC1 gene analysis in primary congenital glaucoma. Mol Vis 2010; 16:1996-2006.

Tanwar M, Sihota R, Dada T et al. Sturge-Weber syndrome with congenital glaucoma and cytochrome P450 (CYP1B1) gene mutations. J Glaucoma 2010; 19:398-404.

Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010; 56:696-708.

Trubicka J, Grabowska-Kłujszo E, Suchy J et al. Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer 2010; 10:420.

Udomsuk L, Jarukamjorn K, Putalun W, Sakuma T, Kawasaki Y, Nemoto N. Modified expression of aryl hydrocarbon receptor-related genes by deoxymiroestrol, a phytoestrogen, in mouse hepatocytes in primary culture. J Ethnopharmacol 2011; 137:902-8.

Umannová L, Machala M, Topinka J et al. Benzo[a]pyrene and tumor necrosis factor-α coordinately increase genotoxic damage and the production of proinflammatory mediators in alveolar epithelial type II cells. Toxicol Lett 2011; 206:121-9.

Uno S, Dalton TP, Dragin N et al. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 2006; 69:1103-14.

Uno Y, Matsushita A, Yamazaki H. CYP1B1 is polymorphic in cynomolgus and rhesus macaques. J Vet Med Sci 2011; 73:1229-31.

Uppstad H, Øvrebø S, Haugen A, Mollerup S. Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines. Toxicol Lett 2010; 192:221-8.

van de Sande WW, Fahal A, Tavakol M, van Belkum A. Polymorphisms in catechol-O-methyltransferase and cytochrome p450 subfamily 19 genes predispose towards Madurella mycetomatis-induced mycetoma susceptibility. Med Mycol 2010; 48:959-68.

Wang F, Zou YF, Sun GP, Su H, Huang F. Association of CYP1B1 gene polymorphisms with susceptibility to endometrial cancer: a meta-analysis. Eur J Cancer Prev 2011; 20:112-20.

Wang H, Leung LK. The carotenoid lycopene differentially regulates phase I and II enzymes in dimethylbenz[a]anthracene-induced MCF-7 cells. Nutrition 2010; 26:1181-7.

Wang J, Joshi AD, Corral R et al. Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk. Int J Cancer 2011. doi:10. 1002/ijc. 26199.

Wang Q, Li H, Tao P et al. Soy isoflavones, CYP1A1, CYP1B1, and COMT polymorphisms, and breast cancer: A case-control study in Southwestern China. DNA Cell Biol 2011; 30:585-95.

Wang S, Chanock S, Tang D et al. Effect of gene-environment Interactions on mental development in African American, Dominican, and Caucasian mothers and newborns. Ann Hum Genet 2010; 74:46-56.

Wang X, Hawkins BT, Miller DS. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 2011; 25:644-52.

Williams-Brown MY, Salih SM, Xu X et al. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol 2011; 126:78-86.

Wills LP, Matson CW, Landon CD, di Giulio RT. Characterization of the recalcitrant CYP1 phenotype found in Atlantic killifish (Fundulus heteroclitus) inhabiting a Superfund site on the Elizabeth River, VA. Aquat Toxicol 2010; 99:33-41.

Xu W, Zhou Y, Hang X, Shen D. Current evidence on the relationship between CYP1B1 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep 2011. doi:10. 1007/s11033-011-1041-6.

Yang X, Liao M, Yang Z, Guo J, Gao Q. Effect of Panax notoginseng on genes expression of CYP and GST in lung tissues of rats. Zhongguo Zhong Yao Za Zhi 2009; 34:2236-40.

Yao L, Fang F, Wu Q, Zhong Y, Yu L. No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40,303 subjects. Breast Cancer Res Treat 2010; 122:237-42.

Zhu ZY, Mu YQ, Fu XM, Li SM, Zhao FX. Association of CYP1B1 gene polymorphisms and the positive expression of estrogen alpha and estrogen beta with endometrial cancer risk. Eur J Gynaecol Oncol 2011; 32:188-91.

Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO. Acute doxorubicin toxicity differentially alters cytochrome p450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos 2011; 39:1440-50.

CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6)

Aagaard-Tillery K, Spong CY, Thom E. Pharmacogenomics of maternal tobacco use: metabolic gene polymorphisms and risk of adverse pregnancy outcomes. Obstet Gynecol 2010; 115:568-77.

Abass K, Reponen P, Mattila S, Pelkonen O. Metabolism of α-thujone in human hepatic preparations in vitro. Xenobiotica 2011; 41:101-11.

Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J 2009; 9:274-82.

Altarescu G, Rachmilewitz D, Zevin S. Relationship between CYP2A6 genetic polymorphism, as a marker of nicotine metabolism, and ulcerative colitis. Isr Med Assoc J 2011; 13:87-90.

Apinan R, Tassaneeyakul W, Mahavorasirikul W et al. The influence of CYP2A6 polymorphisms and cadmium on nicotine metabolism in Thai population. Environ Toxicol Pharmacol 2009; 28:420-4.

Ariyoshi N, Sawamura Y, Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun 2001; 281:810-4.

Ariyoshi N, Sekine H, Nakayama K, Saito K, Miyamoto A, Kamataki T. Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese. Pharmacogenetics 2004; 14:701-5.

Ariyoshi N, Sekine H, Saito K, Kamataki T. Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics 2002; 12:501-4.

Ariyoshi N, Takahashi Y, Miyamoto M et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics 2000; 10:687-93.

Bidwell LC, Garrett ME, McClernon FJ et al. A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults. Nicotine Tob Res 2011. doi:10. 1093/ntr/ntr125.

Bloom J, Hinrichs AL, Wang JC et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics 2011; 21:403-16.

Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 2011; 7:715-26.

Chiang HC, Wang CY, Lee HL, Tsou TC. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation-a mammalian cell-based mutagenesis approach. Toxicol Appl Pharmacol 2011; 253:145-52.

Chuah B, Goh BC, Lee SC et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011; 102:478-83.

Daigo S, Takahashi Y, Fujieda M et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12:299-306.

Di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-9.

Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009; 10:754-80.

Diaz GJ, Murcia HW, Cepeda SM. Bioactivation of aflatoxin B1 by turkey liver microsomes: responsible cytochrome P450 enzymes. Br Poult Sci 2010; 51:828-37.

Diaz GJ, Murcia HW, Cepeda SM. Cytochrome P450 enzymes involved in the metabolism of aflatoxin B1 in chickens and quail. Poult Sci 2010; 89:2461-9.

Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol 2010; 66:571-8.

Fernandez-Salguero P, Hoffman SM, Cholerton S et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57:651-60.

Fowler JH, Settle JE, Christakis NA. Correlated genotypes in friendship networks. Proc Natl Acad Sci USA 2011; 108:1993-7.

Fukami T, Nakajima M, Higashi E et al. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos 2005; 33:1202-10.

Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Pharmacol 2005; 70:801-8.

Fukami T, Nakajima M, Matsumoto I, Zen Y, Oda M, Yokoi T. Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci 2010; 101:1024-8.

Fukami T, Nakajima M, Yamanaka H, Fukushima Y, McLeod HL, Yokoi T. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos 2007; 35:515-20.

Fukami T, Nakajima M, Yoshida R et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004; 76:519-27.

Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J 2005; 5:271-5.

Gu DF, Hinks LJ, Morton NE, Day INM. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64:383-90.

Haberl M, Anwald B, Klein K et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 2005; 15:609-24.

Hadidi H, Zahlsen K, Idle JR, Cholerton S. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol 1997; 35:903-7.

Heravi RE, Ramezani M, Behravan J. Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population. DNA Cell Biol 2010; 29:369-73.

Hioki T, Fukami T, Nakajima M, Yokoi T. Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Drug Metab Dispos 2011; 39:1345-52.

Hirose T, Fujita K, Nishimura K et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol Rep 2010; 24:529-36.

Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008; 18:67-75.

Hoffman SMG, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001; 11:687-98.

Hukkanen J, Jacob III P, Peng M, Dempsey D, Benowitz NL. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2010; 69:152-9.

Iqbal J, Sakloetsakun D, Bernkop-Schnürch A. Thiomers: Inhibition of cytochrome P450 activity. Eur J Pharm Biopharm 2011; 78:361-5.

Jin M, Arya P, Patel K et al. Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. Alcohol Clin Exp Res 2011; 35:132-9.

Jin M, Earla R, Shah A et al. A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: implications in oxidative stress in HIV + smokers. J Neuroimmune Pharmacol 2011. doi:10. 1007/s11481-011-9283-6.

Johnson GE, Quick EL, Parry EM, Parry JM. Metabolic influences for mutation induction curves after exposure to Sudan-1 and para red. Mutagenesis 2010; 25:327-33.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011; 41:851-62.

Kim KP, Jang G, Hong YS et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011; 104:605-12.

Kitagawa K, Kunugita N, Kitagawa M, Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 2001; 276:17830-5.

Kiyotani K, Fujieda M, Yamazaki H et al. Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab Pharmacokinet 2002; 17:482-7.

Kiyotani K, Yamazaki H, Fujieda M et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 2003; 13:689-95.

Krishnakumar D, Gurusamy U, Dhandapani K et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol 2011. doi:10. 1111/j. 1472-8206. 2010. 00917. x.

Ku CS, Pawitan Y, Sim X et al. Genomic copy number variations in three Southeast Asian populations. Hum Mutat 2010; 31:851-7.

Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009; 23:2101-6.

Li D, Huang X, Han K, Zhan CG. Catalytic mechanism of cytochrome P450 for 5’-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. J Am Chem Soc 2011; 133:7416-27.

Liu T, David SP, Tyndale RF et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 2011; 106:985-94.

Liu ZY, Dai MH, Tao YF, Chen DM, Yuan ZH. Inhibition of cytochrome P450 2A participating in coumarin 7-hydroxylation in pig liver microsomes. J Vet Pharmacol Ther 2011; 34:424-9.

London SJ, Idle JR, Daly AK, Coetzee GA. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353:898-9.

Ma WJ, Lv GD, Zheng ST et al. DNA polymorphism and risk of esophageal squamous cell carcinoma in a population of North Xinjiang, China. World J Gastroenterol 2010; 16:641-7.

Matsunaga T, Nomoto M, Kozak CA, Gonzalez FJ. Structure and in vitro transcription of the rat CYP2A1 and CYP2A2 genes and regional localization of the CYP2A gene subfamily on mouse chromosome 7. Biochemistry 1990; 29:1329-41.

Mitchell AL, Bale AE, Gonzalez F, McBride OW. Mapping of cytochrome p450 IIA, IIB, and IIF subfamilies on chromosome 19 by linkage analysis. Cytogenet Cell Genet 1989; 51:1045.

Miyamoto M, Umetsu Y, Dosaka-Akita H et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 1999; 261:658-60.

Miyazawa M, Marumoto S, Takahashi T, Nakahashi H, Haigou R, Nakanishi K. Metabolism of (+)- and (-)-menthols by CYP2A6 in human liver microsomes. J Oleo Sci 2011; 60:127-32.

Mizutani T. Toxicity of xanthene food dyes by inhibition of human drug-metabolizing enzymes in a noncompetitive manner. J Environ Public Health 2009. doi:10. 1155/2009/953952.

Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009; 39:795-802.

Mwenifumbo JC, Al Koudsi N, Ho MK et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 2008; 29:679-88.

Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q et al. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 2008; 83:115-21.

Mwenifumbo JC, Zhou Q, Benowitz NL, Sellers EM, Tyndale RF. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics 2010; 11:189-98.

Nakajima M, Fukami T, Yamanaka H et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006; 80:282-97.

Nakajima M, Kwon JT, Tanaka N et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69:72-8.

Nakajima M, Yamamoto T, Nunoya K et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24:1212-7.

Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokoi T. Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 2004; 569:75-81.

Negishi M, Lindberg R, Burkhart B, Ichikawa T, Honkakoski P, Lang M. Mouse steroid 15-alpha-hydroxylase gene family: identification of type II P450(15-alpha) as coumarin 7-hydroxylase. Biochemistry 1989; 28:4169-72.

Nelson DR, Koymans L, Kamataki T et al. Cytochrome P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 1996; 6:1-42.

Nunoya K, Yokoi T, Kimura K et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998; 8:239-49.

Nunoya K, Yokoi T, Takahashi Y, Kimura K, Kinoshita M, Kamataki T. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J Biochem 1999; 126:402-7.

Nunoya KI, Yokoi T, Kimura K et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 1999; 289:437-42.

Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 2010; 38:1218-29.

Oscarson M, Gullstén H, Rautio A et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 1998; 438:201-5.

Oscarson M, McLellan RA, Asp V et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 2002; 20:275-83.

Oscarson M, McLellan RA, Gullstén H et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448:105-10.

Oscarson M, McLellan RA, Gullstén H et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460:321-7.

Park SR, Kong SY, Nam BH et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer 2011; 104:1126-34.

Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284:455-60.

Pitarque M, von Richter O, Rodríguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 2004; 23:258-66.

Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr A 2010; 1217:7942-8.

Rao Y, Hoffmann E, Zia M et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58:747-55.

Rasmussen MK, Zamaratskaia G, Ekstrand B. In vitro cytochrome P450 2E1 and 2A activities in the presence of testicular steroids. Reprod Domest Anim 2011; 46:149-54.

Rodriguez S, Cook DG, Gaunt TR, Nightingale CM, Whincup PH, Day IN. Combined analysis of CHRNA5, CHRNA3 and CYP2A6 in relation to adolescent smoking behaviour. J Psychopharmacol 2011; 25:915-23.

Sabol SZ, Hamer DH. An improved assay shows no association between the CYP2A6 gene and cigarette smoking behavior. Behav Genet 1999; 29:257-61.

Saito S, Iida A, Sekine A et al. Catalog of 680 variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48:249-70.

Siedlinski M, Cho MH, Bakke P et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 2011; 66:894-902.

Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.

Soriano A, Vicente J, Carcas C et al. Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. Fundam Clin Pharmacol 2011; 25:627-32.

Sturgess JE, George TP, Kennedy JL, Heinz A, Müller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict Biol 2011; 16:357-76.

Takeuchi H, Saoo K, Matsuda Y et al. 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Mol Med Report 2009; 2:585-8.

Tamaki Y, Arai T, Sugimura H et al. Association between cancer risk and drug metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in Japanese cases of lung cancer. Drug Metab Pharmacokinet 2011. doi:10. 2133/dmpk. DMPK-11-RG-046.

Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010; 112:320-3.

Tanii H, Shitara Y, Horie T. Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. Eur J Clin Pharmacol 2011; 67:1017-25.

Thorgeirsson TE, Gudbjartsson DF, Surakka et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42:448-53.

Tiong KH, Yiap BC, Tan EL, Ismail R, Ong CE. Functional characterization of cytochrome P450 2A6 allelic variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22. Drug Metab Dispos 2010; 38:745-51.

Tiong KH, Yiap BC, Tan EL, Ismail R, Ong CE. In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity. Xenobiotica 2010; 40:458-66.

Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, Kusano M. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol 2011; 22:355-61.

Uehara S, Murayama N, Yamazaki H, Uno Y. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica 2010; 40:621-9.

Ueng YF, Chen CC, Chung YT et al. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br J Pharmacol 2011; 163:1250-62.

von Richter O, Pitarque M, Rodríguez-Antona C et al. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics 2004; 14:369-79.

Wang H, Bian T, Liu D et al. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Pharmacogenomics 2011; 12:481-92.

Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011; 103:1342-6.

Williams JM, Gandhi KK, Benowitz NL. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. Cancer Epidemiol Biomarkers Prev 2010; 19:2582-9.

Xu C, Rao YS, Xu B et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 2002; 290:318-24.

Xu Y, Shen Z, Shen J, Liu G, Li W, Tang Y. Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK. J Mol Graph Model 2011; 30:1-9.

Yamamiya I, Yoshisue K, Matsushima E, Nagayama S. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil. Drug Metab Dispos 2010; 38:1267-76.

Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29:1322-9.

Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 gene in Japanese. Pharm Res 1998; 15:517-24.

Yokota S, Higashi E, Fukami T, Yokoi T, Nakajima M. Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem Pharmacol 2011; 81:289-94.

Yongvanit P, Phanomsri E, Namwat N et al. Hepatic cytochrome P450 2A6 and 2E1 status in peri-tumor tissues of patients with Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol Int 2011. doi:10. 1016/j. parint. 2011. 06. 026.

Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74:69-76.

Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 2002; 54:511-7.

Zhang QY, Gu J, Su T et al. Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. Biochem Biophys Res Commun 2005; 338:318-24.

Zhou X, Zhuo X, Xie F et al. Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. J Pharmacol Exp Ther 2010; 332:578-87.

CYP2B6 (cytochrome P450, family 2, subfamily B, polypeptide 6)

Abass K, Reponen P, Mattila S, Pelkonen O. Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem Biol Interact 2010; 185:163-73.

Abass K, Reponen P, Mattila S, Pelkonen O. Metabolism of α-thujone in human hepatic preparations in vitro. Xenobiotica 2011; 41:101-11.

Abass K, Turpeinen M, Pelkonen O. An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes. J Environ Sci Health B 2009; 44:553-63.

Al Koudsi N, Tyndale RF. Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica 2010; 40:381-92.

Anderson LE, Dring AM, Hamel LD, Stoner MA. Modulation of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) by 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives, ligands of peripheral benzodiazepine receptor (PBR). Toxicol Lett 2011; 202:148-54.

Arab-Alameddine M, di Iulio J, Buclin T et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009; 85:485-94.

Arenaz I, Vicente J, Fanlo A et al. Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam Clin Pharmacol 2010; 24:247-53.

Ariyoshi N, Iga Y, Hirata K et al. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab Pharmacokinet 2010; 25:298-306.

Ariyoshi N, Ohara M, Kaneko M et al. Gln172His replacement overcomes effects on the metabolism of cyclophosfamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab Dispos 2011; 39:2045-8.

Bachleda P, Vrzal R, Dvorák Z. Activation of MAPKs influences the expression of drug-metabolizing enzymes in primary human hepatocytes. Gen Physiol Biophys 2009; 28:316-20.

Bae JW, Jang CG, Lee SY. Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol 2011. doi:10. 1177/0091270010388651.

Bae SK, Cao S, Seo KA et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos 2008; 36:1679-88.

Black JL, Litzow MR, Hogan WJ et al. Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. Leuk Res 2011. doi:10. 1016/j. leukres. 2011. 06. 020.

Bray J, Sludden J, Griffin MJ et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102:1003-9.

Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010; 88:383-9.

Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 2011; 16:142-4.

Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother 2010; 65:1889-93.

Casabar RC, Das PC, Dekrey GK et al. Endosulfan induces CYP2B6 and CYP3A4 by activating the pregnane X receptor. Toxicol Appl Pharmacol 2010; 245:335-43.

Chan CY, New LS, Ho HK, Chan EC. Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation. Toxicol Lett 2011; 206:314-24.

Chen J, Sun J, Ma Q et al. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit 2010; 32:573-8.

Chen Y, Liu L, Laille E, Kumar G, Surapaneni S. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. Cancer Chemother Pharmacol 2010; 65:995-1000.

Chou M, Bertrand J, Segeral O et al. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010; 54:4432-9.

Chou YC, Chung YT, Liu TY et al. The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J Pharm Sci 2010; 99:1063-77.

Chung JY, Cho JY, Lim HS et al. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos 2011; 39:92-7.

Chung JY, Jang SB, Lee YJ, Park MS, Park K. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 2011; 51:53-9.

Ciccacci C, Borgiani P, Ceffa S et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11:23-31.

Cohen K, Grant A, Dandara C et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687-95.

Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 2009; 78:184-90.

Croom EL, Wallace AD, Hodgson E. Human variation in CYP-specific chlorpyrifos metabolism. Toxicology 2010; 276:184-91.

Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism 2011; 60:1584-9.

Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S. Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug Metab Dispos 2009; 37:1991-3.

di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-9.

Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy 2009; 29:1089-102.

Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18:515-23.

Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2010; 11:1223-34.

Fan L, Wang JC, Jiang F et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 2009; 65:403-9.

Feidt DM, Klein K, Hofmann U et al. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos 2010; 38:1589-97.

Fernandes BJ, Miranda Silva CD, Andrade JM, Matthes AD, Coelho EB, Lanchote VL. Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. Cancer Chemother Pharmacol 2011; 68:897-904.

Fokina VM, Patrikeeva SL, Zharikova OL, Nanovskaya TN, Hankins GV, Ahmed MS. Transplacental transfer and metabolism of buprenorphine in preterm human placenta. Am J Perinatol 2011; 28:25-32.

Fonseca F, de la Torre R, Díaz L et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 2011. doi:10. 1371/journal. pone. 0019527.

Foxenberg RJ, Ellison CA, Knaak JB, Ma C, Olson JR. Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion. Toxicology 2011; 285:57-66.

Funakoshi N, Duret C, Pascussi JM et al. Comparison of hepatic-like cell production from human embryonic stem cells and adult liver progenitor cells: CAR transduction activates a battery of detoxification genes. Stem Cell Rev 2011; 7:518-31.

Ganesan S, Sahu R, Walker LA, Tekwani BL. Cytochrome P450-dependent toxicity of dapsone in human erythrocytes. J Appl Toxicol 2010; 30:271-5.

Gatanaga H, Hayashida T, Tsuchiya K et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230-7.

Gatanaga H, Oka S. Successful genotype-tailored treatment with small-dose efavirenz. AIDS 2009; 23:433-4.

Gay SC, Shah MB, Talakad JC et al. Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2. 0-A resolution. Mol Pharmacol 2010; 77:529-38.

Genovese S, Epifano F, Curini M, Menger D, Zembruski NC, Weiss J. In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression. Phytomedicine 2011; 18:586-91.

Giantin M, Lopparelli RM, Zancanella V et al. Effects of illicit dexamethasone upon hepatic drug metabolizing enzymes and related transcription factors mRNAs and their potential use as biomarkers in cattle. J Agric Food Chem 2010; 58:1342-9.

Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010; 7:32.

Gozalo C, Gérard L, Loiseau P et al. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-Naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 Trial. Basic Clin Pharmacol Toxicol 2011. doi:10. 1111/j. 1742-7843. 2011. 00780. x.

Gupta D, Venkatesh M, Wang H et al. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res 2008; 14:5332-40.

Habtewold A, Amogne W, Makonnen E et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011; 66:2350-61.

Hagihara K, Kazui M, Kurihara A et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009; 37:2145-52.

Halpert JR. Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. Drug Metab Dispos 2011; 39:1113-21.

Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, Kunze KL. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug Metab Dispos 2010; 38:963-72.

Helsby NA, Hui CY, Goldthorpe MA et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 2010; 70:844-53.

Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14:225-38.

Hiratsuka M, Hinai Y, Konno Y, Nozawa H, Konno S, Mizugaki M. Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals. Drug Metab Pharmacokinet 2004; 19:155-8.

Hofmann MH, Blievernicht JK, Klein K et al. Aberrant splicing caused by single nucleotide polymorphism c. 516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325:284-92.

Honda M, Muroi Y, Tamaki Y et al. Functional characterization of CYP2B6 allelic variants in demethylation of anti-malarial artemether. Drug Metab Dispos 2011; 39:1860-5.

Inoue K, Negishi M. Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene. J Biol Chem 2008; 283:10425-32.

Jacob RM, Johnstone EC, Neville MJ et al. Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin Chem 2004; 50:1372-7.

Jamshidi Y, Moreton M, McKeown DA et al. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother 2010; 65:2614-9.

Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011; 39:98-105.

Kanno Y, Inoue Y, Inouye Y. 5-aminoimidazole-4-carboxamide-1-beta-ribofuranoside (AICAR) prevents nuclear translocation of constitutive androstane receptor by AMP-activated protein kinase (AMPK) independent manner. J Toxicol Sci 2010; 35:571-6.

Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 2011. doi:10. 1016/j. thromres. 2011. 07. 022.

Khokhar JY, Miksys SL, Tyndale RF. Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. Brain Res 2010; 1348:1-9.

Kim H, Bae SK, Park SJ et al. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. Br J Clin Pharmacol 2010; 70:126-31.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011; 41:851-62.

Kim KA, Song WK, Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009; 86:511-8.

King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22:1709-17.

Klein K, Lang T, Saussele T et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-73.

Lamba V, Lamba J, Yasuda K et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003; 307:906-22.

Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.

Lang T, Klein K, Richter T et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004; 311:34-43.

Lau AJ, Yang G, Rajaraman G, Baucom CC, Chang TK. Differential effect of meclizine on the activity of human pregnane X receptor and constitutive androstane receptor. J Pharmacol Exp Ther 2011; 336:816-26.

Lei HP, Ji W, Lin J et al. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 2009; 68:201-6.

Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 2011. doi:10. 1111/j. 1369-1600. 2011. 00349. x.

Li L, Hassan HE, Tolson AH, Ferguson SS, Eddington ND, Wang H. Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells. J Pharmacol Exp Ther 2010; 335:562-71.

Lindfelt T, O’Brien J, Song JC, Patel R, Winslow DL. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Ann Pharmacother 2010; 44:1572-8.

Lo R, Burgoon L, Macpherson L, Ahmed S, Matthews J. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Biochim Biophys Acta 2010; 1799:469-79.

Lorico A, Mercapide J, Solodushko V, Alexeyev M, Fodstad O, Rappa G. Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma. Cancer Gene Ther 2008; 15:605-15.

Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet 2009; 54:564-71.

Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, Flockhart DA. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 2011. doi:10. 1007/s10549-011-1699-4.

Mahungu TW, Nair D, Smith CJ et al. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving efavirenz. Clin Pharmacol Ther 2009; 86:204-11.

McErlane V, Yakkundi A, McCarthy HO et al. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med 2005; 7:851-9.

Mehlotra RK, Cheruvu VK, Blood Zikursh MJ et al. Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis 2011; 204:291-8.

Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 2009; 10:730-53.

Molnari JC, Hassan HE, Moeller BM, Myers AL. Drug interaction study between bupropion and ticlopidine in male CF-1 mice. Biol Pharm Bull 2011; 34:447-51.

Mürdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89:708-17.

Mukonzo JK, Röshammar D, Waako P et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009; 68:690-9.

Nakajima M, Komagata S, Fujiki Y et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 2007; 17:431-45.

Ngaimisi E, Mugusi S, Minzi O et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011; 90:406-13.

Niu RJ, Zheng QC, Zhang JL, Zhang HX. Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods. J Mol Model 2011. doi:10. 1007/s00894-011-0970-2.

Noppers I, Olofsen E, Niesters M et al. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology 2011; 114:1435-45.

Owen A, Khoo SH. Pharmacogenetics of antiretroviral agents. Curr Opin HIV AIDS 2008; 3:288-95.

Ozsvár Z, Solymossi Z, Monostory K. Methyldopa-induced acute reactive hepatitis in pregnancy, drug-metabolizing capacity of the liver. Orv Hetil 2010; 151:457-61.

Piton A, Rauch C, Langouet S, Guillouzo A, Morel F. Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes. Toxicol In Vitro 2010; 24:452-9.

Puccinelli E, Gervasi PG, La Marca M, Beffy P, Longo V. Expression and inducibility by phenobarbital of CYP2C33, CYP2C42, CYP2C49, CYP2B22, and CYP3As in porcine liver, kidney, small intestine, and nasal tissues. Xenobiotica 2010; 40:525-35.

Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49:513-9.

Roca B. Pharmacogenomics of antiretrovirals. Recent Pat Antiinfect Drug Discov 2008; 3:132-5.

Rotger M, Saumoy M, Zhang K et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics 2007; 17:885-90.

Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81:557-66.

Saito S, Iida A, Sekine A et al. Catalog of 680 variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48:249-70.

Salminen KA, Meyer A, Jerabkova L et al. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phytomedicine 2011; 18:533-8.

Shin HC, Kim HR, Cho HJ et al. Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos 2009; 30:411-21.

Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011; 20:111-8.

Small DS, Farid NA, Payne CD et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010; 49:777-98.

Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.

Sridar C, Snider NT, Hollenberg PF. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 2011; 39:782-8.

Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica 2010; 40:357-67.

Strehlau R, Martens L, Coovadia A et al. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J 2011; 30:1001-3.

Sugatani J, Osabe M, Kurosawa M, Kitamura N, Ikari A, Miwa M. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression. Drug Metab Dispos 2010; 38:177-86.

Svärd J, Spiers JP, Mulcahy F, Hennessy M. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and Sub-Saharan Africans. J Acquir Immune Defic Syndr 2010; 55:536-49.

Takizawa D, Kakizaki S, Horiguchi N et al. Histone deacetylase inhibitors induce cytochrome P450 2B by activating nuclear receptor constitutive androstane receptor. Drug Metab Dispos 2010; 38:1493-8.

Talakad JC, Shah MB, Walker GS, Xiang C, Halpert JR, Dalvie D. Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4. Drug Metab Dispos 2011; 39:539-50.

ter Heine R, Scherpbier HJ, Crommentuyn KM et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008; 13:779-87.

Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 2010; 20:520-3.

Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010; 85:190-200.

Tsuchiya K, Gatanaga H, Tachikawa N et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319:1322-6.

Uehara S, Murayama N, Nakanishi Y, Zeldin DC, Yamazaki H, Uno Y. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 2011; 339:654-61.

Uno Y, Iwasaki K, Yamazaki H, Nelson DR. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 2011; 43:346-61.

Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis). J Vet Med Sci 2009; 71:1653-6.

Uttayamakul S, Likanonsakul S, Manosuthi W et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010; 7:8.

Veiga MI, Asimus S, Ferreira PE et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 2009; 65:355-63.

Wang CJ, Shao H, Shang M, Zhang W. Association between CYP2B6, CYP2D6, GSTP1 genetic polymorphisms and urinary styrene metabolites in professional workers. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2009; 27:589-92.

Wang D, Li L, Fuhrman J, Ferguson S, Wang H. The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes. Pharm Res 2011; 28:2034-44.

Wang J, Sönnerborg A, Rane A et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16:191-8.

Wang SC, Ho IK, Tsou HH et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 2011; 31:463-9.

Wang X, Abdelrahman DR, Fokina VM, Hankins GD, Ahmed MS, Nanovskaya TN. Metabolism of bupropion by baboon hepatic and placental microsomes. Biochem Pharmacol 2011; 82:295-303.

Wang X, Abdelrahman DR, Zharikova OL et al. Bupropion metabolism by human placenta. Biochem Pharmacol 2010; 79:1684-90.

Washio I, Maeda M, Sugiura C et al. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 2011; 39:1-3.

Watanabe T, Sakuyama K, Sasaki T et al. Functional characterization of 26 CYP2B6 allelic variants (CYP2B6. 2-CYP2B6. 28, except CYP2B6. 22). Pharmacogenet Genomics 2010; 20:459-62.

Winoto J, Song H, Hines C, Nagaraja H, Rovin BH. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy. Clin Nephrol 2011; 75:451-7.

Wyen C, Hendra H, Siccardi M et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 2011; 66:2092-8.

Yang K, Koh KH, Jeong H. Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. Drug Metab Lett 2010; 4:129-33.

Yao R, Yasuoka A, Kamei A et al. Dietary flavonoids activate the constitutive androstane receptor (CAR). J Agric Food Chem 2010; 58:2168-73.

Yao S, Barlow WE, Albain KS et al. Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 2010; 16:6169-76.

Yuan J, Guo S, Hall D et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25:1271-80.

Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility. Ann Hematol 2011; 90:293-9.

Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392:1093-108.

Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of cytochrome P450 2B6 (CYP2B6. 4 – CYP2B6. 9) exhibit altered rates of metabolism for bupropion and efavirenz: A charge-reversal mutation in the K139E variant (CYP2B6. 8) impairs formation of a functional P450-reductase complex. J Pharmacol Exp Ther 2011; 338:803-9.

Zhou SF, Di YM, Chan E et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008; 9:738-84.

Zukunft J, Lang T, Richter T et al. A natural CYP2B6 TATA box polymorphism (-82T→C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 2005; 67:1772-82.

CYP2C8 (cytochrome P450, family 2, subfamily C, polypeptide 8)

Arun Kumar AS, Chakradhara Rao US, Umamaheswaran G et al. Haplotype structures of common variants of CYP2C8, CYP2C9, and ADRB1 genes in a South Indian population. Genet Test Mol Biomarkers 2011; 15:407-13.

Bahadur N, Leathart JB, Mutch E et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64:1579-89.

Bergmann TK, Brasch-Andersen C, Gréen H et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011; 11:113-20.

Bergmann TK, Gréen H, Brasch-Andersen C et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011; 67:693-700.

Calixto LA, de Oliveira AR, Jabor VA, Bonato PS. In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction. Eur J Drug Metab Pharmacokinet 2011; 36:159-66.

Campayo M, Viñolas N, Navarro A et al. Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancer. J Surg Res 2011; 167:5-12.

Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 2011; 108:55-62.

Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 2009; 10:567-78.

Chiba K, Morimoto K. Genetic marker of statin-induced rhabdomyolysis. Yakugaku Zasshi 2011; 131:247-53.

Dai D, Zeldin DC, Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.

Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009; 10:1489-510.

Deng Y, Edin ML, Theken KN et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011; 25:703-13.

Ding FX, Shen HC, Wilsie LC et al. Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A. Bioorg Med Chem Lett 2010; 20:3372-5.

Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro 2011; 25:21-7.

Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 2008; 64:967-70.

Durrmeyer X, Hovhannisyan S, Médard Y et al. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? PLoS One 2010. doi:10. 1371/journal. pone. 0012329.

Edin ML, Wang Z, Bradbury JA et al. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 2011; 25:3436-47.

Edvardsen H, Brunsvig PF, Solvang H et al. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J 2010; 10:513-23.

English BC, Baum CE, Adelberg DE et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 2010; 6:579-83.

Flachsbart F, Ufer M, Kleindorp R, Nikolaus S, Schreiber S, Nebel A. Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population. J Gerontol A Biol Sci Med Sci 2011; 66:1186-91.

Fransson MN, Gréen H, Litton JE, Friberg LE. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos 2011; 39:247-55.

Gao Y, Liu D, Wang H, Zhu J, Chen C. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica 2010; 40:467-75.

Gil JP. Amodiaquine pharmacogenetics. Pharmacogenomics 2008; 9:1385-90.

Główka F, Karaźniewicz-Łada M, Grześkowiak E, Rogozinska D, Romanowski W. Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet 2011; 36:167-73.

Gökalp O, Gunes A, Cam H et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol 2011. doi:10. 1007/s00228-011-1078-4.

Graefe-Mody EU, Jungnik A, Ring A, Woerle HJ, Dugi KA. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther 2010; 48:652-61.

Gréen H, Khan MS, Jakobsen-Falk I, Avall-Lundqvist E, Peterson C. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. J Pharm Sci 2011. doi:10. 1002/jps. 22680.

Hanioka N, Matsumoto K, Saito Y, Narimatsu S. Functional characterization of CYP2C8. 13 and CYP2C8. 14: catalytic activities toward paclitaxel. Basic Clin Pharmacol Toxicol 2010; 107:565-9.

Haschke-Becher E, Kirchheiner J, Trummer O et al. Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics 2010; 11:1359-65.

He J, Qiu Z, Li N et al. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol 2011; 67:701-7.

Hichiya H, Tanaka-Kagawa T, Soyama A et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005; 33:630-6.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 2011; 89:579-86.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 2011; 39:1977-86.

Hu G, Johnson EF, Kemper B. CYP2C8 exists as a dimer in natural membranes. Drug Metab Dispos 2010; 38:1976-83.

Ikeda T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab Pharmacokinet 2011; 26:60-70.

Illingworth NA, Boddy AV, Daly AK, Veal GJ. Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol 2011; 162:989-99.

Jacobson PA, Schladt D, Oetting WS et al. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation 2011; 91:309-16.

Jernström H, Bågeman E, Rose C, Jönsson PE, Ingvar C. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer 2009; 101:1817-23.

Jiang H, Zhong F, Sun L, Feng W, Huang ZX, Tan X. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8. Amino Acids 2011; 40:1195-204.

Kamdem LK, Liu Y, Stearns V et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010; 70:854-69.

Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 2010; 88:223-30.

Karonen T, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. Eur J Clin Pharmacol 2011; 67:151-5.

Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8. 3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 2011; 82:681-91.

Kaspera R, Naraharisetti SB, Tamraz B et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenet Genomics 2010; 20:619-29.

Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011; 71:443-54.

Kim DK, Liu KH, Jeong JH et al. In vitro metabolism of magnolin and characterization of cytochrome P450 enzymes responsible for its metabolism in human liver microsomes. Xenobiotica 2011; 41:358-71.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011; 41:851-62.

Kirchheiner J, Thomas S, Bauer S et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006; 80:657-67.

Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13:289-95.

Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf 2010; 9:633-41.

Kosel M, Wild W, Bell A et al. Eicosanoid formation by a cytochrome P450 isoform expressed in the pharynx of Caenorhabditis elegans. Biochem J 2011; 435:689-700.

Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009; 10:124.

Lee CR, Imig JD, Edin ML et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010; 24:3770-81.

Marciante KD, Durda JP, Heckbert SR et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011; 21:280-8.

Marciante KD, Totah RA, Heckbert SR et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008; 18:535-43.

Michaud V, Frappier M, Dumas MC, Turgeon J. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One 2010. doi:10. 1371/journal. pone. 0015666.

Muschler E, Lal J, Jetter A et al. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol 2009; 105:374-9.

Nakajima Y, Yoshitani T, Fukushima-Uesaka H et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther 2006; 80:179-91.

Naraharisetti SB, Lin YS, Rieder MJ et al. Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos 2010; 38:889-93.

Nebot N, Crettol S, d’Esposito F, Tattam B, Hibbs DE, Murray M. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 2010; 161:1059-69.

Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008; 47:463-74.

Nithipatikom K, Brody DM, Tang AT et al. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci 2010; 101:2629-36.

Pavlov TS, Ilatovskaya DV, Levchenko V, Mattson DL, Roman RJ, Staruschenko A. Effects of cytochrome P450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am J Physiol Renal Physiol 2011; 301:672-81.

Pedersen RS, Brasch-Andersen C, Sim SC et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010; 66:1199-205.

Peethambaram P, Fridley BL, Vierkant RA et al. Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol Genet 2011; 2:185-95.

Qian L, Zolfaghari R, Ross AC. Liver-specific cytochrome P450 CYP2C22 is a direct target of retinoic acid and a retinoic acid-metabolizing enzyme in rat liver. J Lipid Res 2010; 51:1781-92.

Qu YQ, Fang ZZ, Yang L et al. Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie 2011; 66:216-21.

Quintieri L, Palatini P, Moro S, Floreani M. Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin. Drug Metab Pharmacokinet 2011. doi:10. 2133/dmpk. DMPK-11-RG-048.

Rana R, Chen Y, Ferguson SS, Kissling GE, Surapureddi S, Goldstein JA. Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos 2010; 38:591-9.

Rodenburg EM, Visser LE, Danser AH et al. Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenet Genomics 2010; 20:426-34.

Rodríguez-Antona C, Niemi M, Backman JT et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 2008; 8:268-77.

Roustit M, Blondel E, Villier C, Fonrose X, Mallaret MP. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Ann Pharmacother 2010; 44:764-7.

Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 2010; 38:1261-6.

Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV. Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metab Dispos 2010; 38:1211-7.

Ruzilawati AB, Gan SH. CYP3A4 genetic polymorphism influences repaglinide’s pharmacokinetics. Pharmacology 2010; 85:357-64.

Saito Y, Katori N, Soyama A et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 2007; 17:461-71.

Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 2007; 18:164-73.

Schwartz JI, Stroh M, Gao B et al. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone. Cardiovasc Ther 2009; 27:239-45.

Soyama A, Saito Y, Komamura K et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 2002; 17:374-7.

Stamer UM, Zhang L, Stüber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics 2010; 11:843-64.

Suarez-Kurtz G, Genro JP, de Moraes MO et al. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 89.

Such E, Cervera J, Terpos E et al. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica 2011; 96:1557-9.

Sun DX, Lu JC, Fang ZZ et al. Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside. Phytother Res 2010; 24:1670-5.

Szczesna-Skorupa E, Kemper B. Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol Pharmacol 2011; 79:340-50.

Tan AR, Dowlati A, Jones SF et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010; 15:1253-61.

Teh LK, Zahri MK, Zakaria ZA, Ismail R, Salleh MZ. Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography. J Clin Pharm Ther 2010; 35:723-8.

Thatcher JE, Zelter A, Isoherranen N. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem Pharmacol 2010; 80:903-12.

Tomalik-Scharte D, Fuhr U, Hellmich M et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 2011; 39:927-32.

Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008; 36:73-80.

Usui T, Hashizume T, Katsumata T, Yokoi T, Komuro S. In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug Metab Dispos 2011; 39:1303-10.

Vandenbrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Evaluation of CYP2C8 inhibition in vitro: Utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 2011; 39:1546-54.

Ventura V, Solà J, Celma C, Peraire C, Obach R. In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification. Drug Metab Dispos 2011; 39:1235-46.

Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54:1609-16.

Weise A, Prause S, Eidens M et al. Prevalence of CYP450 gene variations in patients with type 2 diabetes. Clin Lab 2010; 56:311-8.

Weiss JR, Baer MR, Ambrosone CB et al. Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2007; 16:1038-41.

Xu X, Zhang XA, Wang DW. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 2011; 63:597-609.

Yeo CW, Lee SJ, Lee SS et al. Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metab Dispos 2011; 39:711-6.

Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392:1093-108.

Zhang LF, Hu X, Wang P, Zhang L. Metabolism of osthol in isolated hepatocytes of rat. Yao Xue Xue Bao 2009; 44:1131-5.

Zheng N, Zou P, Wang S, Sun D. In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes. Drug Metab Dispos 2011; 39:627-35.

Zhou L, Naraharisetti SB, Liu L et al. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010; 31:228-42.

CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9)

Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Céron D. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. Br J Clin Pharmacol 2001; 52:456-7.

Abdul MI, Jiang X, Williams KM et al. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol 2010; 69:508-15.

Agúndez JA, Martínez C, Pérez-Sala D, Carballo M, Torres MJ, García-Martín E. Pharmacogenomics in aspirin intolerance. Curr Drug Metab 2009; 10:998-1008.

Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-9.

Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10:511-8.

Allabi AC, Gala JL, Horsmans Y et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004; 76:113-8.

Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005; 15:779-86.

Allabi AC, Horsmans Y, Alvarez JC et al. Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects. Eur J Drug Metab Pharmacokinet 2011. doi:10. 1007/s13318-011-0056-7

Ames PR, Margaglione M, Ciampa A et al. Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome. Thromb Res 2011; 127:595-9.

Amini-Shirazi N, Ghahremani MH, Ahmadkhaniha R et al. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Methods 2010; 20:452-7.

Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol 2010; 17:208-13.

Andrade RJ, Agúndez JA, Lucena MI, Martínez C, Cueto R, García-Martín E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009; 10:956-70.

Aynacioglu AS, Brockmöller J, Bauer S et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48:409-15.

Azarpira N, Namazi S, Hendijani F, Banan M, Darai M. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacol Rep 2010; 62:740-6.

Babaoglu MO, Yasar U, Sandberg M et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60:337-42.

Bae JW, Choi CI, Jang CG, Lee SY. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 2011; 71:550-5.

Bae JW, Choi CI, Kim MJ et al. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 2011; 32:1303-8.

Bae JW, Kim JH, Choi CI et al. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch Pharm Res 2009; 32:269-73.

Bailey KM, Romaine SP, Jackson BM et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet 2010; 3:276-85.

Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24:1401-3.

Bamba Y, Yun YS, Kunugi A, Inoue H. Compounds isolated from Curcuma aromatica Salisb. inhibit human P450 enzymes. J Nat Med 2011; 65:583-7.

Banu H, Renuka N, Vasanthakumar G. Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies. Biochimie 2011; 93:1028-36.

Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol 2011; 51:561-74.

Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-8.

Blaisdell J, Jorge-Nebert LF, Coulter S et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14:527-37.

Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005; 70:1096-103.

Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64:871-6.

Bolbrinker J, Beige J, Huber M et al. Role of CYP2C9 genetic variants for salt sensitivity and the regulation of the renin-angiotensin-aldosterone system in normotensive men. J Hypertens 2011; 29:56-61.

Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996; 49:305-8.

Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011; 72:442-50.

Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5:2429-36.

Brenner SS, Herrlinger C, Dilger K et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42:283-92.

Burmester JK, Berg RL, Glurich I, Yale SH, Schmelzer JR, Caldwell MD. Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses. Clin Med Res 2011. doi:10. 3121/cmr. 2011. 951.

Caraco Y, Muszkat M, Wood AJ. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 2001; 11:587-96.

Carbonell N, Verstuyft C, Massard J et al. CYP2C9*3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. Clin Pharmacol Ther 2010; 87:693-8.

Cha PC, Mushiroda T, Takahashi A et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010; 19:4735-44.

Chan AT, Zauber AG, Hsu M et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009; 136:2127-36.

Chang SY, Li W, Traeger SC et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos 2008; 36:2513-22.

Chen K, Wang R, Wen SY, Li J, Wang SQ. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide. J Clin Pharm Ther 2005; 30:241-9.

Choi CI, Kim MJ, Chung EK et al. CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol 2011. doi:10. 1007/s00228-011-1098-0.

Choi CI, Kim MJ, Jang CG, Park YS, Bae JW, Lee SY. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam. Basic Clin Pharmacol Toxicol 2011. doi:10. 1111/j. 1742-7843. 2011. 00751. x.

Choi DH, Li C, Choi JS. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol 2010; 62:908-14.

Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy 2006; 26:868-71.

Chow HH, Garland LL, Hsu CH et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 2010; 3:1168-75.

Christiansen A, Backensfeld T, Denner K, Weitschies W. Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. Eur J Pharm Biopharm 2011; 78:166-72.

Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31:53-9.

Cojocaru V, Balali-Mood K, Sansom MS, Wade RC. Structure and dynamics of the membrane-bound cytochrome P450 2C9. PLoS Comput Biol 2011. doi:10. 1371/journal. pcbi. 1002152.

Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7:203-10.

DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315:1085-90.

Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011; 18:1159-64.

Dickmann LJ, Rettie AE, Kneller MB et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60:382-7.

Djaffar-Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Pharmacogenetics of coumarin dosing: Prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. Genet Test Mol Biomarkers 2011; 15:827-30.

Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008; 42:1822-31.

Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, Llerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003; 59:221-5.

Dorado P, Sosa-Macias MG, Peñas-Lledó EM et al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J 2011; 11:108-12.

Drăgan CA, Peters FT, Bour P et al. Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems. Appl Biochem Biotechnol 2011; 163:965-80.

Dunn BK, Greene MH, Kelley JM et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int J Mol Epidemiol Genet 2010; 1:332-49.

Efrati E, Elkin H, Sprecher E, Krivoy N. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Curr Drug Saf 2010; 5:190-3.

Eiden C, Cociglio M, Hillaire-Buys D et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica 2010; 40:701-6.

Elliot DJ, Suharjono, Lewis BC et al. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol 2007; 64:450-7.

Estany-Gestal A, Salgado-Barreira A, Sánchez-Diz P, Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review. Pharmacogenet Genomics 2011; 21:357-64.

Fang ZZ, Zhang YY, Ge GB et al. Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline, and assessment of its herb-drug interactions. Phytother Res 2011; 25:256-63.

Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 2010; 69:193-9.

Ferder N, Eby CS, Deych E et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 2010; 8:95-100.

Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004; 109:178-83.

Fischer V, Johanson L, Heitz F et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27:410-6.

Flockhart DA, O’Kane D, Williams MS et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10:139-50.

Foster BC, Arnason JT, Saleem A et al. Comparative study of hops-containing products on human cytochrome P450-mediated metabolism. J Agric Food Chem 2011; 59:5159-63.

Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84:326-31.

Gan GG, Phipps ME, Lee MM et al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol 2011; 90:635-41.

García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76:119-27.

Godbillon J, Richard J, Gerardin A, Meinertz T, Kasper W, Jähnchen E. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981; 12:621-9.

Goldstein JA, Blaisdell JA, Limdi NA. A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy. Blood Cells Mol Dis 2009; 42:155-8.

Gong IY, Tirona RG, Schwarz UI et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011; 118:3163-71.

Goto S, Seo T, Murata T et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 2007; 29:118-21.

Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol 2010; 50:829-34.

Gra O, Mityaeva O, Berdichevets I et al. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians. Genet Test Mol Biomarkers 2010; 14:329-42.

Graefe-Mody EU, Brand T, Ring A et al. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Int J Clin Pharmacol Ther 2011; 49:300-10.

Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ. Assessment of the Pharmacokinetic Interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet 2011; 26:123-9.

Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005; 35:853-61.

Guo Y, Zhang Y, Wang Y et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33:749-53.

Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333:447-58.

Hallberg P, Karlsson J, Kurland L et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20:2089-93.

Hamberg AK, Dahl ML, Barban M et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81:529-38.

Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54:33-41.

Hanatani T, Fukuda T, Ikeda M et al. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J 2001; 1:288-92.

Hao B, Chen ZW, Zhou XJ et al. Identification of phase-I metabolites and chronic toxicity study of the Kv1. 3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica 2011; 41:198-211.

Harmsze AM, van Werkum JW, Moral F et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011; 22:98-102.

Harmsze AM, van Werkum JW, Ten Berg JM et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31:3046-53.

Haschke-Becher E, Kirchheiner J, Trummer O et al. Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics 2010; 11:1359-65.

He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372:16-28.

He SM, Zhou ZW, Li XT, Zhou SF. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem 2011; 18:667-713.

Helldén A, Bergman U, Engström Hellgren K et al. Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. Eur J Clin Pharmacol 2010; 66:791-5.

Herman D, Locatelli I, Grabnar I et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5:193-202.

Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy. Thromb Haemost 2006; 95:192-4.

Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-8.

Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30:853-8.

Ho BE, Shen DD, McCune JS et al. Effects of garlic on cytochromes P450 2C9- and 3A4-mediated drug metabolism in human hepatocytes. Sci Pharm 2010; 78:473-81.

Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 2011; 67:471-6.

Hong X, Zhang S, Mao G et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61:627-34.

Hu Z, Yang X, Ho PC et al. Herb-drug interactions: a literature review. Drugs 2005; 65:1239-82.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 2003; 59:213-9.

Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004; 26:534-40.

Iida I, Miyata A, Arai M et al. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5’-hydroxylation. Drug Metab Dispos 2004; 32:7-9.

Ikejiri M, Wada H, Sakamoto Y et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol 2010; 92:302-5.

Imai J, Ieiri I, Mamiya K et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10:85-9.

Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 2008; 36:2429-33.

International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-64.

Jetter A, Kinzig-Schippers M, Skott A et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 2004; 60:165-71.

Ji HY, Kim SY, Kim DK, Jeong JH, Lee HS. Effects of eupatilin and jaceosidin on cytochrome p450 enzyme activities in human liver microsomes. Molecules 2010; 15:6466-75.

Ji HY, Liu KH, Lee H et al. Corydaline inhibits multiple cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 2011; 16:6591-602.

Jiang D, Bai X, Zhang Q et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol 2009; 65:1187-93.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011; 89:165-70.

Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol 2010; 23:939-45.

Jose L, Binila C, Chandy SJ, Mathews JE, Mathews KP. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. J Assoc Physicians India 2008; 56:250-2.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 2010; 15:817-29.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011; 50:25-39.

Kalgutkar AS, Nguyen HT, Vaz AD et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003; 31:1240-50.

Kamiyama E, Yoshigae Y, Kasuya A, Takei M, Kurihara A, Ikeda T. Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes. Drug Metab Pharmacokinet 2007; 22:267-75.

Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53:445-9.

Kazierad DJ, Martin DE, Blum RA et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62:417-25.

Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010; 66:689-96.

Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11:803-8.

Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9:71-80.

Kim CS, Choi SJ, Park CY, Li C, Choi JS. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 2010; 30:79-85.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011; 41:851-62.

Kim SH, Kim SH, Yoon HJ et al. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. Eur J Clin Pharmacol 2011; 67:121-7.

Kim Y, Park K, Kang W. Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits. Biopharm Drug Dispos 2010; 31:443-9.

Kimura Y, Ito H, Hatano T. Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol Pharm Bull 2010; 33:1977-82.

King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004; 14:813-22.

Kirby LC, Johnson BM, Adams LM et al. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin. J Clin Pharmacol 2010; 50:566-75.

Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12:101-9.

Kirchheiner J, Brockmöller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71:286-96.

Kirchheiner J, Kudlicz D, Meisel C et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74:186-94.

Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmöller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72:62-75.

Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12:571-80.

Kirchheiner J, Meineke I, Müller G et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet 2004; 43:267-78.

Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmöller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55:51-61.

Kirchheiner J, Störmer E, Meisel C, Steinbach N, Roots I, Brockmöller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13:473-80.

Kirchheiner J, Ufer M, Walter EC et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14:19-26.

Kjærstad MB, Taxvig C, Nellemann C, Vinggaard AM, Andersen HR. Endocrine disrupting effects in vitro of conazole antifungals used as pesticides and pharmaceuticals. Reprod Toxicol 2010; 30:573-82.

Kolukisaoglu Ü, Wendler C, Goerdes D, Diener A, Thurow K. Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19. J Enzyme Inhib Med Chem 2010; 25:876-86.

Kovac MK, Rakicevic LB, Radojkovic DP. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC. -1639 A/A and CYP2C9*1/*3 genotypes. J Thromb Thrombolysis 2011; 32:368-71.

Kramer MA, Rettie AE, Rieder MJ, Cabacungan ET, Hines RN. Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol Pharmacol 2008; 73:1751-60.

Kringen MK, Haug KB, Grimholt RM et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol 2011. doi:10. 1155/2011/739751.

Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33:1027-35.

Kumar A, Remmel RP, Mann HJ, Beilman GJ. Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model. J Surg Res 2011; 167:231-43.

Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK, Mittal B. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet 2011; 17 Suppl 1:32-40.

Kwon MJ, On YK, Ki CS et al. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype. Clin Chim Acta 2011; 412:2343-5.

Lane S, Al-Zubiedi S, Hatch E et al. The population pharmacokinetics of R and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2011. doi:10. 1111/j. 1365-2125. 2011. 04051. x.

Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn 2009; 11:216-25.

Lee AY, Kim MJ, Chey WY, Choi J, Kim BG. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004; 60:155-9.

Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 2003; 58:791-4.

Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin Pharmacol Ther 2002; 72:562-71.

Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23:720-5.

Lee HW, Lim MS, Lee J et al. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. J Clin Pharm Ther 2011. doi:10. 1111/j. 1365-2710. 2010. 01238. x.

Lee SK, Kim Y, Jin C et al. Inhibitory effects of deoxypodophyllotoxin from Anthriscus sylvestris on human CYP2C9 and CYP3A4. Planta Med 2010; 76:701-4.

Li C, Lim SC, Kim J, Choi JS. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Eur J Drug Metab Pharmacokinet 2011; 36:175-82.

Li T, Lange LA, Li X et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 2006; 43:740-4.

Li T, Li N, Guo Q et al. Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Eur J Drug Metab Pharmacokinet 2011. doi:10. 1007/s13318-011-0050-0.

Li Y, Slatter JG, Zhang Z et al. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab Dispos 2008; 36:469-73.

Lim JS, Chen XA, Singh O et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 2011; 71:737-50.

Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 2002; 325:1333.

Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 2008; 64:9-15.

Limdi NA, Beasley TM, Crowley MR et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008; 9:1445-58.

Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65:365-75.

Liu L, Xiao J, Peng ZH, Chen Y. In vitro metabolism of glycyrrhetic acid by human cytochrome P450. Yao Xue Xue Bao 2011; 46:81-7.

Llerena A, Dorado P, Berecz R, González AP, Peñas-Lledó EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004; 59:869-73.

López M, Dorado P, Monroy N et al. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabol Drug Interact 2011; 26:5-12.

López-Rodríguez R, Novalbos J, Gallego-Sandín S et al. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res 2008; 58:77-84.

Lundblad MS, Ohlsson S, Johansson P, Lafolie P, Eliasson E. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clin Pharmacol Ther 2006; 79:287-8.

Luxembourg B, Schneider K, Sittinger K et al. Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thromb Haemost 2011; 105:169-80.

Maekawa K, Fukushima-Uesaka H, Tohkin M et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16:497-514.

Mamiya K, Ieiri I, Shimamoto J et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39:1317-23.

Man M, Farmen M, Dumaual C et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 2010; 50:929-40.

Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004; 32:566-71.

Margaglione M, Colaizzo D, D’Andrea G et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84:775-8.

Margolis JM, O’Donnell JP, Mankowski DC, Ekins S, Obach RS. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28:1187-91.

Markatos CN, Grouzi E, Politou M et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008; 9:1631-8.

Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol 2001; 51:627-30.

Martínez C, Blanco G, García-Martín E, Agúndez JA. Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs. Farm Hosp 2006; 30:240-8.

Martínez C, Blanco G, Ladero JM et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004; 141:205-8.

Martínez C, García-Martín E, Blanco G, Gamito FJ, Ladero JM, Agúndez JA. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 2005; 59:62-9.

Masek V, Anzenbacherová E, Machová M, Brabec V, Anzenbacher P. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs 2009; 20:305-11.

Matimba A, Del-Favero J, van Broeckhoven C, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009; 3:169-90.

McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004; 43:97-120.

Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63:1135-41.

Miki A, Ohtani H, Sawada Y. Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model. J Clin Pharm Ther 2010. doi:10. 1111/j. 1365-2710. 2010. 01229. x.

Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995; 272:1076-81.

Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 2011; 12:953-63.

Miura M, Takahashi N, Kanno S et al. Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. Clin Chim Acta 2011; 412:2002-6.

Miyagata Y, Nakai K, Sugiyama Y. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin. Int Heart J 2011; 52:44-9.

Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab 2009; 10:1075-126.

Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II. Curr Drug Metab 2009; 10:1127-50.

Muszkat M, Bialer O, Blotnick S et al. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. Clin Ther 2010; 32:347-56.

Mwinyi J, Cavaco I, Yurdakok B, Mkrtchian S, Ingelman-Sundberg M. The ligands of estrogen receptor alpha regulate cytochrome P4502C9 (CYP2C9) expression. J Pharmacol Exp Ther 2011; 338:302-9.

Nagy LD, Mocny CS, Diffenderfer LE et al. Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction. Drug Metab Dispos 2011; 39:974-83.

Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26:261-6.

Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004; 34:415-27.

Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010; 11:323-32.

Ngo N, Brantley SJ, Carrizosa DR et al. The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation. J Exp Pharmacol 2010; 2010:83-91.

Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72:326-32.

Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000; 22:230-2.

Northwood EL, Elliott F, Forman D et al. Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics 2010; 20:315-26.

Odani A, Hashimoto Y, Otsuki Y et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62:287-92.

Orsi FA, Annichino Bizzacchi JM, de Paula EV, Ozelo MC, Langley MR, Weck KE. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thromb Res 2010; 126:206-10.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro determination of the effect of Andrographis paniculata extracts and andrographolide on human hepatic cytochrome P450 activities. J Nat Med 2011; 65:440-7.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica. J Ethnopharmacol 2010; 130:275-83.

Paul S, Pant MC, Parmar D, Verma J. Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer. Indian J Cancer 2011; 48:223-9.

Peiró AM, Novalbos J, Zapater P et al. Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacol Res 2009; 59:62-8.

Perera MA, Gamazon E, Cavallari LH et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011; 89:408-15.

Perini JA, Struchiner CJ, Silva-Assunção E et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 2008; 84:722-8.

Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 2005; 78:362-9.

Pilotto A, Seripa D, Franceschi M et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133:465-71.

Pinheiro SP, Gates MA, Devivo I et al. Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. Int J Mol Epidemiol Genet 2010; 1:320-31.

Pozzi A, Popescu V, Yang S et al. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem 2010; 285:12840-50.

Prashanth S, Kumar AA, Madhu B, Rama N, Sagar JV. Pharmacokinetic and pharmacodynamic drug interactions of carbamazepine and glibenclamide in healthy albino Wistar rats. J Pharmacol Pharmacother 2011; 2:7-10.

Pratt VM, Zehnbauer B, Wilson JA et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn 2010; 12:835-46.

Pustylnyak VO, Gulyaeva LF, Lyakhovich VV. Induction of cytochrome P4502B: role of regulatory elements and nuclear receptors. Biochemistry 2007; 72:608-17.

Qayyum A, Najmi MH, Farooqi ZU. Determination of pharmacokinetics of flurbiprofen in Pakistani population using modified HPLC method. J Chromatogr Sci 2011; 49:108-13.

Qu YQ, Fang ZZ, Yang L et al. Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie 2011; 66:216-21.

Quintieri L, Bortolozzo S, Stragliotto S et al. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. Drug Metab Pharmacokinet 2010; 25:466-76.

Ramasamy K, Narayan SK, Shewade DG, Chandrasekaran A. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients. Ther Drug Monit 2010; 32:762-6.

Rathore SS, Agarwal SK, Pande S, Mittal T, Mittal B. Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population. Biosci Trends 2010; 4:333-7.

Rehmel JL, Eckstein JA, Farid NA et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34:600-7.

Rendic S, Nolteernsting E, Schänzer W. Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl 1999; 735:73-83.

Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.

Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, Wrighton SA. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther 2001; 297:1044-50.

Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33:1567-75.

Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30:3247-55.

Rordorf CM, Choi L, Marshall P, Mangold JB. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2005; 44:1247-66.

Rosenborg S, Stenberg M, Otto S et al. Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clin Pharmacol Ther 2010; 88:343-6.

Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010; 55:582-9.

Rulcova A, Prokopova I, Krausova L et al. Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes. J Thromb Haemost 2010; 8:2708-17.

Sachse-Seeboth C, Pfeil J, Sehrt D et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 2009; 85:273-6.

Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997; 283:698-703.

Sánchez MB, Herranz JL, Leno C et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010; 19:93-101.

Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 2004; 32:484-9.

Sandberg M, Yasar U, Strömberg P, Höög JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002; 54:423-9.

Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7:97-104.

Sandwall P, Lo MW, Jonzon B et al. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). Eur J Clin Pharmacol 1999; 55:279-83.

Sangviroon A, Panomvana D, Tassaneeyakul W, Namchaisiri J. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab Pharmacokinet 2010; 25:531-8.

Saour JN, Shereen AW, Saour BJ, Mammo LA. CYP2C9 polymorphism studies in the Saudi population. Saudi Med J 2011; 32:347-52.

Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007; 32:641-9.

Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 2006; 79:511-20.

Schalekamp T, Brassé BP, Roijers JF et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80:13-22.

Schalekamp T, Oosterhof M, van Meegen E et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004; 76:409-17.

Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj M, de Boer A. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 2004; 75:394-402.

Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010; 88:214-22.

Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 2010; 70:393-9.

Schmelzle M, Dizdar L, Matthaei H et al. Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9). Prostaglandins Other Lipid Mediat 2011; 94:25-33.

Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106:2329-33.

Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97:296-301.

Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979; 28:41-51.

Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11:781-91.

Sekino K, Kubota T, Okada Y et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59:589-92.

Semiz S, Dujic T, Ostanek B et al. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J Basic Med Sci 2010; 10:287-91.

Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández-Gutiérrez B, Ladero JM, Díaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004; 36:82-4.

Shahin MH, Khalifa SI, Gong Y et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011; 21:130-5.

Shao H, Ren XM, Liu NF et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther 2010; 35:351-60.

Siller M, Anzenbacher P, Anzenbacherov E, Dole Al K, Strnad M. In vitro interaction of a novel neutrophil growth factor with human liver microsomal cytochromes P450 and the contribution of UDP-glucuronosyltransferases to its metabolism. Xenobiotica 2011; 41:934-44.

Shen S, Marchick MR, Davis MR, Doss GA, Pohl LR. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 1999; 12:214-22.

Shi R, Li J, Cao X, Zhu X, Lu X. Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation. J Mol Model 2011; 17:1941-51.

Shimamoto J, Ieiri I, Urae A et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 2000; 56:65-8.

Shintani M, Ieiri I, Inoue K et al. Genetic polymorphisms and functional characterization of the 5’-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001; 70:175-82.

Shiotani A, Sakakibara T, Nomura M et al. Aspirin-induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol 2010; 25 Suppl 1:31-4.

Shirolkar SC, Fiuzat M, Becker RC. Dronedarone and vitamin K antagonists: a review of drug-drug interactions. Am Heart J 2010; 160:577-82.

Shobha JC, Muppidi MR. Interaction between voriconazole and glimepiride. J Postgrad Med 2010; 56:44-5.

Shon JH, Yoon YR, Kim KA et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002; 12:111-9.

Shon JH, Yoon YR, Kim MJ et al. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol 2005; 59:552-63.

Shrif NE, Won HH, Lee ST et al. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 2011; 67:1119-30.

Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14:465-9.

Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005; 44:797-814.

Siller M, Anzenbacher P, Anzenbacherova E, Dolezal K, Popa I, Strnad M. Interactions of olomoucine II with human liver microsomal cytochromes P450. Drug Metab Dispos 2009; 37:1198-202.

Soga Y, Nishimura F, Ohtsuka Y et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 2004; 74:827-34.

Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.

Spreafico M, Lodigiani C, van Leeuwen Y et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008; 9:1237-50.

Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008; 47:565-94.

Stempak D, Bukaveckas BL, Linder M, Koren G, Baruchel S. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin Pharmacol Ther 2005; 78:309-10.

Sullivan-Klose TH, Ghanayem BI, Bell DA et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-9.

Sun DX, Lu JC, Fang ZZ et al. Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside. Phytother Res 2010; 24:1670-5.

Surapureddi S, Rana R, Goldstein JA. NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes. Pharmacol Res 2011; 63:405-13.

Surendiran A, Pradhan SC, Agrawal A et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011; 67:797-801.

Suriapranata IM, Tjong WY, Wang T et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet 2011; 12:80.

Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006; 72:148-54.

Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics 2010; 11:1517-23.

Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40:587-603.

Takahashi H, Ieiri I, Wilkinson GR et al. 5’-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103:3055-7.

Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10:95-104.

Takanohashi T, Kubo S, Nakayama A, Mihara R, Hayashi M. Inhibition of human liver microsomal CYP by nateglinide. J Pharm Pharmacol 2010; 62:592-7.

Tang C, Shou M, Rushmore TH, Mei Q et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11:223-35.

Tang W, Stearns RA, Wang RW, Chiu SH, Baillie TA. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 1999; 12:192-9.

Tàssies D, Freire C, Pijoan J et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87:1185-91.

Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Nat Acad Sci USA 2005; 102:5507-12.

Teh LK, Langmia IM, Fazleen Haslinda MH et al. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. J Clin Pharm Ther 2011. doi:10. 1111/j. 1365-2710. 2011. 01262. x.

Teichert M, Eijgelsheim M, Uitterlinden AG et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet Genomics 2011; 21:26-34.

Teichert M, Visser LE, Uitterlinden AG et al. Selective serotonin reuptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol 2011; 72:798-805.

Thijssen HH, Drittij MJ, Vervoort LM, de Vries-Hanje JC. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70:292-8.

Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28:1284-90.

Thijssen HH, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther 2003; 74:61-8.

Thörn HA, Lundahl A, Schrickx JA, Dickinson PA, Lennernäs H. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 2011; 43:89-98.

Tirkkonen T, Heikkilä P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med 2010; 268:359-66.

Tomalik-Scharte D, Maiter D, Kirchheiner J, Ivison HE, Fuhr U, Arlt W. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 2010; 163:919-24.

Toon S, Heimark LD, Trager WF, O’Reilly RA. Metabolic fate of phenprocoumon in humans. J Pharm Sci 1985; 74:1037-40.

Toselli F, Matthias A, Bone KM, Gillam EM, Lehmann RP. Metabolism of the major Echinacea alkylamide N-isobutyldodeca-2E,4E,8Z,10Z-tetraenamide by human recombinant cytochrome P450 enzymes and human liver microsomes. Phytother Res 2010; 24:1195-201.

Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30:385-90.

Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol 1997; 52:293-8.

Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58:412-7.

Tsimberidou AM, Takimoto CH, Moulder S et al. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther 2011; 10:209-17.

Tsujimoto M, Higuchi K, Shima D et al. Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro. J Pharm Pharmacol 2010; 62:133-8.

Twardowschy CA, Werneck LC, Scola RH, de Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arq Neuropsiquiatr 2011; 69:153-8.

Uchida S, Shimada K, Misaka S et al. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet 2010; 25:605-10.

Uchida S, Watanabe H, Nishio S et al. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin Pharmacol Ther 2003; 74:505-8.

Ufer M, Kammerer B, Kahlich R et al. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 2004; 34:847-59.

Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004; 60:173-82.

Uno Y, Iwasaki K, Yamazaki H, Nelson DR. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 2011; 43:346-61.

van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11:287-91.

van Schie RM, Wessels JA, le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011; 32:1909-17.

VanAlstine MA, Hough LB. Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome p450s. Drug Metab Dispos 2011; 39:1221-6.

Veenstra DL, Blough DK, Higashi MK et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77:353-64.

Veronese ME, Doecke CJ, Mackenzie PI et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289:533-8.

Veronese ME, Miners JO, Rees DL, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993; 3:86-93.

Verstuyft C, Morin S, Robert A et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001; 11:735-7.

Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004; 76:18-26.

Villagra D, Duconge J, Windemuth A et al. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta 2010; 411:1306-11.

Visser LE, van Schaik RH, van Vliet M et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92:61-6.

Visser LE, van Vliet M, van Schaik RH et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004; 14:27-33.

Voora D, Koboldt DC, King CR et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87:445-51.

Vormfelde SV, Engelhardt S, Zirk A et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther 2004; 76:557-66.

Vorob’eva NM, Panchenko EP, Dobrovol’skiĭ AB et al. Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage. Ter Arkh 2011; 83:59-65.

Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784-92.

Wang H, Negishi M. Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors. Curr Drug Metab 2003; 4:515-25.

Wang R, Chen K, Wen SY, Li J, Wang SQ. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther 2005; 78:90-2.

Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998; 44:1085-95.

Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007; 80:1415-9.

Watzka M, Geisen C, Bevans CG et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 2011; 9:109-18.

Wen JH, Xiong YQ. The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats. Eur J Drug Metab Pharmacokinet 2011. doi:10. 1007/s13318-011-0048-7.

Wen MS, Lee M, Chen JJ et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84:83-9.

Wen SY, Wang H, Sun OJ, Wang SQ. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol 2003; 9:1342-6.

Wendt B, Mulbaier M, Wawro S et al. Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: alleviating drug-drug interactions through use of PubChem data and comparative molecular field analysis guided synthesis. J Med Chem 2011; 54:3982-6.

Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002; 16:56-60.

Wester MR, Lasker JM, Johnson EF, Raucy JL. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 2000; 28:354-9.

Wijnen PA, Bekers O, Drent M. Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers. Mol Diagn Ther 2011; 15:177-80.

Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 2007; 8:851-61.

Wu AH, Wang P, Smith A et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9:169-78.

Wynne HA, Long A, Nicholson E, Ward A, Keir D. Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? Br J Clin Pharmacol 1998; 45:405-8.

Xiong Y, Wang M, Fang K et al. A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics 2011; 97:277-81.

Yamada H, Ishii Y, Yamamoto M, Oguri K. Induction of the hepatic cytochrome P450 2B subfamily by xenobiotics: research history, evolutionary aspect, relation to tumorigenesis, and mechanism. Curr Drug Metab 2006; 7:397-409.

Yamakawa Y, Hamada A, Nakashima R et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 2011; 33:244-50.

Yamamoto Y, Takahashi Y, Nishimura S, Ikumi Y, Mishima N, Kagawa Y. Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy. Yakugaku Zasshi 2011; 131:809-15.

Yang SH, Cho YA, Choi JS. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin 2011; 32:967-72.

Yang ZF, Cui HW, Hasi T, Jia SQ, Gong ML, Su XL. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res 2010; 9:1844-51.

Yasar U, Annas A, Svensson JO, Lazorova L, Artursson P, Al-Shurbaji A. Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica 2005; 35:785-96.

Yasar U, Eliasson E, Forslund-Bergengren C et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57:729-35.

Yasar U, Forslund-Bergengren C, Tybring G et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71:89-98.

Yasar U, Sain-Guven G, Yardimci Y, Kilicarslan A, Babaoglu MO, Bozkurt A. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. Basic Clin Pharmacol Toxicol 2011; 109:73-7.

Yasar U, Tybring G, Hidestrand M et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29:1051-6.

Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T. Metabolism of sesamin by cytochrome P450 in human liver microsomes. Drug Metab Dispos 2010; 38:2117-23.

Yeung JH, Or PM. Polysaccharide peptides from Coriolus versicolor competitively inhibit tolbutamide 4-hydroxylation in specific human CYP2C9 isoform and pooled human liver microsomes. Phytomedicine 2011; 18:1170-5.

Yin OQ, Gallagher N, Fischer D et al. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig 2011; 31:169-79.

Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 2005; 78:370-7.

Yin T, Maekawa K, Kamide K et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31:1549-57.

Yoo HD, Kim MS, Cho HY, Lee YB. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. Eur J Clin Pharmacol 2011; 67:889-98.

Zhai G, Teumer A, Stolk L et al. Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms. PLoS Genet 2011. doi:10. 1371/journal. pgen. 1002025

Zhang X, Li L, Ding X, Kaminsky LS. Identification of cytochrome p450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 2011; 39:1433-9.

Zhang Y, Si D, Chen X et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 2007; 64:67-74.

Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol 2005; 59:14-7.

Zhao F, Loke C, Rankin SC et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76:210-9.

Zhong SL, Liu Y, Yu XY et al. The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. Eur J Clin Pharmacol 2011; 67:581-90.

Zhou K, Donnelly L, Burch L et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2010; 87:52-6.

Zi J, Liu D, Ma P et al. Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions. Drug Metab Pharmacokinet 2010; 25:343-50.

CYP2C18 (cytochrome P450, family 2, subfamily C, polypeptide 18)

Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35:1687-93.

Bort R, Gómez-Lechón MJ, Castell JV, Jover R. Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. Arch Biochem Biophys 2004; 426:63-72.

Bort R, Macé K, Boobis A, Gómez-Lechón MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 58:787-96.

Du L, Neis MM, Ladd PA, Keeney DS. Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther 2006; 319:1162-71.

Finta C, Zaphiropoulos PG. The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics 2000; 63:433-8.

Foti RS, Dickmann LJ, Davis JA et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica 2008; 38:264-80.

Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29:242-51.

Ha-Duong NT, Dijols S, Marques-Soares C, Minoletti C, Dansette PM, Mansuy D. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily. J Med Chem 2001; 44:3622-31.

Hamitouche S, Poupon J, Dreano Y, Amet Y, Lucas D. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes. Toxicol Lett 2006; 167:221-30.

Ikediobi O, Aouizerat B, Xiao Y, Gandhi M, Gebhardt S, Warnich L. Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 2011; 5:265-82.

Inoue K, Yamazaki H, Shimada T. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian. Xenobiotica 1998; 28:403-11.

Jorgensen AL, Al-Zubiedi S, Zhang JE et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 2009; 19:800-12.

Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005; 18:1868-75.

Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13:289-95.

Knüpfer H, Schmidt R, Stanitz D, Brauckhoff M, Schönfelder M, Preiss R. CYP2C and IL-6 expression in breast cancer. Breast 2004; 13:28-34.

Kubota T, Hibi N, Chiba K. Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population. Biochem Pharmacol 1998; 55:2039-42.

Läpple F, von Richter O, Fromm MF et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003; 13:565-75.

Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003; 144:3382-98.

Lee MT, Chen CH, Chou CH et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009; 10:1905-13.

Löfgren S, Baldwin RM, Carlerös M et al. Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos 2009; 37:1505-12.

Löfgren S, Baldwin RM, Hiratsuka M et al. Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. Drug Metab Dispos 2008; 36:955-62.

Löfgren S, Ekman S, Terelius Y, Fransson-Steen R. Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model. Acta Vet Scand 2008; 50:47.

Mamiya K, Ieiri I, Miyahara S et al. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics 1998; 8:87-90.

Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000; 58:1341-8.

Marques-Soares C, Dijols S, Macherey AC et al. Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes. Biochemistry 2003; 42:6363-9.

Modugno F, Knoll C, Kanbour-Shakir A, Romkes M. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat 2003; 82:191-7.

Neff JA, Moody DE. Differential N-demethylation of l-alpha-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem Biophys Res Commun 2001; 284:751-6.

Niwa T, Fujimoto M, Kishimoto K, Yabusaki Y, Ishibashi F, Katagiri M. Metabolism and interaction of bisphenol A in human hepatic cytochrome P450 and steroidogenic CYP17. Biol Pharm Bull 2001; 24:1064-7.

Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull 2005; 28:1711-6.

Ohhira S, Enomoto M, Matsui H. In vitro metabolism of tributyltin and triphenyltin by human cytochrome P-450 isoforms. Toxicology 2006; 228:171-7.

Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299:849-57.

Smith G, Ibbotson SH, Comrie MM et al. Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol 2006; 155:275-81.

Teichert M, Eijgelsheim M, Rivadeneira F et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009; 18:3758-68.

Teksin ZS, Lee IJ, Nemieboka NN et al. Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 2009; 72:471-7.

Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Identification and characterization of CYP2C18 in the cynomolgus macaque (Macaca fascicularis). J Vet Med Sci 2010; 72:225-8.

Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121:23-34.

Wang HH, Liao YW, Chiang HL, Wu JY, Chen YT. Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population. Pharmacogenomics 2009; 10:359-74.

Warner SC, Finta C, Zaphiropoulos PG. Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene. Mol Biol Evol 2001; 18:1841-8.

Winter HR, Wang Y, Unadkat JD. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos 2000; 28:865-8.

Yengi LG, Xiang Q, Pan J et al. Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem 2003; 316:103-10.

CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19)

Afrin LB, Afrin JB. Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant 2011; 25:271-5.

Afsar NA, Haenisch S, Mateen A et al. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol 2010; 107:570-6.

Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89:65-74.

Ashbee HR, Gilleece MH. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplant 2011. doi:10. 1038/bmt. 2011. 146.

Babalola CP, Adejumo O, Ung D et al. Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. J Clin Pharm Ther 2010; 35:471-7.

Badruddin A, Gorelick PB. Antiplatelet therapy for prevention of recurrent stroke. Curr Treat Options Neurol 2009; 11:452-9.

Bae JW, Jang CG, Lee SY. Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol 2011. doi:10. 1177/0091270010388651.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, Ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011. doi:10. 1136/bmj. d4588.

Berge M, Guillemain R, Trégouet DA et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011; 67:253-60.

Blaisdell J, Mohrenweiser H, Jackson J et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002; 12:703-11.

Bogman K, Silkey M, Chan SP, Tomlinson B, Weber C. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients. Eur J Clin Pharmacol 2010; 66:1005-15.

Bozdag G, Alp A, Saribas Z, Tuncer S, Aksu T, Gurgan T. CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis. Reprod Biomed Online 2010; 20:286-90.

Brasch-Andersen C, Møller MU, Christiansen L et al. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol 2011; 67:1131-7.

Chaudhry AS, Kochhar R, Kohli KK. Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians. Indian J Med Res 2009; 130:437-43.

Chaudhry AS, Urban TJ, Lamba JK et al. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther 2010; 332:599-611.

Chen L, Qin S, Xie J et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 2008; 9:691-702.

Chen WY, Chang WL, Tsai YC, Cheng HC, Lu CC, Sheu BS. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am J Gastroenterol 2010; 105:1046-52.

Chen Y, Liu HF, Liu L, Nguyen K, Jones EB, Fretland AJ. The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. Xenobiotica 2010; 40:536-46.

Chiu KW, Nakano T, Hu TH et al. Influence of CYP2C19 genotypes on graft pathological findings and postoperative liver function in recipients after living-donor liver transplantation. Ann Transplant 2010; 15:38-43.

Chiu KW, Tai WC, Nakano T et al. Donor graft does not affect the P450 2C19 genotype expressed in peripheral blood in recipients of living donor liver transplantation. Clin Transplant 2010; 24:830-4.

Cho H, Choi MK, Cho DY et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol 2011. doi:10. 1177/0091270011408611.

Clark D, Morgan A, Hananeia L, Coulter D, Olds R. Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology. Pharmacoepidemiol Drug Saf 2000; 9:393-400.

Close SL. Clopidogrel pharmacogenetics: metabolism and drug interactions. Drug Metabol Drug Interact 2011; 26:45-51.

Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 2002; 24:737-41.

Damle BD, Uderman H, Biswas P, Crownover P, Lin C, Glue P. Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Br J Clin Pharmacol 2009; 68:682-9.

de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-8.

de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-22.

de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 2011; 11:359-67.

Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 2011; 38:5449-52.

Drögemöller BI, Wright GE, Niehaus DJ et al. Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 2010; 11:1095-103.

Elliot DJ, Suharjono, Lewis BC et al. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol 2007; 64:450-7.

Fæste CK, Ivanova L, Uhlig S. In vitro metabolism of the mycotoxin enniatin B in different species and cytochrome p450 enzyme phenotyping by chemical inhibitors. Drug Metab Dispos 2011; 39:1768-76.

Ferguson RJ, de Morais SM, Benhamou S et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284:356-61.

Flaherty KT, Lathia C, Frye RF et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1585-0.

Foxenberg RJ, Ellison CA, Knaak JB, Ma C, Olson JR. Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion. Toxicology 2011; 285:57-66.

Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Otani K. Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity. Ther Drug Monit 2004; 26:529-33.

Fukasawa T, Yasui-Furukori N, Suzuki A, Inoue Y, Tateishi T, Otani K. Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. Eur J Clin Pharmacol 2005; 61:791-5.

Fukushima-Uesaka H, Saito Y, Maekawa K et al. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet 2005; 20:300-7.

Furuta K, Adachi K, Ohara S et al. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study. J Int Med Res 2010; 38:1473-83.

Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70:383-92.

Furuta T, Kodaira C, Nishino M et al. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 2009; 30:294-300.

Furuta T, Shirai N, Kodaira M et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81:521-8.

Furuta T, Shirai N, Watanabe F et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72:453-60.

Furuta T, Sugimoto M, Kodaira C et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol 2009; 65:693-8.

Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Droździk M. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol 2010; 66:681-7.

Ghodke Y, Joshi K, Patwardhan B. Traditional medicine to modern pharmacogenomics: Ayurveda Prakriti type and CYP2C19 gene polymorphism associated with the metabolic variability. Evid Based Complement Alternat Med 2009. doi:10. 1093/ecam/nep206.

Giusti B, Gori AM, Marcucci R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17:1057-64.

Giusti B, Gori AM, Marcucci R, Abbate R. Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opin Drug Metab Toxicol 2010; 6:393-407.

Graham DY, Javed SU, Keihanian S, Abudayyeh S, Opekun AR. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol 2010; 45:816-20.

Grover S, Gourie-Devi M, Baghel R et al. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 2010; 11:927-41.

Grün B, Krautter S, Riedel KD, Mikus G. Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole. Br J Clin Pharmacol 2009; 68:712-20.

Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001; 40:12112-22.

Harmsze AM, de Boer A, Boot H et al. Interaction between clopidogrel and proton pump inhibitors. Ned Tijdschr Geneeskd 2011; 155:2442.

Hassan A, Burhenne J, Riedel KD et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 2011; 33:86-93.

Hayashi M, Matsumoto N, Takenoshita-Nakaya S et al. Individual metabolic capacity evaluation of cytochrome P450 2C19 by protein and activity in the small intestinal mucosa of Japanese pancreatoduodenectomy patients. Biol Pharm Bull 2011; 34:71-6.

Helsby N, Goldthorpe M, Gow P, de Zoysa J. Is the prevalence of CYP2C19 genetic variants different in Pacific people than in New Zealand Europeans? N Z Med J 2010; 123:37-41.

Helsby NA, Hui CY, Goldthorpe MA et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 2010; 70:844-53.

Helsby NA, Lo WY, Sharples K et al. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br J Cancer 2008; 99:1251-5.

Helsby NA, Lo WY, Thompson P, Laking GR. Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? Cancer Chemother Pharmacol 2010; 66:405-7.

Hidestrand M, Oscarson M, Salonen JS et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson’s disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 2001; 29:1480-4.

Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108:2244-7.

Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56:134-43.

Hunfeld NG, Mathot RA, Touw DJ et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008; 65:752-60.

Hunfeld NG, Valkhoff VE, Touw DJ, Sturkenboom MC, Kuipers EJ. Clopidogrel and proton pump inhibitors: insufficient evidence of interaction. Ned Tijdschr Geneeskd 2011; 155:2404.

Hwang SJ, Jeong YH, Kim IS et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3:450-9.

Hwang SJ, Jeong YH, Kim IS et al. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 2011; 127:23-8.

Ibeanu GC, Blaisdell J, Ferguson RJ et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999; 290:635-40.

Ibeanu GC, Blaisdell J, Ghanayem BI et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8:129-35.

Ibeanu GC, Goldstein JA, Meyer U et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286:1490-5.

Inomata S, Nagashima A, Itagaki F et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005; 78:647-55.

Isomura Y, Yamaji Y, Ohta M et al. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol 2010; 45:1045-52.

Iwamoto T, Ishibashi M, Fujieda A, Masuya M, Katayama N, Okuda M. Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. Pharmacotherapy 2010; 30:661-5.

Iwamoto T, Monma F, Fujieda A, Nakatani K, Katayama N, Okuda M. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther 2011; 33:1077-80.

Janha RE, Sisay-Joof F, Hamid-Adiamoh M et al. Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics 2009; 10:1423-31.

Jeong YH, Kim IS, Park Y et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010; 3:731-41.

Ji HY, Liu KH, Lee H et al. Corydaline inhibits multiple cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 2011; 16:6591-602.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011; 89:165-70.

Jin Y, Pollock BG, Frank E et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 2010; 50:62-72.

Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 Allele on the pharmacokinetics of omeprazole and pantoprazole in children: Evidence for a differential effect. Drug Metab Dispos 2010; 38:894-7.

Kelly RP, Close SL, Farid NA et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol 2011. doi:10. 1111/j. 1365-2125. 2011. 04049. x.

Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010; 66:689-96.

Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84:236-42.

Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J Clin Pharm Ther 2010; 35:697-703.

Kim SH, Kim SH, Bahn JW et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10:1767-79.

Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011; 33:213-24.

Kinoshita Y, Matsumoto N, Watanabe M et al. Comparison of the effects of omeprazole and rabeprazole on ticlopidine metabolism in vitro. J Pharmacol Sci 2011; 117:19-26.

Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004; 26:530-4.

Koski A, Sistonen J, Ojanperä I, Gergov M, Vuori E, Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci Int 2006; 158:177-83.

Lane S, Al-Zubiedi S, Hatch E et al. The population pharmacokinetics of R and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2011. doi:10. 1111/j. 1365-2125. 2011. 04051. x.

Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 2011; 57:86-93.

Lee JB, Lee KA, Lee KY. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease. Yonsei Med J 2011; 52:734-8.

Lee S, Kim BH, Nam WS et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2011. doi:10. 1177/0091270010395510.

Lee VW, Chau TS, Chan AK et al. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. J Clin Pharm Ther 2010; 35:343-50.

Lehr T, Yuan J, Hall D et al. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet Genomics 2011; 21:721-30.

Li T, Li N, Guo Q et al. Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Eur J Drug Metab Pharmacokinet 2011. doi:10. 1007/s13318-011-0050-0.

Li Y, Jiang Z, Xiao Y, Li L, Gao Y. Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro. Hematol Oncol 2011. doi:10. 1002/hon. 992.

Liou JM, Chen CC, Chen MJ et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011; 66:1847-52.

Liou YH, Lin CT, Wu YJ, Wu LS. The high prevalence of the poor and ultrarapid metabolite alleles in CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J Hum Genet 2006; 51:857-63.

Liu XL, Wang ZJ, Yang Q et al. Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease. Chin Med J 2010; 123:3178-83.

Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010; 69:222-30.

Ma Y, Ni W, Zhu W, Xiong Y, Deng X. Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population. Blood Press 2011; 20:166-70.

Maeda A, Ando H, Asai T et al. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther 2011; 89:229-33.

Mahajan MK, Uttamsingh V, Daniels JS, Gan LS, LeDuc BW, Williams DA. In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos 2011; 39:693-702.

Małek LA, Przyłuski J, Spiewak M et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 2010; 117:81-7.

Matsusue A, Hara K, Kageura M et al. An autopsy case of rhabdomyolysis related to vegetamin and genetic analysis of the rhabdomyolysis-associated genes. J Forensic Leg Med 2010; 17:46-9.

McAlpine DE, Biernacka JM, Mrazek DA et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33:14-20.

Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312-9.

Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304:1821-30.

Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011; 12:861-72.

Miura M, Motoyama S, Hinai Y et al. Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration. Xenobiotica 2010; 40:630-6.

Miura M, Niioka T, Kagaya H et al. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. J Clin Pharm Ther 2011; 36:208-16.

Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011; 58:581-8.

Morita J, Kobayashi K, Wanibuchi A et al. A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4’-hydroxylation. Drug Metab Pharmacokinet 2004; 19:236-8.

Mrazek DA, Biernacka JM, O’Kane DJ et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011; 21:1-9.

Mwinyi J, Cavaco I, Pedersen RS et al. Regulation of CYP2C19 expression by estrogen receptor α: implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol 2010; 78:886-94.

Mwinyi J, Hofmann Y, Pedersen RS et al. The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sci 2010; 86:699-706.

Nebert DW, Adesnik M, Coon MJ et al. The P450 gene superfamily: recommended nomenclature. DNA 1987; 6:1-11.

Ngamjanyaporn P, Thakkinstian A, Verasertniyom O et al. Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatol Int 2010; 31:1215-8.

Nishino M, Sugimoto M, Kodaira C et al. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol 2011; 51:1079-86.

Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 2010; 38:1381-91.

Ogilvie BW, Yerino P, Kazmi F et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011; 39:2020-33.

Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009; 115:952-61.

Onizuka M, Kunii N, Toyosaki M et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 2011; 46:1113-7.

Painter JN, Nyholt DR, Morris A et al. High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19. Fertil Steril 2011; 95:2236-40.

Pan X, Li Y, Qiu Y et al. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. Clin Ther 2010; 32:2003-11.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). J Ethnopharmacol 2011; 133:881-7.

Paré G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363:1704-14.

Park KW, Park JJ, Lee SP et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 2011; 97:641-7.

Parker GB, Brotchie HL, Hyett M. Tolerance to desvenlafaxine in rapid metabolizing depressed patients. Int Clin Psychopharmacol 2011; 26:84-7.

Perini JA, Vargens DD, Santana IS et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res 2009; 42:1179-84.

Pratt VM, Zehnbauer B, Wilson JA et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and association for molecular pathology collaborative project. J Mol Diagn 2010; 12:835-46.

Qin XP, Xie HG, Wang W et al. Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999; 66:642-6.

Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010; 66:871-7.

Rehmel JL, Eckstein JA, Farid NA et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34:600-7.

Richardson TH, Jung F, Griffin KJ et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 1995; 323:87-96.

Rideg O, Háber A, Botz L et al. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. Cell Biochem Funct 2011; 29:562-8.

Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol 2010; 70:43-51.

Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30:3247-55.

Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 83:322-7.

Rudberg I, Reubsaet JL, Hermann M, Refsum H, Molden E. Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro. Drug Metab Dispos 2009; 37:2340-8.

Ruiter R, Bijl MJ, van Schaik RH et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 2010; 11:1367-75.

Salminen KA, Leppänen J, Venäläinen JI et al. Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics. Drug Metab Dispos 2011; 39:412-8.

Santos PC, Soares RA, Santos DB et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 2011; 12:13.

Satyanarayana Chakradhara Rao U, Devendran A, Satyamoorthy K, Shewade DG, Krishnamoorthy R, Chandrasekaran A. Functional characterization of promoter region polymorphisms of human CYP2C19 gene. Mol Biol Rep 2011; 38:4171-9.

Satyanarayana CR, Devendran A, Jayaraman M et al. Influence of the genetic polymorphisms in the 5’ flanking and exonic regions of CYP2C19 on proguanil oxidation. Drug Metab Pharmacokinet 2009; 24:537-48.

Schenk PW, van Vliet M, Mathot RA et al. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J 2010; 10:219-25.

Scholz I, Oberwittler H, Riedel KD et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68:906-15.

Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25:5187-93.

Schwab M, Klotz U, Hofmann U et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005; 78:627-34.

Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J 2011. doi:10. 1038/tpj. 2011. 5.

Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol 2010; 6:409-24.

Serrano D, Lazzeroni M, Zambon CF et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian tamoxifen prevention trial. Pharmacogenomics J 2011; 11:100-7.

Sheng YC, Wang K, He YC, Yang J, Zheng QS. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 2010; 66:1165-9.

Sheu BS, Cheng HC, Yeh YC, Chang WL. CYP2C19 Genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles Grade C & D. J Gastroenterol Hepatol 2011. doi:10. 1111/j. 1440-1746. 2011. 06848. x.

Shi HY, Yan J, Zhu WH et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol 2010; 66:1131-6.

Shrestha K, Hughes JD, Lee YP, Parsons R. The prevalence of co-administration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19:35-42.

Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121:512-8.

Sibbing D, Koch W, Massberg S et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32:1605-13.

Sim SC, Nordin L, Andersson TM et al. Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 2010; 153:1160-6.

Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79:103-13.

Simon T, Steg PG, Gilard M et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123:474-82.

Simon T, Verstuyft C, Mary-Krause M et al Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-75.

Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4’-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61:574-82.

Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.

Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 8:1678-84.

Soyinka JO, Onyeji CO. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur J Pharm Sci 2010; 39:213-8.

Steimer W, Zöpf K, von Amelunxen S et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51:376-85.

Sugimoto M, Furuta T, Shirai N et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76:290-301.

Sverko A, Sobočanec S, Kušić B et al. Superoxide dismutase and cytochrome P450 isoenzymes might be associated with higher risk of renal cell carcinoma in male patients. Int Immunopharmacol 2011; 11:639-45.

Takada K, Arefayene M, Desta Z et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50:2202-10.

Tamura T, Kurata M, Inoue S et al. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping. Nagoya J Med Sci 2011; 73:25-31.

Tanaka A, Nagamatsu T, Yamaguchi M et al. Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother 2011; 45:1.

Tantry US, Bliden KP, Wei C et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010; 3:556-66.

Thieme D, Rolf B, Sachs H, Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med 2008; 122:149-55.

Timm R, Kaiser R, Lötsch J et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005; 5:365-73.

Tiroch KA, Sibbing D, Koch W et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010; 160:506-12.

Trenk D, Hochholzer W, Fromm MF et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; 4:429-36.

Tsai MH, Lin KM, Hsiao MC et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010; 11:537-46.

Tseng A, Macarthur RD. Profile of etravirine for the treatment of HIV infection. Ther Clin Risk Manag 2010; 6:49-58.

Tsimberidou AM, Lewis N, Reid T et al. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1635-7.

Tu JH, Hu DL, Dai LL et al. Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Xenobiotica 2010; 40:393-9.

Uno T, Sugimoto K, Sugawara K, Tateishi T. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. J Clin Pharm Ther 2008; 33:67-73.

van Schaik RH, Kok M, Sweep FC et al. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics 2011; 12:1137-46.

Vangsted AJ, Søeby K, Klausen TW et al. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with multiple myeloma. BMC Cancer 2010; 10:404.

von Ahsen N, Tzvetkov M, Karunajeewa HA et al. CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. Int J Mol Epidemiol Genet 2010; 1:310-9.

Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376:1320-8.

Wang H, An N, Wang H et al. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4’-hydroxylation and omeprazole 5’-hydroxylation. Drug Metab Dispos 2011; 39:830-7.

Wang H, Kim RA, Sun D et al. Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica 2011; 41:826-35.

Wang Y, Zhang H, Meng L et al. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol 2010; 66:563-9.

Ward RM, Tammara B, Sullivan SE et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol 2010; 66:555-61.

Wen B, Moore DJ. Bioactivation of glafenine by human liver microsomes and peroxidases: Identification of electrophilic iminoquinone species and GSH conjugates. Drug Metab Dispos 2011; 39:1511-21.

Wester MR, Lasker JM, Johnson EF, Raucy JL. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 2000; 28:354-9.

Winitthana T, Niwattisaiwong N, Patarapanich C, Tantisira MH, Lawanprasert S. In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450. Toxicol In Vitro 2011; 25:890-6.

Winoto J, Song H, Hines C, Nagaraja H, Rovin BH. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy. Clin Nephrol 2011; 75:451-7.

Wu JQ, Zhu LP, Ou XT, Xu B, Zhang QQ, Weng XH. The polymorphism of cytochrome P(450) 2C19 gene in patients with invasive fungal infections. Zhonghua Nei Ke Za Zhi 2010; 49:138-41.

Xiao ZS, Goldstein JA, Xie HG et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281:604-9.

Xu HR, Chen WL, Li XN, Chu NN. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol 2010; 48:947-52.

Yadav SS, Ruwali M, Pant MC, Shukla P, Singh RL, Parmar D. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Mutat Res 2010; 684:49-55.

Yamagishi H, Koike T, Ohara S et al. Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers. World J Gastroenterol 2008; 14:2049-54.

Yamamoto K, Hokimoto S, Chitose T et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011; 57:194-201.

Yan SD, Chen M, Li Q et al. The value of combining CYP2C19*2 polymorphism with classic risk factors in prediction of clinical prognosis in acute coronary syndrome patients. Cardiology 2011; 119:15-20.

Yang JC, Wang HL, Chern HD et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy 2011; 31:227-38.

Yang JC, Yang YF, Uang YS, Lin CJ, Wang TH. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol 2009; 67:503-10.

Yang YN, Wang XL, Ma YT et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost 2010; 16:579-83.

Yasu T, Ikee R, Miyasaka Y, Chubachi H, Saito S. Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study. Yakugaku Zasshi 2010; 130:1743-50.

Yildirim Yaroğlu H, Calikoğlu M, Tamer Gümüş L. CYP2C19 gene polymorphism may be a risk factor for bronchial asthma. Med Princ Pract 2011; 20:39-42.

Yokono A, Morita S, Someya T, Hirokane G, Okawa M, Shimoda K. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 2001; 21:549-55.

Yoo HD, Cho HY, Lee YB. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol 2010; 69:27-37.

Zabalza M, Subirana I, Sala J et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2011. doi:hrt. 2011. 227652.

Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep 2011. doi:10. 1007/s11033-011-1204-5.

Zendehdel N, Biramijamal F, Hossein-Nezhad A et al. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Arch Iran Med 2010; 13:406-12.

Zhang D, Wang X, Yang M, Wang G, Liu H. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica 2011; 41:511-7.

Zhang L, Mei Q, Li QS, Hu YM, Xu JM. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. J Clin Pharm Ther 2010; 35:713-22.

Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 2002; 30:314-8.

Zhang Y, Si D, Chen X et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 2007; 64:67-74.

Zhao F, Wang J, Yang Y et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008; 13:532-41.

Zhou Q, Yu XM, Lin HB et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J 2009; 9:380-94.

Zuo XC, Zhang BK, Jia SJ et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 2010; 66:503-9.

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6)

Aarnoutse RE, Kleinnijenhuis J, Koopmans PP et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2005; 78:664-74.

Abaut AY, Chevanne F, Le Corre P. Influence of efflux transporters on liver, bile and brain disposition of amitriptyline in mice. Int J Pharm 2009; 378:80-5.

Abbas R, Chow CP, Browder NJ et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 2000; 19:178-84.

Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999; 65:465-72.

Abduljalil K, Frank D, Gaedigk A et al. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 2010; 88:643-51.

Abraham JE, Maranian MJ, Driver KE et al. CYP2D6 gene variants and their association with breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2011; 20:1255-8.

Abraham JE, Maranian MJ, Driver KE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010; 12:64.

Aceves Avila FJ, Esquivel Nava GA, Gallegos Arreola MP, Gómez Meda B, Zúñiga González G, Ramos-Remus C. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status. J Rheumatol 2004; 31:1335-9.

Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 1998; 64:8-17.

Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. Interindividual variability in acetaminophen sulfation by human fetal liver:implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol 2008; 82:155-65.

Afshar M, Thormann W. Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450 SUPERSOMES: Evidence for atypical kinetics by CYP2D6 and CYP3A4. Electrophoresis 2006; 27:1526-36.

Agúndez JA, Ledesma MC, Ladero JM, Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57:265-9.

Agúndez JA, Martínez C, Ledesma MC, Ladona MG, Ladero JM, Benítez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994; 55:412-7.

Agúndez JA, Ramirez R, Hernandez M, Llerena A, Benítez J. Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. Pharmacogenetics 1997; 7:337-40.

Agúndez JA, Rodríguez I, Olivera M et al. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing 1997; 26:147-51.

Ahern TP, Christensen M, Cronin-Fenton DP et al. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev 2011; 20:1937-43.

Ahern TP, Pedersen L, Cronin-Fenton DP, Sørensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009; 18:2562-4.

Ahmad A, Shahabuddin S, Sheikh S et al. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther 2010; 88:814-7.

Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 2006; 29:587-98.

Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 2002; 12:375-83.

Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 2007; 17:989-93.

Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-6.

Akutsu T, Kobayashi K, Sakurada K, Ikegaya H, Furihata T, Chiba K. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 2007; 35:72-8.

Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006; 65:278-90.

Albers LJ, Reist C, Helmeste D, Vu R, Tang SW. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996; 59:189-96.

Albers LJ, Reist C, Vu RL et al. Effect of venlafaxine on imipramine metabolism. Psychiatry Res 2000; 96:235-43.

Albertí JJ, Sentellas S, Salvà M. In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism. Biochem Pharmacol 2011; 81:761-76.

Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41:959-98.

Alderman CP, Hundertmark JD, Soetratma TW. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust N Z J Psychiatry 1997; 31:601-3.

Alderman J, Preskorn SH, Greenblatt DJ et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997; 17:284-91.

Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 2008; 42:884-93.

Alexandrino-Silva C, Nadalini Mauá FH, de Andrade AG, de Toledo Ferraz Alves TC. Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms. J Psychopharmacol 2008; 22:214-6.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Suppl 2:5-99.

Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine,fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999; 19:155-63.

Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000; 40:58-66.

Algeciras-Schimnich A, O’Kane DJ, Snozek CL. Pharmacogenomics of tamoxifen and irinotecan therapies. Clin Lab Med 2008; 28:553-67.

Allam MF, Serrano del Castillo A, Fernández-Crehuet Navajas R. Smoking and Parkinson’s disease: explanatory hypothesis. Int J Neurosci 2002; 112:851-4.

Allegaert K, de Hoon J, Naulaers G, van de Velde M. Neonatal clinical pharmacology: recent observations of relevance for anaesthesiologists. Acta Anaesthesiol Belg 2008; 59:283-8.

Allegaert K, van den Anker JN, de Hoon JN et al. Covariates of tramadol disposition in the first months of life. Br J Anaesth 2008; 100:525-32.

Allegaert K, van den Anker JN, Naulaers G, de Hoon J. Determinants of drug metabolism in early neonatal life. Curr Clin Pharmacol 2007; 2:23-9.

Allegaert K, van Schaik RH, Vermeersch S et al. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants. Pediatr Res 2008; 63:674-9.

Allorge D, Harlow J, Boulet O et al. In-vitro analysis of the contribution of CYP2D6. 35 to ultra-rapid metabolism. Pharmacogenetics 2001; 11:739-41.

Al-Shurbaji A, Säwe J. The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype. Eur J Clin Pharmacol 2002; 57:877-81.

Aman MG, Vinks AA, Remmerie B et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007; 29:1476-86.

Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001; 41:443-51.

Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 1999; 39:297-309.

Ammon S, Marx C, Behrens C et al. Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers. BMC Clin Pharmacol 2002; 2:2.

Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:464-70.

Andersson T, Miners JO, Veronese ME et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36:521-30.

Andreassen TN, Eftedal I, Klepstad P et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol 2011. doi:10. 1007/s00228-011-1093-5.

Anji A, Kumari M. Supplementing the liquid alcohol diet with chow enhances alcohol intake in C57 BL/6 mice. Drug Alcohol Depend 2008; 97:86-93.

Anthony M, Romero K, Malone DC et al. Warfarin interactions with substances listed in drug information compendia and in the FDA-Approved label for warfarin sodium. Clin Pharmacol Ther 2009; 86:425-9.

Antia U, Tingle MD, Russell BR. Metabolic interactions with piperazine-based ‘party pill’ drugs. J Pharm Pharmacol 2009; 61:877-82.

Anttila AK, Rasanen L, Leinonen EV. Fluvoxamine augmentation increases serum mirtazapine concentrations three-to fourfold. Ann Pharmacother 2001; 35:1221-3.

Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7:249-64.

Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J 2008; 15:100-21.

Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet 2002; 41:1021-42.

Appiah-Opong R, Commandeur JN, Axson C, Vermeulen NP. Interactions between cytochromes P450, glutathione S-transferases and Ghanaian medicinal plants. Food Chem Toxicol 2008; 46:3598-603.

Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 2007; 235:83-91.

Ardies CM, Smith TJ, Kim S, Yang CS. Induction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) activation in rat lung microsomes by chronic ethanol consumption and repeated running exercise. Cancer Lett 1996; 103:209-18.

Arranz MJ, Dawson E, Shaikh S et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995; 39:417-20.

Arukwe A. Modulation of brain steroidogenesis by affecting transcriptional changes of steroidogenic acute regulatory (StAR) protein and cholesterol side chain cleavage (P450scc) in juvenile Atlantic salmon (Salmo salar) is a novel aspect of nonylphenol toxicity. Environ Sci Technol 2005; 39:9791-8.

Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev 2007; 25:76-97.

Asimus S, Elsherbiny D, Hai TN et al. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 2007; 21:307-16.

Attar-Herzberg D, Apel A, Gang N, Dvir D, Mayan H. The serotonin syndrome: initial misdiagnosis. Isr Med Assoc J 2009; 11:367-70.

Aung GL, O’Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother 2010; 44:1850-4.

Avenoso A, Spinà E, Campo G et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997; 35:335-9.

Avent KM, DeVoss JJ, Gillam EM. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem Res Toxicol 2006; 19:914-20.

Ayoub N, Lucas C, Kaddoumi A. Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev 2011; 12:1127-40.

Azuma J, Hasunuma T, Kubo M et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol 2011. doi:10. 1007/s00228-011-1094-4.

Azuma J, Nonen S. Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol 2009; 65:3-17.

Babbar S, Chanda S, Bley K. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 2010; 40:807-16.

Bachus R, Bickel U, Thomsen T, Roots I, Kewitz H. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9:661-8.

Badal S, Williams SA, Huang G et al. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri. Fitoterapia 2011; 82:230-6.

Badyal DK, Dadhich AP. Cytochrome P450 and drug interactions. Indian J of Pharmacol 2001; 33:248-59.

Bae SK, Cao S, Seo KA et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine)metabolites in human liver microsomes. Drug Metab Dispos 2008; 36:1679-88.

Bak S, Tsiropoulos I, Kjaersgaard JO et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33:1465-73.

Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 1999; 21:105-15.

Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997; 43:619-26.

Banning AM. Respiratory depression following medication change from tramadol to morphine. Ugeskr Laeger 1999; 161:6500-1.

Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001; 29:30-5.

Bapiro TE, Hasler JA, Ridderström M, Masimirembwa CM. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6. 17 (CYP2D6. 17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol 2002; 64:1387-98.

Barclay ML, Sawyers SM, Begg EJ et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003; 13:627-32.

Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos 2001; 29:1173-5.

Bareggi SR, Mundo E, Dell’Osso B, Altamura AC. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 2007; 3:741-53.

Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 1999; 48:395-401.

Baudhuin LM, Miller WL, Train L et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol 2010; 106:402-8.

Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31:444-69.

Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol 1998; 13 Suppl 5:35-43.

Bebia Z, Buch SC, Wilson JW et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004; 76:618-27.

Becker C, Bray-French K, Drewe J. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol 2010; 6:1437-44.

Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86:250-6.

Becquemont L, Chazouilleres O, Serfaty L et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 2002; 71:488-95.

Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Brentano C, Jaillon P. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27:1068-73.

Begré S, von Bardeleben U, Ladewig D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22:211-5.

Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100:1052-7.

Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002; 42:1219-27.

Bellec G, Dréano Y, Lozach P, Ménez JF, Berthou F. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis 1996; 17:2029-34.

Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998; 54:261-4.

Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000; 14:301-19.

Benetton SA, Fang C, Yang YO et al. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 2007; 22:78-87.

Benoit E, Delatour P, Olivier L, Caldwell J. (-)-R-fenoprofen: formation of fenoprofenyl-coenzyme A by rat liver microsomes. Biochem Pharmacol 1995; 49:1717-20.

Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59:45-50.

Berle JØ, Steen VM, Aamo TO, Breilid H, Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65:1228-34.

Berry BW, Jamali F. Presystemic and systemic chiral inversion of R-(-)-fenoprofen in the rat. J Pharmacol Exp Ther 1991; 258:695-701.

Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31:289-93.

Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29:192-209.

Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 1997; 391:14-21.

Berwaerts J, Cleton A, Herben V et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009; 42:158-63.

Beszłej JA, Grzesiak M, Milejski P. Acute dyskinetic syndrome during chloropromazine treatment of a female patient with CYP2D6 poor metabolism phenotype. Psychiatr Pol 2007; 41:495-501.

Beulz-Riché D, Grudé P, Puozzo C et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 2005; 19:545-53.

Bharucha AE, Skaar T, Andrews CN et al. Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil 2008; 20:891-9.

Bialecka M, Klodowska-Duda G, Honczarenko K et al. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson’s disease. Parkinsonism Relat Disord 2007; 13:224-9.

Bible KC, Lensing JL, Nelson SA et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11:5935-41.

Bidlack WR, Brown RC, Mohan C. Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity. Fed Proc 1986; 45:142-8.

Bijl MJ, Luijendijk HJ, van den Berg JF et al. Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. Pharmacogenomics 2009; 10:541-7.

Bijl MJ, van Schaik RH, Lammers LA et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009; 118:125-30.

Bijl MJ, Visser LE, Hofman A et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008; 65:558-64.

Bijl MJ, Visser LE, van Schaik RH et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 2009; 85:45-50.

Bisaga A, Kos T, Wójcikowski J, Daniel WA, Popik P. Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice. Drug Alcohol Depend 2008; 95:147-51.

Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today 2010; 46:567-79.

Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 2006; 45:1-11.

Blake MJ, Gaedigk A, Pearce RE et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007; 81:510-6.

Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005; 70:1096-103.

Blevins-Primeau AS, Sun D, Chen G et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009; 69:1892-900.

Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29:769-84.

Blume N, Leonard J, Xu ZJ, Watanabe O, Remotti H, Fishman J. Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells. Arch Biochem Biophys 2000; 381:191-204.

Bock KW, Schrenk D, Forster A et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4:209-18.

Bomsien S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol 2007; 63:821-7.

Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996; 128:421-5.

Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2002; 35:50-6.

Boni J, Abbas R, Leister C et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 2009; 64:263-70.

Bonn B, Masimirembwa CM, Aristei Y, Zamora I. The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition. Drug Metab Dispos 2008; 36:2199-210.

Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996; 49:305-8.

Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003; 9:97-140.

Boriani G, Biffi M, Diemberger I, Domenichini G, Marziali A, Martignani C. Atrial fibrillation: Adverse effects of “pill-in-the-pocket” treatment and propafenone-carvedilol interaction. Int J Cardiol 2010; 140:242-3.

Borlak JT, Harsany V, Schneble H, Haegele KD. pNAT and CYP2D6 gene polymorphism in epileptic patients. Biochem Pharmacol 1994; 48:1717-20.

Borobia AM, Novalbos J, Guerra-López P et al. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res 2009; 59:393-8.

Bosso JA, Liu Q, Evans WE, Relling MV. CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosis. Pharmacotherapy 1996; 16:749-53.

Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993; 43:120-6.

Bourrié M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27:288-96.

Bozina N, Jovanović N, Lovrić M, Medved V. Clinical significance of a CYP2D6 poor metabolizer-a patient with schizophrenia on risperidone treatment. Ther Drug Monit 2008; 30:748-51.

Brachtendorf L, Jetter A, Beckurts KT, Hölscher AH, Fuhr U. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 2002; 90:144-9.

Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3:229-43.

Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000; 68:401-11.

Brandes LJ, Queen GM, LaBella FS. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol 2000; 45:298-304.

Brannan MD, Reidenberg P, Radwanski E et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58:269-78.

Brauch H, Jordan VC. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the ‘personalised’ approach? Eur J Cancer 2009; 45:2274-83.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009; 55:1770-82.

Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brøsen K, Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 2002; 40:609-16.

Bressler R. Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 2006; 61:12-8.

Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004; 36:723-46.

Briest S, Stearns V. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol 2009; 7:185-92.

Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik T, Soback S. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther Drug Monit 2000; 22:510-6.

Brockmöller J, Kirchheiner J, Schmider J et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72:438-52.

Brockmöller J, Meineke I, Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultrarapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 2007; 81:699-707.

Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung 2003; 53:814-22.

Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10:545-58.

Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol 1990; 39:1045-53.

Broly F, Marez D, Lo Guidice JM et al. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet 1995; 96:601-3.

Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993; 3:123-30.

Brøsen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol 1998; 13 Suppl 5:45-7.

Brøsen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004; 59:5-12.

Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44:349-55.

Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11:275-83.

Brøsen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991; 49:609-17.

Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 2007; 150:623-6.

Broussolle E, Thobois S. Genetics and environmental factors of Parkinson disease. Rev Neurol 2002; 158:11-23.

Brown MA, Edwards S, Hoyle E et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Molec Genet 2000; 9:1563-6.

Brynne N, Böttiger Y, Hallén B, Bertilsson L. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol 1999; 47:145-50.

Brynne N, Forslund C, Hallén B, Gustafsson LL, Bertilsson L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999; 48:564-72.

Brynne N, Svanström C, Aberg-Wistedt A, Hallén B, Bertilsson L. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 1999; 48:553-63.

Bu HZ. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Curr Drug Metab 2006; 7:231-49.

Bucaretchi F, de Capitani EM, Mello SM et al. Serotonin syndrome following sibutramine poisoning in a child, with sequential quantification of sibutramine and its primary and secondary amine metabolites in plasma. Clin Toxicol 2009; 47:598-601.

Bullock P, Pearce R, Draper A et al. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab Dispos 1995; 23:736-48.

Busby WF Jr, Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999; 27:246-9.

Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease. Aging Health 2005; 1:303-48.

Cacabelos R. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiat Dis Treat 2007; 3:303-33.

Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Methods Find Exp Clin Pharmacol 2007; 29(Suppl B):1-91.

Cacabelos R. Pharmacogenetic basis for therapeutic optimization in Alzheimer’s disease. Mol Diagn Ther 2007; 11:385-405.

Cacabelos R. Pharmacogenomics and therapeutic prospect in dementia. Eur Arch Psychiatry Clin Neurosci 2008; 258 Suppl 1:28-47.

Cacabelos R. Pharmacogenomics in Alzheimer’s disease. Methods Mol Biol 2008; 448:213-357.

Cacabelos R, Fernández-Novoa L, Álvarez A et al. Cholinesterase inhibitors in dementia. Tem years of Donepezil in Alzheimer’s disease and CNS disorders (1996-2006): Therapeutic assessment and pharmacogenetics. Gen-T EuroEspes J 2007; (Suppl 1):1-52.

Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci 2011; 65:3-19.

Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Curr Alzheimer Res 2007; 4:479-500.

Cacabelos R, Martínez-Bouza R. Genomics and pharmacogenomics of schizophrenia. CNS Neurosci Ther 2011; 17:541-65.

Cacabelos R, Martínez-Bouza R. Genomics and pharmacogenomics of dementia. CNS Neurosci Ther 2011; 17:566-76.

Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer’s disease. Drugs Future 2006; 31(Suppl B):5-146.

Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 2007; 8:612-22.

Cai WM, Chen B, Cai MH, Zhang YD. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. Zhongguo Yao Li Xue Bao 1999; 20:720-4.

Cai WM, Chen B, Zhang WX. Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clin Pharmacol Ther 2007; 81:95-8.

Cai WM, Chen B, Zhou Y, Zhang YD. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. Clin Pharmacol Ther 1999; 66:516-21.

Cai WM, Nikoloff DM, Pan RM et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J 2006; 6:343-50.

Cai X, Wang RW, Edom RW et al. Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. Drug Metab Dispos 2004; 32:584-6.

Cai Y, Shen XZ, Zhou CH, Wang JY. Abnormal expression of Smurf2 during the process of rat liver fibrosis. Chin J Dig Dis 2006; 7:237-45.

Cairns W, Smith CA, McLaren AW, Wolf CR. Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 1996; 271:25269-76.

Calarge CA, Miller del D. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol 2011; 21:163-9.

Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37:177-93.

Callaghan JT, Cerimele BJ, Kassahun KJ et al. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997; 37:971-8.

Candiotti KA, Yang Z, Rodriguez Y et al. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption. Pain Med 2009; 10:799-805.

Canturk P, Caner V, Oruc N et al. The mRNA expression of cytochrome P450 isoforms in human gastric tissue. Hepatogastroenterology 2010; 57:372-6.

Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011; 12:570-7.

Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996; 278:1165-74.

Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine’s respiratory, psychomotor and miotic effects. J Pharmacol Exp Ther 1997; 281:330-6.

Caraco Y, Sheller J, Wood AJ. Impact of ethnic origin and quinidine coadministration on codeine’s disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999; 290:413-22.

Caraco Y, Wilkinson GR, Wood AJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996; 60:396-404.

Carmo H, Brulport M, Hermes M et al. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘Ecstasy’) cytotoxicity. Pharmacogenet Genomics 2006; 16:789-99.

Carmo H, Brulport M, Hermes M et al. CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). Toxicology 2007; 229:236-44.

Carr LG, Zeng D, Li TK. Failure to find exon 7 polymorphism of the ADH7 gene in Chinese, Japanese, African-Americans, and Caucasians. Alcohol Clin Exp Res 1996; 20:418-9.

Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodríguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60:183-90.

Carrillo JA, Herráiz AG, Ramos SI, Gervasini G, Vizcaíno S, Benítez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23:119-27.

Carrillo JA, Ramos SI, Herraiz AG et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 1999; 19:494-9.

Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23:523-41.

Caslake MJ, Stewart G, Day SP et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003; 171:245-53.

Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 2005; 27:680-2.

Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007; 40:107-10.

Castrioto A, Tambasco N, Rossi A, Calabresi P. Acute dystonia induced by the combination of midodrine and perphenazine. J Neurol 2008; 255:767-8.

Cavallari LH, Limdi NA. Warfarin pharmacogenomics. Curr Opin Mol Ther 2009; 11:243-51.

Cederbaum AI. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense in liver cells. J Gastroenterol Hepatol 2006; 21 Suppl 3:22-5.

Chainuvati S, Nafziger AN, Leeder JS et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”. Clin Pharmacol Ther 2003; 74:437-47.

Chan E, Hegde A, Chen X. Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol 2009; 61:451-8.

Chang SY, Chen C, Yang Z, Rodrigues AD. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos 2009; 37:1667-75.

Chang SY, Li W, Traeger SC et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos 2008; 36:2513-22.

Chao YC, Young TH, Chang WK, Tang HS, Hsu CT. An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end-stage organ damage in a Chinese population. Hepatology 1995; 22:1409-14.

Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003; 31:1391-7.

Chaung WW, Jacob A, Ji Y, Wang P. Suppression of PGC-1 alpha by ethanol: implications of its role in alcohol induced liver injury. Int J Clin Exp Med 2008; 1:161-70.

Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61:81-110.

Chen B, Cai WM. Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. Acta Pharmacol Sin 2003; 24:1277-80.

Chen C, Zhao W, Lu Y et al. High-throughput detection of highly benzimidazole-resistant allele E198A with mismatch primers in allele-specific real-time polymerase chain reaction. Pest Manag Sci 2009; 65:413-9.

Chen CP, Lin SP, Chern SR et al. A de novo 7. 9 Mb deletion in 22q13. 2→qter in a boy with autistic features, epilepsy, developmental delay, atopic dermatitis and abnormal immunological findings. Eur J Med Genet 2010; 53:329-32.

Chen S, Li X. Transposable elements are enriched within or in close proximity to xenobiotic-metabolizing cytochrome P450 genes. BMC Evol Biol 2007; 7:46.

Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther 2003; 73:264-71.

Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991; 31:381-90.

Cherner M, Bousman C, Everall I et al. Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings. J Int Neuropsychol Soc 2010; 16:890-901.

Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR. Metabolism of vanoxerine,1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos 2001; 29:1216-20.

Chetty M, Murray M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 2007; 8:307-13.

Chhun S, Verstuyft C, Rizzo-Padoin N et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol 2009; 68:226-37.

Chianella C, Gragnaniello D, Maisano Delser P et al. BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 2011; 67:1147-57.

Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 1995; 275:1527-34.

Chico LK, Behanna H, Hu W, Zhong G, Roy SM, Watterson DM. Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database. Drug Metab Dispos 2009; 37:2204-11.

Chida M, Yokoi T, Nemoto N, Inaba M, Kinoshita M, Kamataki T. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics 1999; 9:287-93.

Chinta SJ, Pai HV, Upadhya SC, Boyd MR, Ravindranath V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res Mol Brain Res 2002; 103:49-61.

Cho HY, Lee YB. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res 2006; 29:525-33.

Cho KH, Lee SM. Altered activity of cytochrome P450 in alcoholic fatty liver exposed to ischemia/reperfusion. Arch Pharm Res 2007; 30:50-7.

Chou YC, Chung YT, Liu TY et al. The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J Pharm Sci 2010; 99:1063-77.

Chow HH, Garland LL, Hsu CH et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 2010; 3:1168-75.

Chow HH, Hakim IA, Vining DR et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006; 15:2473-6.

Chow MS, White CM, Lau CP, Fan C, Tang MO. Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation. J Clin Pharmacol 2001; 41:92-6.

Chow T, Imaoka S, Hiroi T, Funae Y. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab Dispos 1999; 27:188-92.

Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: Is the ‘glass of molecular mimicry’ half full or half empty? J Autoimmun 2010; 34:38-44.

Christen U, Holdener M, Hintermann E. Animal models for autoimmune hepatitis. Autoimmun Rev 2007; 6:306-11.

Christensen M, Andersson K, Dalén P et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73:517-28.

Christensen M, Tybring G, Mihara K et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002; 71:141-52.

Christopher LJ, Hong H, Vakkalagadda BJ et al. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans. Drug Metab Dispos 2010; 38:2049-59.

Chun J, Kent UM, Moss RM, Sayre LM, Hollenberg PF. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane. Drug Metab Dispos 2000; 28:905-11.

Chyka PA, Erdman AR, Christianson G et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45:95-131.

Ciccone PE, Ramabadran K, Jessen LM. Potential interactions of methylphenidate and atomoxetine with dextromethorphan. J Am Pharm Assoc 2006; 46:472-8.

Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol 2010; 6:1551-64.

Ciusani E, Zullino DF, Eap CB, Brawand-Amey M, Brocard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol 2004; 18:559-66.

Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos 2010; 38:1393-6.

Clarke JA, Cutler M, Gong I, Schwarz UI, Freeman D, Dasgupta M. Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study. Am J Geriatr Pharmacother 2011; 9:224-33.

Clinard F, Sgro C, Bardou M et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol 2004; 60:279-83.

Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010; 28:4029-37.

Cobaugh DJ, Erdman AR, Booze LL et al. Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45:918-42.

Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997; 25:985-93.

Coecke S, Bogni A, Langezaal I, Worth A, Hartung T, Monshouwer M. The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects. Toxicol In Vitro 2001; 15:553-6.

Coffey GL, Botts SR, de Leon J. High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:770-4.

Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos 2000; 21:353-64.

Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10:1212-8.

Colburn DE, Giles FJ, Oladovich D, Smith JA. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004; 9:217-21.

Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson’s disease. J Pharmacol Exp Ther 1996; 277:685-90.

Coller JK, Joergensen C, Foster DJ et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int J Clin Pharmacol Ther 2007; 45:410-7.

Coller JK, Krebsfaenger N, Klein K et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54:157-67.

Congiu M, Mashford ML, Slavin JL, Desmond PV. Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J Gastroenterol Hepatol 2009; 24:1038-44.

Connor H. Serotonin syndrome after single doses of co-amoxiclav during treatment with venlafaxine. J R Soc Med 2003; 96:233-4.

Contreras AV, Monge-Cazares T, Alfaro-Ruiz L et al. Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican mestizos. Pharmacogenomics 2011; 12:745-56.

Conus P, Bondolfi G, Eap CB, Macciardi F, Baumann P. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry 1996; 29:108-10.

Corchero J, Granvil CP, Akiyama TE et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001; 60:1260-7.

Court MH, Duan SX, von Moltke LL et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299:998-1006.

Cowpland C, Su GM, Murray M, Puddey IB, Croft KD. Effect of alcohol on cytochrome p450 arachidonic acid metabolism and blood pressure in rats and its modulation by red wine polyphenolics. Clin Exp Pharmacol Physiol 2006; 33:183-8.

Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 1998; 15 Suppl:45-51.

Crettol S, Déglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80:668-81.

Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997; 53:171-8.

Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69:1157-65.

Curry SC, Watts DJ, Katz KD, Bikin D, Bukaveckas BL. The effect of single-dose tramadol on oxycodone clearance. J Emerg Med 2007; 33:407-11.

Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63:769-802.

Dagle JM, Fisher TJ, Haynes SE et al. Cytochrome P450 (CYP2D6) genotype is associated with elevated systolic blood pressure in preterm infants after discharge from the neonatal intensive care unit. J Pediatr 2011; 159:104-9.

Dahabreh I, Terasawa T, Castaldi P, Trikalinos TA. CYP2D6 testing to predict response to tamoxifen in women with breast cancer. Pharmacogenomic. PLoS Curr 2010. doi:10. 1371/currents. RRN1176.

Daher W, Pelinski L, Klieber S et al. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos 2006; 34:667-82.

Dahl ML, Iselius L, Alm C et al. Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur J Clin Pharmacol 1993; 44:445-50.

Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274:516-20.

Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000; 22:114-7.

Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 2003; 3:362-70.

Dai Z, Papp AC, Wang D, Hampel H, Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1:24.

Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63:444-52.

Dalén P, Dahl ML, Roh HK et al. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. Br J Clin Pharmacol 2003; 55:630-4.

Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996; 6:319-28.

Daly AK, Leathart JB, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet 1995; 95:337-41.

Damkier P, Brøsen K. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin Pharmacol Ther 2000; 68:199-209.

Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999; 48:829-38.

Damme B, Darmer D, Pankow D. Induction of hepatic cytochrome P4502E1 in rats by acetylsalicylic acid or sodium salicylate. Toxicology 1996; 106:99-103.

Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004; 18:113-23.

Dandara C, Masimirembwa CM, Magimba A et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001; 57:11-7.

D’Andrea G, Brisdelli F, Bozzi A. AZT: an old drug with new perspectives. Curr Clin Pharmacol 2008; 3:20-37.

Daniel WA, Haduch A, Wójcikowski J. Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. Eur Neuropsychopharmacol 2005; 15:103-10.

Darby JK, Pasta DJ, Wilson MG, Herbert J. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig 2008; 28:553-64.

D’Arrigo C, Migliardi G, Santoro V et al. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res 2005; 52:497-501.

Dasbiswas A, Shinde S, Dasbiswas D. S-metoprolol: the 2008 clinical review. J Indian Med Assoc 2008; 106:259-62.

Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. Br J Clin Pharmacol 2006; 61:321-5.

Davies BJ, Coller JK, Somogyi AA, Milne RW, Sallustio BC. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos 2007; 35:128-38.

Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. Br J Clin Pharmacol 2008; 65:347-54.

Davies SJ, Westin AA, Castberg I et al. Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand 2010; 122:444-53.

Davis MP. Does trazodone have a role in palliating symptoms? Support Care Cancer 2007; 15:221-4.

Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs 1997; 53 Suppl 2:18-24.

Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that may interfere with codeine bioactivation. Eur J Drug Metab Pharmacokinet 1992; 17:115-20.

de Craemer D, van den Branden C, Pauwels M, Vamecq J. Peroxisome-proliferating effects of fenoprofen in mice. Lipids 1998; 33:539-43.

de la Torre R, Farré M, Roset PN et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 2004; 26:137-44.

de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34:159-72.

de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005; 46:262-73.

de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47:75-85.

de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol 2004; 24:656-60.

de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr 2008; 13:133-5.

de Leon J, Susce MT, Johnson M et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 2009; 14:19-34.

de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 2006; 10:135-51.

de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66:15-27.

de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25:448-56.

de Palma G, Dick FD, Calzetti S et al. A case-control study of Parkinson’s disease and tobacco use: gene-tobacco interactions. Mov Disord 2010; 25:912-9.

de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 2011; 11:359-67.

Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 2001; 40:441-72.

Dehal SS, Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 1999; 27:681-8.

D’empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: Are pharmacokinetic variations clinically relevant? J Psychiatr Pract 2011; 17:330-9.

Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson’s disease. Ann Neurol 2004; 55:897.

Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008; 30:1956-75.

Desai M, Tanus-Santos JE, Li L et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J 2003; 3:105-13.

Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41:23-6.

Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999; 65:10-20.

Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285:428-37.

Desta Z, Soukhova N, Mahal SK, Flockhart DA. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28:789-800.

Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310:1062-75.

Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002; 30:336-43.

Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-58.

Dettling M, Sachse C, Brockmöller J et al. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 2000; 152:80-6.

Dettling M, Sachse C, Müller-Oerlinghausen B et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000; 33:218-20.

DeVane CL, Markowitz JS, Carson SW et al. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol 2000; 20:347-9.

Di Consiglio E, Meneguz A, Testai E. Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. Toxicol Appl Pharmacol 2005; 205:237-46.

Dick FD, de Palma G, Ahmadi A et al. Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med 2007; 64:673-80.

Dickmann LJ, Tay S, Senn TD et al. Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochem Pharmacol 2008; 75:1677-87.

Diefenbach K, Jaeger K, Wollny A, Penzel T, Fietze I, Roots I. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med 2008; 9:579-82.

Dieudonné AS, Lambrechts D, Claes B et al. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. Breast Cancer Res Treat 2009; 118:531-8.

Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 1999; 9:551-9.

Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000; 67:512-20.

Dilger K, Meisel P, Hofmann U, Eichelbaum M. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert’s syndrome. Ther Drug Monit 2000; 22:366-8.

Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985; 260:9057-67.

Dixit V, Hariparsad N, Desai P, Unadkat JD. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 2007; 28:257-62.

Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35:1853-9.

Dixon CM, Colthup PV, Serabjit-Singh CJ et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23:1225-30.

Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 2009; 29:744-8.

Djuv A, Nilsen OG. Aloe vera juice: IC(50) and dual mechanistic inhibition of CYP3A4 and CYP2D6. Phytother Res 2011. doi:10. 1002/ptr. 3564.

Dodd S, Boulton DW, Burrows GD, DeVane CL, Norman TR. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol 2001; 16:541-4.

Dohmen K, Baraona E, Ishibashi H et al. Ethnic differences in gastric sigma-alcohol dehydrogenase activity and ethanol first-pass metabolism. Alcohol Clin Exp Res 1996; 20:1569-76.

Doki K, Homma M, Kuga K et al. Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 2006; 62:919-26.

Doki K, Homma M, Kuga K et al. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 2007; 63:951-7.

Doki K, Homma M, Kuga K, Aonuma K, Kohda Y. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 2009; 68:89-96.

Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging 2010; 27:625-40.

Dong H, Haining RL, Thummel KE, Rettie AE, Nelson SD. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos 2000; 28:1397-400.

Donovan JL, Chavin KD, Devane CL et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32:906-8.

Dorado P, Peñas-Lledó EM, de la Rubia A, Llerena A. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics 2009; 10:1083-9.

Dorajoo R, Pereira BP, Yu Z et al. Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy. Life Sci 2008; 82:823-30.

Dorne JL, Walton K, Slob W, Renwick AG. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem Toxicol 2002; 40:1633-56.

Dragoni S, Bellik L, Frosini M et al. l-Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes. Xenobiotica 2003; 33:181-95.

Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 2003; 41:934-7.

D’Souza DL, Dimmitt DC, Robbins DK, Nezamis J, Simms L, Koch KM. Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol 2001; 41:455-8.

Dunbar L, Miles W, Wheeler A, Sheridan J, Pulford J, Butler R. The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis. N Z Med J 2009; 122:29-34.

Durić G, Svetel M, Nikolaevic SI, Dragadević N, Gavrilović J, Kostić VS. Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson’s disease. Vojnosanit Pregl 2007; 64:25-30.

Eagling VA, Howe JL, Barry MJ, Back DJ. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3’-amino-3’-deoxythymidine. Biochem Pharmacol 1994; 48:267-76.

Eap CB, Bender S, Gastpar M et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22:209-14.

Eap CB, Bertel-Laubscher R, Zullino D, Amey M, Baumann P. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiatry 2000; 33:112-5.

Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997; 17:113-7.

Eap CB, Bondolfi G, Zullino D et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21:330-4.

Eap CB, Bondolfi G, Zullino D et al. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 2001; 23:228-31.

Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41:1153-93.

Eap CB, Guentert TW, Schãublin-Loidl M et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59:322-31.

Eap CB, Lima CA, Macciardi F, Woggon B, Powell K, Baumann P. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. Ther Drug Monit 1998; 20:7-13.

Easterbrook J, Fackett D, Li AP. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4’-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem Biol Interact 2001; 134:243-9.

Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001; 29:141-4.

Easton N, Fry J, O’Shea E, Watkins A, Kingston S, Marsden CA. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res 2003; 987:144-54.

Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M. Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metab Pharmacokinet 2005; 20:294-9.

Echizen H, Tanizaki M, Tatsuno J et al. Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos 2000; 28:937-44.

Eichelbaum M, Baur MP, Dengler HJ et al. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987; 23:455-8.

Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57:119-37.

Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-7.

Elbaz A, Levecque C, Clavel J et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson’s disease. Ann Neurol 2004; 55:430-4.

Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 2005; 1:299-306.

Elkalioubie A, Allorge D, Robriquet L et al. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer. Eur J Clin Pharmacol 2011; 67:855-8.

Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002; 12:55-8.

Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 2000; 10:9-11.

Emoto C, Murase S, Sawada Y, Iwasaki K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 2005; 20:351-7.

Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 2003; 18:287-95.

Endo T, Ban M, Hirata K, Yamamoto A, Hara Y, Momose Y. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. Drug Metab Dispos 2007; 35:476-83.

Endrizzi K, Fischer J, Klein K et al. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Anal Biochem 2002; 300:121-31.

Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995; 29 Suppl 1:10-8.

Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488-95.

Ernst E. St John’s wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137:316-9.

Evans DA, Harmer D, Downham DY et al. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet 1983; 20:321-9.

Evans DC, O’Connor D, Lake BG, Evers R, Allen C, Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003; 31:861-9.

Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993; 91:2150-4.

Evert B, Griese EU, Eichelbaum M. Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994; 4:271-4.

Ewald AH, Maurer HH. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicol Lett 2008; 183:52-7.

Factor SA, Steenland NK, Higgins DS et al. Postural instability/gait disturbance in Parkinson’s disease has distinct subtypes: an exploratory analysis. J Neurol Neurosurg Psychiatry 2011; 82:564-8.

Fagerholm U. Prediction of human pharmacokinetics-gut-wall metabolism. J Pharm Pharmacol 2007; 59:1335-43.

Fan L, Zhang W, Guo D et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 2008; 83:471-6.

Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999; 359:147-51.

Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 2003; 42:1383-92.

Farré M, Abanades S, Roset PN et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 2007; 323:954-62.

Felmlee MA, Lon HK, Gonzalez FJ, Yu AM. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 2008; 36:435-41.

Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J Clin Psychopharmacol 2002; 22:326-9.

Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50:551-9.

Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22:633-58.

Fetterman JW Jr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 2009; 66:1169-79.

Findling RL, Nucci G, Piergies AA et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31:1274-85.

Fisman S, Reniers D, Diaz P. Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol 1996; 6:133-8.

Fleeman N, Dundar Y, Dickson R et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 2011; 11:1-14.

Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000; 39:413-27.

Fletcher B, Goldstein DB, Bradman AL, Weale ME, Bradman N, Thomas MG. High-throughput analysis of informative CYP2D6 compound haplotypes. Genomics 2003; 81:166-74.

Flockhart DA, Drici MD, Kerbusch T et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000; 20:317-24.

Fogelman SM, Schmider J, Venkatakrishnan K et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20:480-90.

Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-59.

Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006; 6:1249-65.

Foltynie T, Sawcer S, Brayne C, Barker RA. The genetic basis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73:363-70.

Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol 2000; 50:77-80.

Forget P, le Polain de Waroux B, Wallemacq P, Gala JL. Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. J Pain Symptom Manage 2008; 36:92-6.

Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract 2007; 7:352-6.

Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47:403-12.

Foti RS, Dickmann LJ, Davis JA et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica 2008; 38:264-80.

Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63:321-33.

Franklin MR, Hathaway LB. 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab Dispos 2008; 36:2539-46.

Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007; 17:695-707.

Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br J Clin Pharmacol 2002; 53:155-62.

Frye RF, Zgheib NK, Matzke GR et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006; 80:235-45.

Fu Y, Fan CH, Deng HH et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27:328-32.

Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the «cocktail» approach. Clin Pharmacol Ther 2007; 81:270-83.

Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 57:595-601.

Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H. Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther 2005; 43:327-34.

Fujita T, Kawase A, Niwa T et al. Comparative evaluation of 12 immature citrus fruit extracts for the inhibition of cytochrome P450 isoform activities. Biol Pharm Bull 2008; 31:925-30.

Fukuda T, Nishida Y, Imaoka S et al. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000; 380:303-8.

Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000; 56:175-80.

Fukumoto K, Kobayashi T, Tachibana K et al. Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet 2006; 21:501-5.

Funck-Brentano C, Becquemont L, Kroemer HK et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55:256-69.

Funck-Brentano C, Boëlle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 2005; 61:821-9.

Furman KD, Grimm DR, Mueller T et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 2004; 14:279-84.

Fuselli S, Dupanloup I, Frigato E et al. Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 2004; 12:916-24.

Fux R, Mörike K, Pröhmer AM et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005; 78:378-87.

Gaedigk A, Bhathena A, Ndjountché L et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 2005; 5:173-82.

Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48:943-50.

Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 2006; 34:563-9.

Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002; 72:76-89.

Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 2008; 64:465-75.

Gaedigk A, Eklund JD, Pearce RE et al. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin Pharmacol Ther 2007; 81:817-20.

Gaedigk A, Frank D, Fuhr U. Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. Eur J Clin Pharmacol 2009; 65:97-100.

Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999; 9:669-82.

Gaedigk A, Isidoro-García M, Pearce RE et al. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur J Clin Pharmacol 2010; 66:859-64.

Gaedigk A, Ndjountché L, Gaedigk R, Leeder JS, Bradford LD. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther 2003; 73:575-6.

Gaedigk A, Ndjountché L, Leeder JS, Bradford LD. Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clin Pharmacol Ther 2005; 77:228-30.

Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem 2003; 49:1008-11.

Galbally M, Lewis AJ, Lum J, Buist A. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 2009; 43:846-54.

Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006; 318:1220-9.

Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Kumaraswamy N, Larmie ET. Relationship between Type A and B personality and debrisoquine hydroxylation capacity. Br J Clin Pharmacol 2004; 57:785-9.

Gan SH, Ismail R, Wan Adnan WA, Zulmi W. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diagn Ther 2007; 11:171-81.

Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol 2009; 241:14-22.

Garcia-Barceló M, Chow LY, Lam KL, Chiu HF, Wing YK, Waye MM. Occurrence of CYP2D6 gene duplication in Hong Kong Chinese. Clin Chem 2000; 46:1411-3.

Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58:521-90.

Gardner ER, Burger H, van Schaik RH et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006; 80:192-201.

Gardner-Stephen DA, Mackenzie PI. Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression. Curr Drug Metab 2008; 9:439-52.

Gareri P, de Fazio P, Gallelli L et al. Venlafaxine-propafenone interaction resulting in hallucinations and psicomotor agitation. Ann Pharmacother 2008; 42:434-8.

Garnett WR. Clinical implications of drug interactions with coxibs. Pharmacotherapy 2001; 21:1223-32.

Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11:203-26.

Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351:2827-31.

Gassó P, Mas S, Alvarez S et al. Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. Pharmacogenomics 2010; 11:1725-31.

Geisel J, Kivistö KT, Griese EU, Eichelbaum M. The efficacy of simvastatin is not influenced by CYP2D6 polymorphism. Clin Pharmacol Ther 2002; 72:595-6.

Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16:36-44.

Gerstenberg G, Aoshima T, Fukasawa T et al. Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit 2003; 25:463-8.

Gex-Fabry M, Eap CB, Oneda B et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30:474-82.

Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 1997; 43:137-44.

Ghassabian S, Chetty M, Tattam BN et al. A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Ther Drug Monit 2009; 31:239-46.

Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, Lennard MS. CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet 2008; 23:101-5.

Giessmann T, Modess C, Hecker U et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004; 75:213-22.

Gil Berglund E, Johannsson G, Beck O, Bengtsson BA, Rane A. Growth hormone replacement therapy induces codeine clearance. Eur J Clin Invest 2002; 32:507-12.

Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151:737-48.

Gjerde J, Hauglid M, Breilid H et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008; 19:56-61.

Glaeser H, Drescher S, Eichelbaum M, Fromm MF. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 2005; 59:199-206.

Glatt H. Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 2000; 129:141-70.

Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23:9312-8.

Goetz MP, Schaid DJ, Wickerham DL et al. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P-1 and P-2 clinical trials. Clin Cancer Res 2011. doi:10. 1158/1078-0432. CCR-11-0860.

Goetz MP, Suman VJ, Couch FJ et al. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008; 14:5864-8.

Gołab-Janowska M, Honczarenko K, Gawrońska-Szklarz B, Potemkowski A. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer’s disease and Parkinson’s disease with dementia. Neurol Neurochir Pol 2007; 41:113-21.

Gonzalez FJ. CYP3A4 and pregnane X receptor humanized mice. J Biochem Mol Toxicol 2007; 21:158-62.

González I, Peñas-Lledó EM, Pérez B, Dorado P, Álvarez M, Llerena A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008; 9:833-40.

González-Tejera G, Gaedigk A, Corey S. Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients. P R Health Sci J 2010; 29:299-304.

Gore M, Sadosky A, Leslie D, Sheehan AH. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the U. K. and Germany Mediplus databases. Pain Pract 2008; 8:253-62.

Gorski JC, Huang SM, Pinto A et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75:89-100.

Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 2008; 64:1163-73.

Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008; 64:275-82.

Gossen D, de Suray JM, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4:11.

Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull 2004; 27:684-90.

Gough AC, Miles JS, Spurr NK et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347:773-6.

Graff DW, Williamson KM, Pieper JA et al. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 2001; 41:97-106.

Gram LF, Brøsen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993; 35:649-52.

Gram LF, Hansen MG, Sindrup SH et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993; 15:18-24.

Grasmäder K, Verwohlt PL, Kühn KU et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004; 60:473-80.

Grasmäder K, Verwohlt PL, Rietschel M et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60:329-36.

Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981; 6:89-105.

Greenblatt DJ, von Moltke LL, Giancarlo GM, Garteiz DA. Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharm Drug Dispos 2003; 24:87-94.

Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 2004; 199:354-63.

Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 1999; 9:715-23.

Griese EU, Zanger UM, Brudermanns U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8:15-26.

Grönlund J, Saari TI, Hagelberg N, Neuvonen PJ, Olkkola KT, Laine K. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. Antimicrob Agents Chemother 2011; 55:1063-7.

Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 2010; 70:78-87.

Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig 2011; 31:143-53.

Grossman I. ADME pharmacogenetics: current practices and future outlook. Expert Opin Drug Metab Toxicol 2009; 5:449-62.

Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry 2003; 36:3-6.

Grözinger M, Härtter S, Hiemke C, Griese EU, Röschke J. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. Clin Neuropharmacol 1998; 21:127-9.

Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42:1243-85.

Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson’s disease. Am J Geriatr Pharmacother 2006; 4:330-46.

Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 2010; 8:331-73.

Gueorguieva I, Jackson K, Wrighton SA, Sinha VP, Chien JY. Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. Br J Clin Pharmacol 2010; 70:523-36.

Gunes A, Spina E, Dahl ML, Scordo MG. ABCB1 polymorphisms influence steady-state plasma levels of 9-Hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 2008; 30:628-33.

Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2011. doi:10. 1007/s00228-011-1108-2.

Guo Y, Li F, Ma XC, Cheng XG, Zhou HH, Klaassen CD. CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica 2011; 41:996-1005.

Gupta S, Banfield C, Kantesaria B, Flannery B, Herron J. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol 2004; 44:1252-9.

Gurley BJ, Gardner SF, Hubbard MA et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76:428-40.

Gurley BJ, Gardner SF, Hubbard MA et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22:525-39.

Gurley BJ, Gardner SF, Hubbard MA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77:415-26.

Gurley BJ, Swain A, Barone GW et al. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2007; 35:240-5.

Gustafsson LL, Eriksson LS, Dahl ML, Eleborg L, Ericzon BG, Nyberg A. Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship? J Intern Med 1996; 240:311-4.

Guthrie SK, Hariharan M, Kumar AA, Bader G, Tandon R. The effect of paroxetine on thiothixene pharmacokinetics. J Clin Pharm Ther 1997; 22:221-6.

Gwak HS, Oh JH, Han HK. Effects of non-steroidal anti-inflammatory drugs on the pharmacokinetics and elimination of aciclovir in rats. J Pharm Pharmacol 2005; 57:393-8.

Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39:321-6.

Haefeli WE, Bargetzi MJ, Follath F, Meyer UA. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 1990; 15:776-9.

Haffen E, Vandel P, Broly F et al. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 1999; 32:232-4.

Hagelberg NM, Nieminen TH, Saari TI et al. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 2009; 65:263-71.

Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001; 51:169-73.

Hägg S, Spigset O, Lakso HA, Dahlqvist R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001; 57:493-7.

Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008; 34:355-81.

Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998; 28:35-72.

Håkonsen GD, Pettersen MH, Skurtveit S, Giverhaug T. Concomitant use of warfarin, analgesics and anti-inflammatory agents. Tidsskr Nor Laegeforen 2009; 129:1217-20.

Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 1995; 40:369-78.

Halling J, Petersen MS, Damkier P et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 2005; 61:491-7.

Halling J, Petersen MS, Grandjean P, Weihe P, Brosen K. Genetic predisposition to Parkinson’s disease: CYP2D6 and HFE in the Faroe Islands. Pharmacogenet Genomics 2008; 18:209-12.

Halling J, Weihe P, Brosen K. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients. Ther Drug Monit 2008; 30:271-5.

Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol 2008; 65:134-8.

Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26:536-9.

Hamelin BA, Turgeon J, Vallée F, Bélanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60:512-21.

Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3’ splice recognition site. Am J Hum Genet 1990; 47:994-1001.

Hanioka N, Okumura Y, Saito Y et al. Catalytic roles of CYP2D6. 10 and CYP2D6. 36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae. Biochem Pharmacol 2006; 71:1386-95.

Hanioka N, Ozawa S, Jinno H et al. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 2002; 30:391-6.

Hao B, Chen ZW, Zhou XJ et al. Identification of phase-I metabolites and chronic toxicity study of the Kv1. 3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica 2011; 41:198-211.

Hara Y, Nakajima M, Miyamoto KI, Yokoi T. Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions. Xenobiotica 2005; 35:549-60.

Harada S. Classification of alcohol metabolizing enzymes and polymorphisms-specificity in Japanese. Nihon Arukoru Yakubutsu Igakkai Zasshi 2001; 36:85-106.

Haritos VS, Ching MS, Ghabrial H et al. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Pharmacogenetics 1998; 8:423-32.

Haritos VS, Ghabrial H, Ahokas JT, Ching MS. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 2000; 10:591-603.

Harrill AH, Watkins PB, Su S et al. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 2009; 19:1507-15.

Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol 2007; 63:159-63.

Harrison-Findik DD. Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease? World J Gastroenterol 2009; 15:1186-93.

Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000; 67:1-6.

Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 2002; 19:1034-7.

Hashemi-Soteh SM, Sarzare F, Merat F, Salehifar E, Shiran MR. Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3, *4, and *6) within an Iranian population (Mazandaran). Genet Test Mol Biomarkers 2011. doi:10. 1089/gtmb. 2011. 0033.

Hassan BA, Yusoff ZB. Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 2011; 12:185-91.

Hasselstrøm J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact 2006; 21:187-211.

Hauser IA, Schaeffeler E, Gauer S et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501-11.

Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009; 41:619-28

Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy 2005; 25:303-7.

Hayashi S, Hirao A, Nakamura H, Yamamura K, Mizuno K, Yamashita H. Discovery of 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: integrated drug-design and structure-activity relationships for orally potent, metabolically stable and potential-risk reduced novel non-peptide Nociceptin/Orphanin FQ receptor agonist as antianxiety drug. Chem Biol Drug Des 2009; 74:369-81.

He K, Woolf TF, Kindt EK, Fielder AE, Talaat RE. Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. Biochem Pharmacol 2001; 62:191-8.

He N, Xie HG, Collins X, Edeki T, Yan Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin Exp Pharmacol Physiol 2006; 33:813-5.

He N, Zhang WQ, Shockley D, Edeki T. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 2002; 57:847-51.

He YJ, Brockmöller J, Schmidt H, Roots I, Kirchheiner J. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? J Anal Toxicol 2008; 32:178-82.

He YJ, Zhang W, Tu JH et al. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab Dispos 2008; 36:1453-6.

Hedenmalm K, Lindh JD, Säwe J, Rane A. Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur J Clin Pharmacol 2004; 60:369-72.

Hedenmalm K, Sundgren M, Granberg K, Spigset O, Dahlqvist R. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity. Ther Drug Monit 1997; 19:643-9.

Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14:49-58.

Heinig R, Böttcher MF. Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers. Clin Drug Investig 2005; 25:115-23.

Hellman K, Roos E, Osterlund A et al. Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. Br J Clin Pharmacol 2003; 56:337-40.

Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol 2007; 101:350-8.

Hemeryck A, de Vriendt C, Belpaire FM. Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol 2000; 20:428-34.

Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006; 39:121-7.

Hendset M, Hermann M, Lunde H, Refsum H, Molden E. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63:1147-51.

Hendset M, Molden E, Enoksen TB, Refsum H, Hermann M. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit 2010; 32:787-90.

Henry NL, Rae JM, Li L, Azzouz F et al. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 2009; 117:571-5.

Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 2008; 64:483-7.

Herraiz T, Guillén H, Arán VJ, Idle JR, Gonzalez FJ. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol Appl Pharmacol 2006; 216:387-98.

Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356:2069-70.

Herrlin K, Yasui-Furukori N, Tybring G, Widén J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003; 56:415-21.

Hersh EV, Moore PA. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 2004; 135:298-311.

Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007; 29:2477-97.

Hesse LM, Venkatakrishnan K, Court MH et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28:1176-83.

Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos 2001; 29:133-40.

Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003; 17:513-32.

Hidestrand M, Shankar K, Ronis MJ, Badger TM. Effects of light and dark beer on hepatic cytochrome P-450 expression in male rats receiving alcoholic beverages as part of total enteral nutrition. Alcohol Clin Exp Res 2005; 29:888-95.

Hilleret H, Voirol P, Bovier P et al. Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer. Ther Drug Monit 2002; 24:567-9.

Hintermann E, Holdener M, Bayer M et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmun 2011. doi:10. 1016/j. jaut. 2011. 06. 005.

Hiratsuka M. Development of simplified and rapid detection assay for genetic polymorphisms influencing drug response and its clinical applications. Yakugaku Zasshi 2002; 122:451-63.

Hiroi T, Chow T, Imaoka S, Funae Y. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 2002; 30:970-6.

Hiroi T, Imaoka S, Chow T, Yabusaki Y, Funae Y. Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol 1997; 53:1937-9.

Hiroi T, Ohishi N, Imaoka S, Yabusaki Y, Fukui H, Funae Y. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol Exp Ther 1995; 272:939-44.

Ho MT, Kelly EJ, Bodor M, Bui T, Kowdley KV, Ho RJ. Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects. Ann Hepatol 2011; 10:327-32.

Ho RH, Tirona RG, Leake BF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130:1793-806.

Ho SH, Singh M, Holloway AC, Crankshaw DJ. The Effects of commercial preparations of herbal supplements commonly used by women on the biotransformation of fluorogenic substrates by human cytochromes P450. Phytother Res 2011. doi:10. 1002/ptr. 3371.

Ho SL, Kung MH, Li LS, Lauder IJ, Ramsden DB. Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson’s disease in Chinese and Caucasians. Eur J Neurol 1999; 6:323-9.

Ho T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Physician 2007; 10:467-72.

Hodgson E, Rose RL. Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol 2007; 21:182-6.

Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 2002; 122:2049-63.

Hokkanen J, Tolonen A, Mattila S, Turpeinen M. Metabolism of hyperforin, the active constituent of St. John’s wort, in human liver microsomes. Eur J Pharm Sci 2011; 42:273-84.

Honda M, Nozawa T, Igarashi N et al. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. Biol Pharm Bull 2005; 28:1476-9.

Hong H, Su H, Ma L et al. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor. Drug Metab Dispos 2011; 39:1658-67.

Horiuchi I, Nozawa T, Fujii N et al. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. Biol Pharm Bull 2008; 31:976-80.

Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9:576-86.

Hoyumpa AM Jr. Alcohol interactions with benzodiazepines and cocaine. Adv Alcohol Subst Abuse 1984; 3:21-34.

Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35:275-91.

Hsu ES. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther 2010; 17:476-86.

Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 2008; 4:1209-20.

Huang CW, Lai ML, Lin MS, Lee HL, Huang JD. Dose-response relationships of propranolol in Chinese subjects with different CYP2D6 genotypes. J Chin Med Assoc 2003; 66:57-62.

Huang H, Wang H, Sinz M et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007; 26:258-68.

Huang ML, van Peer A, Woestenborghs R et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257-68.

Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59:42-55.

Huang Z. Impact of Impurities on IC(50) Values of P450 Inhibitors. Drug Metab Lett 2011; 5:156-62.

Huang Z, Fasco MJ, Kaminsky LS. Alternative splicing of CYP2D mRNA in human breast tissue. Arch Biochem Biophys 1997; 343:101-8.

Huezo-Diaz P, Perroud N, Spencer E et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 2011. doi:10. 1177/0269881111414451.

Hui-Chen L, Yang Y, Na W, Ming D, Jian-Fang L, Hong-Yuan X. Pharmacokinetics of the enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in healthy male and female chinese volunteers. Chirality 2004; 16:112-8.

Hukkanen J, Mäntylä M, Kangas L et al. Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol Toxicol 1998; 82:93-7.

Hulbert AJ, Turner N, Storlien LH, Else PL. Dietary fats and membrane function: implications for metabolism and disease. Biol Rev Camb Philos Soc 2005; 80:155-69.

Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004; 57:287-97.

Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, Laine K. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008; 83:342-8.

Ieiri I, Yamada S, Seto K et al. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 2003; 36:192-6.

Igarashi K, Kasuya F, Fukui M, Usuki E, Castagnoli N Jr. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. Life Sci 1995; 57:2439-46.

Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003; 13:163-8.

Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6-13.

Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005; 207(2 Suppl):52-6.

Ingelman-Sundberg M, Johansson I, Yin H et al. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993; 10:447-52.

Ingelman-Sundberg M, Sim SC. Intronic polymorphisms of cytochromes P450. Hum Genomics 2010; 4:402-5.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodríguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526.

Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008; 112(3 Suppl):695-9.

International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-64.

Irvin WJ Jr, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 2011; 29:3232-9.

Isaac MT. Treating depression with SNRIs: who will benefit most? CNS Spectr 2008; 13(7 Suppl 11):15-21.

Isayama F, Froh M, Bradford BU et al. The CYP inhibitor 1-aminobenzotriazole does not prevent oxidative stress associated with alcohol-induced liver injury in rats and mice. Free Radic Biol Med 2003; 35:1568-81.

Isaza CA, Henao J, López AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 2000; 22:695-705.

Ishak KJ, Tan Y, Glass J, Luong D, Caro JJ. Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia. Clin Ther 2008; 30:1251-63.

Ishida K, Taguchi M, Akao T, Hashimoto Y. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells. Biol Pharm Bull 2009; 32:513-6.

Ishiguro A, Kubota T, Sasaki H, Iga T. A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype. Clin Chim Acta 2004; 347:217-21.

Ishiguro A, Kubota T, Soya Y et al. High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction. Anal Biochem 2005; 337:256-61.

Ishii Y, Nakamura K, Tsutsumi K, Kotegawa T, Nakano S, Nakatsuka K. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol 2000; 40:193-9.

Ismail R, Teh LK, Amir J, Alwi Z, Lopez CG. Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia. J Clin Pharm Ther 2003; 28:279-84.

Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006; 31:99-109.

Isobe T, Hichiya H, Hanioka N et al. Different effects of desipramine on bufuralol 1’’-hydroxylation by rat and human CYP2D enzymes. Biol Pharm Bull 2005; 28:634-40.

Itagaki S, Gopal E, Zhuang L et al. Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). Pharm Res 2006; 23:1209-16.

Ito K, Kubota Y, Toda T, Suto S, Ikarashi N, Sugiyama K. Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein. Drug Metab Pharmacokinet 2009; 24:108-13.

Iwahashi K. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol Psychiatry 1994; 36:781-2.

Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 1995; 18:233-6.

Iwahashi K, Suwaki H, Matsuo Y, Ichikawa Y, Hosokawa K. Correspondence of increased debrisoquine 4-monooxygenase activity with seizure-susceptibility in Mongolian gerbils. J Neurol Sci 1994; 121:18-21.

Iwahashi K, Yoshihara E, Nakamura K et al. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. Neuropsychobiology 1999; 39:33-7.

Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004; 32:1351-8.

Jaanson P, Marandi T, Kiivet RA et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 2002; 162:67-73.

Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002; 49:461-7.

Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2). Life Sci 2003; 73:2841-54.

Jägestedt M, von Bahr C. Combination of serotonergic agents resulted in severe adverse effects. Lakartidningen 2004; 101:1618-9.

Jan MW, ZumBrunnen TL, Kazmi YR et al. Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug Metabol Drug Interact 2002; 19:1-11.

Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41:719-39.

Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 2009; 10:1157-67.

Jaquenoud Sirot E, Knezevic B, Morena GP et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009; 29:319-26.

Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998; 56:691-707.

Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005; 27:1685-95.

Jenner P. Genetic susceptibility and the occurrence of Parkinson’s disease. Parkinsonism Relat Disord 1999; 5:173-7.

Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51:73-8.

Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006; 45:469-91.

Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994; 16:1-12.

Jerling M, Dahl ML, Aberg-Wistedt A et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59:423-8.

Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16:368-74.

Jerling M, Merlé Y, Mentré F, Mallet A. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6-an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994; 38:453-62.

Ji HY, Kim SY, Kim DK, Jeong JH, Lee HS. Effects of eupatilin and jaceosidin on cytochrome p450 enzyme activities in human liver microsomes. Molecules 2010; 15:6466-75.

Ji L, Pan S, Marti-Jaun J, Hänseler E, Rentsch K, Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002; 48:983-8.

Jiang K, Li K, Qin F, Lu X, Li F. Assessment of a novel β2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities. Toxicol In Vitro 2011; 25:1033-8.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011; 89:165-70.

Jiang XL, Shen HW, Yu AM. Pinoline may be used as a probe for CYP2D6 activity. Drug Metab Dispos 2009; 37:443-6.

Jin SK, Chung HJ, Chung MW et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther 2008; 33:567-73.

Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97:30-9.

Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten CJ. CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos 2011; 39:191-8.

Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90:11825-9.

Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46:452-9.

Johnson BM, Song IH, Adkison KK et al. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. J Clin Pharmacol 2006; 46:577-87.

Johnson JA, Herring VL, Wolfe MS, Relling MV. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000; 294:1099-105.

Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290:1116-25.

Joos AA, König F, Frank UG, Kaschka WP, Mörike KE, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry 1997; 30:266-70.

Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 1999; 9:217-28.

Joshi M, Tyndale RF. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. Drug Metab Dispos 2006; 34:647-52.

Joshi M, Tyndale RF. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology 2006; 50:568-75.

Jover F, Cuadrado JM, Andreu L, Merino J. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 2002; 25:251-3.

Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 1998; 431:227-30.

Jung SM, Kim KA, Cho HK et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 2005; 78:520-8.

Jürgens G, Christensen HR, Brøsen K, Sonne J, Loft S, Olsen NV. Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. Clin Pharmacol Ther 2002; 71:214-20.

Jürgens G, Lange KH, Reuther LØ, Rasmussen BB, Brøsen K, Christensen HR. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clin Pharmacol Ther 2002; 71:162-8.

Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22:849-57.

Jurima-Romet M, Foster BC, Casley WL et al. CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Can J Physiol Pharmacol 1997; 75:165-72.

Kadokura T, den Adel M, Krauwinkel WJ, Takeshige T, Nishida A. The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects. Eur J Clin Pharmacol 2008; 64:605-9.

Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990; 265:17209-14.

Kaisary A, Smith P, Jaczq E et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47:5488-93.

Kakihara S, Yoshimura R, Shinkai K et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005; 20:71-8.

Kalgutkar AS, Tugnait M, Zhu T et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos 2011; 39:1609-19.

Kalgutkar AS, Zhou S, Fahmi OA, Taylor TJ. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6. Drug Metab Dispos 2003; 31:596-605.

Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49:369-79.

Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010; 61:63-75.

Kamimura H, Oishi S, Matsushima H et al. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998; 28:909-22.

Kang RH, Jung SM, Kim KA et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol 2009; 29:272-7.

Kaplan HL, Busto UE, Baylon GJ et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997; 281:103-8.

Kapoor N, Pant AB, Dhawan A et al. Differences in sensitivity of cultured rat brain neuronal and glial cytochrome P450 2E1 to ethanol. Life Sci 2006; 79:1514-22.

Kappers WA, Groene EM, Kleij LA et al. Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P4502C10. Xenobiotica 1996; 26:1231-9.

Karim A, Noveck R, McMahon FG et al. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol 1997; 37:267-78.

Karol MD, Locke CS, Cavanaugh JH. Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment. J Clin Pharmacol 2000; 40:301-8.

Kashuba AD, Nafziger AN, Kearns GL et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998; 64:257-68.

Kastelova A, Yanev S. Propranolol as an inhibitor of some cytochrome P450-dependent monooxygenase activities in native and induced rat liver microsomes. Methods Find Exp Clin Pharmacol 2002; 24:189-94.

Kasuya F, Tatsuki T, Ohta M, Kawai Y, Igarashi K. Purification, characterization, and mass spectrometric sequencing of a medium chain acyl-CoA synthetase from mouse liver mitochondria and comparisons with the homologues of rat and bovine. Protein Expr Purif 2006; 47:405-14.

Kato D, Kawanishi C, Kishida I et al. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. Psychiatry Clin Neurosci 2005; 59:504-7.

Kato D, Kawanishi C, Kishida I et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 2007; 63:991-6.

Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000; 55:843-52.

Katoh M, Sawada T, Soeno Y et al. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 2007; 96:428-37.

Kaushal N, Robson MJ, Vinnakota H et al. Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J 2011; 13:336-46.

Kawanishi C. Genetic predisposition to neuroleptic malignant syndrome: implications for antipsychotic therapy. Am J Pharmacogenomics 2003; 3:89-95.

Kawanishi C, Furuno T, Onishi H et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr Genet 2000; 10:145-7.

Kawanishi C, Shimoda Y, Fujimaki J et al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 1998; 160:102-4.

Kawase A, Fujii A, Negoro M et al. Differences in cytochrome P450 and nuclear receptor mRNA levels in liver and small intestines between SD and DA rats. Drug Metab Pharmacokinet 2008; 23:196-206.

Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3:247-68.

Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011; 71:443-54.

Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000; 9:2903-11.

Kelly DV, Béïque LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002; 36:827-30.

Kemal C, Casida JE. Coenzyme A esters of 2-aryloxyphenoxypropionate herbicides and 2-arylpropionate antiinflammatory drugs are potent and stereoselective inhibitors of rat liver acetyl-CoA carboxylase. Life Sci 1992; 50:533-40.

Kennedy MJ, Abdel-Rahman SM, Kashuba AD, Leeder JS. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol 2004; 44:708-14.

Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement. Clin Ther 2008; 30:1687-99.

Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther 2008; 84:674-8.

Kennedy SH, McCann SM, Masellis M et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002; 63:181-6.

Kerbusch T, Wählby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003; 56:639-52.

Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68:207-13.

Khalil WF, Saitoh T, Shimoda M, Kokue E. In vitro cytochrome P450-mediated hepatic activities for five substrates in specific pathogen free chickens. J Vet Pharmacol Ther 2001; 24:343-8.

Kharasch ED, Hankins DC, Jubert C, Thummel KE, Taraday JK. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Drug Metab Dispos 1999; 27:717-23.

Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106:97-132.

Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006; 94:261-71.

Kikuchi R, McCown M, Olson P et al. Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver. Drug Metab Dispos 2010; 38:1954-61.

Kim EY, Lee SS, Jung HJ et al. Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. Clin Chim Acta 2010; 411:2043-8.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011; 41:851-62.

Kim JR, Seo HB, Cho JY et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008; 66:802-10.

Kim JY, Baek M, Lee S et al. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4’-dimethoxy-5,6,5’,6’-dimethylenedioxybiphenyl-2,2’-dicarboxylate. Drug Metab Dispos 2001; 29:1555-60.

Kim JY, Lee S, Kim DH, Kim BR, Park R, Lee BM. Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes. J Toxicol Environ Health A 2002; 65:373-81.

Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 2004; 60:575-81.

Kim KA, Park JY. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Drug Metab Dispos 2003; 31:1090-2.

Kim KA, Park PW, Liu KH et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 2008; 48:66-72.

Kim SJ, Kang HS, Jung SY et al. Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med 2010; 88:1123-31.

Kim YD, Eom SY, Ogawa M et al. Ethanol-induced oxidative DNA damage and CYP2E1 expression in liver tissue of Aldh2 knockout mice. J Occup Health 2007; 49:363-9.

Kim YD, Oyama T, Isse T, Kim H, Kawamoto T. Expression levels of hepatic cytochrome P450 enzymes in Aldh2-deficient mice following ethanol exposure: a pilot study. Arch Toxicol 2005; 79:192-5.

Kim YW, Kim YK, Kim DK, Sheen YY. Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor. Xenobiotica 2008; 38:451-64.

Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-904.

Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57:540-4.

Kirchheiner J, Brøsen K, Dahl ML et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173-92.

Kirchheiner J, Heesch C, Bauer S et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004; 76:302-12.

Kirchheiner J, Henckel HB, Franke L et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 2005; 15:579-87.

Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmöller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004; 24:647-52.

Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmöller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008; 28:78-83.

Kirchheiner J, Rodríguez-Antona C. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs 2009; 23:181-91.

Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmöller J. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics 2003; 13:721-8.

Kirchheiner J, Schmidt H, Tzvetkov M et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7:257-65.

Kirchheiner J, Seeringer A, Godoy AL et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 2011; 16:333-41.

Kishimoto R, Ogishi Y, Ueda M et al. Gender-related differences in mouse hepatic ethanol metabolism. J Nutr Sci Vitaminol 2002; 48:216-24.

Kishimoto R, Ueda M, Yoshinaga H, Goda K, Park SS. Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice. J Nutr Sci Vitaminol 1999; 45:275-86.

Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997; 98:273-92.

Kishimoto W, Hiroi T, Shiraishi M et al. Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology 2004; 145:699-705.

Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 2005; 26:59-65.

Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99:995-9.

Kiyotani K, Shimizu M, Kumai T, Kamataki T, Kobayashi S, Yamazaki H. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. Eur J Clin Pharmacol 2010; 66:1065-8.

Klein K, Tatzel S, Raimundo S et al. A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6. Drug Metab Dispos 2007; 35:1247-50.

Klotz U. Tramadol-the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003; 53:681-7.

Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 2007; 46:985-96.

Klotz U, Ammon E. Clinical and toxicological consequences of the inductive potential of ethanol. Eur J Clin Pharmacol 1998; 54:7-12.

Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2011; 50:281-94.

Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991; 101:1680-91.

Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 2000l; 49:343-51.

Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25:853-62.

Kobayashi K, Abe S, Nakajima M et al. Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab Dispos 1999; 27:1429-33.

Kobayashi K, Chiba K, Yagi T et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280:927-33.

Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27:763-6.

Kobayashi K, Mimura N, Fujii H et al. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 2000; 6:3297-303.

Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, Chiba K. Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 1999; 27:860-5.

Koers H. Priapism caused by simultaneous use of zuclopentixol and paroxetine. Ned Tijdschr Geneeskd 1999; 143:208-10.

Köhnke MD, Griese EU, Stösser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002; 35:116-8.

Köhnke MD, Lutz U, Wiatr G et al. Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. Eur J Clin Pharmacol 2006; 62:333-4.

Komatsu T, Honda K, Kubota A, Kitazawa T, Hiraga T, Teraoka H. Molecular cloning and expression of cytochrome P450 2D6 in the livers of domestic cats. J Vet Med Sci 2010; 72:1633-6.

Kong WM, Chik Z, Ramachandra M, Subramaniam U, Aziddin RE, Mohamed Z. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules 2011; 16:7344-56.

Konishi M, Ishii H. Role of microsomal enzymes in development of alcoholic liver diseases. J Gastroenterol Hepatol 2007; 22 Suppl 1:7-10.

Kornhuber J, Weigmann H, Röhrich J et al. Region specific distribution of levomepromazine in the human brain. J Neural Transm 2006; 113:387-97.

Koski A, Ojanperä I, Sistonen J, Vuori E, Sajantila A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol 2007; 28:259-61.

Kot M, Daniel WA. Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep 2007; 59:296-305.

Kotlyar M, Brauer LH, Tracy TS et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005; 25:226-9.

Kotsuma M, Hanzawa H, Iwata Y, Takahashi K, Tokui T. Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos 2008; 36:1938-43.

Kotsuma M, Tokui T, Freudenthaler S, Nishimura K. Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. Drug Metab Dispos 2008; 36:1505-11.

Kotsuma M, Tokui T, Ishizuka-Ozeki T et al. CYP2D6-Mediated metabolism of a novel acyl coenzyme A: cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528. Drug Metab Dispos 2008; 36:529-34.

Kouhi H, Hamzeiy H, Barar J, Asadi M, Omidi Y. Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Genet Test Mol Biomarkers 2009; 13:665-70.

Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278:21-30.

Koyama E, Chiba K, Tani M, Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997; 281:1199-210.

Koyama E, Tanaka T, Chiba K et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4’-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996; 16:286-93.

Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007; 35:180-4.

Krishnaswamy S, Hao Q, Al-Rohaimi A et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 2005; 313:1340-6.

Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A. Investigation of sarizotan’s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol 2006; 62:277-84.

Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92:949-53.

Kubo M, Koue T, Inaba A et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20:55-64.

Kubo M, Koue T, Maune H, Fukuda T, Azuma J. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007; 22:358-66.

Kubota A, Stegeman JJ, Goldstone JV et al. Cytochrome P450 CYP2 genes in the common cormorant: Evolutionary relationships with 130 diapsid CYP2 clan sequences and chemical effects on their expression. Comp Biochem Physiol C Toxicol Pharmacol 2011; 153:280-9.

Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000; 50:31-4.

Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37:435-56.

Kudo S, Okumura H, Miyamoto G, Ishizaki T. Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine. Drug Metab Dispos 1999; 27:303-8.

Kudo S, Uchida M, Odomi M. Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol 1997; 52:479-85.

Kuehl GE, Bigler J, Potter JD, Lampe JW. Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos 2006; 34:199-202.

Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33:1027-35.

Kuhn UD, Kirsch M, Merkel U et al. Reboxetine and cytochrome P450-comparison with paroxetine treatment in humans. Int J Clin Pharmacol Ther 2007; 45:36-46.

Kumar GN, Dykstra J, Roberts EM et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999; 27:902-8.

Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277:423-31.

Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2011; 67:63-71.

Kumpulainen H, Mähönen N, Laitinen ML et al. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure. J Med Chem 2006; 49:1207-11.

Kunii T, Fukasawa T, Yasui-Furukori N et al. Interaction study between enoxacin and fluvoxamine. Ther Drug Monit 2005; 27:349-53.

Kurokohchi K, Yoneyama H, Nishioka M, Ichikawa Y. Inhibitory effect of rifampicin on the depressive action of interleukin-1 on cytochrome P-450-linked monooxygenase system. Metabolism 2001; 50:231-6.

Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997; 62:145-56.

Kusumoto M, Ueno K, Oda A et al. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. Clin Pharmacol Ther 2001; 69:104-7.

Kvernmo T, Houben J, Sylte I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem 2008; 8:1049-67.

Labbé L, Abolfathi Z, Robitaille NM, St-Maurice F, Gilbert M, Turgeon J. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. Ther Drug Monit 1999; 21:191-9.

Labbé L, O’Hara G, Lefebvre M et al. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther 2000; 68:44-57.

Labbé L, Robitaille NM, Lefez C et al. Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man. Ther Drug Monit 2004; 26:492-8.

Labbé L, Sirois C, Pilote S et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000; 10:425-38.

Labellarte M, Biederman J, Emslie G et al. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43:1497-505.

Lacroix I, Lapeyre-Mestre M, Bagheri H et al. Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol 2004; 18:201-6.

Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995; 58:264-8.

Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 2009; 39:11-21.

Laine K, de Bruyn S, Björklund H et al. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Eur J Clin Pharmacol 2004; 59:893-8.

Laine K, Kytölä J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004; 26:685-7.

Laine K, Tybring G, Härtter S et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70:327-35.

Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79:461-79.

Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32:447-54.

Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22:1001-6.

Lane HY, Liu YC, Huang CL et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26:128-34.

Langford NJ, Martin U, Ruprah M, Ferner RE. Alternative venlafaxine kinetics in overdose. J Clin Pharm Ther 2002; 27:465-7.

Lapeyre-Mestre M, de Castro AM, Bareille MP et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006; 20:391-5.

Lapierre P, Béland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun 2006; 26:82-9.

Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004; 39:1066-74.

Łapiński Ł, Orzechowska-Juzwenko K, Wiela-Hojeńska A et al. Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. Pharmacol Rep 2011; 63:149-56.

Lash TL, Cronin-Fenton D, Ahern TP et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011; 103:489-500.

Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009; 10:825-33.

Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brøsen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005; 77:312-23.

Le Corre P, Parmer RJ, Kailasam MT et al. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 2004; 76:139-53.

Le Guellec C, Lacarelle B, Catalin J, Durand A. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol 1993; 32:491-5.

Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8:529-41.

Ledl M, Hohenecker J, Francesconi C, Roots I, Bauer MF, Roden M. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetologia 2005; 48:1996-8.

Lee E, Ryan S, Birmingham B et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78:330-41.

Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol 2011; 98:231-64.

Lee HK, Lewis LD, Tsongalis GJ et al. Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 2006; 367:196-200.

Lee HW, Kim DW, Phapale PB et al. In vitro inhibitory effects of Wen-pi-tang-Hab-Wu-ling-san on human cytochrome P450 isoforms. J Clin Pharm Ther 2011; 36:496-503.

Lee JT, Kroemer HK, Silberstein DJ et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990; 322:1764-8.

Lee SJ, Lee SS, Jung HJ et al. Discovery of novel functional variants and extensive evaluation of CYP2D6 geneticpolymorphisms in Koreans. Drug Metab Dispos 2009; 37:1464-70.

Lee SY, Ki CS, Hong KS, Kim JW. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication. J Korean Med Sci 2004; 19:750-2.

Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4’-hydroxylation in human liver. Life Sci 1993; 52:29-34.

Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 2007; 63:575-82.

Lelas S, Wegert S, Otton SV, Sellers EM, France CP. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug Alcohol Depend 1999; 54:239-49.

Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32:403-25.

Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40:93-102.

Leppert W. Dihydrocodeine as an opioid analgesic for the treatment of moderate to severe chronic pain. Curr Drug Metab 2010; 11:494-506.

Lessard E, Fortin A, Bélanger PM, Beaune P, Hamelin BA, Turgeon J. Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics 1997; 7:381-90.

Lessard E, Yessine MA, Hamelin BA et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21:175-84.

Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology 2000; 147:378-83.

Leung VW, Shalansky SJ, Lo MK, Jadusingh EA. Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. Ann Pharmacother 2009; 43:875-81.

Levo A, Koski A, Ojanperä I, Vuori E, Sajantila A. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int 2003; 135:9-15.

Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36 Suppl 5:8-13.

Li C, Kuchimanchi M, Hickman D et al. In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans. Drug Metab Dispos 2009; 37:1378-94.

Li GC, Yang J, Zhou T, Chen ZG, Chen W. CYP2D6 genotypes and phenotypes in Chinese Han, Uygur and Kazakh populations. Yao Xue Xue Bao 2011; 46:238-42.

Li J, Gödecke T, Chen SN et al. In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica 2011. doi:10. 3109/00498254. 2011. 603385.

Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13:3731-7.

Li L, Pan RM, Porter TD et al. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes. Drug Metab Dispos 2006; 34:1411-6.

Li SB, Xue Y, Lv XY et al. In vitro effect of ozagrel on mushroom tyrosinase. Protein J 2009; 28:182-8.

Li T, Li N, Guo Q et al. Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Eur J Drug Metab Pharmacokinet 2011. doi:10. 1007/s13318-011-0050-0.

Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32:821-7.

Li Y, Ren G, Wang YX et al. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J Transl Med 2011; 9:62.

Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW. In vitro assessment of metabolic drug-drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. Xenobiotica 2010; 40:721-9.

Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcohol Clin Exp Res 1999; 23:991-1007.

Lieber CS, Gentry RT, Baraona E. First pass metabolism of ethanol. Alcohol Alcohol Suppl 1994; 2:163-9.

Lieu C, Shi J, Donat F et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002; 41 Suppl 2:19-26.

Lilienfeld S. Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev 2002; 8:159-76.

Lillibridge JH, Liang BH, Kerr BM et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26:609-16.

Lim JS, Chen XA, Singh O et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 2011; 71:737-50.

Lim KS, Cho JY, Jang IJ et al. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 2008; 66:660-6.

Lim YC, Li L, Desta Z et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 2006; 318:503-12.

Lim YP, Kuo SC, Lai ML, Huang JD. Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction. Pharmacogenet Genomics 2009; 19:11-24.

Lin T, Pan K, Mordenti J, Pan L. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography. J Pharm Sci 2007; 96:2485-93.

Lindh JD, Annas A, Meurling L, Dahl ML, AL-Shurbaji A. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003; 59:401-6.

Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005; 78:540-50.

Lindros KO, Badger T, Ronis M, Ingelman-Sundberg M, Koivusalo M. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor. J Pharmacol Exp Ther 1995; 275:79-83.

Linnet K, Wiborg O. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1996; 18:629-34.

Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med 2009; 47:503-15.

Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002; 22:169-73.

Liu A, Yang J, Zhao X et al. Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats. Pharmacol Rep 2011; 63:157-64.

Liu G, Liu Y, Liu R, Dong F, Zhang Z. Effects of Flos carthami on CYP2D6 and on the pharmacokinetics of metoprolol in rats. Evid Based Complement Alternat Med 2011. doi:10. 1155/2011/207076.

Liu KH, Kim MJ, Jeon BH et al. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. J Clin Pharm Ther 2006; 31:83-91.

Liu KH, Kim MJ, Shon JH et al. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 2005; 35:27-38.

Liu KH, Lee YM, Shon JH et al. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica 2004; 34:429-38.

Liu LG, Yan H, Zhang W et al. Induction of heme oxygenase-1 in human hepatocytes to protect them from ethanol-induced cytotoxicity. Biomed Environ Sci 2004; 17:315-26.

Liu S, Frye RF, Branch RA, Venkataramanan R, Fung JJ, Burckart GJ. Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation. J Clin Pharmacol 2005; 45:666-73.

Liukas A, Hagelberg NM, Kuusniemi K, Neuvonen PJ, Olkkola KT. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol 2011; 31:302-8.

Liukas A, Kuusniemi K, Aantaa R et al. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging 2011; 28:41-50.

Lleo A, Shimoda S, Ishibashi H, Gershwin ME. Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. J Gastroenterol 2011; 46 Suppl 1:29-38.

Llerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 2002; 16:361-4.

Llerena A, de la Rubia A, Berecz R, Dorado P. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry 2004; 37:69-73.

Llerena A, Dorado P, Ramírez R et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 85.

Lobo ED, Bergstrom RF, Reddy S et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008; 47:191-202.

Locuson CW, Wienkers LC, Jones JP, Tracy TS. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos 2007; 35:1174-81.

Löfgren S, Hagbjörk AL, Ekman S, Fransson-Steen R, Terelius Y. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 2004; 34:811-34.

Lohse AW, Obermayer-Straub P, Gerken G et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson’s disease – possible association with a steroid-resistant transplant rejection episode. J Hepatol 1999; 31:149-55.

Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999; 37:91-104.

London SJ, Daly AK, Leathart JB, Navidi WC, Carpenter CC, Idle JR. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 1997; 18:1203-14.

Lotrich FE, Rosen J, Pollock BG. Dextromethorphan-induced delirium and possible methadone interaction. Am J Geriatr Pharmacother 2005; 3:17-20.

Lötsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 2009; 124:168-84.

Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, Geisslinger G. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009; 144:119-24.

Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004; 43:983-1013.

Lötsch J, Skarke C, Schmidt H et al. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther 2006; 79:35-48.

Lötsch J, Skarke C, Tegeder I, Geisslinger G. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 2002; 41:31-57.

Lötsch J, von Hentig N, Freynhagen R et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009; 19:429-36.

Lourenco MT, Kennedy SH. Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2009; 5:127-36.

Løvlie R, Daly AK, Idle JR, Steen VM. Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics 1997; 7:149-52.

Løvlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001; 11:45-55.

Lu AH, Shu Y, Huang SL, Wang W, Ou-Yang DS, Zhou HH. In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin 2000; 21:747-52.

Lu C, Hatsis P, Berg C, Lee FW, Balani SK. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metab Dispos 2008; 36:1255-60.

Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31:1352-60.

Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 2008; 44:723-38.

Lukkari E, Taavitsainen P, Juhakoski A, Pelkonen O. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol Toxicol 1998; 82:161-6.

Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 1999; 226:327-338.

Luo YP, Chen HC, Khan MA et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol 2011; 32:215-22.

Lurcott G. The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesth Prog 1998; 45:154-6.

Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28:125-30.

Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 2006; 50:1130-5.

MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 2001; 7:1-24.

Madadi P, Ciszkowski C, Gaedigk A et al. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine. Curr Drug Saf 2011; 6:36-9.

Madadi P, Hildebrandt D, Gong IY et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 2010; 126:986-9.

Madadi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics 2008; 9:1267-84.

Madadi P, Ross CJ, Hayden MR et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85:31-5.

Madadi P, Shirazi F, Walter FG, Koren G. Establishing causality of CNS depression in breastfed infants following maternal codeine use. Paediatr Drugs 2008; 10:399-404.

Madan A, Fisher A, Jin L, Chapman D, Bozigian HP. In vitro metabolism of indiplon and an assessment of its drug interaction potential. Xenobiotica 2007; 37:736-52.

Madan A, Graham RA, Carroll KM et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31:421-31.

Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22:1212-9.

Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 2002; 42:1211-8.

Madeira M, Levine M, Chang TK, Mirfazaelian A, Bellward GD. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos 2004; 32:460-7.

Maezawa Y, Yamauchi M, Toda G, Suzuki H, Sakurai S. Alcohol-metabolizing enzyme polymorphisms and alcoholism in Japan. Alcohol Clin Exp Res 1995; 19:951-4.

Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf 2011; 34:1-19.

Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther 2007; 32:161-7.

Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W et al. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J Clin Pharm Ther 2011. doi:10. 1111/j. 1365-2710. 2011. 01271. x.

Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977; 2:584-6.

Malhotra B, Darsey E, Crownover P, Fang J, Glue P. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol 2011; 72:226-34.

Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46:556-63.

Malhotra B, Sachse R, Wood N. Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol 2009; 65:551-60.

Mankowski DC, Lawton MP, Ekins S. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates. Xenobiotica 2000; 30:745-54.

Mankowski DC. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 1999; 27:1024-8.

Mann A, Miksys S, Lee A, Mash DC, Tyndale RF. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 2008; 55:1147-55.

Mann A, Tyndale RF. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Eur J Neurosci 2010; 31:1185-93.

Mannens GS, Snel CA, Hendrickx J et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002; 30:553-63.

Mannheimer B, Bahr CV, Pettersson H, Eliasson E. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther Drug Monit 2008; 30:565-9.

Mano Y, Usui T, Kamimura H. In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes. Biopharm Drug Dispos 2005; 26:35-9.

Mano Y, Usui T, Kamimura H. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes. Drug Metab Dispos 2007; 35:602-6.

Mano Y, Usui T, Kamimura H. Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos 2007; 35:1182-7.

Mano Y, Usui T, Kamimura H. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol 2007; 63:211-6.

Mano Y, Usui T, Kamimura H. Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. J Pharm Sci 2008; 97:2805-10.

Manoguerra AS, Erdman AR, Woolf AD et al. Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2008; 46:661-76.

Mantione KJ, Cadet P, Zhu W et al. Endogenous morphine signaling via nitric oxide regulates the expression of CYP2D6 and COMT: autocrine/paracrine feedback inhibition. Addict Biol 2008; 13:118-23.

Mao ZL, Alak A, Wheeler JJ, Keirns J. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers. Drug Metab Lett 2011; 5:114-25.

Mao ZL, Townsend RW, Gao C, Wheeler JJ, Kastrissios H, Keirns J. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter. J Clin Pharmacol 2011. doi:10. 1177/0091270011408425.

Marandi T, Dahl ML, Rägo L, Kiivet R, Sjöqvist F. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Eur J Clin Pharmacol 1997; 53:257-60.

Marchioni E, Perucca E, Soragna D et al. Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology 1996; 46:853.

Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A. Characterization of cytochrome P450 2D6. 1 (CYP2D6. 1), CYP2D6. 2, and CYP2D6. 17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos 2002; 30:595-601.

Marez D, Legrand M, Sabbagh N et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.

Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum Genet 1996; 97:668-70.

Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995; 5:305-11.

Marez-Allorge D, Ellis SW, Lo Guidice JM, Tucker GT, Broly F. A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype. Pharmacogenetics 1999; 9:393-6.

Margolis JM, O’Donnell JP, Mankowski DC, Ekins S, Obach RS. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28:1187-91.

Marraffa JM, Lang L, Ong G, Lehmann DF. Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene. Clin Pharmacol Ther 2006; 79:282-6.

Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother 2007; 8:119-27.

Martínez C, Albet C, Agúndez JA et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999; 65:369-76.

Marucci G, Finaurini S, Buccioni M et al. In vitro metabolism studies of new adenosine A 2A receptor antagonists. Drug Metab Lett 2008; 2:301-7.

Masek V, Anzenbacherová E, Machová M, Brabec V, Anzenbacher P. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs 2009; 20:305-11.

Mash DC, Kovera CA, Pablo J et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 2000; 914:394-401.

Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996; 51:117-22.

Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42:713-9.

Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3:275-80.

Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother 1997; 31:175-7.

Masubuchi Y, Fujita S, Chiba M, Kagimoto N, Umeda S, Suzuki T. Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol. Biochem Pharmacol 1991; 41:861-5.

Masubuchi Y, Hosokawa S, Horie T et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994; 22:909-15.

Matin N, Kurani A, Kennedy CA, Liu QY. Dextromethorphan-induced near-fatal suicide attempt in a slow metabolizer at cytochrome P450 2D6. Am J Geriatr Pharmacother 2007; 5:162-5.

Matsui A, Azuma J, Witcher JW et al. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. J Clin Pharmacol 2011. doi:10. 1177/0091270011398657.

Matsunaga E, Zanger UM, Hardwick JP, Gelboin HV, Meyer UA, Gonzalez FJ. The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 1989; 28:7349-55.

Matsunaga M, Yamazaki H, Kiyotani K et al. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. Drug Metab Dispos 2009; 37:699-701.

Matsusue A, Hara K, Kashiwagi M, Kageura M, Sugimura T, Kubo S. Genetic analysis of the rhabdomyolysis-associated genes in forensic autopsy cases of methamphetamine abusers. Leg Med 2011; 13:7-11.

Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit 2004; 26:127-31.

Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995; 29:292-332.

Maynard GL, Soni P. Thioridazine interferences with imipramine metabolism and measurement. Ther Drug Monit 1996; 18:729-31.

Mayol RF, Jajoo HK, Klunk LJ, Blair IA. Metabolism of the antipsychotic drug tiospirone in humans. Drug Metab Dispos 1991; 19:394-9.

McAlpine DE, Biernacka JM, Mrazek DA et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33:14-20.

McAlpine DE, O’Kane DJ, Black JL, Mrazek DA. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc 2007; 82:1065-8.

McElroy S, Sachse C, Brockmoller J et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci 2000; 2:33.

McEnroe JD, Fleishaker JC. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet 2005; 44:237-46.

McGinnity DF, Griffin SJ, Moody GC et al. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metab Dispos 1999; 27:1017-23.

McGinnity DF, Parker AJ, Soars M, Riley RJ. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab Dispos 2000; 28:1327-34.

McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, Hutchison M. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005; 35:39-50.

McKillop D, Wild MJ, Butters CJ, Simcock C. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 1998; 28:845-53.

Melkersson KI, Scordo MG, Gunes A, Dahl ML. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 2007; 68:697-704.

Mellick GD. CYP450, genetics and Parkinson’s disease: gene x environment interactions hold the key. J Neural Transm Suppl 2006; 159-65.

Mellström B, Säwe J, Bertilsson L, Sjöqvist F. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther 1986; 39:369-71.

Mendoza R, Wan YJ, Poland RE et al. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 2001; 70:552-60.

Meskar A, Plee-Gautier E, Amet Y, Berthou F, Lucas D. Alcohol-xenobiotic interactions. Role of cytochrome P450 2E1. Pathol Biol 2001; 49:696-702.

Meyer MC, Baldessarini RJ, Goff DC, Centorrino F. Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Saf 1996; 15:333-46.

Meyer MR, Peters FT, Maurer HH. Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. Toxicol Lett 2009; 190:54-60.

Michalets EL, Smith LK, van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 1998; 32:761-5.

Michaud V, Mouksassi MS, Labbé L et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit 2006; 28:779-83.

Migliardi G, D’Arrigo C, Santoro V et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol 2007; 30:107-13.

Mihara K, Otani K, Ishida M et al. Increases in plasma concentration of m chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. Ther Drug Monit 1997; 19:43-5.

Mihara K, Otani K, Suzuki A et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology 1997; 133:95-8.

Mihara K, Suzuki A, Kondo T et al. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Ther Drug Monit 2000; 22:245-9.

Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003; 45:122-32.

Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002; 82:1376-87.

Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 2004; 36:313-33.

Miksys S, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to Parkinson’s disease. J Neural Transm Suppl 2006; 177-80.

Miksys SL, Cheung C, Gonzalez FJ, Tyndale RF. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Drug Metab Dispos 2005; 33:1495-502.

Miksys SL, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002; 27:406-15.

Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector S. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J Pharmacol Exp Ther 1994; 268:546-51.

Minato K, Suzuki R, Asagarasu A, Matsui T, Sato M. Biotransformation of 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a novel 5-hydroxytryptamine (5-HT)1A agonist/5-HT3 antagonist, in human hepatic cytochrome P450 enzymes. Drug Metab Dispos 2008; 36:831-40.

Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17:327-44.

Miners JO, Day RO. Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes. Br J Clin Pharmacol 2007; 63:380-1.

Mirghani RA, Yasar U, Zheng T et al. Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. Drug Metab Dispos 2002; 30:1368-71.

Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf 1997; 17:390-406.

Mitsunaga Y, Kubota T, Ishiguro A et al. Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population. Mutat Res 2002; 505:83-5.

Miura M, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica 2007; 37:169-79.

Miura M, Otani K, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica 2005; 35:455-65.

Mizuno D, Hiroi T, Ng P, Kishimoto W, Imaoka S, Funae Y. Regulation of CYP2D expression in rat brain by toluene. Osaka City Med J 2003; 49:49-56.

Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35:99-106.

Mo SL, Liu WF, Chen Y et al. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria Baicalensis (Huangqin, Baikal Skullcap). Comb Chem High Throughput Screen 2012; 15:36-80.

Moe M, Lien S, Aasmundstad T et al. Association between SNPs within candidate genes and compounds related to boar taint and reproduction. BMC Genet 2009; 10:32.

Molden E, Asberg A, Christensen H. Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. Drug Metab Dispos 2002; 30:1-3.

Molden E, Garcia BH, Braathen P, Eggen AE. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 2005; 61:119-25.

Molden E, Johansen PW, Bøe GH et al. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther 2002; 72:333-42.

Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28:744-9.

Montané E, Barriocanal A, Isern I, Parajon T, Costa J. Multiple drug interactions – induced serotonin syndrome: a case report. J Clin Pharm Ther 2009; 34:485-7.

Montoya L, Ambros L, Kreil V et al. A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. Vet Res Commun 2004; 28:415-28.

Moree WJ, Li BF, Zamani-Kord S et al. Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. Bioorg Med Chem Lett 2010; 20:5874-8.

Mori Y, Koide A, Kobayashi Y, Morimura K, Kaneko M, Fukushima S. Effect of ethanol treatment on metabolic activation and detoxification of esophagus carcinogenic N-nitrosamines in rat liver. Mutagenesis 2002; 17:251-6.

Mörike K, Kivistö KT, Schaeffeler E et al. Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial. Clin Pharmacol Ther 2008; 84:104-10.

Morimoto M, Reitz RC, Morin RJ, Nguyen K, Ingelman-Sundberg M, French SW. CYP-2E1 inhibitors partially ameliorate the changes in hepatic fatty acid composition induced in rats by chronic administration of ethanol and a high fat diet. J Nutr 1995; 125:2953-64.

Morita N, Kusuhara H, Nozaki Y, Endou H, Sugiyama Y. Functional involvement of rat organic anion transporter 2 (Slc22a7) in the hepatic uptake of the nonsteroidal anti-inflammatory drug ketoprofen. Drug Metab Dispos 2005; 33:1151-7.

Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol 2000; 20:141-9.

Morrow PK, Serna R, Broglio K et al. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 2011. doi:10. 1002/cncr. 26407.

Morse MA, Lu J, Stoner GD, Murphy SE, Peterson LA. Metabolism of N-nitrosobenzylmethylamine by human cytochrome P-450 enzymes. J Toxicol Environ Health A 1999; 58:397-411.

Mosher CM, Tai G, Rettie AE. CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. J Pharmacol Exp Ther 2009; 329:938-44.

Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; CD003491.

Muijsers RB, Plosker GL, Noble S. Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Drugs Aging 2002; 19:377-92.

Mula M, Monaco F. Carbamazepine-risperidone interactions in patients with epilepsy. Clin Neuropharmacol 2002; 25:97-100.

Mulder AB, van Lijf HJ, Bon MA et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70:546-51.

Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006; 15:107-14.

Muñoz S, Vollrath V, Vallejos MP et al. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 1998; 8:343-51.

Muralidharan G, Cooper JK, Hawes EM, Korchinski ED, Midha KK. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Eur J Clin Pharmacol 1996; 50:121-8.

Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160:1830-5.

Murphy M, Antia U, Chang HY et al. Party pills and drug-drug interactions. N Z Med J 2009; 122:3564.

Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006; 58:871-85.

Murray S, Odupitan AO, Murray BP, Boobis AR, Edwards RJ. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Xenobiotica 2001; 31:135-51.

Muscatello MR, Bruno A, Pandolfo G, Micò U, Settineri S, Zoccali R. Emerging treatments in the management of schizophrenia – focus on sertindole. Drug Des Devel Ther 2010; 4:187-201.

Muschler E, Lal J, Jetter A et al. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol 2009; 105:374-9.

Musshoff F, Madea B, Stüber F, Stamer UM. Enantioselective determination of ondansetron and 8-hydroxyondansetron in human plasma from recovered surgery patients by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2010; 34:581-6.

Muzeeb S, Basha SJ, Shashikumar D, Mullangi R, Srinivas NR. Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3 and 1A8. Eur J Drug Metab Pharmacokinet 2006; 31:299-309.

Nagele P, Liggett SB. Genetic Variation, β-blockers, and perioperative myocardial infarction. Anesthesiology 2011; 115:879-90.

Naito T, Takashina Y, Yamamoto K et al. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol 2011; 51:1529-38.

Nakagami T, Yasui-Furukori N, Saito M et al. Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction. J Clin Psychopharmacol 2005; 25:89-91.

Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005; 78:43-51.

Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26:261-6.

Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 1998; 46:55-62.

Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 1999; 27:1381-91.

Nakajima M, Suzuki M, Yamaji R et al. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica 1999; 29:1191-202.

Nakajima M, Yoshida R, Shimada N, Yamazaki H, Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001; 29:1110-3.

Nakamura A, Tougou K, Kitazumi H et al. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes. Arzneimittelforschung 2005; 55:744-8.

Nakamura K, Ariyoshi N, Iwatsubo T et al. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull 2005; 28:882-5.

Nakamura K, Yokoi T, Inoue K et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996; 6:449-57.

Nakamura K, Yokoi T, Kodama T et al. Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther 1998; 284:437-42.

Nakamura S, Tezuka Y, Ushiyama A et al. Ipso substitution of bisphenol A catalyzed by microsomal cytochrome P450 and enhancement of estrogenic activity. Toxicol Lett 2011; 203:92-5.

Nakamura Y. Chemoprevention by isothiocyanates: molecular basis of apoptosis induction. Forum Nutr 2009; 61:170-81.

Nakao M, Muramoto Y, Hisadome M et al. The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6. Eur J Clin Pharmacol 2007; 63:345-53.

Nakashima A, Kawashita H, Masuda N et al. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica 2005; 35:589-602.

Nakashima D, Takama H, Ogasawara Y et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol 2007; 47:1311-9.

Nanji AA, Jokelainen K, Fotouhinia M et al. Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. Am J Physiol Gastrointest Liver Physiol 2001; 281:1348-56.

Naranjo CA, Sproule BA, Knoke DM. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1999; 14 Suppl 2:35-47.

Narimatsu S, Kobayashi N, Masubuchi Y et al. Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes. Chem Biol Interact 2000; 127:73-90.

Narimatsu S, Masubuchi Y, Hosokawa S, Ohmori S, Kitada M, Suzuki T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol Pharm Bull 1994; 17:803-7.

Narimatsu S, Nakata T, Shimizudani T et al. Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19. Chem Biol Interact 2011; 189:146-52.

Narimatsu S, Takemi C, Kuramoto S et al. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s. Chirality 2003; 15:333-9.

Narimatsu S, Takemi C, Tsuzuki D et al. Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. J Pharmacol Exp Ther 2002; 303:172-8.

Narimatsu S, Yonemoto R, Saito K et al. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2006; 71:1377-85.

Natsui K, Mizuno Y, Tani N, Yabuki M, Komuro S. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes. Eur J Drug Metab Pharmacokinet 2007; 32:233-40.

Navasumrit P, Ward TH, O’Connor PJ, Nair J, Frank N, Bartsch H. Ethanol enhances the formation of endogenously and exogenously derived adducts in rat hepatic DNA. Mutat Res 2001; 479:81-94.

Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997; 60:265-71.

Nelson LS, Erdman AR, Booze LL et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45:315-32.

Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 2009; 57:731-3.

Neu P, Seyfert S, Brockmöller J, Dettling M, Marx P. Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency. Pharmacopsychiatry 2002; 35:26-8.

Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008; 47:463-74.

Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80:565-81.

Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1:1-93.

Newman WG, Hadfield KD, Latif A et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008; 14:5913-8.

Newman-Tancredi A, Assié MB, Leduc N, Ormière AM, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005; 8:341-56.

Ng J, Sansone RA, McDonald S. Akathisia and abnormal movements of the upper extremities with venlafaxine and methimazole. Gen Hosp Psychiatry 2009; 31:388-90.

Nicholl DJ, Bennett P, Hiller L et al. A study of five candidate genes in Parkinson’s disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 1999; 53:1415-21.

Nichols AI, Fatato P, Shenouda M et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009; 49:219-28.

Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011; 31:155-67.

Nicolas JM, Collart P, Gerin B et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999; 27:250-4.

Nicolas JM, Whomsley R, Collart P, Roba J. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact 1999; 123:63-79.

Nielsen KK, Flinois JP, Beaune P, Brøsen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996; 277:1659-64.

Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 2000; 33:893-901.

Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, Kähönen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007; 67:237-45.

Nieminen T, Uusitalo H, Mäenpää J et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol 2005; 61:811-9.

Nieminen TH, Hagelberg NM, Saari TI et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009; 110:1371-8.

Nishida Y, Fukuda T, Yamamoto I, Azuma J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 2000; 10:567-70.

Nishigaki R, Totsuka Y, Takamura-Enya T, Sugimura T, Wakabayashi K. Identification of cytochrome P-450s involved in the formation of APNH from norharman with aniline. Mutat Res 2004; 562:19-25.

Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47:779-92.

Niwa T, Inoue S, Shiraga T, Takagi A. No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug. Biol Pharm Bull 2005; 28:188-91.

Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull 2005; 28:1813-6.

Niwa T, Maekawa Y, Fujimoto M et al. Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Biol Pharm Bull 2002; 25:235-8.

Niwa T, Murayama N, Umeyama H, Shimizu M, Yamazaki H. Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food. Drug Metab Lett 2011; 5:216-9.

Niwa T, Murayama N, Yamazaki H. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Curr Drug Metab 2011; 12:412-35.

Niwa T, Murayama N, Yamazaki H. Heterotropic cooperativity in oxidation mediated by cytochrome p450. Curr Drug Metab 2008; 9:453-62.

Niwa T, Okada K, Hiroi T, Imaoka S, Narimatsu S, Funae Y. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol Pharm Bull 2008; 31:348-51.

Niwa T, Shiraga T, Hashimoto T, Kagayama A. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull 2004; 27:97-9.

Niwa T, Shiraga T, Hashimoto T, Kagayama A. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull 2004; 27:415-7.

Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull 2005; 28:1711-6.

Niwa T, Shiraga T, Mitani Y, Terakawa M, Tokuma Y, Kagayama A. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos 2000; 28:1128-34.

Niwa T, Shiraga T, Takagi A. Drug-drug interaction of antifungal drugs. Yakugaku Zasshi 2005; 125:795-805.

Niwa T, Tsutsui M, Kishimoto K, Yabusaki Y, Ishibashi F, Katagiri M. Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A. Biol Pharm Bull 2000; 23:498-501.

Niwa T, Yamamoto S, Saito M et al. Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2006; 29:1931-5.

Niwa T, Yamamoto S, Saito M, Shiraga T, Takagi A. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi 2007; 127:209-16.

Nomoto M, Nakatsuka A, Nagai M et al. Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson’s disease. Rinsho Shinkeigaku 2005; 45:895-8.

Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995; 28:26-40.

Nordin C, Dahl ML, Eklundh T, Eriksson M, Sjöberg S. CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype. Eur Neuropsychopharmacol 2003; 13:333-5.

Norlén M, Allard P. Reduction in number of dopamine uptake sites but unchanged number of piperazine-acceptor/CYP450IID6 binding sites in the human caudate nucleus in aging. Neurosci Lett 1996; 209:161-4.

Nossaman VE, Ramadhyani U, Kadowitz PJ, Nossaman BD. Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol. Anesthesiol Clin 2010; 28:647-66.

Nozawa M, Ohnuma T, Matsubara Y et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008; 30:35-40.

Nozawa T, Taguchi M, Tahara K et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 2005; 46:713-20.

Ntukidem NI, Nguyen AT, Stearns V et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther 2008; 83:702-10.

Nyberg S, Dahl ML, Halldin C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology 1995; 119:345-8.

Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005; 39:543-6.

Nyunt MM, Becker S, MacFarland RT et al. Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47:559-65.

Obach RS. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 2000; 28:1069-76.

Obach RS. Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction. Drug Metab Dispos 2001; 29:1057-67.

Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33:262-70.

Ochi S, Kawasoe K, Abe M et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Gen Hosp Psychiatry 2011. doi:10. 1016/j. genhosppsych. 2011. 03. 003.

Ochiai Y, Katsu H, Okino S, Wakutsu N, Nakayama K. Case of prolonged recovery from serotonin syndrome caused by paroxetine. Seishin Shinkeigaku Zasshi 2003; 105:1532-8.

O’Connell MB, Frye RF, Matzke GR et al. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol 2006; 46:1299-307.

Oertel B, Lötsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 2008; 9:179-94.

Oesterheld JR. A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol 1998; 8:161-74.

Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics 2004; 45:84-7.

Oh YH, Han HK. Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats. Acta Pharmacol Sin 2006; 27:119-22.

O’Hara GE, Philippon F, Gilbert M et al. Combined administration of quinidine and propafenone for atrial fibrillation: The CAQ-PAF study. J Clin Pharmacol 2011. doi:10. 1177/0091270011399574.

Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:347-50.

Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003; 58:659-61.

Ohara K, Tanabu S, Yoshida K, Ishibashi K, Ikemoto K, Shibuya H. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:945-9.

Ohnuma T, Shibata N, Matsubara Y, Arai H. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br J Clin Pharmacol 2003; 56:315-20.

Oinonen T, Ronis M, Wigell T, Tohmo K, Badger T, Lindros KO. Growth hormone-regulated periportal expression of CYP2C7 in rat liver. Biochem Pharmacol 2000; 59:583-9.

Oishi M, Chiba K, Malhotra B, Suwa T. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences. Drug Metab Pharmacokinet 2011; 26:236-41.

Oishi M, Chiba K, Malhotra B, Suwa T. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos 2010; 38:1456-63.

Ojanperä S, Rasanen I, Sistonen J, Pelander A, Vuori E, Ojanperä I. Quantification of drugs in plasma without primary reference standards by liquid chromatography-chemiluminescence nitrogen detection: application to tramadol metabolite ratios. Ther Drug Monit 2007; 29:423-8.

Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos 1997; 25:970-7

Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997; 25:740-4.

Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomas and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59:298-309.

Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 2000; 50:563-71.

O’Mathúna B, Farré M, Rostami-Hodjegan A et al. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 2008; 28:523-9.

Onalan O, Cumurcu BE, Bekar L. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc 2008; 83:595-9.

Onitilo AA, McCarty CA, Wilke RA et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 2009; 115:643-50.

Ono S, Mihara K, Suzuki A et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002; 162:50-4.

Ooi JP, Kuroyanagi M, Sulaiman SF, Muhammad TS, Tan ML. Andrographolide and 14-deoxy-11, 12-didehydroandrographolide inhibit cytochrome P450s in HepG2 hepatoma cells. Life Sci 2011; 88:447-54.

Orishiki M, Matsuo Y, Nishioka M, Ichikawa Y. In vivo administration of H2 blockers, cimetidine and ranitidine, reduced the contents of the cytochrome P450IID (CYP2D) subfamily and their activities in rat liver microsomes. Int J Biochem 1994; 26:751-8.

Osbild S, Bour J, Maunit B et al. Interaction of the electrophilic ketoprofenyl-glucuronide and ketoprofenyl-coenzyme A conjugates with cytosolic glutathione S-transferases. Drug Metab Dispos 2008; 36:260-7.

Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997; 52:1034-40.

Otani K, Tybring G, Mihara K et al. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients. Eur J Clin Pharmacol 1998; 53:347-9.

Otani K, Ujike H, Sakai A et al. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci Lett 2008; 434:88-92.

Otani M, Fukuda T, Naohara M et al. Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol 2003; 59:395-9.

Othman AA, Newman AH, Eddington ND. The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. J Pharm Sci 2008; 97:5453-70.

Othman AA, Syed SA, Newman AH, Eddington ND. Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther 2007; 320:344-53.

Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41:149-56.

Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-9.

Ouellet D, Bramson C, Roman D et al. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. Br J Clin Pharmacol 2007; 63:59-66.

Ouellet D, Hsu A, Qian J et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42:3107-12.

Ou-Yang DS, Huang SL, Wang Wet al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 2000; 49:145-51.

Oyama T, Kim YD, Isse T et al. A pilot study on subacute ethanol treatment of ALDH2 KO mice. J Toxicol Sci 2007; 32:421-8.

Ozawa S, Soyama A, Saeki M et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004; 19:83-95.

Ozdemir V, Bertilsson L, Miura J et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17:339-47.

Ozdemir V, Fourie J, Busto U, Naranjo CA. Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Clin Pharmacokinet 1996; 31:372-85.

Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62:334-47.

Ozdemir V, Naranjo CA, Shulman RW et al. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998; 18:198-207.

Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53:235-9.

Pacifici GM. Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. Int J Clin Pharmacol Ther 2004; 42:488-95.

Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 2009; 48:303-11.

Pai HV, Kommaddi RP, Chinta SJ, Mori T, Boyd MR, Ravindranath V. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J Biol Chem 2004; 279:27383-9.

Palacio L, Falla D, Tobon I et al. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a Hispanic population Isolate. Clin Appl Thromb Hemost 2010; 16:83-90.

Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer. Acta Oncol 2007; 46:361-6.

Pan JJ, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. Ann Pharmacother 2003; 37:209-11.

Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 1999; 55:599-604.

Pan L, Vander Stichele R, Rosseel MT, Berlo JA, de Schepper N, Belpaire FM. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit 1999; 21:489-97.

Pan LP, de Vriendt C, Belpaire FM. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998; 8:383-9.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro effects of active constituents and extracts of Orthosiphon stamineus on the activities of three major human cDNA-expressed cytochrome P450 enzymes. Chem Biol Interact 2011; 190:1-8.

Pandey SC, Piano MR, Pandey GN. Alterations in serotonin1B (5HT1B) receptor subtypes in the brain of ethanol-treated rats. Drug Alcohol Depend 1996; 41:219-25.

Pandit S, Mukherjee PK, Ponnusankar S, Venkatesh M, Srikanth N. Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6. Fitoterapia 2011; 82:369-74.

Pandit S, Ponnusankar S, Bandyopadhyay A, Ota S, Mukherjee PK. Exploring the possible metabolism mediated interaction of Glycyrrhiza glabra extract with CYP3A4 and CYP2D6. Phytother Res 2011; 25:1429-34.

Panserat S, Mura C, Gérard N et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet 1994; 94:401-6.

Panserat S, Mura C, Gérard N et al. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol 1995; 40:361-7.

Panserat S, Sica L, Gérard N, Mathieu H, Jacqz-Aigrain E, Krishnamoorthy R. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br J Clin Pharmacol 1999; 47:121-4.

Pappas P, Stephanou P, Vasiliou V, Marselos M. Anti-inflammatory agents and inducibility of hepatic drug metabolism. Eur J Drug Metab Pharmacokinet 1998; 23:457-60.

Parang K, Wiebe LI, Knaus EE. Novel approaches for designing 5’-O-ester prodrugs of 3’-azido-2’, 3’-dideoxythymidine (AZT). Curr Med Chem 2000; 7:995-1039.

Paris BL, Ogilvie BW, Scheinkoenig JA et al. In vitro inhibition and induction of human liver cytochrome P450 (CYP) enzymes by milnacipran. Drug Metab Dispos 2009; 37:2045-54.

Park HS, Choi JY, Lee MJ et al. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci 2011; 26:1007-13.

Park JY, Shon JH, Kim KA et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol 2006; 26:135-42.

Parker GB, Brotchie HL, Hyett M. Tolerance to desvenlafaxine in rapid metabolizing depressed patients. Int Clin Psychopharmacol 2011; 26:84-7.

Parker RB, Soberman JE. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy 2011; 31:630-41.

Parkman HP, Jacobs MR, Mishra A et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci 2011; 56:115-24.

Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 2005; 33:1446-52.

Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008; 18:921-6.

Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44:175-86.

Patel M, Tang BK, Kalow W. (S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 1995; 5:43-9.

Patroneva A, Connolly SM, Fatato P et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008; 36:2484-91.

Paul KL, Bhatara VS. Anticholinergic delirium possibly associated with protriptyline and fluoxetine. Ann Pharmacother 1997; 31:1260-1.

Paulzen M, Clement HW, Gründer G. Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol 2008; 11:289-91.

Paus E, Jonzier-Perey M, Cochard N, Eap CB, Baumann P. Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit 2004; 26:366-74.

Pavone LM, Spina A, Rea S et al. Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF-beta(1) signalling. J Mol Cell Cardiol 2009; 47:691-7.

Payami H, Lee N, Zareparsi S et al. Parkinson’s disease, CYP2D6 polymorphism, and age. Neurology 2001; 56:1363-70.

Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 2005; 77:458-67.

Peñas-Lledó EM, Dorado P, Agüera Z et al. CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 78.

Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44:879-94.

Pérez de los Cobos J, Siñol N, Trujols J et al. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007; 89:190-4.

Perfetti X, O’Mathúna B, Pizarro N et al. Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab Dispos 2009; 37:1448-55.

Perloff ES, Mason AK, Dehal SS et al. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 2009; 39:99-112.

Persad AS, Stedeford T, Tanaka S, Chen L, Banasik M. Parkinson’s disease and CYP2D6 polymorphism in Asian populations: A meta-analysis. Neuroepidemiology 2003; 22:357-61.

Persson J, Hasselström J, Maurset A et al. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol 2002; 57:869-75.

Perwitasari DA, Wessels JA, van der Straaten RJ et al. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol 2011; 41:1168-76.

Peters EJ, Slager SL, Kraft JB et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008. doi:10. 1371/journal. pone. 0001872.

Peters FT, Dragan CA, Kauffels A et al. Biotechnological synthesis of the designer drug metabolite 4’-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6-a versatile alternative to multistep chemical synthesis. J Anal Toxicol 2009; 33:190-7.

Peters FT, Dragan CA, Wilde DR et al. Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4’-hydroxymethyl-alpha pyrrolidinobutyrophenone. Biochem Pharmacol 2007; 74:511-20.

Peterschmitt MJ, Burke A, Blankstein L et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 2011; 51:695-705.

Petersen DD, Kong AN, Jorge LF, Nebert DW, Arias TD. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama. Pharmacogenetics 1991; 1:136-42.

Petsalo A, Turpeinen M, Pelkonen O, Tolonen A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. J Chromatogr A 2008; 1215:107-15.

Pham PA, la Porte CJ, Lee LS et al. Differential Effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009; 53:4385-92

Pichard L, Gillet G, Bonfils C, Domergue J, Thénot JP, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23:1253-62.

Pirmohamed M, Kitteringham NR, Quest LJ et al. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pharmacogenetics 1995; 5:351-7.

Platts SH, Shi SJ, Meck JV. Akathisia with combined use of midodrine and promethazine. JAMA 2006; 295:2000-1.

Plesnicar BK, Zalar B, Breskvar K, Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 2006; 20:829-33.

Poggi JC, Barissa GR, Donadi EA et al. Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol 2006; 46:1328-36.

Polasek TM, Miners JO. Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 2008; 65:87-97.

Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008; 4:1-15.

Ponnusankar S, Pandit S, Babu R, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibitory potential of Triphala-a Rasayana from Ayurveda. J Ethnopharmacol 2011; 133:120-5.

Poon LH, Kang GA, Lee AJ. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother 2010; 44:1080-9.

Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26:289-93.

Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51:289-95.

Pozzato G, Franzin F, Moretti M et al. Effects of omeprazole on ethanol metabolism: an in vitro and in vivo rat and human study. Pharmacol Res 1994; 29:47-58.

Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 Suppl 1:35-42.

Prakash C, O’Donnell J, Khojasteh-Bakht SC. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride. Drug Metab Dispos 2007; 35:1071-80.

Preskorn S, Patroneva A, Silman H et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29:39-43.

Preskorn SH, Greenblatt DJ, Flockhart D et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007; 27:28-34.

Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In: Bloom FE, Kupfer DJ. (Eds.). Psychopharmacology: The fourth generation of progress. Raven Press, New York, 1995.

Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008; 14:368-78.

Preskorn SH, Shah R, Neff M, Golbeck AL, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract 2007; 13:5-12.

Presle N, Lapicque F, Fournel-Gigleux S, Magdalou J, Netter P. Stereoselective irreversible binding of ketoprofen glucuronides to albumin. Characterization of the site and the mechanism. Drug Metab Dispos 1996; 24:1050-7.

Pribová M, Gregorová J, Drsata J. Inhibition of aromatic amino acid decarboxylase by a group of non-steroidal anti-inflammatory drugs. Pharmacol Res 1992; 25:271-7.

Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28:99-112.

Priou P, Gagnadoux F, Dehé C et al. Drug-induced pneumonitis in a patient treated with venlafaxine and propanolol. Rev Mal Respir 2008; 25:610-3.

Prisant LM. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker. J Clin Pharmacol 2008; 48:225-39.

Projean D, Baune B, Farinotti R et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 2003; 31:748-54.

Prows CA, Nick TG, Saldaña SN et al. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol 2009; 19:385-94.

Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25:1191-9.

Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003; 56:120-4.

Pulido T, Sandoval J, Roquet I et al. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. Eur J Clin Invest 2009; 39 Suppl 2:14-8.

Puozzo C, Lens S, Reh C et al. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005; 44:977-88.

Qian MR, Chen J, Liu Y, Yu LS, Chen SQ, Zeng S. CYP2D6*1, CYP2D6*10 co-expressed with CYPOR in Bac-to-Bac expression system and activity determination. Yao Xue Xue Bao 2011; 46:207-12.

Qin S, Shen L, Zhang A et al. Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 2008; 92:152-8.

Qiu F, Zhang R, Sun J et al. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 2008; 36:1308-14.

R Yang X, Pfeiffer RM, Goldstein AM. Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the naevoid basal cell carcinoma syndrome. J Med Genet 2006; 43:16.

Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2:349-51.

Rae JM, Sikora MJ, Henry NL et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 2009; 9:258-64.

Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002; 30:525-30.

Raffa RB, Stone DJ Jr. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. J Pharmacol Exp Ther 2008; 325:500-6.

Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10:577-81.

Raimundo S, Toscano C, Klein K et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 2004; 76:128-38.

Ramaekers JG, Conen S, de Kam PJ et al. Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology 2011; 215:321-32.

Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (+/-)-3,4-methylenedioxymethamphetamine (“Ecstasy”) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 2002; 63:2111-9.

Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004; 65:1642-53.

Ramírez J, Innocenti F, Schuetz EG et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004; 32:930-6.

Ramón y Cajal T, Altés A, Paré L et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010; 119:33-8

Ramoz N, Boni C, Downing AM et al. A haplotype of the norepinephrine transporter (Net) Gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology 2009; 34:2135-42.

Rao ML, Hiemke C, Grasmäder K, Baumann P; TDM Arbeitsgruppe Der AGNP. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr 2001; 69:510-7.

Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46:281-90.

Rasmussen E, Eriksson B, Oberg K, Bondesson U, Rane A. Selective effects of somatostatin analogs on human drug-metabolizing enzymes. Clin Pharmacol Ther 1998; 64:150-9.

Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28:263-75.

Rau T, Diepenbruck S, Diepenbruck I, Eschenhagen T. The 2988G>A polymorphism affects splicing of a CYP2D6 minigene. Clin Pharmacol Ther 2006; 80:555-8.

Rau T, Heide R, Bergmann K et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12:465-72.

Rau T, Wuttke H, Michels LM et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009; 85:269-72.

Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Cussac D. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol 2007; 376:93-105.

Ravindranath V, Kommaddi RP, Pai HV. Unique cytochromes P450 in human brain: implication in disease pathogenesis. J Neural Transm Suppl 2006; 167-71.

Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75:234-41.

Rebsamen MC, Desmeules J, Daali Y et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 2009; 9:34-41.

Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, McConn DJ. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008; 36:1198-201.

Rehmel JL, Eckstein JA, Farid NA et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34:600-7.

Relling MV, Evans WE, Fonné-Pfister R, Meyer UA. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res 1989; 49:68-71.

Remmel RP, Crews BC, Kozak KR, Kalgutkar AS, Marnett LJ. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites. Drug Metab Dispos 2004; 32:113-22.

Renwick AB, Mistry H, Ball SE, Walters DG, Kao J, Lake BG. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28:337-48.

Renwick AB, Surry D, Price RJ, Lake BG, Evans DC. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms. Xenobiotica 2000; 30:955-69.

Rieutord A, Stupans I, Shenfield GM, Gross AS. Gliclazide hydroxylation by rat liver microsomes. Xenobiotica 1995; 25:1345-54.

Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41:181-6.

Ring BJ, Gillespie JS, Binkley SN, Campanale KM, Wrighton SA. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos 2002; 30:957-61.

Rittenbach KA, Baker GB. Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine. Drug Metab Lett 2007; 1:97-100.

Rittenbach KA, Holt A, Ling L, Shan J, Baker GB. Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes. Cell Mol Neurobiol 2007; 27:179-90.

Roberts BJ, Knights KM. Inhibition of rat peroxisomal palmitoyl-CoA ligase by xenobiotic carboxylic acids. Biochem Pharmacol 1992; 44:261-7.

Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004; 19:17-23.

Robertson P, DeCory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000; 28:664-71.

Robey RW, Honjo Y, Morisaki K et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003; 89:1971-8.

Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007; 26:39-57.

Rocha A, Coelho EB, Lanchote VL. Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. Can J Physiol Pharmacol 2008; 86:770-6.

Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7:1-10.

Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33:1567-75.

Rodríguez-Antona C, Gurwitz D, de Leon J et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 2009; 10:685-99.

Rodríguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogen 2006; 25:1679-91.

Roh HK, Chung JY, Oh DY et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52:265-71.

Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001; 57:671-5.

Rokavec M, Schroth W, Amaral SM et al. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer. Cancer Res 2008; 68:9799-808.

Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008; 9:905-33.

Romkes M, Chern HD, Lesnick TG et al. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer. Carcinogenesis 1996; 17:1057-62.

Rosen H. Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs Today 2008; 44:661-8.

Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 2009; 16:204-15.

Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26:572-5.

Rowland K, Ellis SW, Lennard MS, Tucker GT. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes. Br J Clin Pharmacol 1996; 42:390-3.

Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56:58-65.

Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit 2006; 28:102-5.

Rudek MA, Zhao M, Smith NF et al. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res 2005; 11:8503-11.

Ryu JY, Song IS, Sunwoo YE et al. Development of the “Inje cocktail” for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 2007; 82:531-40.

Sabolovic N, Heydel JM, Li X et al. Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 2004; 1675:120-9.

Sachse C, Brockmöller J, Bauer S, Reum T, Roots I. A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 1996; 6:269-72.

Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-95.

Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998; 8:181-5.

Sadzuka Y, Inoue C, Hirooka S, Sugiyama T, Umegaki K, Sonobe T. Effects of theanine on alcohol metabolism and hepatic toxicity. Biol Pharm Bull 2005; 28:1702-6.

Sahi J, Black CB, Hamilton GA et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003; 31:439-46.

Sahi J, Sinz MW, Campbell S et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact 2006; 159:156-68.

Sai K, Saito Y. Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol 2011; 7:967-88.

Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005; 28:677-94.

Saito M, Kawana J, Ohno T et al. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Biol Pharm Bull 2010; 33:1378-84.

Sakuyama K, Sasaki T, Ujiie S et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6. 2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 2008; 36:2460-7.

Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10:27-34.

Salminen KA, Meyer A, Jerabkova L et al. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phytomedicine 2011; 18:533-8.

Salsali M, Holt A, Baker GB. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol 2004; 24:63-76.

Samer CF, Daali Y, Wagner M et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 2010; 160:919-30.

Samer CF, Piguet V, Dayer P, Desmeules JA. Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can J Anaesth 2005; 52:806-21.

Sams C, Mason HJ, Rawbone R. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol Lett 2000; 116:217-21.

Sanchez RI, Wang RW, Newton DJ et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32:1287-92.

Sandee D, Morrissey K, Agrawal V et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 2010; 20:677-86.

Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systemic review and meta-analysis. Genet Med 2005; 7:97-104.

Santt O, Baranova H, Albuisson E, Bignon YJ, Lucotte G. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson’s disease. Eur J Neurol 2004; 11:247-51.

Saruwatari J, Matsunaga M, Ikeda K et al. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 2006; 62:995-1001.

Sato A, Okura Y, Minagawa S et al. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clin Proc 2004; 79:1444-8.

Sauer JM, Long AJ, Ring B et al. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther 2004; 308:410-8.

Sauer JM, Ponsler GD, Mattiuz EL et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31:98-107.

Saussele T, Burk O, Blievernicht JK et al. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther 2007; 82:265-74.

Saxena R, Shaw GL, Relling MV et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994; 3:923-6.

Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 2011; 50:371-403.

Schenekar T, Winkler KA, Troyer JL, Weiss S. Isolation and characterization of the CYP2D6 gene in Felidae with comparison to other mammals. J Mol Evol 2011; 72:222-31.

Schenk PW, van Fessem MA, Verploegh-van Rij S et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008; 13:597-605.

Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005; 17:447-54.

Schlienger RG, Klink MH, Eggenberger C, Drewe J. Seizures associated with therapeutic doses of venlafaxine and trimipramine. Ann Pharmacother 2000; 34:1402-5.

Schmider J, Greenblatt DJ, von Moltke LL et al. Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors. J Clin Pharmacol 1997; 37:193-200.

Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996; 41:339-43.

Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995; 275:592-7.

Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44:495-8.

Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5:627-35.

Schoedel KA, Tyndale RF. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochim Biophys Acta 2003; 1619:283-90.

Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4:151-60.

Schwartz JI, Liu F, Stroh M et al. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. Am J Ther 2009; 16:215-23.

Scott J, Pache D, Keane G, Buckle H, O’Brien N. Prolonged anticholinergic delirium following antihistamine overdose. Australas Psychiatry 2007; 15:242-4.

Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004; 18:379-96.

Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40:263-81.

Seeringer A, Brockmöller J, Bauer S, Kirchheiner J. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. Eur J Clin Pharmacol 2008; 64:883-8.

Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med 2008; 28:619-26.

Segura M, Farré M, Pichini S et al. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 2005; 44:649-60.

Sehrt D, Meineke I, Tzvetkov M, Gültepe S, Brockmöller J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 2011; 12:783-95.

Semiz S, Dujic T, Ostanek B et al. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J Basic Med Sci 2010; 10:287-91.

Senda C, Yamaura Y, Kobayashi K et al. Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes. Br J Clin Pharmacol 2001; 52:100-3.

Seripa D, Bizzarro A, Pilotto A et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease. Pharmacogenet Genomics 2011; 21:225-30.

Sevoz C, Benoit E, Buronfosse T. Thioesterification of 2-arylpropionic acids by recombinant acyl-coenzyme A synthetases (ACS1 and ACS2). Drug Metab Dispos 2000; 28:398-402.

Shader RI, Granda BW, von Moltke LL, Giancarlo GM, Greenblatt DJ. Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharm Drug Dispos 1999; 20:385-8.

Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31:493-502.

Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004; 10:4270-5.

Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird’s eye view. Curr Drug Metab 2003; 4:105-29.

Sharma A, Pibarot P, Pilote S et al. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther 2005; 313:1172-81.

Sharp CF, Gardiner SJ, Jensen BP et al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenomics J 2009; 9:175-84.

Shelepova T, Nafziger AN, Victory J et al. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 2005; 45:1413-21.

Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:1694-9.

Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin Pharmacother 2003; 4:1175-83.

Shen H, He MM, Liu H et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6. 1, CYP2D6. 10, and CYP2D6. 17. Drug Metab Dispos 2007; 35:1292-300.

Shen HW, Jiang XL, Winter JC, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 2010; 11:659-66.

Shen HW, Jiang XL, Yu AM. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice. Drug Metab Dispos 2011; 39:1227-34.

Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int 2011; 207:183-7.

Shilliday FB, Walker DP, Gu C et al. Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett 2010; 4:162-72.

Shimada T, Mimura M, Inoue K et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 1997; 71:401-8.

Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 2001; 11:143-56.

Shimoda K, Morita S, Hirokane G, Yokono A, Someya T, Takahashi S. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol Toxicol 2000; 86:245-9.

Shimoda K, Someya T, Yokono A et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol 2002; 22:371-8.

Shin JG, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 2001; 51:45-52.

Shin JG, Park JY, Kim MJ et al. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002; 30:1102-7.

Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999; 27:1078-84.

Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112:71-105.

Shord SS, Cavallari LH, Gao W et al. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. Eur J Clin Pharmacol 2009; 65:651-8.

Shulman RW, Ozdemir V. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 1997; 42 Suppl 1:4-9.

Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008; 7:181-94.

Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11:237-45.

Simon HU, Malhotra B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Wkly 2009; 139:146-51.

Sinclair JF, Szakacs JG, Wood SG et al. Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice. Toxicol Appl Pharmacol 2000; 168:114-22.

Sindrup SH, Brøsen K, Gram LF et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:278-87.

Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5:335-46.

Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993; 53:335-9.

Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 2008; 312:131-8.

Singh M, Khanna VK, Shukla R, Parmar D. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson’s disease. Dis Markers 2010; 28:87-93.

Singh S, Kumar V, Vashisht K et al. Role of genetic polymorphisms of CYP1A1, CYP3A5, CYP2C9, CYP2D6 and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides. Toxicol Appl Pharmacol 2011. doi:10. 1016/j. taap. 2011. 08. 021.

Singh V, Parmar D, Singh MP. Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes? Cancer Invest 2008; 26:769-83.

Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19:170-9.

Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17:93-101.

Skinner MH, Kuan HY, Pan A et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73:170-7.

Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34:256-61.

Skrętkowicz J, Baranska M, Rychlik-Sych M. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic sclerosis. Eur J Clin Pharmacol 2009; 65:971-6.

Slama R, Gräbsch C, Lepeule J et al. Maternal fine particulate matter exposure, polymorphism in xenobiotic-metabolizing genes and offspring birth weight. Reprod Toxicol 2010; 30:600-12.

Smith C, Stamm SC, Riggs JE et al. Ethanol-mediated CYP1A1/2 induction in rat skeletal muscle tissue. Exp Mol Pathol 2000; 69:223-32.

Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:613-24.

Smith JC, Curry SC. Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. J Med Toxicol 2011; 7:220-3.

Smith TJ. Mechanisms of carcinogenesis inhibition by isothiocyanates. Expert Opin Investig Drugs 2001; 10:2167-74.

Snoeck E, van Peer A, Sack M et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122:223-9.

Snozek CL, O’Kane DJ, Algeciras-Schimnich A. Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 William Beaumont Hospital symposium on molecular pathology. J Mol Diagn 2009; 11:381-9.

Solai LK, Mulsant BH, Pollock BG et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997; 58:440-3.

Solai LK, Pollock BG, Mulsant BH et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002; 22:481-6.

Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.

Somer M, Kallio J, Pesonen U, Pyykkö K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 2000; 49:549-54.

Someya T, Shimoda K, Suzuki Y et al. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 2003; 28:1501-5.

Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81:429-44.

Somogyi AA, Menelaou A, Fullston SV. CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica 2004; 34:875-87.

Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998; 251:893-8.

Sosa-Macías M, Dorado P, Alanis-Bañuelos RE, Llerena A, Lares-Asseff I. Influence of CYP2D6 deletion, multiplication, -1584C→G, 31G→A and 2988G→a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos. Pharmacology 2010; 86:30-6.

Soundararajan CC, Adhin A, Tripathi M, Prasad HK, Jain S, Vivekanandhan S. Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians. J Neural Transm 2006; 113:1873-6.

Sowinski KM, Burlew BS. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Pharmacotherapy 1997; 17:1305-10.

Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA. Racial differences in propranolol enantiomer kinetics following simultaneous i. v. and oral administration. Br J Clin Pharmacol 1996; 42:339-46.

Soyama A, Kubo T, Miyajima A et al. Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene. Drug Metab Pharmacokinet 2004; 19:313-9.

Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38:15-22.

Spanakis M, Vizirianakis IS, Mironidou-Tzouveleki M, Niopas I. A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. Biomed Chromatogr 2009; 23:1131-7.

Spigset O, Axelsson S, Norström A, Hägg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001; 57:653-8.

Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96:379-84.

Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology 1995; 117:413-6.

Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996; 18:60-4.

Spina E, Avenoso A, Facciolà G et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13:141-5.

Spina E, Avenoso A, Salemi M et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000; 33:213-7.

Spina E, Avenoso A, Scordo MG et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002; 22:419-23.

Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monit 2001; 23:675-8.

Spina E, D’Arrigo C, Migliardi G et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004; 26:386-90.

Spina E, D’Arrigo C, Migliardi G et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit 2006; 28:599-602.

Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100:4-22.

Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15:243-6.

Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30:1206-27.

Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19:299-320.

Spina E, Scordo MG, D’Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003; 17:517-38.

Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH. Identification of cytochrome P450 enzymes involved in the metabolism of 4’-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 2003; 33:989-98.

Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997; 33:454-71.

Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002; 301:945-52.

Sridar C, Snider NT, Hollenberg PF. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 2011; 39:782-8.

Staack RF, Paul LD, Schmid D, Roider G, Rolf B. Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt Technol Biomed Life Sci 2007; 855:127-33.

Stamer UM, Lee EH, Rauers NI et al. CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg 2011; 113:48-54.

Stamer UM, Lehnen K, Höthker F et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105:231-8.

Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007; 82:41-7.

Stamer UM, Stüber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107:926-9.

Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 1999; 13:313-7.

Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-64.

Stedman CA, Begg EJ, Kennedy MA, Roberts R, Wilkinson TJ. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002; 17:187-90.

Steen VM, Molven A, Aarskog NK, Gulbrandsen AK. Homologous unequal cross-over involving a 2. 8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet 1995; 4:2251-7.

Steimer W, Zöpf K, von Amelunxen S et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50:1623-33.

Steinkellner H, Rabot S, Freywald C et al. Effects of Cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat Res 2001; 480-1:285-97.

Stephan PL, Jaquenoud Sirot E, Mueller B, Eap CB, Baumann P. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. Pharmacopsychiatry 2006; 39:150-2.

Sternieri E, Coccia CP, Pinetti D, Ferrari A. Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. Expert Opin Drug Metab Toxicol 2006; 2:961-79.

Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A. Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol 2006; 2:981-1007.

Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008; 42:1290-7.

Stevens JC, Marsh SA, Zaya MJ et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 2008; 36:1587-93.

Stingl JC, Esslinger C, Tost H et al. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage 2011. doi:10. 1016/j. neuroimage. 2011. 07. 052.

Stingl JC, Parmar S, Huber-Wechselberger A et al. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin 2010; 26:2535-42.

Störmer E, Brockmöller J, Roots I, Schmider J. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology 2000; 151:312-20.

Störmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28:1168-75.

Strauch K, Lutz U, Bittner N, Lutz WK. Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles. Food Chem Toxicol 2009; 47:1928-35.

Stresser DM, Mason AK, Perloff ES et al. Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine. Drug Metab Dispos 2009; 37:695-8.

Styles JA, Davies A, Lim CK et al. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 1994; 15:5-9.

Subehan, Usia T, Iwata H, Kadota S, Tezuka Y. Mechanism-based inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants. J Ethnopharmacol 2006; 105:449-55.

Subehan, Usia T, Kadota S, Tezuka Y. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum. Planta Med 2006; 72:527-32.

Subrahmanyam V, Renwick AB, Walters DG et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001; 29:1146-55.

Subrahmanyam V, Renwick AB, Walters DG, Price RJ, Tonelli AP, Lake BG. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms. Xenobiotica 2002; 32:521-34.

Subramanian M, Low M, Locuson CW, Tracy TS. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos 2009; 37:1682-9.

Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 2006; 6:351-6.

Sugiyama T, Shinozuka K, Sano A et al. Effects of various Ginkgo biloba extracts and proanthocyanidin on hepatic cytochrome P450 activity in rats. Shokuhin Eiseigaku Zasshi 2004; 45:295-301.

Sun H, Ehlhardt WJ, Kulanthaivel P, Lanza DL, Reilly CA, Yost GS. Dehydrogenation of indoline by cytochrome P450 enzymes: a novel “aromatase” process. J Pharmacol Exp Ther 2007; 322:843-51.

Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1356-8.

Suzuki A, Iida I, Tanaka F et al. Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos 1999; 27:1254-9.

Suzuki A, Otani K, Ishida M et al. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit 1997; 19:261-4.

Suzuki A, Yasui-Furukori N, Mihara K et al. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 2003; 25:192-6.

Suzuki T, Mihara K, Nakamura A et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2011; 33:21-4.

Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006; 31:825-31.

Suzuki Y, Someya T, Shimoda K et al. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther Drug Monit 2001; 23:363-8.

Swaisland HC, Cantarini MV, Fuhr R, Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 2006; 45:633-44.

Swaisland HC, Ranson M, Smith RP et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005; 44:1067-81.

Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci 1997; 42:335-9.

Sweet RA, Pollock BG, Mulsant BH et al. Pharmacologic profile of perphenazine’s metabolites. J Clin Psychopharmacol 2000; 20:181-7.

Syvälahti EK, Taiminen T, Saarijärvi S et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25:24-32.

Szewczuk-Bogusławska M, Kiejna A, Beszłej JA, Orzechowska-Juzwenko K, Milejski P. Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol 2004; 56:491-4.

Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, Pelkonen O. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol 2000; 86:215-21.

Taavitsainen P, Juvonen R, Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 2001; 29:217-22.

Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56:135-40.

Taguchi M, Nozawa T, Kameyama T et al. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur J Clin Pharmacol 2003; 59:385-8.

Taguchi M, Nozawa T, Mizumaki K et al. Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients. Biol Pharm Bull 2004; 27:1642-8.

Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40:587-603.

Takahashi H, Wilkinson GR, Nutescu EA et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance doses of warfarin in Japanese, Caucasians and African Americans. Pharmacogenet Genomics 2006; 16:101-10.

Takanohashi T, Kubo S, Nakayama A, Mihara R, Hayashi M. Inhibition of human liver microsomal CYP by nateglinide. J Pharm Pharmacol 2010; 62:592-7.

Takehashi M, Alioto T, Stedeford T et al. Septin 3 gene polymorphism in Alzheimer’s disease. Gene Expr 2004; 11:263-70.

Takekuma Y, Takenaka T, Kiyokawa M et al. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Biol Pharm Bull 2007; 30:537-42.

Takekuma Y, Takenaka T, Yamazaki K, Ueno K, Sugawara M. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. Biol Pharm Bull 2007; 30:2146-53.

Takeshita M, Miura M, Ohkubo T, Sugawara K. Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol. Enantiomer 2000; 5:189-95.

Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009. doi:10. 1371/journal. pgen. 1000433.

Tamminga WJ, Wemer J, Oosterhuis B et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999; 55:177-84.

Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001; 57:717-22.

Tanaka AA, Nagamatsu T, Yamaguchi M et al. Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother 2010. doi:10. 1345/aph. 1P301.

Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998; 23:247-55.

Tanaka E, Misawa S. Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants – an update. J Clin Pharm Ther 1998; 23:331-6.

Tanaka M, Kobayashi D, Murakami Y et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11:261-7.

Tang JC, Zhang JN, Wu YT, Li ZX. Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv. ) Diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res 2006; 20:1046-51.

Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: Is it somehow foreseeable? World J Gastroenterol 2009; 15:2817-33.

Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999; 65:570-5.

Tateishi T, Watanabe M, Kumai T et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 2000; 67:2913-20.

Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171:109-12.

Taylor TJ, Diringer K, Russell T et al. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. Clin Pharmacokinet 2006; 45:989-1001.

Teft WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 2011; 39:558-62.

Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001; 26:205-11.

Tennezé L, Tarral E, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther 2002; 72:112-22.

Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003; 43:44-8.

Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003; 2:123-32.

ter Laak MA, Temmink AH, Koeken A, van ‘t Veer NE, van Hattum PR, Cobbaert CM. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity. Pediatr Neurol 2010; 43:159-62.

Terao T, Ohmori O, Shinkai T. A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration. Acta Psychiatr Scand 1999; 99:388-90.

Terra SG, Pauly DF, Lee CR et al. Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005; 77:127-37.

Terrier N, Benoit E, Senay C et al. Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide. Mol Pharmacol 1999; 56:226-34.

Testino SA Jr, Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2003; 30:1459-67.

Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther 2007; 82:555-65.

Thi L, Shaw D, Bird J. Warfarin potentiation: a review of the “FAB-4” significant drug interactions. Consult Pharm 2009; 24:227-30.

Thibaut R, Schnell S, Porte C. The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in-vitro study. Environ Sci Technol 2006; 40:5154-60.

Thieme D, Rolf B, Sachs H, Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med 2008; 122:149-55.

Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy 2009; 29:822-31.

Thomas P, Srivastava V, Singh A et al. Correlates of response to olanzapine in a North Indian Schizophrenia sample. Psychiatry Res 2008; 161:275-83.

Thompson CM, Kawashima H, Strobel HW. Isolation of partially purified P450 2D18 and characterization of activity toward the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys 1998; 359:115-21.

Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet Genomics 2009; 19:556-8.

Thörn HA, Lundahl A, Schrickx JA, Dickinson PA, Lennernäs H. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 2011; 43:89-98.

Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38:461-74.

Tirkkonen T, Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther 2004; 76:639-47.

Tiwari AK, Souza RP, Müller DJ. Pharmacogenetics of anxiolytic drugs. J Neural Transm 2009; 116:667-77.

Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, Pelkonen O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 2007; 42:960-6.

Tomic Z, Milijasevic B, Sabo A et al. Diclofenac and ketoprofen liver toxicity in rat. Eur J Drug Metab Pharmacokinet 2008; 33:253-60.

Toscano C, Klein K, Blievernicht J et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 2006; 16:755-66.

Toscano C, Raimundo S, Klein K, Eichelbaum M, Schwab M, Zanger UM. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenet Genomics 2006; 16:767-70.

Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol 2009; 39:651-6.

Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005; 192:633-9.

Tran A, Rey E, Pons G et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997; 62:490-504.

Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50:209-15.

Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17:307-24.

Troost J, Tatami S, Tsuda Y et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 2011; 72:247-56.

Troost PW, Lahuis BE, Hermans MH et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27:52-7.

Tsai G, Crisostomo G, Rosenblatt ML, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995; 7:91-5.

Tsao YY, Gugger JJ. Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Ann Pharmacother 2009; 43:1366-9.

Tugnait M, Hawes EM, McKay G, Eichelbaum M, Midha KK. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem Biol Interact 1999; 118:171-89.

Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004; 32:626-31.

Tushar T, Vinod T, Rajan S, Shashindran C, Adithan C. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers. Basic Clin Pharmacol Toxicol 2007; 100:269-72.

Tyagi P, Tyagi V. Mirabegron, a β3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010; 13:713-22.

Tyndale R, Aoyama T, Broly F et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991; 1:26-32.

Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7:375-9.

Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991; 31:655-60.

Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991; 40:63-8.

Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmöller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 75.

Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmöller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 2011; 90:143-50.

Uchida T, Watanabe T, van Hoogdalem EJ, Higuchi S. In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyltransferase, by liver microsomes in man. J Pharm Pharmacol 1996; 48:1049-56.

Ueda M, Hirokane G, Morita S et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:486-91.

Uehlinger C, Crettol S, Chassot P et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol 2007; 27:273-8.

Ueng YF, Don MJ, Jan WC, Wang SY, Ho LK, Chen CF. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450. Drug Metab Dispos 2006; 34:821-7.

Ueno K, Tamamura A, Matsumoto K et al. Evaluation of mexiletine clearance in a Japanese population. Ann Pharmacother 2002; 36:241-5.

Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20(1 Suppl):25-8.

Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Pharmacopsychiatry 2005; 38:171-7.

Ulvila J, Arpiainen S, Pelkonen O et al. Regulation of Cyp2a5 transcription in mouse primary hepatocytes: roles of hepatocyte nuclear factor 4 and nuclear factor I. Biochem J 2004; 381:887-94.

Umehara K, Shimokawa Y, Miyamoto G. Effect of probucol on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2002; 25:1112-4.

Umehara K, Shimokawa Y, Miyamoto G. Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2004; 27:1151-3.

Uno Y, Uehara S, Kohara S, Murayama N, Yamazaki H. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Drug Metab Dispos 2010; 38:1486-92.

Upadhya SC, Tirumalai PS, Boyd MR, Mori T, Ravindranath V. Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch Biochem Biophys 2000; 373:23-34.

Upreti VV, Eddington ND. Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. J Pharm Sci 2008; 97:1593-605.

Upthagrove AL, Nelson WL. Importance of amine pKa and distribution coefficient in the metabolism of fluorinated propranolol derivatives. Preparation, identification of metabolite regioisomers, and metabolism by CYP2D6. Drug Metab Dispos 2001; 29:1377-88.

Urdaneta A, Siso A, Urdaneta B et al. Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib. Brain Res Bull 2009; 80:56-61.

Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008; 9:410-8.

Usia T, Watabe T, Kadota S, Tezuka Y. Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. Biol Pharm Bull 2005; 28:1021-4.

Usia T, Watabe T, Kadota S, Tezuka Y. Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod 2005; 68:64-8.

Valles J, Artigas R, Mas M et al. Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency. Methods Find Exp Clin Pharmacol 2006; 28 Suppl A:21-8.

Valoti M, Fusi F, Frosini M, Pessina F, Tipton KF, Sgaragli GP. Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl. Eur J Pharmacol 2000; 391:199-206.

van der Kuy PH, van den Heuvel HA, Kempen RW, Vanmolkot LM. Pharmacokinetic interaction between nortriptyline and terbinafine. Ann Pharmacother 2002; 36:1712-4.

van der Lee MJ, Blenke AA, Rongen GA et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007; 51:4098-104.

van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med 2006; 64:160-2.

van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev 2006; 27:17-25.

van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 2005; 27:478-83.

van Erp NP, Gelderblom H, Karlsson MO et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007; 13:7394-400.

van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29 Suppl 1:1-9.

Van LM, Hargreaves JA, Lennard MS, Tucker GT, Rostami-Hodjegan A. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. Eur J Pharm Sci 2007; 32:8-16.

van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract 2009; 13:345-8.

van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005; 23:513-22.

van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008; 11:77-98.

Vandel P, Haffen E, Nezelof S, Broly F, Kantelip JP, Sechter D. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. Hum Psychopharmacol 2004; 19:293-8.

Vandel S, Bertschy G, Baumann P et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995; 31:347-53.

Vanden Bossche H, Ausma J, Bohets H et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. , and Microsporum canis. Antimicrob Agents Chemother 2004; 48:3272-8.

VanderVaart S, Berger H, Sistonen J et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit 2011; 33:425-32.

Varley CK. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. Paediatr Drugs 2001; 3:613-27.

Varsaldi F, Miglio G, Scordo MG et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006; 62:721-6.

Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol 1995; 26:1469-75.

Veenstra DL, You JHS, Rieder MJ et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15:687-91.

Veiga MI, Asimus S, Ferreira PE et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 2009; 65:355-63.

Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol 1998; 50:265-74.

Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 1999; 39:567-77.

Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111-80.

Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64:1147-61.

Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008; 14:3306-12.

Vermeir M, Naessens I, Remmerie B et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008; 36:769-79.

Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004; 4:247-55.

Vets E, Rossignol JF, Jackson AS. Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. Am J Health Syst Pharm 2009; 66:838-42.

Vevelstad M, Pettersen S, Tallaksen C, Brørs O. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol 2009; 65:795-801.

Vickers AE, Sinclair JR, Zollinger M et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999; 27:1029-38.

Vidali M, Occhino G, Ivaldi A et al. Detection of auto-antibodies against cytochrome P4502E1 (CYP2E1) in chronic hepatitis C. J Hepatol 2007; 46:605-12.

Vietri M, de Santi C, Pietrabissa A, Mosca F, Pacifici GM. Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000; 56:81-7.

Vilar R, Coelho H, Rodrigues E et al. Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson’s disease. Eur J Neurol 2007; 14:156-61.

Vinayagamoorthy N, Krishnamurthi K, Devi SS et al. Genetic polymorphism of CYP2D6*2 C→T 2850, GSTM1, NQO1 genes and their correlation with biomarkers in manganese miners of Central India. Chemosphere 2010; 81:1286-91.

Voirol P, Jonzier-Perey M, Porchet F et al. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 2000; 855:235-43.

Volland C, Benet LZ. In vitro enantioselective glucuronidation of fenoprofen. Pharmacology 1991; 43:53-60.

Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Mäenpää J. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol 2011; 108:297-303.

Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Mäenpää J, Pelkonen O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos 2007; 35:1135-41.

von Bahr C, Movin G, Nordin C et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49:234-40.

von Moltke LL, Greenblatt DJ, Ciraulo DA et al. Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. J Clin Psychopharmacol 1998; 18:338-41.

von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15:125-31.

von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29:1102-9.

von Moltke LL, Greenblatt DJ, Granda BW et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001; 41:85-91.

von Moltke LL, Greenblatt DJ, Grassi JM et al. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 1998; 50:997-1004.

Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab Dispos 2001; 29:41-7.

Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007; 27:888-909.

Waade RB, Christensen H, Rudberg I, Refsum H, Hermann M. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009; 31:233-8.

Wade AE. Effects of dietary fat on drug metabolism. J Environ Pathol Toxicol Oncol 1986; 6:161-89.

Wadelius M, Chen LY, Downes K et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5:262-70.

Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997; 62:400-7.

Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: a review of its use in depressive disorders. CNS Drugs 2001; 15:231-59.

Walker DK, Alabaster CT, Congrave GS et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos 1996; 24:447-55.

Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004; 32:647-60.

Wan J, Shi J, Hui L et al. Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environ Health Perspect 2002; 110:1213-8.

Wan YJ, Poland RE, Han G et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001; 11:489-99.

Wang DL, Liang Y, Chen WD, Xie L, Wang GJ, Liu XD. Identification of ginkgolide B metabolites in urine and rat liver cytochrome P450 enzymes responsible for their formation in vitro. Acta Pharmacol Sin 2008; 29:376-84.

Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62:927-31.

Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003; 31:742-7.

Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology 2006; 183:490-9.

Wang L, Yu L, Zhang AP et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 2007; 21:837-42.

Wang LQ, James MO. Inhibition of sulfotransferases by xenobiotics. Curr Drug Metab 2006; 7:83-104.

Wang N, Han JL, Mi YC et al. Relationships between the gene polymorphisms of drug metabolizing enzymes and the outcome of the first induction chemotherapy in patients with de novo acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011; 19:327-31.

Wang RW, Liu L, Cheng H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos 1996; 24:786-91.

Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53:410-8.

Wang SL, Lai MD, Huang JD. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab Dispos 1999; 27:385-8.

Wang XD. Alcohol, vitamin A, and cancer. Alcohol 2005; 35:251-8.

Wang Y, Zhou L, Dutreix C et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008; 65:885-92.

Wang Z, Lee B, Pearce D et al. Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol 2011. doi:10. 1177/0091270011414575.

Washio T, Arisawa H, Kohsaka K, Yasuda H. Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol Pharm Bull 2001; 24:1263-6.

Wassenberg T, Willemsen MA, Geurtz PB et al. Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox. Mol Genet Metab 2010; 101:349-56.

Watanabe J, Suzuki Y, Fukui N et al. Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Ther Drug Monit 2008; 30:705-8.

Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9:7.

Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-37.

Weinshilboum R. Pharmacogenomics of endocrine therapy in breast cancer. Adv Exp Med Biol 2008; 630:220-31.

Weise A, Prause S, Eidens M et al. Prevalence of CYP450 gene variations in patients with type 2 diabetes. Clin Lab 2010; 56:311-8.

Wen B, Ma L, Rodrigues AD, Zhu M. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos 2008; 36:841-50.

Wen B, Ma L, Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact 2008; 173:59-67.

Wen B, Moore DJ. Bioactivation of glafenine by human liver microsomes and peroxidases: Identification of electrophilic iminoquinone species and GSH conjugates. Drug Metab Dispos 2011; 39:1511-21.

Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29:1359-61.

Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001; 52:547-53.

Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57:799-804.

Wenk M, Todesco L, Krähenbühl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004; 57:495-9.

Wennerholm A, Dandara C, Sayi J et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71:77-88.

Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 2001; 11:417-27.

Wennerholm A, Johansson I, Massele AY et al. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 1999; 9:707-14.

Wennerholm A, Nordmark A, Pihlsgård M, Mahindi M, Bertilsson L, Gustafsson LL. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. Eur J Clin Pharmacol 2006; 62:539-46.

Werner U, Lamprecht C, Werner D et al. Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. Int J Clin Pharmacol Ther 2006; 44:397-400.

Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003; 74:130-7.

Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med 2008; 9:315-44.

Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21:645-53.

White IN. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab 2003; 4:223-39.

Whyte EM, Romkes M, Mulsant BH et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 2006; 21:542-9.

Wienkers LC, Allievi C, Hauer MJ, Wynalda MA. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999; 27:1334-40.

Wienkers LC, Wynalda MA. Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos 2002; 30:1372-7.

Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352:2211-21.

Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41:343-70.

Williams JA, Andersson T, Andersson TB et al. PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol 2008; 48:849-89.

Williams PA, Cosme J, Ward A, Angove HC, Matak Vinković D, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424:464-8.

Wilner KD, Demattos SB, Anziano RJ, Apseloff G, Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol 2000; 49 Suppl 1:43-7.

Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004; 65:810-8.

Winitthana T, Niwattisaiwong N, Patarapanich C, Tantisira MH, Lawanprasert S. In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450. Toxicol In Vitro 2011; 25:890-6.

Winter JC, Amorosi DJ, Rice KC, Cheng K, Yu AM. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice. Pharmacol Biochem Behav 2011; 99:311-5.

Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006; 45:137-68.

Witte LP, Mulder WM, de la Rosette JJ, Michel MC. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009; 19:13-9.

Wójcikowski J, Maurel P, Daniel WA. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 2006; 34:471-6.

Wójcikowski J, Pichard-Garcia L, Maurel P, Daniel WA. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol 2003; 138:1465-74.

Wójcikowski J, Pichard-Garcia L, Maurel P, Daniel WA. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol 2004; 14:199-208.

Wolf CR, Smith G, Smith RL. Science, medicine, and the future: Pharmacogenetics. BMJ 2000; 320:987-90.

Wolf KK, Wood SG, Allard JL et al. Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice. Drug Metab Dispos 2007; 35:1223-31.

Woolf AD, Erdman AR, Nelson LS et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45:203-33.

Wright GE, Niehaus DJ, Drögemöller BI, Koen L, Gaedigk A, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010; 74:340-50.

Wu D, Cederbaum AI. Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1. Toxicol Appl Pharmacol 2005; 207(2 Suppl):70-6.

Wu D, Otton SV, Sproule BA et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993; 35:30-4.

Wu H, Yu W, Huang L et al. Effect of sodium ozagrel on the activity of rat CYP2D6. Eur J Pharmacol 2007; 573:55-9.

Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009; 69:1722-7.

Wuttke H, Rau T, Heide R et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72:429-37.

Wyen C, Fuhr U, Frank D et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84:75-82.

Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41:815-50.

Xu BQ, Ishii M, Ding LR, Fischer NE, Inaba T. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci 2003; 72:1953-62.

Xu X, Liu HY, Liu L, Xie L, Liu XD. The influence of a newly developed quinolone: antofloxacin, on CYP activity in rats. Eur J Drug Metab Pharmacokinet 2008; 33:1-7.

Xu Y, Sun Y, Yao L et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008; 19:1423-9.

Yadav S, Dhawan A, Singh RL, Seth PK, Parmar D. Expression of constitutive and inducible cytochrome P450 2E1 in rat brain. Mol Cell Biochem 2006; 286:171-80.

Yagihashi T, Mizuno M, Chino B et al. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum Psychopharmacol 2009; 24:301-8.

Yamamoto T, Hagima N, Nakamura M, Kohno Y, Nagata K, Yamazoe Y. Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine. Drug Metab Dispos 2003; 31:60-6.

Yamamoto T, Suzuki A, Kohno Y. High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. Xenobiotica 2003; 33:823-39.

Yamamoto T, Suzuki A, Kohno Y. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 2004; 34:87-101.

Yamamoto T, Suzuki A, Kohno Y, Nagata K, Yamazoe Y. Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. Curr Drug Metab 2006; 7:135-46.

Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for cytochrome P450 2D6. Drug Metab Dispos 2011; 39:2049-56.

Yamazaki H, Gillam EM, Dong MS, Johnson WW, Guengerich FP, Shimada T. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch Biochem Biophys 1997; 342:329-37.

Yamazaki H, Guo Z, Persmark M et al. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 1994; 46:568-77.

Yamazaki H, Kiyotani K, Tsubuko S et al. Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab Pharmacokinet 2003; 18:269-71.

Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 2000; 30:61-70.

Yamazaki S, Toth LN, Black ML, Duncan JN. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. Drug Metab Dispos 2004; 32:398-404.

Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26:421-38.

Yang Y, Wu K, Yuan H, Yu M. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther 2009; 25:163-71.

Yao D, Ding S, Burchell B, Wolf CR, Friedberg T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000; 294:387-95.

Yao HT, Chang YW, Lan SJ, Chen CT, Hsu JT, Yeh TK. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci 2006; 79:2432-40.

Yao M, Zhu M, Sinz MW et al. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007; 44:211-23.

Yao P, Hao L, Nussler N et al. The protective role of HO-1 and its generated products (CO, bilirubin, and Fe) in ethanol-induced human hepatocyte damage. Am J Physiol Gastrointest Liver Physiol 2009; 296:1318-23.

Yao YM, Cao W, Cao YJ et al. Effect of sinomenine on human cytochrome P450 activity. Clin Chim Acta 2007; 379:113-8.

Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T. Metabolism of sesamin by cytochrome P450 in human liver microsomes. Drug Metab Dispos 2010; 38:2117-23.

Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, Woosley RL. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 2002; 53:519-25.

Yasui N, Otani K, Kaneko S et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17:333-5.

Yasui N, Tybring G, Otani K et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 1997; 7:369-74.

Yasui-Furukori N, Hidestrand M, Spina E, Facciolá G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29:1263-8.

Yasui-Furukori N, Kondo T, Mihara K et al. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J Clin Pharmacol 2002; 42:1083-8.

Yasui-Furukori N, Mihara K, Takahata T et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004; 57:569-75.

Yasui-Furukori N, Saito M, Inoue Y et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 2007; 63:51-6.

Yasukochi Y, Satta Y. Evolution of the CYP2D gene cluster in humans and four non-human primates. Genes Genet Syst 2011; 86:109-16.

Ye L, Tang L, Gong Y et al. Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine. Xenobiotica 2011; 41:46-58.

Yin JY, Huang Q, Yang Y et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 2009; 19:206-16.

Yin OQ, Shi XJ, Tomlinson B, Chow MS. Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Drug Metab Dispos 2005; 33:1283-7.

Yin SJ, Ni YB, Wang SM, Wang X, Lou YQ, Zhang GL. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther 2011. doi:10. 1111/j. 1365-2710. 2011. 01298. x.

Yokoi T, Kosaka Y, Chida M et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996; 6:395-401.

Yokota H, Tamura S, Furuya H et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993; 3:256-63.

Yonezawa E, Matsumoto K, Ueno K et al. Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol 2002; 42:342-6.

Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006; 62:35-46.

Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer 2009; 45:1904-8.

Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol 2011; 164:433-43.

Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 2000; 67:175-84.

Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 1995; 39:421-31.

Yoshimura R, Ueda N, Nakamura J. Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine. Int Clin Psychopharmacol 2000; 15:233-5.

Yu A, Kneller BM, Rettie AE, Haining RL. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6. 1, 2D6. 2, 2D6. 10, and 2D6. 17 allelic isoforms. J Pharmacol Exp Ther 2002; 303:1291-300.

Yu AM. Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J 2008; 10:242-53.

Yu AM, Haining RL. Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos 2006; 34:1167-74.

Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13:173-81.

Yu C, Shin YG, Kosmeder JW, Pezzuto JM, van Breemen RB. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 2003; 17:307-13.

Yu J, Paine MJ, Maréchal JD et al. In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab Dispos 2006; 34:1386-92.

Yu KS, Yim DS, Cho JY et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69:266-73.

Yuan H, Yu M, Yang Y, Wu K, Lin X, Li J. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma-a pilot study. J Ocul Pharmacol Ther 2010; 26:497-501.

Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002; 30:1311-9.

Yubero-Lahoz S, Pardo R, Farré M et al. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet 2011; 50:319-29.

Yue J, Khokhar J, Miksys S, Tyndale RF. Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. Eur J Pharmacol 2009; 609:88-95.

Yue J, Miksys S, Hoffmann E, Tyndale RF. Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci 2008; 33:54-63.

Yue QY, Säwe J. Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 1997; 52:41-7.

Yue QY, Zhong ZH, Tybring G et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998; 64:384-90.

Yukawa E, Hokazono T, Yukawa M et al. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. Clin Pharmacokinet 2002; 41:153-9.

Yukawa E, Ichimaru R, Maki T et al. Interindividual variation of serum haloperidol concentrations in Japanese patients-clinical considerations on steady-state serum level-dose ratios. J Clin Pharm Ther 2003; 28:97-101.

Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996; 51:165-72.

Zamuner S, Johnson BM, Pagliarusco S et al. Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. Br J Clin Pharmacol 2010; 70:537-46.

Zanger UM, Fischer J, Raimundo S et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11:573-85.

Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8:743-59.

Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:23-37.

Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392:1093-108.

Zebothsen I, Kunze T, Clement B. Inhibitory effects of cytostatically active 6-aminobenzo[c]phenanthridines on cytochrome P450 enzymes in human hepatic microsomes. Basic Clin Pharmacol Toxicol 2006; 99:37-43.

Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther 2006; 80:257-63.

Zhai S, Sausville EA, Senderowicz AM et al. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i. v. infusion in patients with refractory neoplasms. Anticancer Drugs 2003; 14:125-35.

Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7:9-37.

Zhang JW, Liu Y, Li W, Hao DC, Yang L. Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes. Eur J Clin Pharmacol 2006; 62:497-502.

Zhang L, Weddle DL, Thomas P et al. Low levels of expression of cytochromes P-450 in normal and cancerous fetal pancreatic tissues of hamsters treated with NNK and/or ethanol. Toxicol Sci 2000; 56:313-23.

Zhang M, Moore GA, Barclay ML, Begg EJ. Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3025-30.

Zhang S, Song N, Li Q, Fan H, Liu C. Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 871:78-89.

Zhang W, Deng S, Chen XP et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther 2008; 30:1283-9.

Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 2001; 29:897-902.

Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 2002; 30:314-8.

Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 2003; 31:768-72.

Zhang W, Yu BN, He YJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006; 373:99-103.

Zhang WY, Tu YB, Haining RL, Yu AM. Expression and functional analysis of CYP2D6. 24, CYP2D6. 26, CYP2D6. 27, and CYP2D7 isozymes. Drug Metab Dispos 2009; 37:1-4.

Zhang X, Lalezari JP, Badley AD et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004; 75:558-68.

Zhao J, Leemann T, Dayer P. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 1992; 51:575-81.

Zhao T, He YQ, Wang J, Ding KM, Wang CH, Wang ZT. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-Carboline alkaloids, harmine derivatives. Phytother Res 2011; 25:1671-7.

Zhao Y, Hellum BH, Liang A, Nilsen OG. The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine. Phytother Res 2011. doi:10. 1002/ptr. 3554.

Zhao Y, Zhai D, Chen X et al. Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats. Toxicology 2007; 230:145-50.

Zheng J, Chen B, Jiang B et al. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res 2010; 33:243-6.

Zhou D, Zhang M, Ye X et al. In vitro metabolism of α7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite. Xenobiotica 2011; 41:232-42.

Zhou L, Erickson RR, Hardwick JP, Park SS, Wrighton SA, Holtzman JL. Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450. J Pharmacol Exp Ther 1997; 281:785-90.

Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 2004; 18:262-76.

Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35:35-98.

Zhou SF, Di YM, Chan E et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008; 9:738-84.

Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41:89-295.

Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 2009; 16:2661-805.

Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009; 16:3480-675.

Zhu HJ, Wang JS, Markowitz JS et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 2006; 317:850-7.

Zhu M, Zhao W, Jimenez H et al. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 2005; 33:500-7.

Zhu W. CYP2D6: a key enzyme in morphine synthesis in animals. Med Sci Monit 2008; 14:15-8.

Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. J Immunol 2005; 175:7357-62.

Zhu W, Mantione KJ, Shen L et al. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: cyp2d6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling. Med Sci Monit 2005; 11:397-404.

Zientek M, Miller H, Smith D et al. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 2008; 58:206-14.

Zimmermann T, Hoppe-Lotichius M, Körner A et al. The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation. Transpl Int 2011; 24:1059-67.

Zoccali R, Muscatello MR, Torre DL et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 2003; 48:411-4.

Zourková A, Cesková E, Hadasová E, Ravcuková B. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther 2007; 33:343-55.

Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007; 55:310-7.

Zwisler ST, Enggaard TP, Noehr-Jensen L et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 2009; 104:335-44.

CYP2E1 (cytochrome P450, family 2, subfamily E, polypeptide 1)

Abdelmegeed MA, Moon KH, Chen C, Gonzalez FJ, Song BJ. Role of cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during acetaminophen toxicity. Biochem Pharmacol 2010; 79:57-66.

Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 2011; 141:603-10.

Aboutabl ME, Zordoky BN, El-Kadi AO. 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 2009; 158:1808-19.

Al-Belooshi T, John A, Tariq S, Al-Otaiba A, Raza H. Increased mitochondrial stress and modulation of mitochondrial respiratory enzyme activities in acetaminophen-induced toxicity in mouse macrophage cells. Food Chem Toxicol 2010; 48:2624-32.

Al-Otaiba A, John A, Al-Belooshi T, Raza H. Redox homeostasis and respiratory metabolism in camels (Camelus dromedaries): comparisons with domestic goats and laboratory rats and mice. J Comp Physiol B 2010; 180:1121-32.

An JH, Kim DS, Lee YH et al. Proteomic analysis of the protective effects of Platycodi Radix in liver of chronically alcoholic rats. J Med Food 2009; 12:1190-8.

Anantharaman D, Samant TA, Sen S, Mahimkar MB. Polymorphisms in tobacco metabolism and DNA repair genes modulate oral precancer and cancer risk. Oral Oncol 2011; 47:866-72.

Arnold C, Konkel A, Fischer R, Schunck WH. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep 2010; 62:536-47.

Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011; 35:630-7.

Bae SH, Sung SH, Cho EJ et al. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology 2011; 53:945-53.

Bajt ML, Ramachandran A, Yan HM et al. Apoptosis-inducing factor modulates mitochondrial oxidant stress in acetaminophen hepatotoxicity. Toxicol Sci 2011; 122:598-605.

Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 2010. doi:10. 1371/journal. pone. 0009570.

Bansal S, Liu CP, Sepuri NB et al. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J Biol Chem 2010; 285:24609-19.

Bardag-Gorce F, Oliva J, Wong W et al. S-adenosylmethionine decreases the peak blood alcohol levels 3 h after an acute bolus of ethanol by inducing alcohol metabolizing enzymes in the liver. Exp Mol Pathol 2010; 89:217-21.

Bardag-Gorce F. Proteasome inhibitor treatment in alcoholic liver disease. World J Gastroenterol 2011; 17:2558-62.

Barry KH, Zhang Y, Lan Q et al. Genetic variation in metabolic genes, occupational solvent exposure, and risk of non-hodgkin lymphoma. Am J Epidemiol 2011; 173:404-13.

Bazo AP, Salvadori D Jr, Salvadori RA et al. DNA repair gene polymorphism is associated with the genetic basis of atherosclerotic coronary artery disease. Cardiovasc Pathol 2011; 20:9-15.

Bell LN, Molleston JP, Morton MJ et al. Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. J Clin Gastroenterol 2011; 45:800-7.

Bell LN, Temm CJ, Saxena R et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg 2010; 251:1041-8.

Benites J, Valderrama JA, Taper H, Buc Calderon P. An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities. Invest New Drugs 2011; 29:760-7.

Bezerra FJ, do Vale NB, de Oliveira Macedo B, Rezende AA, Almeida MG. Evaluation of antioxidant parameters in rats treated with sevoflurane. Rev Bras Anestesiol 2010; 60:162-9, 93-7.

Bhave VS, Donthamsetty S, Latendresse JR, Cunningham ML, Mehendale HM. Secretory phospholipase A2-mediated progression of hepatotoxicity initiated by acetaminophen is exacerbated in the absence of hepatic COX-2. Toxicol Appl Pharmacol 2011; 251:173-80.

Bianchino G, Cittadini A, Grieco V et al. Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 genes and cancer risk in a Southern Italian population: a case-control study. Anticancer Res 2011; 31:1359-65.

Bird MG, Wetmore BA, Letinski DJ et al. Influence of toluene co-exposure on the metabolism and genotoxicity of benzene in mice using continuous and intermittent exposures. Chem Biol Interact 2010; 184:233-9.

Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26:312-8.

Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett 2010; 291:120-9.

Brocic M, Supic G, Zeljic K et al. Genetic polymorphisms of ADH1C and CYP2E1 and risk of oral squamous cell carcinoma. Otolaryngol Head Neck Surg 2011; 145:586-93.

Bulchandani DG, Nachnani JS, Nookala A et al. Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis. Eur J Gastroenterol Hepatol 2010; 22:1245-52.

Cantor KP, Villanueva CM, Silverman DT et al. Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. Environ Health Perspect 2010; 118:1545-50.

Caro AA, Thompson S, Tackett J. Increased oxidative stress and cytotoxicity by hydrogen sulfide in HepG2 cells overexpressing cytochrome P450 2E1. Cell Biol Toxicol 2011; 27:439-53.

Cederbaum A. Nrf2 and antioxidant defense against CYP2E1 toxicity. Expert Opin Drug Metab Toxicol 2009; 5:1223-44.

Cederbaum AI. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J Gastroenterol 2010; 16:1366-76.

Chacko BK, Srivastava A, Johnson MS et al. Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis. Hepatology 2011; 54:153-63.

Chan WH, Liao JW, Chou CP, Chan PK, Wei CF, Ueng TH. Induction of CYP1A1, 2B, 2E1 and 3A in rat liver by organochlorine pesticide dicofol. Toxicol Lett 2009; 190:150-5.

Chandrasekaran K, Swaminathan K, Kumar SM, Chatterjee S, Clemens DL, Dey A. Elevated glutathione level does not protect against chronic alcohol mediated apoptosis in recombinant human hepatoma cell line VL-17A over-expressing alcohol metabolizing enzymes-alcohol dehydrogenase and Cytochrome P450 2E1. Toxicol In Vitro 2011; 25:969-78.

Chatterjee S, Lyle N, Mandal A, Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther 2010; 35:465-70.

Chen KH, Lin BR, Chien CT, Ho CH. Emblica officinalis Gaertn. Attentuates N-Nitrosodiethylamine-induced apoptosis, autophagy, and inflammation in rat livers. J Med Food 2011; 14:746-55.

Chen ML, Tsai SH, Ip SP, Ko KM, Che CT. Long-term treatment with a “Yang-invigorating” Chinese herbal formula, Wu-Zi-Yan-Zong-Wan, reduces mortality and liver oxidative damage in chronic alcohol-intoxicated rats. Rejuvenation Res 2010; 13:459-67.

Chihara T, Shimpo K, Kaneko T, Beppu H, Tomatsu A, Sonoda S. Inhibitory effects of high temperature- and pressure-treated garlic on formation of 1,2-dimethylhydrazine-induced mucin-depleted foci and O(6)-methylguanine DNA adducts in the rat colorectum. Asian Pac J Cancer Prev 2009; 10:827-31.

Cichoz-Lach H, Celiński K, Wojcierowski J, Słomka M, Lis E. Genetic polymorphism of alcohol-metabolizing enzyme and alcohol dependence in Polish men. Braz J Med Biol Res 2010; 43:257-61.

Ciuclan L, Ehnert S, Ilkavets I et al. TGF-beta enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I. J Hepatol 2010; 52:407-16.

Cohen JI, Roychowdhury S, McMullen MR, Stavitsky AB, Nagy LE. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 2010; 139:664-74.

Cooper HL, Groves JT. Molecular probes of the mechanism of cytochrome P450. Oxygen traps a substrate radical intermediate. Arch Biochem Biophys 2011; 507:111-8.

Curry-McCoy TV, Osna NA, Nanji AA, Donohue TM Jr. Chronic ethanol consumption results in atypical liver injury in copper/zinc superoxide dismutase deficient mice. Alcohol Clin Exp Res 2010; 34:251-61.

Cury NM, Russo A, Galbiatti AL et al. Polymorphisms of the CYP1A1 and CYP2E1 genes in head and neck squamous cell carcinoma risk. Mol Biol Rep 2011. doi:10. 1007/s11033-011-0831-1.

Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. Genet Test Mol Biomarkers 2011; 15:423-9.

Das J, Ghosh J, Manna P, Sil PC. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res 2010; 44:340-55.

Deka M, Bose M, Baruah B et al. Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India. World J Gastroenterol 2010; 16:4800-8.

Denucci SM, Tong M, Longato L et al. Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. Gastroenterol Res Pract 2010. doi:10. 1155/2010/312790.

Dey A, Kumar SM. Cytochrome P450 2E1 and hyperglycemia-induced liver injury. Cell Biol Toxicol 2011; 27:285-310.

Dhillon VS, Thomas P, Iarmarcovai G, Kirsch-Volders M, Bonassi S, Fenech M. Genetic polymorphisms of genes involved in DNA repair and metabolism influence micronucleus frequencies in human peripheral blood lymphocytes. Mutagenesis 2011; 26:33-42.

Doi H, Horie T. Salicylic acid-induced hepatotoxicity triggered by oxidative stress. Chem Biol Interact 2010; 183:363-8.

Duca RC, Mabondzo A, Bravin F, Delaforge M. In vivo effects of zearalenone on the expression of proteins involved in the detoxification of rat xenobiotics. Environ Toxicol 2010. doi:10. 1002/tox. 20617.

El BK, Hashimoto Y, Muzandu K et al. Protective effect of Pleurotus cornucopiae mushroom extract on carbon tetrachloride-induced hepatotoxicity. Jpn J Vet Res 2009; 57:109-18.

Elbarbry F, Ragheb A, Attia A, Chibbar R, Marfleet T, Shoker A. Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity. Xenobiotica 2010; 40:772-81.

El-Batch M, Hassan AM, Mahmoud HA. Taurine is more effective than melatonin on cytochrome P450 2E1 and some oxidative stress markers in streptozotocin-induced diabetic rats. J Agric Food Chem 2011; 59:4995-5000.

Evans MV, Caldwell JC. Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling for in vivo inhalation gas uptake data exposure in female B6C3F1 mice. Toxicol Appl Pharmacol 2010; 244:280-90.

Fairbrother KS, Grove J, de Waziers I et al. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8:543-52.

Ferguson C, Miksys S, Palmour R, Tyndale RF. Independent and combined effects of ethanol self-administration and nicotine treatment on hepatic CYP2E1 in African Green Monkeys. Drug Metab Dispos 2011. doi:10. 1124/dmd. 111. 040378.

Forkert PG. Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab Rev 2010; 42:355-78.

Garcia SM, Curioni OA, de Carvalho MB, Gattás GJ. Polymorphisms in alcohol metabolizing genes and the risk of head and neck cancer in a Brazilian population. Alcohol Alcohol 2010; 45:6-12.

Gewiese-Rabsch J, Drucker C, Malchow S, Scheller J, Rose-John S. Role of IL-6 trans-signaling in CCl4 induced liver damage. Biochim Biophys Acta 2010; 1802:1054-61.

Ghose R, Omoluabi O, Gandhi A et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 2011; 89:57-64.

Gordillo-Bastidas E, Panduro A, Gordillo-Bastidas D et al. Polymorphisms of alcohol metabolizing enzymes in indigenous Mexican population: unusual high frequency of CYP2E1*c2 allele. Alcohol Clin Exp Res 2010; 34:142-9.

Goto Y, Ohashi K, Utoh R, Yamamoto M, Okano T. Hepatocyte transplantation through the hepatic vein: A new route of cell transplantation to the liver. Cell Transplant 2010. doi:10. 3727/096368910X547417.

Guangwei X, Rongzhu L, Wenrong X et al. Curcumin pretreatment protects against acute acrylonitrile-induced oxidative damage in rats. Toxicology 2010; 267:140-6.

Guo WJ, Wang Q, Lanzi G et al. Gender-specific interactions between alcohol metabolism genes and severity of quantitative alcohol-related-traits in a Tibetan population. Neurosci Lett 2011; 495:22-5.

Guo X, Zeng Y, Deng H et al. Genetic polymorphisms of CYP2E1, GSTP1, NQO1 and MPO and the risk of nasopharyngeal carcinoma in a Han Chinese population of Southern China. BMC Res Notes 2010; 3:212.

Hamdy SM, Bakeer HM, Eskande EF, Sayed ON. Effect of acrylamide on some hormones and endocrine tissues in male rats. Hum Exp Toxicol 2011. doi:10. 1177/0960327111417267.

Han X, Zheng T, Foss FM et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol 2010; 85:51-6.

Han ZX, Yang L, Zhang L, Xu C, Shu WQ. The antagonistic action of epigallocatechin-3-gallate on microcystin LR-induced oxidative damage on hepatocytes of mice and the expression of cytochrome P450 2E1. Zhonghua Yu Fang Yi Xue Za Zhi 2010; 44:24-9.

Hanioka N, Yamamoto M, Tanaka-Kagawa T, Jinno H, Narimatsu S. Functional characterization of human cytochrome P4502E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells. Arch Toxicol 2010; 84:363-71.

Hao C, Liu W, Luan X et al. Aquaporin-4 knockout enhances astrocyte toxicity induced by 1-methyl-4-phenylpyridinium ion and lipopolysaccharide via increasing the expression of cytochrome P4502E1. Toxicol Lett 2010; 198:225-31.

Hata S, Miki Y, Fujishima F et al. Cytochrome 3A and 2E1 in human liver tissue: Individual variations among normal Japanese subjects. Life Sci 2010; 86:393-401.

Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5’-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991; 110:559-65.

Hebeda CB, Pinedo FJ, Vinolo MA, Curi R, Farsky SH. Hydroquinone stimulates inflammatory functions in microvascular endothelial cells via NF-κB nuclear activation. Basic Clin Pharmacol Toxicol 2011; 109:372-80.

Helmig S, Döhrel J, Schneider J. Decreased Cyp2E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. Int J Mol Med 2010; 26:143-9.

Hewitt AJ, Walker KR, Kobus SM, Poklewska-Koziell M, Reynolds JN, Brien JF. Differential effects of chronic ethanol exposure on cytochrome P450 2E1 and the hypothalamic-pituitary-adrenal axis in the maternal-fetal unit of the guinea pig. Neurotoxicol Teratol 2010; 32:164-70.

Hickling KC, Hitchcock JM, Oreffo V et al. Evidence of oxidative stress and associated DNA damage, increased proliferative drive, and altered gene expression in rat liver produced by the cholangiocarcinogenic agent furan. Toxicol Pathol 2010; 38:230-43.

Hong IH, Ji H, Hwa SY et al. The protective effect of ENA actimineral resource A on CCl4-induced liver injury in rats. Mar Biotechnol 2011; 13:462-73.

Hong ZF, Li TJ, Zhao JY. Effect of total alkaloids of Rubus alceaefolius poiron on gene expressions of CYP2E1 and CYP3A1 in rats with acute liver injury. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009; 29:711-5.

Hosono-Fukao T, Hosono T, Seki T, Ariga T. Diallyl trisulfide protects rats from carbon tetrachloride-induced liver injury. J Nutr 2009; 139:2252-6.

Hu S, Shen G, Zhao W, Wang F, Jiang X, Huang D. Paeonol, the main active principles of Paeonia moutan, ameliorates alcoholic steatohepatitis in mice. J Ethnopharmacol 2010; 128:100-6.

Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M. Structural and functional characterization of the 5’-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 1999; 263:286-93.

Hu Y, Oscarson M, Johansson I et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51:370-6.

Huang YF, Chen ML, Liou SH, Chen MF, Uang SN, Wu KY. Association of CYP2E1, GST and mEH genetic polymorphisms with urinary acrylamide metabolites in workers exposed to acrylamide. Toxicol Lett 2011; 203:118-26.

Hukkanen J, Jacob Iii P, Peng M, Dempsey D, Benowitz NL. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2010; 69:152-9.

Hum M, McLaughlin BE, Roman G, Vlahakis JZ, Szarek WA, Nakatsu K. The effects of azole-based heme oxygenase inhibitors on rat cytochromes P450 2E1 and 3A1/2 and human cytochromes P450 3A4 and 2D6. J Pharmacol Exp Ther 2010; 334:981-7.

Irie H, Asano-Hoshino A, Sekino Y, Nogami M, Kitagawa T, Kanda H. Striking LD50 variation associated with fluctuations of CYP2E1-positive cells in hepatic lobule during chronic CCl4 exposure in mice. Virchows Arch 2010; 456:423-31.

Itoga S, Nomura F, Harada S, Tsutsumi M, Takase S, Nakai T. Mutations in the exons and exon-intron junction regions of human cytochrome P-4502E1 gene and alcoholism. Alcohol Clin Exp Res 1999; 23(4 Suppl):13-6.

Ji F, Wang W, Xia ZL et al. Prevalence and persistence of chromosomal damage and susceptible genotypes of metabolic and DNA repair genes in Chinese vinyl chloride-exposed workers. Carcinogenesis 2010; 31:648-53.

Ji F, Zhu SM, Wang AH et al. Genetic susceptibility of DNA damage induced by vinyl chloride monomer exposure. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2010; 28:12-7.

Jia H, Xu A, Yuan J, Gao X, Gao J. Experimental study on cytochrome P450 enzymes after receiving ferment powder caterpillar fungus. Zhongguo Zhong Yao Za Zhi 2009; 34:2079-82.

Jia WH, Pan QH, Qin HD et al. A case-control and a family-based association study revealing an association between CYP2E1 polymorphisms and nasopharyngeal carcinoma risk in Cantonese. Carcinogenesis 2009; 30:2031-6.

Jing L, Jin CM, Li SS et al. Chronic alcohol intake-induced oxidative stress and apoptosis: role of CYP2E1 and calpain-1 in alcoholic cardiomyopathy. Mol Cell Biochem 2011. doi:10. 1007/s11010-011-1022-z.

Jung HY, Kang HE, Choi YH, Kim SH, Lee MG. Time-dependent effects of Klebsiella pneumoniae endotoxin on the pharmacokinetics of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, in rats: restoration of the parameters in 96 hour in KPLPS rats to control levels. Biopharm Drug Dispos 2009; 30:485-93.

Kang JW, Wilkerson HW, Farin FM et al. Mammalian cytochrome CYP2E1 triggered differential gene regulation in response to trichloroethylene (TCE) in a transgenic poplar. Funct Integr Genomics 2010; 10:417-24.

Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 2010; 25:1136-43.

Kato S, Naito Z, Matsuda N et al. Localization of cytochrome P4502E1 enzyme in normal and cancerous gastric mucosa and association with its genetic polymorphism in unoperated and remnant stomach. J Nihon Med Sch 2011; 78:224-34.

Kaviarasan S, Ramamurthy N, Gunasekaran P, Varalakshmi E, Anuradha CV. Induction of alcohol-metabolizing enzymes and heat shock protein expression by ethanol and modulation by fenugreek seed polyphenols in Chang liver cells. Toxicol Mech Methods 2009; 19:116-22.

Kayaaltı Z, Söylemezoğlu T. Distribution of ADH1B, ALDH2, CYP2E1 *6, and CYP2E1 *7B genotypes in Turkish population. Alcohol 2010; 44:415-23.

Keating AF, Rajapaksa KS, Sipes IG, Hoyer PB. Effect of CYP2E1 gene deletion in mice on expression of microsomal epoxide hydrolase in response to VCD exposure. Toxicol Sci 2008; 105:351-9.

Kerzic PJ, Liu WS, Pan MT et al. Analysis of hydroquinone and catechol in peripheral blood of benzene-exposed workers. Chem Biol Interact 2010; 184:182-8.

Khan AJ, Husain Q, Choudhuri G, Parmar D. Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. Drug Alcohol Depend 2010; 109:190-7.

Khan AJ, Sharma A, Choudhuri G, Parmar D. Induction of blood lymphocyte cytochrome P450 2E1 in early stage alcoholic liver cirrhosis. Alcohol 2011; 45:81-7.

Khanal T, Choi JH, Hwang YP, Chung YC, Jeong HG. Protective effects of saponins from the root of Platycodon grandiflorum against fatty liver in chronic ethanol feeding via the activation of AMP-dependent protein kinase. Food Chem Toxicol 2009; 47:2749-54.

Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010; 10:280-90.

Kim SK, Lee SI, Shin CJ, Son JW, Ju G. The genetic factors affecting drinking behaviors of korean young adults with variant aldehyde dehydrogenase 2 genotype. Psychiatry Investig 2010; 7:270-7.

Kim TH, Lee SH, Lee SM. Role of Kupffer cells in pathogenesis of sepsis-induced drug metabolizing dysfunction. FEBS J 2011; 278:2307-17.

Kiyohara C, Miyake Y, Koyanagi M et al. APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson’s disease in a Japanese population. J Neural Transm 2011; 118:1335-44.

Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R. Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genet Cytogenet 2009; 195:143-9.

Knockaert L, Descatoire V, Vadrot N, Fromenty B, Robin MA. Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol In Vitro 2011; 25:475-84.

Koyama N, Yasui M, Oda Y et al. Genotoxicity of acrylamide in vitro: Acrylamide is not metabolically activated in standard in vitro systems. Environ Mol Mutagen 2011; 52:11-9.

Kumar A, Ahmad I, Shukla S et al. Effect of zinc and paraquat co-exposure on neurodegeneration: Modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats. Free Radic Res 2010; 44:950-65.

Kusirisin W, Jaikang C, Chaiyasut C, Narongchai P. Effect of polyphenolic compounds from Solanum torvum on plasma lipid peroxidation, superoxide anion and cytochrome P450 2E1 in human liver microsomes. Med Chem 2009; 5:583-8.

Lam JL, Jiang Y, Zhang T, Zhang EY, Smith BJ. Expression and functional analysis of hepatic cytochromes P450, nuclear receptors, and membrane transporters in 10- and 25-week-old db/db mice. Drug Metab Dispos 2010; 38:2252-8.

Lee HI, Kim MS, Lee KM et al. Anti-visceral obesity and antioxidant effects of powdered sea buckthorn (Hippophae rhamnoides L. ) leaf tea in diet-induced obese mice. Food Chem Toxicol 2011; 49:2370-6.

Lee HS, Song J, Kim TM et al. Effects of a preparation of combined glutathione-enriched yeast and rice embryo/soybean extracts on ethanol hangover. J Med Food 2009; 12:1359-67.

Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14:622-6.

Lee SY, Oh SJ, Yun KU et al. Expression of hepatic and ovarian cytochrome P450 during estrous cycle in rats. Arch Toxicol 2011. doi:10. 1007/s00204-011-0730-1.

Li L, Porter TD. Chlorzoxazone hydroxylation in microsomes and hepatocytes from cytochrome P450 oxidoreductase-null mice. J Biochem Mol Toxicol 2009; 23:357-63.

Li QD, Li H, Wang MS et al. Multi-susceptibility genes associated with the risk of the development stages of esophageal squamous cell cancer in Feicheng County. BMC Gastroenterol 2011; 11:74.

Lian LH, Wu YL, Song SZ et al. Gentiana manshurica Kitagawa reverses acute alcohol-induced liver steatosis through blocking sterol regulatory element-binding protein-1 maturation. J Agric Food Chem 2010; 58:13013-9.

Liang Q, Sheng Y, Ji L, Min Y, Xia Y, Wang Z. Acetaminophen-induced cytotoxicity on human normal liver L-02 cells and the protection of antioxidants. Toxicol Mech Methods 2010; 20:273-8.

Liao LH, Zhang H, Lai MP, Chen SL, Wu M, Shen N. Single-nucleotide polymorphisms and haplotype of CYP2E1 gene associated with systemic lupus erythematosus in Chinese population. Arthritis Res Ther 2011; 13:11.

Lin J, Zhao J, Li T, Zhou J, Hu J, Hong Z. Hepatoprotection in a rat model of acute liver damage through inhibition of CY2E1 activity by total alkaloids extracted from Rubus alceifolius Poir. Int J Toxicol 2011; 30:237-43.

Liu F, Ichihara S, Mohideen SS, Sai U, Kitoh J, Ichihara G. Comparative study on susceptibility to 1-bromopropane in three mice strains. Toxicol Sci 2009; 112:100-10.

Lu D, Yu X, Du Y. Meta-analyses of the effect of cytochrome P450 2E1 gene polymorphism on the risk of head and neck cancer. Mol Biol Rep 2011; 38:2409-16.

Lu Y, Wu D, Wang X, Ward SC, Cederbaum AI. Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. Free Radic Biol Med 2010; 49:1406-16.

Lu Y, Zhuge J, Wu D, Cederbaum AI. Ethanol induction of CYP2A5: permissive role for CYP2E1. Drug Metab Dispos 2011; 39:330-6.

Lv X, Chen Z, Li J et al. Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress. Inflamm Res 2010; 59:635-45.

Ma T, Huang C, Zong G et al. Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. J Pharm Pharmacol 2011; 63:587-93.

Maciel ME, Oliveira FK, Propst GB, da Graça Bicalho M, Cavalli IJ, Ribeiro EM. Population analysis of xenobiotic metabolizing genes in South Brazilian Euro and Afro-descendants. Genet Mol Biol 2009; 32:723-8.

Magne L, Blanc E, Legrand B et al. ATF4 and the integrated stress response are induced by ethanol and cytochrome P450 2E1 in human hepatocytes. J Hepatol 2011; 54:729-37.

Makaji E, Trambitas CS, Shen P, Holloway AC, Crankshaw DJ. Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms. Toxicol Sci 2010; 113:293-304.

Malik MA, Upadhyay R, Mittal RD, Zargar SA, Mittal B. Association of xenobiotic metabolizing enzymes genetic polymorphisms with esophageal cancer in Kashmir Valley and influence of environmental factors. Nutr Cancer 2010; 62:734-42.

Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. An essential role for MCP-1 in alcoholic liver injury: Regulation of pro-inflammatory cytokines and hepatic steatosis. Hepatology 2011. doi:10. 1002/hep. 24599.

Manimaran A, Sarkar SN, Sankar P. Influence of repeated preexposure to arsenic on acetaminophen-induced oxidative stress in liver of male rats. Food Chem Toxicol 2010; 48:605-10.

Manna P, Bhattacharyya S, Das J, Ghosh J, Sil PC. Phytomedicinal role of Pithecellobium dulce against CCl(4)-mediated hepatic oxidative impairments and necrotic cell death. Evid Based Complement Alternat Med 2011. doi:10. 1093/ecam/neq065.

Martínez C, Galván S, Garcia-Martin E, Ramos MI, Gutiérrez-Martín Y, Agúndez JA. Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes. Hepatology 2010; 51:491-500.

Matsuzaka Y, Kikuti YY, Mizutani A et al. Association study between sick building syndrome and polymorphisms of seven human detoxification genes in the Japanese. Environ Toxicol Pharmacol 2010; 29:190-4.

Mauray A, Felgines C, Morand C, Mazur A, Scalbert A, Milenkovic D. Bilberry anthocyanin-rich extract alters expression of genes related to atherosclerosis development in aorta of apo E-deficient mice. Nutr Metab Cardiovasc Dis 2010. doi:10. 1016/j. numecd. 2010. 04. 011.

McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res 1987; 15:10071.

McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 1998; 152:276-81.

Millonig G, Wang Y, Homann N et al. Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions. Int J Cancer 2011; 128:533-40.

Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 2010; 79:1045-52.

Monks TJ, Butterworth M, Lau SS. The fate of benzene-oxide. Chem Biol Interact 2010; 184:201-6.

Morinaga T, Hasegawa G, Koyama S, Ishihara Y, Nishikawa T. Acute inflammation and immunoresponses induced by ortho-phthalaldehyde in mice. Arch Toxicol 2010; 84:397-404.

Mrozikiewicz PM, Bogacz A, Czerny B et al. The influence of a standardized soybean extract (Glycine max) on the expression level of cytochrome P450 genes in vivo. Ginekol Pol 2010; 81:516-20.

Naiman K, Frei E, Stiborova M. Identification of rat cytochromes P450 metabolizing N-(2-methoxyphenyl)hydroxylamine, a human metabolite of the environmental pollutants and carcinogens o-anisidine and o-nitroanisole. Neuro Endocrinol Lett 2010; 31 Suppl 2:36-45.

Nan Y, Wang R, Zhao S et al. Heme oxygenase-1 prevents non-alcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice. Lipids Health Dis 2010; 9:124.

Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev 2009; 12:362-88.

Neuwelt AJ, Wu YJ, Knap N et al. Using acetaminophen’s toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia 2009; 11:1003-11.

Niu Y, Hu Y, Wu M et al. CYP2E1 Rsa I/Pst I polymorphism contributes to oral cancer susceptibility: a meta-analysis. Mol Biol Rep 2011. doi:10. 1007/s11033-011-0777-3

Niu Y, Yuan H, Leng W, Pang Y, Gu N, Chen N. CYP2E1 Rsa I/Pst I polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls. Med Oncol 2011; 28:182-7.

Njoku DB. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. Expert Opin Drug Metab Toxicol 2010; 6:519-31.

Noh JR, Kim YH, Gang GT et al. Hepatoprotective effects of chestnut (Castanea crenata) inner shell extract against chronic ethanol-induced oxidative stress in C57BL/6 mice. Food Chem Toxicol 2011; 49:1537-43.

Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. Clin Pharmacol Ther 2003; 74:555-68.

Nyagode BA, Lee CM, Morgan ET. Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice. J Pharmacol Exp Ther 2010; 335:480-8.

Ohnuma T, Anan E, Hoashi R et al. Dietary diacetylene falcarindiol induces phase 2 drug-metabolizing enzymes and blocks carbon tetrachloride-induced hepatotoxicity in mice through suppression of lipid peroxidation. Biol Pharm Bull 2011; 34:371-8.

Oliva J, Bardag-Gorce F, Tillman B, French SW. Protective effect of quercetin, EGCG, catechin and betaine against oxidative stress induced by ethanol in vitro. Exp Mol Pathol 2011; 90:295-9.

Onyimba JA, Coronado MJ, Garton AE et al. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice. Biol Sex Differ 2011; 2:2.

Orlicky DJ, Roede JR, Bales E et al. Chronic ethanol consumption in mice alters hepatocyte lipid droplet properties. Alcohol Clin Exp Res 2011; 35:1020-33.

Osna NA, White RL, Donohue TM Jr, Beard MR, Tuma DJ, Kharbanda KK. Impaired methylation as a novel mechanism for proteasome suppression in liver cells. Biochem Biophys Res Commun 2010; 391:1291-6.

Palanisamy N, Manian S. Protective effects of Asparagus racemosus on oxidative damage in isoniazid-induced hepatotoxic rats: an in vivo study. Toxicol Ind Health 2011. doi:10. 1177/0748233711410911.

Park CM, Cha YS, Youn HJ, Cho CW, Song YS. Amelioration of oxidative stress by dandelion extract through CYP2E1 suppression against acute liver injury induced by carbon tetrachloride in Sprague-Dawley rats. Phytother Res 2010; 24:1347-53.

Park JK, Hong IH, Ki MR et al. Vitamin C deficiency increases the binucleation of hepatocytes in SMP30 knock-out mice. J Gastroenterol Hepatol 2010; 25:1769-76.

Park S, Kim AJ, Lee M. Synergic effects of alpha-tocopherol and beta-carotene on tert-butylhydroperoxide-induced HepG2 cell injury. Toxicol Ind Health 2009; 25:311-20.

Peng HC, Chen JR, Chen YL, Yang SC, Yang SS. beta-Carotene exhibits antioxidant and anti-apoptotic properties to prevent ethanol-induced cytotoxicity in isolated rat hepatocytes. Phytother Res 2010; 24 Suppl 2:183-9.

Peng HC, Chen YL, Chen JR et al. Effects of glutamine administration on inflammatory responses in chronic ethanol-fed rats. J Nutr Biochem 2011; 22:282-8.

Persson I, Johansson I, Bergling H et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993; 319:207-11.

Pohl HR, Scinicariello F. The impact of CYP2E1 genetic variability on risk assessment of VOC mixtures. Regul Toxicol Pharmacol 2011; 59:364-74.

Pontes H, de Pinho PG, Fernandes E et al. Metabolic interactions between ethanol and MDMA in primary cultured rat hepatocytes. Toxicology 2010; 270:150-7.

Pooranaperundevi M, Sumiyabanu MS, Viswanathan P, Sundarapandiyan R, Anuradha CV. Insulin resistance induced by a high-fructose diet potentiates thioacetamide hepatotoxicity. Singapore Med J 2010; 51:389-98.

Porubsky PR, Battaile KP, Scott EE. Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. J Biol Chem 2010; 285:22282-90.

Posadas I, Santos P, Blanco A, Muñoz-Fernández M, Ceña V. Acetaminophen induces apoptosis in rat cortical neurons. PLoS One 2010. doi:10. 1371/journal. pone. 0015360.

Pourahmad J, Eskandari MR, Daraei B. A comparison of hepatocyte cytotoxic mechanisms for thallium (I) and thallium (III). Environ Toxicol 2010; 25:456-67.

Pourahmad J, Eskandari MR, Nosrati M, Kobarfard F, Khajeamiri AR. Involvement of mitochondrial/lysosomal toxic cross-talk in ecstasy induced liver toxicity under hyperthermic condition. Eur J Pharmacol 2010; 643:162-9.

Pourahmad J, Hosseini MJ, Eskandari MR, Shekarabi SM, Daraei B. Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica 2010; 40:763-71.

Powell CL, Bradford BU, Craig CP et al. Mechanism for prevention of alcohol-induced liver injury by dietary methyl donors. Toxicol Sci 2010; 115:131-9.

Pratt-Hyatt M, Lin HL, Hollenberg PF. Mechanism-based inactivation of human CYP2E1 by diethyldithocarbamate. Drug Metab Dispos 2010; 38:2286-92.

Prieto-Castelló MJ, Cardona A, Marhuenda D, Roel JM, Corno A. Use of the CYP2E1 genotype and phenotype for the biological monitoring of occupational exposure to styrene. Toxicol Lett 2010; 192:34-9.

Punvittayagul C, Wongpoomchai R, Taya S, Pompimon W. Effect of pinocembrin isolated from Boesenbergia pandurata on xenobiotic-metabolizing enzymes in rat liver. Drug Metab Lett 2011; 5:1-5.

Qu W, Cheng L, Dill AL et al. Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1. Chem Biol Interact 2011; 193:88-96.

Quan J, Piao L, Wang X, Li T, Yin X. Rossicaside B protects against carbon tetrachloride-induced hepatotoxicity in mice. Basic Clin Pharmacol Toxicol 2009; 105:380-6.

Quan J, Yin X, Xu H. Boschniakia rossica prevents the carbon tetrachloride-induced hepatotoxicity in rat. Exp Toxicol Pathol 2011; 63:53-9.

Quiñones L, Lee K, Varela F N et al. Cancer pharmacogenetics: study of genetically determined variations on cancer susceptibility due to xenobiotic exposure. Rev Med Chil 2006; 134:499-515.

Rasmussen MK, Zamaratskaia G, Ekstrand B. In vitro cytochrome P450 2E1 and 2A activities in the presence of testicular steroids. Reprod Domest Anim 2011; 46:149-54.

Reichl FX, Seiss M, Buters J, Behrendt H, Hickel R, Durner J. Expression of CYP450-2E1 and formation of 2,3-epoxymethacrylic acid (2,3-EMA) in human oral cells exposed to dental materials. Dent Mater 2010; 26:1151-6.

Robert Schnatter A, Kerzic PJ, Zhou Y et al. Peripheral blood effects in benzene-exposed workers. Chem Biol Interact 2010; 184:174-81.

Roychowdhury S, McMullen MR, Pritchard MT, Li W, Salomon RG, Nagy LE. Formation of gamma-ketoaldehyde-protein adducts during ethanol-induced liver injury in mice. Free Radic Biol Med 2009; 47:1526-38.

Saewong T, Ounjaijean S, Mundee Y et al. Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Med Chem 2010; 6:57-64.

Saghir SA, Zhang F, Rick DL, Kan L, Bus JS, Bartels MJ. In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul Toxicol Pharmacol 2010; 57:129-35.

Saito S, Iida A, Sekine A et al. Catalog of 680 variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48:249-70.

Sam SS, Thomas V, Reddy KS, Surianarayanan G, Chandrasekaran A. Gene-gene interactions of drug metabolizing enzymes and transporter protein in the risk of upper aerodigestive tract cancers among Indians. Cancer Epidemiol 2010; 34:626-33.

Sampayo R, Lavandera JV, Batlle A, Buzaleh AM. Sevoflurane: its action on heme metabolism and Phase I drug metabolizing system. Cell Mol Biol 2009; 55:140-6.

Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Khuhaprema T, Yoshida T. Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women. Breast Cancer Res Treat 2010; 123:885-93.

Schäfer A, Galuppo P, Fraccarollo D et al. Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes 2010; 59:2001-9.

Sebastian BM, Roychowdhury S, Tang H et al. Identification of a CYP2E1/Bid/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice. J Biol Chem 2011; 286:35989-97.

Sekine S, Ogawa R, Mcmanus MT, Kanai Y, Hebrok M. Dicer is required for proper liver zonation. J Pathol 2009; 219:365-72.

Shaik IH, Mehvar R. Effects of normothermic hepatic ischemia-reperfusion injury on the in vivo, isolated perfused liver, and microsomal disposition of chlorzoxazone, a cytochrome P450 2E1 probe, in rats. J Pharm Sci 2011; 100:5281-8292.

Sharma S, Rana SV. Melatonin inhibits benzene-induced lipid peroxidation in rat liver. Arh Hig Rada Toksikol 2010; 61:11-8.

Shim JY, Kim MH, Kim HD, Ahn JY, Yun YS, Song JY. Protective action of the immunomodulator ginsan against carbon tetrachloride-induced liver injury via control of oxidative stress and the inflammatory response. Toxicol Appl Pharmacol 2010; 242:318-25.

Singh R, Wang Y, Schattenberg JM, Xiang Y, Czaja MJ. Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am J Physiol Gastrointest Liver Physiol 2009; 297:907-17.

Singh S, Sherkhane PD, Kale SP, Eapen S. Expression of a human cytochrome P4502E1 in Nicotiana tabacum enhances tolerance and remediation of γ-hexachlorocyclohexane. N Biotechnol 2011; 28:423-9.

Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP. Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse. J Pineal Res 2011; 50:97-109.

Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.

Song SZ, Choi YH, Jin GY, Li GZ, Yan GH. Protective effect of cornuside against carbon tetrachloride-induced acute hepatic injury. Biosci Biotechnol Biochem 2011; 75:656-61.

Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 2011; 25:803-12.

Stickel F, Seitz HK. Alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2010; 24:683-93.

Suhua W, Rongzhu L, Wenrong X et al. Induction or inhibition of cytochrome P450 2E1 modifies the acute toxicity of acrylonitrile in rats: biochemical evidence. Arch Toxicol 2010; 84:461-9.

Sulc M, Hodek P, Stiborová M. The binding affinity of carcinogenic N-nitrosodimethylamine and N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation. Gen Physiol Biophys 2010; 29:175-85.

Sutti S, Vidali M, Mombello C, Sartori M, Albano E. Conformational anti-cytochrome P4502E1 (CYP2E1) auto-antibodies contribute to necro-inflammatory injury in chronic hepatitis C. J Viral Hepat 2010; 17:685-90.

Sutti S, Vidali M, Mombello C, Sartori M, Ingelman-Sundberg M, Albano E. Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: possible role for molecular mimicry. J Hepatol 2010; 53:431-8.

Svobodova M, Martinkova M, Dracinska H, Frei E, Stiborova M. Rat cytochromes P450 oxidize 2-nitrophenol, a human metabolite of carcinogenic 2-nitroanisole. Neuro Endocrinol Lett 2009; 30 Suppl 1:46-51.

Szele E, Gombos K, Kovács A, Ember I. Effects of purified glycerol from biodiesel on Cyp1a1 and Cyp2e1 expressions in CBA/CA mice. In Vivo 2011; 25:237-40.

Tai J, Yang M, Ni X et al. Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Cancer Genet Cytogenet 2010; 196:76-82.

Takaku T, Mikata K, Matsui M, Nishioka K, Isobe N, Kaneko H. In vitro metabolism of trans-permethrin and its major metabolites, PBalc and PBacid, in humans. J Agric Food Chem 2011; 59:5001-5.

Tan H, Wang Q, Wang A et al. Influence of GSTs, CYP2E1 and mEH polymorphisms on 1, 3-butadiene-induced micronucleus frequency in Chinese workers. Toxicol Appl Pharmacol 2010; 247:198-203.

Tang K, Li X, Xing Q et al. Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in Chinese Han populations from four different geographic areas of Mainland China. Genomics 2010; 95:224-9.

Tang K, Li Y, Zhang Z et al. The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies. BMC Cancer 2010; 10:575.

Tangjarukij C, Navasumrit P, Zelikoff JT, Ruchirawat M. The effects of pyridoxine deficiency and supplementation on hematological profiles, lymphocyte function, and hepatic cytochrome P450 in B6C3F1 mice. J Immunotoxicol 2009; 6:147-60.

Tiwari MN, Singh AK, Ahmad I et al. Effects of cypermethrin on monoamine transporters, xenobiotic metabolizing enzymes and lipid peroxidation in the rat nigrostriatal system. Free Radic Res 2010; 44:1416-24.

Tomicic C, Berode M, Oppliger A et al. Sex differences in urinary levels of several biological indicators of exposure: a human volunteer study. Toxicol Lett 2011; 202:218-25.

Tonack S, Patel S, Jalali M et al. Tetracycline-inducible protein expression in pancreatic cancer cells: effects of CapG overexpression. World J Gastroenterol 2011; 17:1947-60.

Trafalis DT, Panteli ES, Grivas A, Tsigris C, Karamanakos PN. CYP2E1 and risk of chemically mediated cancers. Expert Opin Drug Metab Toxicol 2010; 6:307-19.

Tumer TB, Yilmaz D, Tanrikut C, Sahin G, Ulusoy G, Arinç E. DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia. Leuk Res 2010; 34:1275-81.

Uzma N, Kumar BS, Priyadarsini KI. Hepatoprotective, immunomodulatory, and anti-inflammatory activities of selenocystine in experimental liver injury of rats. Biol Trace Elem Res 2011; 142:723-34.

Viaggi C, Vaglini F, Pardini C, Caramelli A, Corsini GU. MPTP-induced model of Parkinson’s disease in cytochrome P450 2E1 knockout mice. Neuropharmacology 2009; 56:1075-81.

Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 2010; 95:1405-14.

Vuilleumier N, Rossier MF, Chiappe A et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62:423-9.

Wang B, Bai M, Bai Y, Li Q. Liver injury following renal ischemia reperfusion in rats. Transplant Proc 2010; 42:3422-6.

Wang F, Lu Y, Kong L. Compatibility of Banxia Houpo decoction on hepatic CYP450 and renal organicion transporters in mice. Zhongguo Zhong Yao Za Zhi 2011; 36:60-5.

Wang J, Hu Y, Nekvindova J, Ingelman-Sundberg M, Neve EP. IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. Biochem Pharmacol 2010; 80:1592-600.

Wang JS, Hu XY, Zhang W, Yuan J, Yang Y, Fang Q. Construction of CYP2E1 recombinant adenovirus vector and its anti-tumor effects. Zhonghua Yi Xue Za Zhi 2010; 90:2130-5.

Wang SY, Xue J, Zhou J. Preliminary effects of alcohol and Curcuma longa upon CYP2E1 and hematotoxicity in benzene-induced mice. Zhonghua Yi Xue Za Zhi 2009; 89:2429-31.

Wang T, Yu HT, Wang W, Pan YY, He LX, Wang ZY. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res 2010; 38:977-86.

Wang W, Qiu YL, Ji F et al. Genetic polymorphisms in metabolizing enzymes and susceptibility of chromosomal damage induced by vinyl chloride monomer in a Chinese worker population. J Occup Environ Med 2010; 52:163-8.

Wang X, Wu D, Yang L, Cederbaum AI. Hepatotoxicity mediated by pyrazole (CYP2E1) Plus TNF-α treatment occurs in jnk2(-/-) but not in jnk1(-/-) mice. Hepatology 2011. doi:10. 1002/hep. 24540.

Wang Y, Guan S, Acharya P et al. Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitination. J Biol Chem 2011; 286:9443-56.

Wang Y, Seitz HK, Wang XD. Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats. Alcohol Clin Exp Res 2010; 34:567-73.

Wang Y, Yang H, Li L et al. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer 2010; 46:758-64.

Wang YH, Yeh SD, Shen KH et al. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicol Appl Pharmacol 2009; 241:111-8.

Wang YX, Meng XW, Wang YD, Liu Y. MRNA levels of two different enzymes in hepatocellular carcinoma. Hepatogastroenterology 2010; 57:1187-90.

Watanabe J, Hayashi S, Nakachi K et al. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 1990; 18:7194.

Webb A, Lind PA, Kalmijn J et al. The investigation into CYP2E1 in relation to the level of response to alcohol through a combination of linkage and association analysis. Alcohol Clin Exp Res 2011; 35:10-8.

Weerachayaphorn J, Chuncharunee A, Jariyawat S et al. Protection of centrilobular necrosis by Curcuma comosa Roxb. in carbon tetrachloride-induced mice liver injury. J Ethnopharmacol 2010; 129:254-60.

Wiercinska P, Squires EJ. Chlorzoxazone metabolism by porcine cytochrome P450 enzymes and the effect of cytochrome b5. Drug Metab Dispos 2010; 38:857-62.

Wongvijitsuk S, Navasumrit P, Vattanasit U, Parnlob V, Ruchirawat M. Low level occupational exposure to styrene: its effects on DNA damage and DNA repair. Int J Hyg Environ Health 2011; 214:127-37.

Wu D, Cederbaum A. Activation of ASK-1 and downstream MAP kinases in cytochrome P4502E1 potentiated tumor necrosis factor alpha liver injury. Free Radic Biol Med 2010; 49:348-60.

Wu D, Cederbaum A. Cytochrome P4502E1 sensitizes to tumor necrosis factor alpha-induced liver injury through activation of mitogen-activated protein kinases in mice. Hepatology 2008; 47:1005-17.

Wu JY, Yue J, Feng YQ. Determination of brain cytochrome P450 2E1 activity in rat with the probe of chlorzoxazone by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:260-6.

Wu MT, Tzang BS, Chang YY et al. Effects of Antrodia camphorata on alcohol clearance and antifibrosis in livers of rats continuously fed alcohol. J Agric Food Chem 2011; 59:4248-54.

Xi YM, Shi XE, Zhang H et al. Relation of GSTP1 and CTP2E1 polymorphisms with susceptibility to acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011; 19:589-93.

Xu CM, Qian YL, Zhu LJ et al. Abnormal liver function associated with polymorphism of GSTT1, GSTM1 and CYP2E1 in workers exposed to N, N-dimethylformamide. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2009; 27:333-7.

Yan SL, Wu ST, Yin MC, Chen HT, Chen HC. Protective effects from carnosine and histidine on acetaminophen-induced liver injury. J Food Sci 2009; 74:259-65.

Yan Y, Yang JY, Mou YH, Wang LH, Zhang H, Wu CF. Possible metabolic pathways of ethanol responsible for oxidative DNA damage in human peripheral lymphocytes. Alcohol Clin Exp Res 2011; 35:1-9.

Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med 2010; 235:32-9.

Yang H, Zhou Y, Zhou Z et al. A novel polymorphism rs1329149 of CYP2E1 and a known polymorphism rs671 of ALDH2 of alcohol metabolizing enzymes are associated with colorectal cancer in a southwestern Chinese population. Cancer Epidemiol Biomarkers Prev 2009; 18:2522-7.

Yang HY, Lin HS, Chao JC, Chien YW, Peng HC, Chen JR. Effects of soy protein on alcoholic liver disease in rats undergoing ethanol withdrawal. J Nutr Biochem 2011. doi:10. 1016/j. jnutbio. 2011. 03. 016.

Yang L, Wu D, Wang X, Cederbaum AI. Depletion of cytosolic or mitochondrial thioredoxin increases CYP2E1-induced oxidative stress via an ASK-1-JNK1 pathway in HepG2 cells. Free Radic Biol Med 2011; 51:185-96.

Ye X, Peng T, Liu T et al. Association between aldehyde dehydrogenase-2/cytochrome P450 2E1 genetic polymorphism and habit of alcohol drinking and the susceptibility of hepatocellular carcinoma. Wei Sheng Yan Jiu 2010; 39:42-5.

Yip-Schneider MT, Doyle CJ, McKillop IH et al. Alcohol induces liver neoplasia in a novel alcohol-preferring rat model. Alcohol Clin Exp Res 2011. doi:10. 1111/j. 1530-0277. 2011. 01568. x.

Yogalakshmi B, Viswanathan P, Anuradha CV. Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. Toxicology 2010; 268:204-12.

Yoon Y, Park HD, Park KU, Kim JQ, Chang YS, Song J. Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios. Eur J Clin Pharmacol 2006; 62:627-31.

Yu HS, Oyama T, Isse T et al. Formation of acetaldehyde-derived DNA adducts due to alcohol exposure. Chem Biol Interact 2010; 188:367-75.

Yuan F, Chen J, Wu WJ et al. Effects of matrine and oxymatrine on catalytic activity of cytochrome P450s in rats. Basic Clin Pharmacol Toxicol 2010; 107:906-13.

Yuan W, Jin H, Chung JK, Zheng J. Evidence for cellular protein covalent binding derived from styrene metabolite. Chem Biol Interact 2010; 186:323-30.

Yue J, Dong G, He C, Chen J, Liu Y, Peng R. Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. Toxicology 2009; 264:185-91.

Yun KU, Oh SJ, Oh JM et al. Age-related changes in hepatic expression and activity of cytochrome P450 in male rats. Arch Toxicol 2010; 84:939-46.

Zamaratskaia G, Rasmussen MK, Herbin I, Ekstrand B, Zlabek V. In vitro inhibition of porcine cytochrome P450 by 17β -estradiol and 17α-estradiol. Interdiscip Toxicol 2011; 4:78-84.

Zamule SM, Coslo DM, Chen F, Omiecinski CJ. Differentiation of human embryonic stem cells along a hepatic lineage. Chem Biol Interact 2011; 190:62-72.

Zeng T, Zhang CL, Song FY, Han XY, Xie KQ. The modulatory effects of garlic oil on hepatic cytochrome P450s in mice. Hum Exp Toxicol 2009; 28:777-83.

Zgheib NK, Mitri Z, Geryess E, Noutsi P. Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a Lebanese population: frequency distribution and association with morbid diseases. Genet Test Mol Biomarkers 2010; 14:393-7.

Zhan P, Wang J, Zhang Y et al. CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians. Lung Cancer 2010; 69:19-25.

Zhang J, Yin L, Liang G, Liu R, Fan K, Pu Y. Detection of CYP2E1, a genetic biomarker of susceptibility to benzene metabolism toxicity in immortal human lymphocytes derived from the Han Chinese Population. Biomed Environ Sci 2011; 24:300-9.

Zhang W, Lu D, Dong W et al. Expression of CYP2E1 increases oxidative stress and induces apoptosis of cardiomyocytes in transgenic mice. FEBS J 2011; 278:1484-92.

Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 2002; 30:314-8.

Zhang Y, Liu J. Transgenic alfalfa plants co-expressing glutathione S-transferase (GST) and human CYP2E1 show enhanced resistance to mixed contaminates of heavy metals and organic pollutants. J Hazard Mater 2011; 189:357-62.

Zhou GW, Hu J, Li Q. CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis. World J Gastroenterol 2010; 16:2949-53.

Zhou J, Empey PE, Bies RR, Kochanek PM, Poloyac SM. Cardiac arrest and therapeutic hypothermia interaction with isoform-specific cytochrome P450 drug metabolism. Drug Metab Dispos 2011. doi:10. 1124/dmd. 111. 040642.

Zordoky BN, El-Kadi AO. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicol In Vitro 2010; 24:863-71.

CYP2J2 (cytochrome P450, family 2, subfamily J, polypeptide 2)

Aiba I, Yamasaki T, Shinki T et al. Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids 2006; 71:849-56.

Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009; 46:67-74.

Berlin DS, Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. Pharmacogenet Genomics 2011; 21:308-11.

Bertrand-Thiebault C, Ferrari L, Boutherin-Falson O et al. Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis. Clin Exp Pharmacol Physiol 2004; 31:295-301.

Bièche I, Narjoz C, Asselah T et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007; 17:731-42.

Börgel J, Bulut D, Hanefeld C et al. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc Disord 2008; 8:41.

Borlak J, Walles M, Levsen K, Thum T. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos 2003; 31:888-91.

Chen C, Li G, Liao W et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther 2009; 329:908-18.

Chen C, Wei X, Rao X et al. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J Pharmacol Exp Ther 2011; 336:344-55.

Chen G, Wang P, Zhao G et al. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice. Prostaglandins Other Lipid Mediat 2011. doi:10. 1016/j. prostaglandins. 2011. 06. 009.

Delozier TC, Kissling GE, Coulter SJ et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 2007; 35:682-8.

Dutheil F, Dauchy S, Diry M et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009; 37:1528-38.

Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009; 75:1392-9.

Fava C, Montagnana M, Almgren P et al. The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes. J Hypertens 2010; 28:294-9.

Freedman RS, Wang E, Voiculescu S et al. Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res 2007; 13:5736-44.

Gaedigk A, Baker DW, Totah RA et al. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther 2006; 319:523-32.

Gervasini G, Vizcaino S, Carrillo JA, Caballero MJ, Benitez J. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol 2006; 62:177-86.

Hashizume T, Imaoka S, Mise M et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 2002; 300:298-304.

Hiratsuka M, Hinai Y, Sasaki T et al. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 2007; 35:1730-2.

Huang H, Chang HH, Xu Y et al. Epoxyeicosatrienoic acid inhibition alters renal hemodynamics during pregnancy. Exp Biol Med 2006; 231:1744-52.

Irusta G, Murphy MJ, Perez WD, Hennebold JD. Dynamic expression of epoxyeicosatrienoic acid synthesizing and metabolizing enzymes in the primate corpus luteum. Mol Hum Reprod 2007; 13:541-8.

Jiang JG, Chen CL, Card JW et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 2005; 65:4707-15.

Jiang JG, Chen RJ, Xiao B et al. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 2007; 82:162-74.

Jiang JG, Fu XN, Chen CL, Wang DW. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. Ai Zheng 2009; 28:93-6.

Jiang JG, Ning YG, Chen C et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res 2007; 67:6665-74.

Jiang JG, Shen GF, Chen C, Fu XN, Wang DW. Effects of cytochrome P450 arachidonic acid epoxygenases on the proliferation of tumor cells. Ai Zheng 2009; 28:14-9.

Jiang JH, Jia WH, Qin HD, Liang H, Pan ZG, Zeng YX. Expression of cytochrome P450 enzymes in human nasopharyngeal carcinoma and non-cancerous nasopharynx tissue. Ai Zheng 2004; 23:672-7.

Jie Z, Hong K, Jianhong T, Biao C, Yongmei Z, Jingchuan L. Haplotype analysis of the CYP2J2 gene associated with myocardial infarction in a Chinese Han population. Cell Biochem Funct 2010; 28:435-9.

Kim DH, Vanella L, Inoue K et al. Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγ. Stem Cells Dev 2010; 19:1863-73.

King LM, Gainer JV, David GL et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 2005; 15:7-13.

King LM, Ma J, Srettabunjong S et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002; 61:840-52.

Kirchheiner J, Meineke I, Fuhr U, Rodríguez-Antona C, Lebedeva E, Brockmöller J. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 2008; 9:277-88.

Lafite P, Dijols S, Buisson D et al. Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett 2006; 16:2777-80.

Lafite P, Dijols S, Zeldin DC, Dansette PM, Mansuy D. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys 2007; 464:155-68.

Lee AC, Murray M. Up-regulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2. Mol Pharmacol 2010; 77:987-94.

Lee CA, Neul D, Clouser-Roche A et al. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 2010; 38:347-56.

Lee CR, Imig JD, Edin ML et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010; 24:3770-81.

Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 2007; 17:349-58.

Lee SS, Jeong HE, Liu KH et al. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 2005; 15:105-13.

Liu KH, Kim MG, Lee DJ et al. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 2006; 34:1793-7.

Liu L, Chen C, Gong W et al. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther 2011; 339:451-63.

Ma J, Bradbury JA, King L et al. Molecular cloning and characterization of mouse CYP2J6, an unstable cytochrome P450 isoform. Biochem Pharmacol 2002; 64:1447-60.

Ma J, Ramachandran S, Fiedorek FT Jr, Zeldin DC. Mapping of the CYP2J cytochrome P450 genes to human chromosome 1 and mouse chromosome 4. Genomics 1998; 49:152-5.

Malaplate-Armand C, Ferrari L, Masson C, Siest G, Batt AM. Astroglial CYP1B1 up-regulation in inflammatory/oxidative toxic conditions: IL-1beta effect and protection by N-acetylcysteine. Toxicol Lett 2003; 138:243-51.

Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 2002; 30:1240-5.

Messina A, Nencioni S, Gervasi PG, Gotlinger KH, Schwartzman ML, Longo V. Molecular cloning and enzymatic characterization of sheep CYP2J. Xenobiotica 2010; 40:109-18.

Michaud V, Frappier M, Dumas MC, Turgeon J. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One 2010. doi:10. 1371/journal. pone. 0015666.

Minamiyama Y, Takemura S, Imaoka S, Funae Y, Okada S. Cytochrome P450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates. Drug Metab Pharmacokinet 2007; 22:15-9.

Moshal KS, Zeldin DC, Sithu SD et al. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol 2008; 215:771-81.

Nakayama K, Nitto T, Inoue T, Node K. Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sci 2008; 83:339-45.

Nayeem MA, Zeldin DC, Boegehold MA, Falck JR. Salt modulates vascular response through adenosine A(2A) receptor in eNOS-null mice: role of CYP450 epoxygenase and soluble epoxide hydrolase. Mol Cell Biochem 2011; 350:101-11.

Oleksiak MF, Wu S, Parker C et al. Identification and regulation of a new vertebrate cytochrome P450 subfamily, the CYP2Ps, and functional characterization of CYP2P3, a conserved arachidonic acid epoxygenase/19-hydroxylase. Arch Biochem Biophys 2003; 411:223-34.

Park SW, Heo DS, Sung MW. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cell Oncol 2011. doi:10. 1007/s13402-011-0051-7.

Polonikov AV, Ivanov VP, Solodilova MA et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Dis Markers 2008; 24:119-26.

Polonikov AV, Ivanov VP, Solodilova MA et al. Promoter polymorphism G-50T of a human CYP2J2 epoxygenase gene is associated with common susceptibility to asthma. Chest 2007; 132:120-6.

Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Panfilov VI. Promoter polymorphism G-50T of a human CYP2J2 epoxygenase gene is associated with common susceptibility to asthma. Chest 2007; 132:120-6.

Pucci L, Lucchesi D, Chirulli V et al. Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus. Am J Pharmacogenomics 2003; 3:355-8.

Qu W, Bradbury JA, Tsao CC et al. Cytochrome P450 CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain. J Biol Chem 2001; 276:25467-79.

Sato M, Yokoyama U, Fujita T, Okumura S, Ishikawa Y. The roles of cytochrome p450 in ischemic heart disease. Curr Drug Metab 2011; 12:526-32.

Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011; 1814:186-99.

Siest G, Jeannesson E, Marteau JB et al. Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008; 36:182-9.

Smith HE, Jones JP 3rd, Kalhorn TF et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008; 18:943-53.

Spiecker M, Darius H, Hankeln T et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110:2132-6.

Sun P, Liu W, Lin DH et al. Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct. J Am Soc Nephrol 2009; 20:513-23.

Takeshita H, Tsubota E, Takatsuka H, Kunito T, Fujihara J. Cytochrome P450 2J2*7 polymorphisms in Japanese, Mongolians and Ovambos. Cell Biochem Funct 2008; 26:813-6.

Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61:541-58.

Thomas RD, Green MR, Wilson C et al. Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells. Chem Biol Interact 2006; 160:204-16.

Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 2006; 114:1655-61.

Uno Y, Hosaka S, Matsuno K et al. Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 2007; 466:98-105.

Wang CP, Hung WC, Yu TH et al. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp Clin Endocrinol Diabetes 2010; 118:346-52.

Wang H, Jiang Y, Liu Y et al. CYP2J2*7 single nucleotide polymorphism in a Chinese population. Clin Chim Acta 2006; 365:125-8.

Wang L, Yao J, Chen L, Chen J, Xue J, Jia W. Expression and possible functional roles of cytochromes P450 2J1 (zfCyp 2J1) in zebrafish. Biochem Biophys Res Commun 2007; 352:850-5.

Wang MZ, Saulter JY, Usuki E et al. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos 2006; 34:1985-94.

Wang MZ, Wu JQ, Bridges AS et al. Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos 2007; 35:2067-75.

Wang Y, Wang JN, Liu ZJ, Wei X, Xiao X, Wang DW. Arachidonic acid epoxygenases and their metabolites promote angiogenesis. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33:1122-31.

Wray JA, Sugden MC, Zeldin DC et al. The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. PLoS One 2009. doi:10. 1371/journal. pone. 0015666.

Wu SN, Zhang Y, Gardner CO et al. Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Ann Hum Genet 2007; 71:519-25.

Xiao B, Li X, Yan J et al. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010; 334:784-94.

Xu Y, Ding H, Peng J et al. Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease. Pharmacogenet Genomics 2011; 21:489-94.

Yamasaki T, Izumi S, Ide H, Ohyama Y. Identification of a novel rat microsomal vitamin D3 25-hydroxylase. J Biol Chem 2004; 279:22848-56.

Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 2006; 36:1201-9.

Yoo HH, Kim NS, Lee J, Sohn DR, Jin C, Kim DH. Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica 2009; 39:1-10.

Zhang L, Ding H, Yan J et al. Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population. Pharmacogenet Genomics 2008; 18:45-51.

Zhang Y, El-Sikhry H, Chaudhary KR et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2009; 297:37-46.

Zheng C, Wang L, Li R et al. Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Respir Cell Mol Biol 2010; 43:740-9.

Zhou Y, Chang HH, Du J, Wang CY, Dong Z, Wang MH. Renal epoxyeicosatrienoic acid synthesis during pregnancy. Am J Physiol Renal Physiol 2005; 288:221-6.

Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010; 125:446-63.

←C (Previous)

C (Contd)→

A B C D E F G H I K L M N O P R S T U V W X Z

Thank you!